Note: Descriptions are shown in the official language in which they were submitted.
WO 2022/133420
PCT/US2021/072885
TITLE OF THE INVENTION
BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING
THEM, METHODS AND USES THEREOF
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application No.
63/127,329, filed
December 18, 2020, which is incorporated herein by reference, in its entirety.
FIELD OF THE INVENTION
[0002] The present invention describes novel boron-containing compounds, or
their
pharmaceutically acceptable salts, pharmaceutical compositions containing
them, and their
medical uses. The compounds of the invention have activity as Janus kinase
(JAK) inhibitors
and are useful in the treatment or control of inflammation, auto-immune
diseases, cancer, and
other disorders and indications where modulation of JAK would be desirable.
Also described
herein are methods of treating inflammation, auto-immune diseases, cancer, and
other conditions
susceptible to inhibition of JAK by administering a compound of the invention.
BACKGROUND OF THE INVENTION
[0003] Protein kinases are families of enzymes that catalyze the
phosphorylation of specific
residues in proteins, broadly classified into tyrosine and serine/threonine
kinases. Inappropriate
kinase activity, arising from mutation, over-expression, or inappropriate
regulation, dys-
regulation, or de-regulation, as well as over- or under-production of growth
factors or cytokines
has been implicated in many diseases, including but not limited to cancer,
cardiovascular
diseases, allergies, asthma and other respiratory diseases, autoimmune
diseases, inflammatory
diseases, bone diseases, metabolic disorders, and neurological and
neurodegenerative disorders
such as Alzheimer's disease. Inappropriate kinase activity triggers a variety
of biological cellular
responses relating to cell growth, cell differentiation, survival, apoptosis,
mitogenesis, cell cycle
control, and cell mobility implicated in the aforementioned and related
diseases. Thus, protein
kinases have emerged as an important class of enzymes as targets for
therapeutic intervention. In
particular, the JAK family of cellular protein tyrosine kinases (JAK-1, JAK-2,
JAK-3, and Tyk-
2) play a central role in cytokine signaling (Kisseleva et al, Gene, 2002,
285, 1; Yamaoka et al.
Genome Biology 2004, 5, 253)). Upon binding to their receptors, cytokines
activate JAK, which
1
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
then phosphorylate the cytokine receptor, thereby creating docking sites for
signaling molecules,
notably, members of the signal transducer and activator of transcription
(STAT) family that
ultimately lead to gene expression, which stimulates biologic responses such
as an itch signal.
Activation of the JAK-STAT pathway also results in several other ancillary
biologic activities
that contribute to the inflammation and pruritic processes that contribute to
acute allergy in
animals but can also exacerbate clinical signs and contribute to chronic
allergy.
[0004] Atopic dermatitis (AD), also known as eczema, is a common chronic
inflammatory skin
disease, affecting approximately 20% of children and up to 10% of adults and
it imposes a
significant financial and societal burden because of the direct medical costs
and decreased
productivity of individuals with AD. The burden of AD appears to be related
mainly to the
limited methods of treatment. Furthermore, according to the AD treatment
guidelines, there is no
standard of care and treatment may be tailored to an individual's needs.
Topical interventions
are the mainstay of AD therapy. Until now, topical corticosteroids have been
the first-line
treatment. Their use, however, may be limited by potential local and systemic
adverse effects.
Topical calcineurin inhibitors are classified as second-line anti-inflammatory
therapy for AD,
with advantages in long-term maintenance and application to special sites.
Topical calcineurin
inhibitors inhibit calcineurin-dependent T-cell activation; however, a black
box warning about
the potential for developing malignant neoplasms with the use of topical
calcineurin inhibitors
reduces patients' adherence to treatment.
[0005] Psoriasis and psoriatic arthritis are associated with aberrant
inflammation and the
production of proinflammatory mediators. Psoriasis and psoriatic arthritis are
inflammatory
diseases with overlapping features and shared immunologic mechanisms.
Psoriasis is a systemic
disease in that it primarily affects the skin but up to 40% of individuals
with psoriasis may go on
to develop psoriatic arthritis. Psoriatic arthritis typically affects the
peripheral joints and may
occasionally affect the spine and sacroiliac area. Enthesitis, dactylitis, and
nail changes such as
pitting and discoloration are also common manifestations of psoriatic disease
in patients with
joint involvement.
[0006] Pruritus is commonly a significant clinical sign associated with flea
associated dermatitis
in dogs. Medical management of for pruritis may be sought in cases where the
cause of itching is
not identifiable, or treatment of underlying disease does not eliminate
itching. However, control
of itching with antihistamines is usually ineffective, and while treatment
with glucocorticoids
2
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
can be effective, long term use is not ideal due to adverse side effects
including excessive
hunger, thirst, and urination, and increased risk of diabetes and urinary
tract infections.
[0007] JAK inhibition may provide a therapeutic strategy for various immune
and inflammatory
diseases, including rheumatoid arthritis (RA), arthritis, ulcerative colitis,
Crohn's disease,
inflammatory bowel disease (IBD), psoriasis, alopecia areata, atopic
dermatitis, vitiligo,
palmoplantar pustulosis, mucocutaneous disease erythema multiform e, mycosis
fungoides, graft-
versus-host disease, cutaneous lupus, transplant rejection, systemic lupus
erythematosus (SLE),
dermatomyositis, Sjogren's syndrome, dry eye disease, secondary
hypereosinophilic syndrome
(HES), allergy, allergic dermatitis, asthma, vasculitis, multiple sclerosis,
diabetic nephropathy,
cardiovascular disease, artherosclerosis, and cancer. Reference is made to
Schwartz et al., JAK
inhibition as a therapeutic strategy for immune and inflammatory diseases, Nat
Rev Drug
Discov., 2017 Dec 28., 17(1):78, herein incorporated by reference with regard
to the rationale for
targeting JAKs.
[0008] Various classes of compounds have been shown to inhibit JAK enzymes.
For example,
US 8,133,899 B2 (to Pfizer) discloses use of pyrrolo[2,3-D]pyrimidine
compounds as JAK
inhibitors. In particular, oclacitinib (APOQUEL ) is a cyclohexylamino
pyrrolopyrimidine
demonstrated to be a Janus kinase inhibitor that controls clinical signs of
allergic skin disease in
dogs (as disclosed in J. Vet. Pharmacol. Therap. 2014 Aug 37(4): 317-324). In
addition,
published patent application nos. US 2020/0339585, WO 2009/114512 Al and U.S.
Patent No
7,598,257 B2 describe various other JAK inhibitor compounds.
[0009] Published patent applications filed by Merck Sharp & Dohme Corporation
and Intervet
Inc. relating to pyrazole carboxamide compounds as JAK inhibitors include WO
2013/041042
Al, WO 2018/108969 Al, WO 2020/118597 Al, WO 2020/120673 Al, WO 2020/120679
Al,
and W02020221914 Al (all incorporated by reference herein in their entirety).
[0010] Reference is made to Siu et al., The Discovery of 3-(0-Chloro-3-
tnethoxyphenyl)amino)-
I-((3R,45)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide, a
Highly Ligand
Efficient and Efficacious Janus Kincise I Selective Inhibitor with Favorable
Pharmacokinetic
Properties, J. Med. Chem. 2017 Dec 14; 60(23): 9676-9690, herein incorporated
by reference,
with regard to pyrazole carboxamide Janus Kinase 1 inhibitors and their
synthesis.
3
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
There remains a need for therapies targeting and modulating JAK kinases for
the treatment or
control of inflammation, auto-immune diseases, cancer, and other disorders and
indications
where modulation of JAK modulation would be desirable.
INCORPORATION BY REFERENCE
[0011] Any foregoing applications, and all documents cited therein or during
their prosecution
("application cited documents") and all documents cited or referenced in the
application cited
documents, and all documents cited or referenced herein ("herein cited
documents"), and all
documents cited or referenced in herein cited documents, together with any
manufacturer's
instructions, descriptions, product specifications, and product sheets for any
products mentioned
herein or in any document incorporated by reference herein, are hereby
incorporated herein by
reference, and may be employed in the practice of the invention.
[0012] Citation or identification of any document in this application is not
an admission that
such document is available as prior art to the present invention
SUMMARY OF THE INVENTION
In a first aspect, the present invention provides for novel and inventive
boron containing
pyrazole compounds, or their pharmaceutically acceptable salts, pharmaceutical
compositions
containing them, and their medical uses. The compounds of the invention have
activity as Janus
kinase (JAK) inhibitors and are useful in the treatment or control of
inflammation, auto-immune
diseases, cancer, and other disorders and indications where modulation of JAK
would be
desirable.
[0013] In one embodiment, the invention of the present disclosure includes a
compound of
formula (I) and formula (II) below, or a pharmaceutically acceptable salt or a
stereoisomer or a
tautomer thereof; wherein A is selected from the group consisting of
benzo[c][1,2]oxaborol-
1(3H)-ol, 3,4-dihydro-1H-benzo[c][1,2]oxaborinin-1-ol, and 2H-
benzo[e][1,2]oxaborinin-2-ol,
or a derivative thereof, and the variables R27 R37 R47 R4a, R4b7 R5a7 X, n,
and p are defined herein.
4
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
(X) p
\ - CN
(R 5' )11 --------------,.."R3
R2 N'N
\
R4
(I)
R3
(X) p '
-...õ,...õ
R2 ---N
\s
1 t A
N
\ 8
(II),
[0014] In another embodiment, the invention of the present disclosure provides
a compound of
formula (III), or a pharmaceutically acceptable salt or a stereoisomer or a
tautomer thereof;
wherein A is selected from the group consisting of benzo[c][1,2]oxaborol-1(3H)-
ol, 3,4-dihydro-
1H-benzo[c][1,2]oxaborinin-1-ol, and 2H-benzo[e][1,2]oxaborinin-2-ol, or a
derivative thereof,
and the variables R, R4, R4a, and R4I) are defined herein.
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
R
\
1\1'N
.:\: -LNIÃ1.)
\
R4
0
NR 4' R 4b
(III)
[0015] In one embodiment, the variable A in the compound of formula (1), (11),
and III is
selected from
R lb
A 410
R 24 R 3,4
,
HO
01 I 0
i
I
....-"P ,.
R2'' R2a R,3.,1
,
,
RI 1-if..
HO A
R2' R3a
,
,
6
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
i B ,
,
R2a Rla R ill
R lb lb
HO
\ Ri
i
I
,.
. so-
R W
3=1 Frea , ,)
R la R 1 a
OH OH R 14
1 1
I
,,.........ix 0._
'L..õ,......õõ
,
,
OH R 113 ?H Rth
1
...--B _.,...
A
O''' 11101 0, õ.......
, 1
1
...., .........,
R." R la
R1
R2a R 24 R 2a R 24
R 3b R1a R 34 R1=
4
R lb R lb
HO,,, õõ...-0 R1 Fiao
:
R3a* R 3a
Ri
R 2a R 1 a R2a Rla
,and
'
7
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
wherein the variables It'a, Rib, R2a., R2b, R3a, and R31 are defined herein.
[0016] In one embodiment, the invention of the present disclosure provides a
compound of
formula (IV), (IVa) or (IVb), or a pharmaceutically acceptable salt or a
stereoisomer or a
tautomer thereof; wherein A is selected from the group consisting of
benzo[c][1,2]oxaborol-
1(3H)-ol, 3,4-dihydro-1H-benzo[c][1,2]oxaborinin-1-ol, and 2H-
benzo[e][1,2]oxaborinin-2-ol,
or a derivative thereof, such as a moiety selected from any one of A1-A6 as
defined herein, and
the variables R" and R544 in respect of compounds of formula (IV), (IVa) and
(IV)b are defined
herein.
[0017]
X{ '0/4
R =õ õ1,...,õRi
R 2 õ....--
R
N
7 'N-ts1
:e.
\ P
R4
\ / ,,-----
14¨fc A )
----
7\\
.,
R4 iD R4
(IV),
Xg A
õ.--s- 'N.,
Xf Xa
3 1
VI
R2
ii
,...N
\ /
) 144
\ m\s\\ \N
i
/
R4 ) R4
te. 0 R4/
(IVa), and (IVb).
8
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
[0018] One embodiment of the invention of the present disclosure includes a
method for treating
a patient having a disease or disorder susceptible to modulation of JAK
comprising
administering a therapeutically effective amount of a compound of the present
disclosure. In one
aspect, the disease or disorder is one or more of atopic dermatitis, flea
allergy dermatitis,
eczema, pruritus, psoriasis, psoriatic arthritis, Bechet's disease, pityriasis
rubra pilaris, alopecia
areata, discoid lupus erythematosus, vitiligo, palmoplantar pustulosis,
mucocutaneous disease
erythema multiforme, mycosis fungoides, graft-versus-host disease, cutaneous
lupus, rheumatoid
arthritis (RA), arthritis, ulcerative colitis, Crohn's disease, inflammatory
bowel disease (IBD),
transplant rejection, systemic lupus erythematosus (SLE), dermatomyositis,
Sjogren's syndrome,
dry eye disease, secondary hypereosinophilic syndrome (HES), allergy, allergic
dermatitis,
asthma, vasculitis, multiple sclerosis, diabetic nephropathy, cardiovascular
disease,
artherosclerosis, and cancer. In one aspect, the disease or disorder is one or
more of atopic
dermatitis, flea allergy dermatitis, psoriasis, and rheumatoid arthritis. In
one aspect, the
compound is administered in an amount to perturb an immune regulatory pathway
in a cell. In
one aspect, the perturbation results in an effect on the JAK-STAT pathway.
[0019] One embodiment of the present disclosure includes a method of
inhibiting JAK in a
mammalian cell comprising contacting the mammalian cell with a compound of the
present
disclosure. In one aspect, the mammalian cell is a cell from a subject having
an inflammatory
condition.
[0020] One embodiment of the invention of the present disclosure includes a
composition
comprising a compound of the present invention and a pharmaceutically or
veterinary acceptable
carrier.
[0021] One embodiment of the invention of the present disclosure includes a
combination
comprising a compound of the present disclosure, and one or more other
pharmaceutical or
veterinary active substances.
[0022] In another aspect, the invention of the present disclosure provides
methods of treating
inflammation, auto-immune diseases, cancer, and other conditions susceptible
to inhibition of
JAK by administering a compound herein described.
[0023] In one embodiment of the present disclosure, the invention provides a
method for treating
one or more diseases or disorders of inflammation, auto-immune dysfunction,
and cancer
9
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
comprising administering to a subject in need thereof an effective amount of a
compound of the
present disclosure. In one aspect, the disease or disorder is atopic
dermatitis, flea allergy
dermatitis, psoriasis, or rheumatoid arthritis. In one embodiment, the subject
is a mammal. In
one embodiment, the subject is a non-human animal. In one embodiment, the
subject is selected
from livestock mammals, domestic mammals, or companion animals. In one aspect,
the subject
is selected from cattle, sheep, goats, llamas, alpacas, pigs, horses, donkeys,
dogs, and cats. In
one aspect, the subject is a human.
[0024] One embodiment of the invention of the present disclosure includes a
compound of the
present disclosure for use in medicine.
[0025] One embodiment of the invention of the present disclosure includes a
compound of the
present disclosure for the manufacture of a medicament for the treatment of
one or more diseases
or disorder of inflammation, auto-immune dysfunction, and cancer. In one
aspect, the disease or
disorder is atopic dermatitis, psoriasis, or rheumatoid arthritis.
[0026] One embodiment of the invention of the present disclosure includes a
use of a compound
of the present disclosure for the treatment of one or more diseases or
disorders of inflammation,
auto-immune dysfunction, and cancer. In one aspect, the disease or disorder is
atopic dermatitis,
psoriasis, or rheumatoid arthritis.
[0027] One or more aspects and embodiments may be incorporated in a different
embodiment
although not specifically described. That is, all aspects and embodiments may
be combined in
any way or combination.
[0035] The headings used herein are for organizational purposes only and are
not meant to be
used to limit the scope of the description or the claims. As used throughout
this application, the
word "may" is used in a permissive sense (i.e., meaning having the potential
to), rather than the
mandatory sense (i.e., meaning must). Similarly, the words "include",
"including", and
"includes" mean including but not limited to the described variable.
[0036] It is an object of the invention to not encompass within the invention
any previously
known product, process of making the product, or method of using the product
such that the
Applicants reserve the right and hereby disclose a disclaimer of any
previously known product,
process, or method. It is further noted that the invention does not intend to
encompass within the
scope of the invention any product, process, or making of the product or
method of using the
product, which does not meet the written description and enablement
requirements of the
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
USPTO (35 U.S.C. 112, first paragraph) or the EPO (Article 83 of the EPC),
such that
Applicants reserve the right and hereby disclose a disclaimer of any
previously described
product, process of making the product, or method of using the product.
[0037] These and other embodiments are disclosed or are obvious from and
encompassed by the
following Detailed Description.
DETAILED DESCRIPTION
[0038] In a first aspect, the present invention provides for novel and
inventive boron containing
pyrazole compounds, or their pharmaceutically acceptable salts, pharmaceutical
compositions
containing them, and their medical uses.
[0039] The compounds of the invention have activity as Janus kinase (JAK)
inhibitors and are
useful in the treatment or control of inflammation, auto-immune diseases,
cancer, and other
disorders and indications where modulation of JAK would be desirable.
[0028] In one embodiment, the present invention provides for a compound
of formula (I) or formula (II) or a pharmaceutically acceptable salt or a
stereoisomer or a
tautomer thereof:
R)
09 p
C N
(IR 5a )44
R4
-1I7kNR4aR "
(I)
11
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
93
(X) p /
CN
(R5 )tt-'"---
R2 NN
fe
R4
'µ.NIR R 44
(II),
wherein:
R4, Itia, and R41 are independently selected from hydrogen, C1-4a1ky1, and
CH2(oxy) C1-4a1ky1;
each occurrence of n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9;
p is 2, 3, 4, or 5;
X is independently selected from C, N, S, and 0, wherein at least one X is
other than carbon;
A is selected from the group consisting of benzo[c][1,2]oxaborol-1(3H)-ol, 3,4-
dihydro-1H-
benzo[c][1,2]oxaborinin-1-ol, and 2H-benzo[e][1,2]oxaborinin-2-ol, or a
derivative thereof;
R2 and R3 are each independently selected from:
hydrogen,
halogen,
C1-10 alkyl,
C2-10 alkenyl,
C1-10 heteroalkyl,
aryl C0-10 alkyl C0-10 alkyl, C3-g cycloalkyl Co-10 alkyl, heteroaryl Co- 10
alkyl, and
(C3-8)heterocycloalkyl C0-10 alkyl,
wherein each of R2 and R3 are independently substituted with 0, 1, 2, 3, or 4
Rsa sub stituents;
each Tea is independently selected from.
hydrogen,
halogen, except lea is not halogen where substitution position is geminal to X
that is 0,
C1-10 alkyl(oxy)o-t(carbonyl)o-tCo-to alkyl,
C1-10 heteroalkyl(oxy)o-1(carbonyl)o-Co-to alkyl,
C2-to alkenyl(oxy)0-1(carbonypo-Co-to alkyl,
12
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
C2-io alkynyl(oxy)o-t(carbonyl)o-Co-to alkyl, aryl Co-to alkyl(oxy)o-
t(carbonyl)o-ko-to alkyl,
aryl C2-to alkenyl(oxy)o-t(carbonyl)o4Co-to alkyl,
aryl C2-to alkynyl(oxy)o-t(carbonyl)o-Co-to alkyl,
C3-g cycloalkyl Co-io alkyl(oxy)o-i (carbonyl)o-Co-to alkyl,
heteroaryl Co-i0 alkyl(oxy)04(carbony1)04C0-10 alkyl,
(C3-8)heterocycl alkyl Co-to alkyl(oxy)o-t(carbonyl)o4Co-to alkyl,
Ci-to alkyl(carbonyl)o-ioxyCo-to alkyl,
C1-10 heteroalkyl(carbonyl)o-toxyCo-to alkyl,
C2-to alkenyl(carbonyl)o-toxyCo-to
Ci-to heteroalkyl(carbonyl)o-toxyCo-to alkyl,
aryl Co-to alkyl (carbonyl)o-1 oxyCo-to alkyl,
(C3-8)cycloalkyl Co-to alkyl(carbonyl)o-toxyCo-to alkyl,
heteroarylCo-to alkyl(carbonyl)o-toxyCo-to alkyl,
(C3-8)heterocycloalkyl Co-to alkyl(carbonyl)o-toxyCo-to alkyl,
((Co- to)alkyl)t-zaminocarbonyloxy,
(Co- to)heteroalkylaminocarbonyloxy,
aryl (Co- to)alkylaminocarbonyloxy,
(C3 -g)cycloalkyl(Co- th)alkylaminocarbonyloxy,
heteroaryl(Co- to)alkylaminocarbonyloxy,
(C3 -g)heterocycloalkyl(Co- to)alkylaminocarbonyloxy,
Ct-to alkylamino(oxy)o-icarbonylCo-to alkyl,
(Co- to)heteroalkylamino(oxy)o-tcarbonylCo-to alkyl,
C3-8 cycloalkyl Co-to alkylamino(oxy)o-icarbonylCo-to alkyl,
aryl Co-loalkylamino(oxy)o-icarbonylCo-to alkyl,
heteroarylCo- to alkylamino(oxy)o-icarbonylCo- to alkyl,
(C3 -8)heterocycloalkylCo-lo alkylamino(oxy)o-tcarbonylCo-to alkyl,
Ci -1 o al kyl(oxy)o-t carbonyl aminoCoi 0 alkyl,
Ci-to heteroalkyl (oxy)o-tcarbonylaminoC0-10 alkyl,
C3-8 cycloalkyl Co-to alkyl (oxy)o-icarbonylaminoCo-to alkyl,
aryl Co-to alkyl(oxy)o-tcarbonylaminoCo-to alkyl,
heteroaryl Coto alkyl(oxy)o-tcarbonylaminoCo-to alkyl,
13
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
(C3-8)heterocycloalkyl Co-i0 alkyl(oxy)o-icarbonylaminoCo-io alkyl,
-0O2(Co-io alkyl),
-(Co-io alkyl)CO2H,
Oxo (=0),
Ci-to alkylsulfonyl,
Ci-io heteroalkyl sul fonyl , (C3-8) cycloalkyl sulfonyl ,
(C3-8) cycloheteroalkylsulfonyl,
heteroarylsulfonyl,
aryl sulfonyl,
aminosulfonyl,
-SO2N(C1-6a1ky1)1-2,
-S02Ci-6a1ky1,
-S02CF3,
-S02CF2H,
Ci-ioalkylsulfinyl,
amino,
(Co-io alky1)1-2 amino,
C1-4acylamino Co-to alkyl,
hydroxy,
Co-to alkylalkoxy,
cyano,
Ci-6alkylcyano, and
Ci-ohaloalkyl;
wherein R5a is each optionally substituted with 0, 1, 2, 3, or 4 R6 sub
stituents, and R6 is
independently selected from:
halogen,
C1-10 alkyl(oxy)o-i (carbonyl)o-i Co-rn alkyl,
Ci-to heteroalkyl(oxy)o-i(carbony1)0-1C0-10 alkyl,
C2-to alkenyl(oxy)o-i(carbonyl)o-iCo-io alkyl,
aryl Co- io alkyl(oxy)o-i(carbonyl)o-iCo-io alkyl,
aryl C2-10 alkenyl(oxy)o-i(carbonyl)o-iCo-io alkyl,
14
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
aryl Czto alkynyl(oxy)ot(carbonyl)otCo-io alkyl,
C3-8 cycloalkyl Coto alkyl(oxy)ot(carbonyl)o-iCo-io alkyl,
heteroaryl Coto alkyl(oxy)ot(carbonyl)otCoto alkyl,
(C3-g)heterocyc1oa1ky1 Cot o alkyl(oxy)ot (carbonyl)o-iCo-io alkyl,
Cito alkyl(carbonyl)o-ioxyCoto alkyl,
Czto alkenyl(carbonyl)o-loxyCoto alkyl,
Citoheteroalkyl(carbonyl)otoxyCoto alkyl,
aryl Co-io alkyl (carbonyl)otoxyCoto alkyl,
(C3-8)cycloalkyl Co-io alkyl(carbonyl)o-ioxyCoto
heteroarylCo-loalkyl(carbonypo-loxyCoto alkyl,
(C3-8)heterocycloalkyl Coto alkyl(carbonypotoxyCo-lo alkyl,
((Co- io)alkyl)b-zaminocarbonyloxy,
aryl (Coto)alkylaminocarbonyloxy,
(C3 -g)cycloalkyl(Coto)alkylaminocarbonyloxy,
heteroaryl(Coto)alkylaminocarbonyloxy,
(C3 -g)heterocycloalkyl(Coto)alkylaminocarbonyloxy,
Cito alkylamino(oxy)otcarbonylCoto alkyl,
C3-8 cycloalkyl Coto alkylamino(oxy)o-icarbonylCoto alkyl,
aryl Co-ioalkylamino(oxy)ot carbonylCo-io alkyl,
heteroaryl Coto alkylamino(oxy)otcarbonylCoto alkyl,
(C3-8)heterocycloalkyl Coto alkylamino(oxy)ot carbonylCot o alkyl,
Cito alkyl (oxy)otcarbonylaminoCoto alkyl,
C3-8 cycloalkyl Cito alkyl (oxy)otcarbonylaminoCotoalkyl,
aryl Cotoalkyl(oxy)otcarbonylaminoCoto alkyl,
heteroaryl Coto alkyl(oxy)otcarbonylaminoCoto alkyl,
(C3-8)heterocycloalkyl Coto alkyl(oxy)otcarbonylaminoCoto alkyl,
-0O2(Co-10 alkyl),
-(Coto alkyl)CO2H,
Oxo (=0),
Cit oalkylsulfonyl,
Citoheteroalkylsulfonyl,
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
(C3-8) cycloalkylsulfonyl,
(C3-8) cycloheteroalkylsulfonyl,
heteroarylsulfonyl,
aryl sulfonyl,
aminosulfonyl,
-SO2N(C1-6alkyl)1-2,
-S02C t-oalkyl,
-S02CF3,
-S02CF2H,
Ci-io alkylsulfinyl,
-0Si (Ci-to alky1)3
amino,
(Co- to alky1)1-2 amino,
-(oxy)o- 1 (carbonyl)o-iN(Co-loalkyl) 1-2
C1-4acylamino Co-loalkyl,
hydroxy,
Ci-to alkoxy,
cyano, and
C1-6 haloalkyl; and
R6 is optionally substituted with 0, 1, 2, or 3 substituents independently
selected from
hydroxy, (C1-6)alkoxy, halogen, CO2H, -(Co-oalkylCN, -0(C=0)Ci-C6 alkyl, NO2,
trifluoromethoxy, trifluoroethoxy, -N-C(0)0(Co-6)alkyl, Ci-to alkylsulfonyl,
C1-10
heteroalkylsulfonyl, oxo (0=), (C3-8) cycloalkylsulfonyl, (C3-8)
cycloheteroalkylsulfonyl,
heteroarylsulfonyl, aryl sulfonyl, aminosulfonyl, -SO2N(C1-6alkyl)1-2, -SO2C1-
6 alkyl, -
SO2CF3, -S02CF2H, -Ci-to alkylsulfinyl, -0Si (Ci-to alky1)3, -0(o-1)(Ci-
io)haloalkyl, and
NH2.
[0040] In one embodiment of formula (1) or formula (II) or a pharmaceutically
acceptable salt or
a stereoisomer or a tautomer thereof, the variable A is selected from the
following:
16
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
Rib
HO
\
6.
R = R3a
,
R lb R lb
R 2a R 244 R:lia
HO
A
_-----sõ, ...,--
0 i
4.4' - '
Rib
R2-4 i',ea
,
,
H
Fit: R lb
0,\
I
1
A ,--- ..--0-
Ft" 00
R16 R2a 1.a
R-
7 ,
17
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
R111 /p,. lb
HO FIC:
\ RI
g **=,,,., / P ''''N, -A
i
, 31i
RI
R 2 R 3a R" R34
,
t
?H R' ?H Rib
===,,,.õ, , -,..,...
R3 ' ,,AI R3 = - Ri
R2a õR2b ,, R 2a R 2b
R'"" R " Foh R 1 a
R lb R lb
Hiaõ,.., ...... HO,, ,õ,...0
--,\
. Er
R 34 R 34 Ri
R2 Rla R2a R."
,and
=
,
wherein:
[0041] 142, R1a and R" are independently selected from the group consisting of
hydrogen,
halogen, CI-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, cyclopropyl, Ci-C3
haloalkyl, C2-C3
haloalkenyl, C2-C3 haloalkynyl, partially or fully halogenated cyclopropyl,
0(Ci-C3 alkyl), and
0(Ci-C 3 haloalkyl),
[0042] R2' and R3a are independently selected from the group consisting of
hydrogen, halogen,
18
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
Cl-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, or R2a together with R3a form
cyclopropyl, cyclobutyl,
oxetane, or cyclobutanone, wherein each of R2a and R3a is independently
unsubstituted or
substituted with one or more of halogen, hydroxy, amino, alkyl- or
di(alkyl)amino, alkyl,
cycloalkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkoxy,
haloalkoxy, alkylthio,
haloalkylthio, R7 S(0)- , R7 S(0)2 - , R7 C(0)- , R7 R8NC(0)- , R7 OC(0)- ,
117 C(0)0- , R7
C(0)NR8- ,-CN or - NO2; and
[0043] R2b and R3b are independently selected from the group consisting of:
hydrogen, C1-C3
alkyl, C2-C3 alkenyl, C2-C3 alkynyl, or R2b together with R3b form
cyclopropyl, cyclobutyl,
oxetane, or cyclobutane, wherein each of R2b and R31 is independently
unsubstituted or
substituted with one or more of halogen, hydroxy, amino, alkyl- or
di(alkyl)amino, alkyl,
cycloalkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkoxy,
haloalkoxy,
alkylthio, haloalkylthio, R7 S(0)- , R7 S(0)2 - , R7 C(0)- ,
Rs NC(0)-, R7 OC(0)- , R7
C(0)0- , R7 C(0)NR8- ,-CN or - NO2; and
[0044] R7 and R8 are independently hydrogen, alkyl, haloalkyl, thioalkyl,
alkylthioalkyl,
hydroxyalkyl, alkoxy- alkyl, alkenyl, haloalkenyl, alkynyl or haloalkynyl.
[0045] In one embodiment, R2, Wa and Rib are independently selected from the
group
consisting of hydrogen, fluorine, chlorine, bromine, iodine, C1-3 alkyl, Ci-C3
haloalkyl, 0(C1-
C3alkyl), and 0(Ci-C3haloalkyl).
[0046] In one embodiment, R2', R3', R21, and R31 are independently selected
from the group
consisting of hydrogen and Cl-C3 alkyl.
[0047] In one embodiment, Ri, Rla and Rib are independently selected from the
group
consisting of hydrogen, fluorine, chlorine, and C1-C3 alkyl.
[0048] In one embodiment, IV, Ria, and Rib are independently selected from the
group
consisting of hydrogen and fluorine when R3, Rla and/or Rib is ortho position
to the position
where A is attached to nitrogen.
[0049] In another embodiment, each of le, Wa and Rib is independently H or C1-
C3 alkyl, and
each of R2a, R3a, R21, and R3b is independently C1-C3 alkyl.
[0050] In another embodiment, 14_4, R", and RI" are each hydrogen.
[0051] In one embodiment R2 is not halogen. In another embodiment, R3 is
hydrogen, and R2 is
not halogen.
[0052] In one embodiment, each R5' is independently selected from:
19
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
hydrogen,
halogen,
Ci-loalkyl(oxy)o-t(carbonyl)o-tCo-toalkyl,
C1-10 heteroalkyl(oxy)o-i (carbonyl)o-i Co-t alkyl,
C2-toalkynyl(oxy)o-1(carbonyl)o-1Co-lo alkyl,
C2-10 alkenyl(oxy)0-1(carbony1)04C0-10 alkyl,
aryl Co-to alkyl(oxy)o-t(carbonyl)o-tCo-to alkyl,
aryl C2-to alkenyl(oxy)o-t(carbonyl)o-tCo-toalkyl,
aryl C2-10 alkynyl(oxy)o-t(carbonyl)o-tCo-to alkyl,
C3-scycloalkyl Co-toalkyl(oxy)o-t(carbonyl)o-tCo-toalkyl,
heteroaryl Co-toalkyl(oxy)o-t(carbonyl)o-tCo-toalkyl,
(C3-8)heterocycloalkyl Co-toalkyl(oxy)o-t(carbonyl)o-tCo-toalkyl,
C 1- oalkyl(carbonyl)o- oxyCo- toalkyl,
((Co-to)alky1)1-2aminocarbonyloxy,
Ci-loalkylamino(oxy)o-icarbonylCo-loalkyl,
Ci-to alkyl(oxy)o-tcarbonylaminoCotoalkyl,
-0O2(Co-loalkyl),
-(Co-to alkyl)CO2H,
Oxo (=0),
Co-toalkylsulfonyl,
Ci-toheteroalkylsulfonyl,
C3-8cycloa1kylsulfonyl,
C3-gcycloheteroalkylsulfonyl,
heteroaryl sul fon yl ,
arylsulfonyl,
aminosulfonyl,
-SO2N(C1-6alkyl)t-2,
-S020-6alkyl,
-S02CF3,
-S02C142H,
C -1 oalkylsulfinyl,
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
amino,
(Co-io alky1)1-2 amino,
hydroxy,
Co-ioalkylalkoxy,
cyano,
C1-6a1ky1 cyan , and
Ci-ohaloalkyl;
wherein R5a is each optionally substituted with 0, 1, 2, 3, or 4 sub stituent
that is R6.
[0053] In one embodiment, R3 is selected from hydrogen, Ci-nalkyl, (C3-
8)heterocycloa1kyl Co-io
alkyl, and Ci-iicycloalkylCo-io alkyl, wherein 143 is substituted with 0, 1,
2, 3, or 4 R5a
sub stituents.
[0054] As would be understood by one skilled in the art, the IUPAC names for
the variable A in
Formula (I), (II) and (III) herein correspond to the following chemical
structures:
H ___________________________________________________________________________
401B benzo[c][1,2]oxaborol-1(3H)-ol
0
OH
3,4-dihydro-1H-benzo[c][1,2]oxaborinin-1-ol
B,
0
BõOH 2H-benzo[e][1,2]oxaborinin-2-ol
[0055] In one embodiment, the present invention provides for a compound
of formula (III) or a pharmaceutically acceptable salt or a stereoisomer or a
tautomer thereof:
21
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
N-
/
A
R4
NR 4R
(III),
wherein:
A is selected from the group consisting of benzo[c][1,2]oxaborol-1(3H)-ol, 3,4-
dihydro-1H-
benzo[c][1,2]oxaborinin-1-ol, and 2H-benzo[e][1,2]oxaborinin-2-ol, or a
derivative thereof;
[0056] R is selected from the group consisting of:
I
I I
0 0
0 0
22
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
õ
0
0 0
N,
"11/µ
/
\\'µ.
*->Fs.'=
õ114L,
23
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
N
N
õN
S
õN
N N.
N
,N-
IIII ____________________ --
24
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
/
i
,,,
i ,,=-
=7_,...N
ii \-J
e
s,v_iii N
N d
\
,
,
<
/-
i N
,
,
Lk
F )
N _____________________________________________________________________ '
N,
,
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
Nõ
______________________________________________________________________ \7-
.....i <, I
N e
N N
r,..N
N
'I's1
,.
,õ,...N
N----''
e
Or''''' , . - = -
,
,
N ,
i
/
\--NI
I
I i
(77?
, 0
,
26
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
\\
t4 \\
';''''''=
i
: 14
> ''
,
,
i 1
/
\/
N ,N
4 ,_._.
1 I
N
,
,
N
N
11 11
1
õ,-
L,,., õ,--
IA'
.1
....,,,
F ..õ.N,
1 riniN
N ..,
,,,,-.' 11---
i
,
,
27
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
N
I I .1
-)1
CN
N-
I I
I
)µ.
N'
1
28
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
F
N
II
I
-....., N
,N
..---- .
=
IT
1 1
0
<01")
7 N
,
N
11,,,,,,,r,
N 11
r
L.---õ,
,.....õ,, ,õ-]
N
./ I
a
-741
1
li
,..N7,1 ' r)
\ -N
N-
S
/
,
,
N N
i 1
y
1
.er0
\_----,---N ,...----N
0
29
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
.-N
I 1
,N
N".
1 I
N ,
,
0
Y
y0N, 0
i,-..
4/ 1"-C1
N ii
N
,
,
0 0 "fr-i
I-5f) .
I/ Ii
N N
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
/
_____________________________________________________________________________
0
r-CN
(, )
i õN-
O
fr-tN>
i
N
N /4/
, N
,
1
P----
0
/
\---- 6 'y\-----Cil
N f......<-...t.
E
J.:
ii .1"
N N
0
/.4
/
1/ d;
N
N
,
,
31
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
.
0 ' - ' 0
-
: r __ N
=
tifil if
N N
/ F
0 ') 0 $,..
-0
14-------
1
fill
N N
F
es
/ __________________ - N
i
N N
32
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
i
le
1 ___________________________________________________________________________
N
i
i
\
r- \\ _
I
i _____________________
,os
r-N
N le=lit
, N
,
i
, ____________________________________ OH
\)...........<3
i
0
F
F--- -'¨\-/ 1
N N
F
/
r.......k.l.
<>õ....../
0
i
i _____________________ N
7.¨ -
N
N ifi
, N .
,
33
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
N
0,
,L---- 01 F '---0/---\T
i
,
>t 'IN
fiff
N iii
, N
\\ \\ - F --
P - 0
t \,N----
,-
/4--o
/ 0
N F F F
0 __________________________________ 0.
i \
0 0
,
zr I
0 p¨
,1¨.
1----\__/-----t0
N r-- __ = \ eN------i
' 0
34
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
N N
\:\
0 _______________________________________________________________ 0 ----
,
el\l¨ts = /--"-\_ /1\I-4,o
e
0
N N
\4\). \
õ0 p 0 __
.4,
1.-4\, ______________________ 1\1"""-\o N-----4
0
r4\\\
o.....-.1¨F
/0----e\O
0
0
N
\ N
\\),_ \
0
i p.,-....,
,
1------ N"-----
,
,
N
1 \ 1 N
\5:
¨0
N
'S\>kc)s
\ 0
0 N\
0 / 0
,
,
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
\\k\
_______________________________________ /
\\\\\ T-1\
I
_______________________________________________________________________
\=.,,,,\õõ,0
0
0 ,
,
z \ 0
0 ---\\ .--
''
i
ts- '
0 0
N F
F---<, ,>
0 1-----(\ 7.----i
0
N , 0 N\.\\\_µ
õ05¨ ,k\.
/0- ,.-
N
t c\ iN-1
\
0
0
,
36
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
N
ii---\
> __________________
z e,
/1* ___________________________________________________________ s'\
0
0
N N
\\¨
i
,
0 0
52,õP N
N
,0
\,\\\
0¨
,
1------\* "IN--
i----\...2---µ
0
0
N N
S\>k ./P7.,-..."F
e 4/
1---------\\ /N----1 2 1.-----------(c /N----\\
0 F _______________________________________________________ , 0
N N
\X\ \
,...- ---"'
0-- 0 0 -----F
1--------- . IN----i 1-----/N-----\c,
___________________ e
0 0
,
37
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
,
N N
________________________________________ 0-0
i
PI¨AP'
\ _______________________________________________________ /
0
0
N
\\ \\\
/ ____________________________________________________________________________
-\\
______________________________________________________________________________
-
/1\1
/
i
N------\\
0 0
,
,
\:\
e
0 --------' .. 1\i'
/ N
0
o
,
,
A
N F
OH
N
is_ss.<
i 0 0
,
38
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
N\\\
i'N's\
õ........ki
/ P¨
/ \
r---\ sp-----
0
o
N , N
\\ F
,0 so---.----"
-F
,
N----<\ "N-----\\
0 0
9 ,
N
, \ N
\ \
0 -----/
i
IN ....................... i
0
N
\\
0
0
N
_______________________________________________________________________ 0_0.
.,.....õ
0 0
,
,
39
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
N N
'4,kµs,,) \
0 -----' i
0 ¨
i .1,_.,, iep....
0 0
,
,
N ,
1
--/
0 ¨
F.,...\_}.4.õ.....1
1----<_2---i
0
0
,
,
N
\:;\
or¨ \
----. \\ \
f C)
iiN-1 1"=====~'~ \ _swieeN ----
0 0
,
,
..--.-
N
\ /
0 ---7¨F
0 ----1
1------------rµ: .. /
õN-----\(,\
0
, 0
,
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
./Th
irNH 0 F F
\)L.F
0
/of fie
7
NH
/ )L--d
N
/
/1/
0
\ 0
0 N
77 IC
I
4fr
OH
41
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
N
111
e
k
I t\iii]
,
,
NJ
1 i N
1,..
0 N-
-,N,-.....
i
R7
,
0
;
N N
P1 PI
õ4õ...õ.. ...."
.....õ -......õ,
A.,,,,....e.õ,........
42
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
N N
,.----
F ,
1
F F F
,and
,
or a stereoisomer thereof, wherein each R" is independently selected from
hydrogen, C1-4a1ky1,
and CH2(oxy)C1-4a1ky1, and R4, R4a, and Rth are independently selected from
hydrogen and Ci-
4alkyl
[0057] According to one embodiment, R in the compound of formula (III) is
selected from the
group consisting of
N N
ri
. I'l
i
.....0
0
N N
Iii i III I
,
10'
,and ,
or an enantiomer thereof
[0058] In one embodiment of the compound of formula (III), R4, Itia and R41
are each
hydrogen
[0059] In one embodiment of the compound of formula (III), 10, R4a and R4b are
each
43
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
hydrogen
[0060] In one embodiment of the compound of formula (III) as described herein,
A is preferably
selected from
R lb
HO
\
ta. ill
R24 Fea
'
R
HO H9,
\
/B- \''',N.
0 I 0 1
,
R2' R 2' 43a
HO
RI \
\
11
Ei
. 113
..."' R
,
,
HO R lb
µ
A HS,
i.-....õ..
0 1 /
1
Rib iti'6 R,la
,
'
44
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
R111 /p,. lb
HO Fic:
\ RI
i
1
RI
R 2 R 3a R" R34
R la R"
,
t
?H R' ? H R"
,-- i
i 1
R3 ' ,,AI R3a = - R1
R'"" R " Ft :th R 1 a
R11' R14
1-1(,),, ...... F-10õ, ,,...Ø ---
\
. Er
R 34 R34 R1
R2 Rla R2a R."
,and
=
,
wherein:
[0061] 141, R1a and R" are independently selected from the group consisting of
hydrogen,
halogen, CI-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, cyclopropyl, Ci-C3
haloalkyl, C2-C3
haloalkenyl, C2-C3 haloalkynyl, partially or fully halogenated cyclopropyl,
0(Ci-C3 alkyl), and
0(Ci-C 3 haloalkyl),
[0062] R2' and R3a are independently selected from the group consisting of
hydrogen, halogen,
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
Cl-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, or R2a together with R3a form
cyclopropyl, cyclobutyl,
oxetane, or cyclobutanone, wherein each of R2a and R3a is independently
unsubstituted or
substituted with one or more of halogen, hydroxy, amino, alkyl- or
di(alkyl)amino, alkyl,
cycloalkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkoxy,
haloalkoxy, alkylthio,
haloalkylthio, R7 S(0)- , R7 S(0)2 - , R7 C(0)- , R7 R8 NC(0)-, R7 OC(0)- , R7
C(0)0- , R7
C(0)NR8- ,-CN or - NO2;
[0063] R2b and R31 are independently selected from the group consisting of:
hydrogen, CI-C3
alkyl, C2-C3 alkenyl, C2-C3 alkynyl, or R2b together with R3b form
cyclopropyl, cyclobutyl,
oxetane, or cyclobutanone, wherein each of leb and R31 is independently
unsubstituted or
substituted with one or more of halogen, hydroxy, amino, alkyl- or
di(alkyl)amino, alkyl,
cycloalkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkoxy,
haloalkoxy, alkylthio,
haloalkylthio, R7 S(0)- , R7 S(0)2 - , R7 C(0)- , R7 le NC(0)-, R7 OC(0)- , R7
C(0)0- , R7
C(0)NR8- ,-CN or - NO2; and
[0064] R7 and R8 are independently hydrogen, alkyl, haloalkyl, thioalkyl,
alkylthioalkyl,
hydroxyalkyl, alkoxy- alkyl, alkenyl, haloalkenyl, alkynyl or haloalkynyl.
[0065] In yet another embodiment of the compound of formula (III), A is
preferably selected
from
R I b R lb
HO.õ, ,0 _fit
fiCk,, ,_õ..0
I i i
R 34 / R 3.3 RI
R1e Ria R2a Ria
OH R lb OH R lb
1 1
.õ......13
R FOC
R2e Rib
R 3b R 1" R 3b fil''
46
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
R lb Rib
HO Ht:
µ Ri tt
13 ----\
0 I 0
\
. .
R1
, R a
' R30
R1 a R ' R 3a /410
,and .
[0066] In one embodiment of the compound of formula (III) as described herein,
R2a, R3a, R217
and R3" are independently selected from the group consisting of hydrogen,
halogen, and Ci-C3
alkyl. In one embodiment, IV, Lea, and Rib are independently selected from the
group consisting
of hydrogen, halogen, and Ci-C3 alkyl. In one embodiment, R1, Rla, and Rl" are
independently
selected from the group consisting of hydrogen and fluorine when R1, 12"
and/or Rl" is ortho
relative to the position where A is attached to nitrogen.
[0067] In one embodiment the compound according to the invention is selected
from the group
consisting of the following:
o 0
i-t2:4"" ...--,,-.=:::\ ..< ¨)
'a
N 1
F=iisr'''' N, ¨.¨..õ.......
[ \ 1..m=.)
=:*
,
(i'Lli 1 '
r,:l N
'
1*---'---, ..----.. -OH
--,.\
____________________ 01 C /
\
t*
0 f)
,....--
I 4.-
II N I
4, , .7'1 I
F8,...¨OH
I \
____________________ .0
a,
µ
47
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
o 9
11
/ _________________________________ 0
lizli -- N ' -1- - '-'_ ¨ -,-----=-=\
N maw* \
1
i
MN' k 4? _______________
ei,
-----...."'---
111
1.--.1.,. 'I" .õ.....-2-3'`,..,
µ k
,B, 0,
-0H
0 0
0 \
1-1214õkrN .....,,,L,,
N
NN
N
0
1 ---
1 \ti
\
0N
0 0
c)1 . .000 ti
/ )
..
!,lawoommei
..._..4 N
-"-.,-----,----t\l/ \ __
t=iti M
N
/\ ,
Si
\IL,
\/ I
B B
"ON
48
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
0 0
1$
...õ,õ.õ..r r----0,\
H2N' N I
/
WowNig.<
i?
ii
.7.------,-----.../
FRI
0 first
se
N ,
,
/
Ho
/==
i
N \
\
-"=-=,...., 7
\ 1
L-,... "------.0H
0 ,,,,--
-N
OH
/
õOH No B
N-N N-N
.....,..1 01111 0 B
,
..,,õ, JI.......
0
N N
H H
0 CI 0
NH2 NH2
00,.....N 0 ,,,,-- piKI
-- F
OH
140 0õ0H 010 5
N-N
B0
, and , N 1
5N
H H
0 Br 0
NH2 N H2
[0068] In one embodiment, the present invention provides for a compound
of formula (IV), (IVa), or (IVb), or a pharmaceutically acceptable salt or a
stereoisomer or a
tautomer thereof:
49
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
Xr '''=)Ka
R3 tzi
N
4
, \ / ef N...14
R
\ /0 R4.1
N-sss,
/ P - C AD
R4
[0069] (IV)
X2 ,X2
,="... "`",õ p,...,-
XS' )cl Xs NN'sX3
4N.,
<,,R1
e
rs3
rk
ii.
N N
t4
\ / - \
N.----e N N 0
P----s's i C:\,,' 0 R4 /
le / /
0 R4 ,
R4
(IVa) (IVb)
wherein:
Xi is selected from the group consisting of-O-, -N(R6)-, and -
C(R7)(R8)-;
X2 is selected from the group consisting of -0-, -N(R6)-, and -
C(R7)(R8)-, or
X2 comprises a bond between Xi and X3;
X3 is selected from the group consisting of -0-, -N(R6)-, and -
C(R7)(R8)-, except Xi and X2
cannot both be -0-, and X2 and X3 cannot both be -0-;
R1 is selected from the group consisting of hydrogen, halogen
(when X3 is -C(R7)(R8)),
hydroxy, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7
cycloalkyl(oxy), wherein
the last four members of the of the above-mentioned R1 group may optionally be
substituted independently of one another with one or more halogen;
R2 is selected from the group consisting of hydrogen, C1-6 alkyl,
C3-7 cycloalkyl, C1-6
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the
above-
mentioned R2 group may optionally be substituted independently of one another
with
one or more halogen;
each R3 is independently selected from the group consisting of hydrogen,
halogen (when Xi is -
C(R7)(R8)), C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7
cycloalkyl(oxy),
wherein the last four members of the above-mentioned R3 group may optionally
be
substituted independently of one another with one or more halogen;
each R4 is independently selected from the group consisting of hydrogen, C1-6
alkyl, C3-7
cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the above-
mentioned
members of each R4 group, except hydrogen, may optionally be substituted
independently of one another with one or more halogen;
A is selected from the group consisting of benzo[c][1,2]oxaborol-
1(3H)-ol, 3,4-dihydro-
lHbenzo[c][1,2]oxaborinin-1-ol, and 2H-benzo[e][1,2]oxaborinin-2-ol, or a
derivative
thereof, such as a moiety selected from any one of A1-A6:
RI 4
HO Rt4
HO
.,..X,
I Ai, 0./ 1
I A2,
A . ..
. ..
..;µ,/ kh. = . = R"
RI
12
1.71.
1 4
0 H R
R"
1 ..1 OH
1
2 0- ... ., ..õ..4
......,,õ)õ
R.I.
A3,
fe
' 2
k 1
N,,,..,
Ai,
n ..-.'''''''=,,,, ,...., . N,....,se,,,
R'''''''
A 1
1.2 I 1 12 tk.
51
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
RI4 R14
0
110 0.
As, or
A6*
0,2
R
R6 is selected from the group consisting of hydrogen, C1-6 alkyl,
C3-7 cycloalkyl, C1-6
alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3_7-cycloalkyl, -
(C1_3-
al ky l)-(C3-6-cycl alkyl), -(C2-3-alky(oxy)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-
(C3-6-
cycloalkyl), 4-7-membered heterocycloalkyl, -(CI-3-alkyl)-(4-7-membered
heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroaryl), wherein the
above-
mentioned members of the R6 group, except hydrogen, may optionally be
substituted
independently of one another by one or more substituents selected from the
group
consisting of C1-6 alkyl and halogen, except halogen may not be adjacent to a
heteroatom;
R7 and R8 are independently selected from the group consisting of hydrogen,
halogen, hydroxy, -
N(R9)(Rio), , _0(R11.) C1-6 alkyl, C3-7 cycloalkyl, C1-6
alkyl(oxy), C3-7 cycloalkyl(oxy), -
COO-C1-6 alkyl, -COO-C3-7-cycloalkyl, -(C1-3-alkyl)-(C3-6-cycloalkyl), -(C2-3-
alkyl(oxy)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6-cycloalkyl), 4-7-membered
heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -heteroaryl,
and -(C1-
3-alkyl)-(heteroaryl), wherein the last fifteen members of the above-mentioned
R7 and
R8 groups may optionally be substituted independently of one another by one or
more
substituents selected from the group consisting of halogen and hydroxy, and
wherein
R7 and R8 may be linked together to form a ring;
R9 and R19 are independently selected from the group consisting of hydrogen,
C1-6 alkyl, C3-7
cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7-
cycloalkyl, -(C1-3-alkyl)-(C3-6-cycloalkyl), -(C2-3-alkyoxyl)-(C2-6-alkyl), -
(C2-3-
alkyl(oxy)-(C3-6-cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-
7-
membered heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroary1);
wherein the
52
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
last fourteen members of the above-mentioned R9 and IV groups may optionally
be
substituted independently of one another by one or more halogen, or R9 and R1
may
be linked together to form a ring;
is selected from the group consisting of hydrogen, C1-6 alkyl, C3-7
cycloalkyl, C1-6
alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7-cycloalkyl, -(C1-
3-
al kyl)-(C3-6-cycloalkyl), -(C2-3-alkyoxyl)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-
(C3-6-
cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered
heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroary1), wherein the
last thirteen
members of the above-mentioned R11 group may optionally be substituted
independently of one another by one or more sub stituents selected from the
group
consisting of halogen and hydroxy, except that said optional substitution may
not be
geminal;
each 1(12 is independently selected from the group consisting of hydrogen,
halogen, C1-6 alkyl,
C3-7 cycloalkyl, 4-7-membered heterocycloalkyl, C1-6 alkyl(oxy), and C3-7
cycloalkyl(oxy), wherein the last four members of the above-mentioned R'2
group
may optionally be substituted independently of one another by one or more
sub stituents selected from the group consisting of halogen and hydroxy,
except when
R32 is adjacent to oxygen, R32 is not halogen, and two adjacent R32 may be
connected
to provide a fused cycloalkyl, such as cyclopropyl; and
R13 and R34 are independently selected from the group consisting of hydrogen,
halogen, cyano,
C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-
alkyl)-(C3-6-
cycloalkyl), -(C2-3-alkyl(oxy)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6-
cycloalkyl), 4-7-
membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -N-
(R6)(R6), -S02-(R6), -S02-(R6)(R6), -S(0)-(R6), and -S-(R6), wherein the last
fourteen
members of the above-mentioned R1-3 and R14 groups may optionally be
substituted
independently of one another by one or more sub stituents selected from the
group
consisting of halogen and hydroxy.
[0070] In one embodiment of the compound of formula (IV), (IVa), and (IVb) as
described
herein
53
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
[0071]
Xi is selected from the group consisting of -0-, -N(R6)-, and -
C(R7)(10-;
X2 is selected from the group consisting of -0-, -N(R6)-, and -
C(R7)(1e)-, or
X2 comprises a bond between Xi and X3;
X3 is -C(R7)(R8)-, except X1 and X2 cannot both be -0-;
121 is selected from the group consisting of hydrogen, C1-6 alkyl,
and C3-7 cycloalkyl, wherein
the last two members of the above-mentioned group may optionally be
substituted independently
of one another with one or more halogen;
R2 is selected from the group consisting of hydrogen, C1-6 alkyl,
and C3-7 cycloalkyl, wherein
the last two members of the above-mentioned R2 group may optionally be
substituted
independently of one another with one or more halogen;
each R3 is independently selected from the group consisting of hydrogen, Ci-6
alkyl, and C3-7
cycloalkyl, wherein the last two members of the above-mentioned R3 group may
optionally be
substituted independently of one another with one or more halogen;
each R4 is independently selected from the group consisting of hydrogen, C1-6
alkyl, and C3-7
cycloalkyl, wherein the last two members of the above-mentioned R4 group may
optionally be
substituted independently of one another with one or more halogen;
A is selected from the group consisting of benzo[c][1,2]oxaborol-
1(3H)-ol, 3,4-dihydro-
lHbenzo[c][1,2]oxaborinin-1-ol, and 2H-benzo[e][1,2]oxaborinin-2-ol, or a
derivative
thereof, such as a moiety selected from any one of A1-A6:
Ri4
HO
HO
R1
/4
0/
0
Al, 1
1
A2,
I
ptsze-=
RA,2
54
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
P14
14
0 H $4.
1 i, OH R
I
0---- ---------, - ----y----- .--- ).µ\-
-, A
412, i
i
...- -,
,
i=?.
,s.s.41
..( y A3, t 1
RI.2õ..--.712..,,,,, ..,---= '",,,,,,,,== fez
R =
'12 1
t
tV4
A4,
1
R R 4
H 0,,
...r3
1 I As, or
A6;
R- s=---"` \--
R.-
/
R6 is selected from the group consisting of hydrogen, C1-6 alkyl,
C3-7 cycloalkyl, C1-6
alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-CI-6 alkyl, -00O-C3-7-cycloalkyl, -(C1-
3-
alkyl)-(C3-6-cycloalkyl), -(C2-3-alky(oxy)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-
6-
cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered
heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroary1), wherein the
above-
mentioned members of the R6 group, except hydrogen, may optionally be
substituted
independently of one another by one or more substituents selected from the
group
consisting of C1-6 alkyl and halogen, except halogen may not be adjacent to a
heteroatom;
R7 and R8 are independently selected from the group consisting of hydrogen, -
C1-6 alkyl, C3-7
cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four
members of the
above-mentioned R7 and R8 groups may optionally be substituted independently
of one another
by one or more substituents selected from the group consisting of halogen and
hydroxy, and R7
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
and R8 may be linked together to form a ring;
R9 and Rl are independently selected from the group consisting of hydrogen,
C1-6 alkyl, C3-7
cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7-
cycloalkyl, -(C1-3-alkyl)-(C3-6-cycloalkyl), -(C2_3-alkyoxyl)-(C2-6-alkyl),
alkyl(oxy)-(C3-6-cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-
7-
membered heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroaryl);
wherein the
last fourteen members of the above-mentioned R9 and R" groups may optionally
be
substituted independently of one another by one or more halogen, or R9 and R"
may
be linked together to form a ring,
is selected from the group consisting of hydrogen, C1-6 alkyl, C3-7
cycloalkyl, C1-6
alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7-cycloalkyl, -(C1-
3-
alkyl)-(C3-6-cycloalkyl), -(C2-3-alkyoxyl)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-
6-
cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered
heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroaryl), wherein the
last thirteen
members of the above-mentioned R" group may optionally be substituted
independently of one another by one or more sub stituents selected from the
group
consisting of halogen and hydroxy, except that said optional substitution may
not be
geminal;
each R" is independently selected from the group consisting of hydrogen,
halogen, C1-6 alkyl,
C3-7 cycloalkyl, 4-7-membered heterocycloalkyl, C1-6 alkyl(oxy), and C3-7
cycloalkyl(oxy), wherein the last four members of the above-mentioned Ru group
may optionally be substituted independently of one another by one or more
substituents selected from the group consisting of halogen and hydroxy, except
when
R12 is adjacent to oxygen, R12 is not halogen, and two adjacent R12 may be
connected
to provide a fused cycloalkyl, such as cyclopropyl;
each R" is independently selected from the group consisting of hydrogen,
halogen, and Ci-
6a1ky1; and
each R" is independently selected from the group consisting of hydrogen,
halogen, cyano, C1-6
alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-alkyl)-
(C3-6-
cycloalkyl), -(C2-3-alkyl(oxy)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6-
cycloalkyl), 4-7-
membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -N-
56
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
(R6)(R6), -S02-(R6), -S02-(R6)(R6), -S(0)-(R6), and -S-(R6), wherein the last
fourteen
members of the above-mentioned RIA group may optionally be substituted
independently of one another by one or more sub stituents selected from the
group
consisting of halogen and hydroxy.
[0072] In one embodiment of the compound of formula (IV), (IVa), and (IV)b as
described
herein
X1 is selected from the group consisting of -0-, -N(R6)-, and -
C(R7)(1e)-;
X2 is selected from the group consisting of -0- and -C(R7)(R8)-,
except Xi and X2 may not
both be -0-, or X2 comprises a bond between Xi and X3,
X3 is -C(R7)(R8)-,
is selected from the group consisting of hydrogen and C1-6 alkyl;
R2 is selected from the group consisting of hydrogen and C1-6
alkyl;
each R3 is independently selected from the group consisting of hydrogen and C1-
6 alkyl;
each R4 is independently selected from the group consisting of hydrogen and C1-
6 alkyl;
A is selected from the group consisting of benzo[c][1,2]oxaborol-
1(3H)-ol, 3,4-dihydro-
lHbenzo[c][1,2]oxaborinin-1-ol, and 2H-benzo[e][1,2]oxaborinin-2-ol, or a
derivative
thereof, such as a moiety selected from any one of Ai-A6:
ize4
HO RE4
Hp
J? \
r
0
Ai, 0
A2,
Rrz/
2
57
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
OH P14
0---- ------;---- -----y 1--------ye3
õ..,
12 ....-^' .--="".- ''''N'' ---
,s.s.41
..( A R ,
tz 7 j2
12 ,...--." ---= '"=,,,
,...--== tZ
R =
1 2 .õ,---=
t
e
A4,
14
R R
I
1-10-,
1.-= - MD. 0
,.....,,õ.,õ , ....
LIAs, or
A6;
õ. 44,
R ' R ' =----` \--R.-
/
k
R6 is selected from the group consisting of hydrogen, C1-6 alkyl,
C3-7 cycloalkyl, C1-6
alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7-cycloalkyl, -(C1-
3-alkyl)-(C3-6-
cycloalkyl), -(C2-3-alky(oxy)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6-
cycloalkyl), 4-7-membered
heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -heteroaryl,
and -(C1-3-alkyl)-
(heteroary1), wherein the above-mentioned members of the R6 group, except
hydrogen, may
optionally be substituted independently of one another by one or more
substituents selected from
the group consisting of C1-6 alkyl and halogen, except halogen may not be
adjacent to a
heteroatom;
R7 and R8 are independently selected from the group consisting of hydrogen and
C1-6 alkyl,
wherein the C1-6 alkyl may optionally be substituted with one or more of
halogen;
R9 and R16 are independently selected from the group consisting of hydrogen,
C1-6 alkyl, C3-7
cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7-
cycloalkyl, -(Ci-3-
alkyl)-(C3-o-cycloalkyl), -(C2-3-alkyoxyl)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-
6-cycloalkyl), 4-7-
membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -
heteroaryl, and -
(CI-3-alkyl)-(heteroaryl); wherein the last fourteen members of the above-
mentioned R9 and RH'
58
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
groups may optionally be substituted independently of one another by one or
more halogen, or
R9 and R1 may be linked together to form a ring;
R11 is selected from the group consisting of hydrogen, C1-6 alkyl,
C3-7 cycloalkyl, C1-6
alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7-cycloalkyl, -(Ci -
3-alkyl)-(C3-6-
cycloalkyl), -(C2-1-alkyoxyl)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6-
cycloalkyl), 4-7-membered
heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -heteroaryl,
and -(C1-3-alkyl)-
(heteroaryl), wherein the last thirteen members of the above-mentioned R"
group may optionally
be substituted independently of one another by one or more substituents
selected from the group
consisting of halogen and hydroxy, except that said optional substitution may
not be geminal,
each R12
is independently selected from the group consisting of hydrogen, halogen,
C1-6
alkyl, C3-7 cycloalkyl, 4-7-membered heterocycloalkyl, C1-6 alkyl(oxy), and C3-
7 cycloalkyl(oxy),
wherein the last four members of the above-mentioned R12 group may optionally
be substituted
independently of one another by one or more substituents selected from the
group consisting of
halogen and hydroxy, except when R12 is adjacent to oxygen, R12 is not
halogen, and two
adjacent R12 may be connected to provide a fused cycloalkyl, such as
cyclopropyl;
R13 is hydrogen, and
each R" is independently selected from the group consisting of hydrogen,
halogen, cyano, C1-6
alkyl, C3-7 cycloalkyl , C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-alkyl)-
(C3-6-cycloalkyl), -(C2-
3-alkyl(oxy)-(C2-6-alkyl), and 4-7-membered heterocycloalkyl, wherein the last
seven members
of the above-mentioned R" group may optionally be substituted independently of
one another
by one or more substituents selected from the group consisting of halogen and
hydroxy.
[0073] In yet another embodiment of the compound of formula (IV), (IVa), and
(IVb) as
described herein
Xi is selected from the group consisting of-O-, -N(R6)-, and -
C(R7)(R8)-;
X2 is selected from the group consisting of -0- and -C(R7)(R8)-,
except Xi and X2 may not
both be -0-, or X2 comprises a bond between Xi and X3;
X3 is -C(R7)(R8)-;
141 is selected from the group consisting of hydrogen and C1-6
alkyl;
R2 is selected from the group consisting of hydrogen and C1-6
alkyl;
each R3 is independently selected from the group consisting of hydrogen and C1-
6 alkyl,
each R4 is independently selected from the group consisting of hydrogen and C1-
6 alkyl,
59
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
A is selected from the group consisting of benzo[c][1,2]oxaborol-
1(3H)-ol, 3,4-dihydro-
lHbenzo[c][1,2]oxaborinin-1-ol, and 2H-benzo[e][1,2]oxaborinin-2-ol, or a
derivative
thereof, such as a moiety selected from any one of A1-A6:
Ri 4
HO R14
HP 1
8
0 /
Ai, 0
1 1
A2,
= .,,,,,, ...,,,i,,,,
\
..".=-,, ,,,,,-- ii 1
2
RI 1 4
OH R
1 Q11
I R:44.
12
R 42
Ai R
A4
34
1
A4,
iil 12 iz 414
k`
km
R14
.,õ,3,....õ ....., .2.,....õõ.õ,....õ I As, or '''\-13."-.
'''',....,-;",--' s'''=,,."-"' =
1
R12,...--..,_,....., = ,..."'"--
,,,,Fcõ, A6;
R2,,...., --, k-m..õ,,,,,- --1
1,2 ,..--'
f-A r
R.
R6 is selected from the group consisting of hydrogen, C1-6 alkyl,
C3-7 cycloalkyl, C1-6
alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-2-cycloalkyl, -(C1-
3-
alkyl)-(C3-6-cycloalkyl), -(C2-3-alky(oxy)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-
6-
cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered
heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroary1), wherein the
above-
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
mentioned members of the R6 group, except hydrogen, may optionally be
substituted
independently of one another by one or more substituents selected from the
group
consisting of C1-6 alkyl and halogen, except halogen may not be adjacent to a
heteroatom;
R7 and R8 are independently selected from the group consisting of hydrogen and
C1-6 alkyl,
wherein the C1-6 alkyl may optionally be substituted with one or more of
halogen;
R9 and R1 are independently selected from the group consisting of hydrogen,
C1-6 alkyl, C3-7
cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7-
cycloalkyl, -(CI-3-
alkyl)-(C3-6-cycloalkyl), -(C2-3-alkyoxyl)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-
6-cycloalkyl), 4-7-
membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -
heteroaryl, and -
(C1-3-alkyl)-(heteroaryl); wherein the last fourteen members of the above-
mentioned R9 and R1
groups may optionally be substituted independently of one another by one or
more halogen, or
R9 and R1 may be linked together to form a ring;
Rti is selected from the group consisting of hydrogen, C1-6 alkyl,
C3-7 cycloalkyl, C1-6
alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-CI-6 alkyl, -COO-C3-7-cycloalkyl, -(CI-
3-alkyl)-(C3-6-
cycloalkyl), -(C2-3-alkyoxyl)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6-
cycloalkyl), 4-7-membered
heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -heteroaryl,
and -(C1-3-alkyl)-
(heteroary1), wherein the last thirteen members of the above-mentioned RH
group may optionally
be substituted independently of one another by one or more substituents
selected from the group
consisting of halogen and hydroxy, except that said optional substitution may
not be geminal;
each R12
is independently selected from the group consisting of hydrogen, halogen,
C1-6
alkyl, C3-7 cycloalkyl, 4-7-membered heterocycloalkyl, C1-6 alkyl(oxy), and C3-
7 cycloalkyl(oxy),
wherein the last four members of the above-mentioned 1412 group may optionally
be substituted
independently of one another by one or more substituents selected from the
group consisting of
halogen and hydroxy, except when R12 is adjacent to oxygen, R12 is not
halogen, and two
adjacent R12 may be connected to provide a fused cycloalkyl, such as
cyclopropyl;
R13 is hydrogen, and
each R" is independently selected from the group consisting of hydrogen,
halogen, cyano, C1-6
alkyl, C3-7 cycloalkyl , C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-alkyl)-
(C3-6-cycloalkyl), -(C2-
3-alkyl(oxy)-(C2-6-alkyl), and 4-7-membered heterocycloalkyl, wherein the last
seven members
of the above-mentioned R14 group may optionally be substituted independently
of one another
61
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
by one or more substituents selected from the group consisting of halogen and
hydroxy.
[0074] In one embodiment of the compound of formula (IV), (IVa), and (IV)b as
described
herein
Xi is selected from the group consisting of-O-, -N(R6)-, and -
C(R7)(1e)-;
X2 is -C(R7)(R8)-;
X3 is -C(R7)(R8)-;
RI-, R2, R3, and R4 are hydrogen;
A is selected from the group consisting of benzo[e][1,2]oxaborol-
1(3H)-ol, 3,4-dihydro-
lHbenzo[e][1,2]oxaborinin-1-ol, and 2H-benzo[e][1,2]oxaborinin-2-ol, or a
derivative
thereof, such as a moiety selected from any one of Ai-A6:
11;4
HO R'4
NO
1 fµ.$ .. J\R14
A \
,,IN
e..,--"*. \
/ / :---' ,---.'
s=
i, 0
1 1 Az
0\\Ii1T
',,,,,, s4,
A
R i2 la/ k
il R .17.,..= s
k 1
4
OH R 1.4
i
L, ,õ OH
I
,6 R' lis
R 2 2
-,....., 1
A3, Pt..
A4,
"... 1
1
R32
3
ltA 12 An
62
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
RI4 R14
0,
I-10 0.
1
As, or A6*
2.
0,2
R
F4,
R6 is selected from the group consisting of hydrogen, C1-6 alkyl,
C3-7 cycloalkyl, C1-6
alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7-cycloalkyl, -(C1-
3-
alkyl)-(C3-6-cycloalkyl), -(C2-3-alky(oxy)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-
6-
cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered
heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroary1), wherein the
above-
mentioned members of the R6 group, except hydrogen, may optionally be
substituted
independently of one another by one or more substituents selected from the
group
consisting of C1-6 alkyl and halogen, except halogen may not be adjacent to a
heteroatom;
R7 and R8 are independently selected from the group consisting of hydrogen and
C1-6 alkyl,
wherein C1-6 alkyl may optionally be substituted with one or more of halogen;
R9 and R" are independently selected from the group consisting of hydrogen, C1-
6 alkyl, C3-7
cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7-
cycloalkyl, -(C1-3-alkyl)-(C3-6-cycloalkyl), -(C2-3-alkyoxyl)-(C2-6-alkyl), -
(C2-3-
alkyl(oxy)-(C3-6-cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-
7-
membered heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroary1);
wherein the
last fourteen members of the above-mentioned R9 and Rth groups may optionally
be
substituted independently of one another by one or more halogen, or R9 and R"
may
be linked together to form a ring;
RH is selected from the group consisting of hydrogen, C1-6 alkyl, C3-7
cycloalkyl, C1-6
alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7-cycloalkyl, -(C1-
3-
alkyl)-(C3-6-cycloalkyl), -(C2-3-alkyoxyl)-(C26-alkyl), -(C2-3-alkyhoxy)-(C3-6-
63
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered
heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroary1), wherein the
last thirteen
members of the above-mentioned R" group may optionally be substituted
independently of one another by one or more sub stituents selected from the
group
consisting of halogen and hydroxy, except that said optional substitution may
not be
geminal;
each R12 is independently selected from the group consisting of hydrogen,
halogen, C1-6 alkyl,
and C3-7 cycloalkyl, wherein the last two substituents may optionally be
substituted
independently of one another by one or more halogen,
R13 is hydrogen; and
each R14 is independently selected from the group consisting of hydrogen,
halogen, cyano, C1-6
alkyl, C3-7 cycloalkyl, and C1-6 alkyl(oxy), wherein the last three members of
the
above-mentioned R14 group may optionally be substituted independently of one
another by one or more halogen.
[0075] In one embodiment of the compound of formula (IV), (IVa), and (IVb) as
described
herein
Xi is selected from the group consisting of -0-, -N(R6)-, and -
C(R7)(R8)-;
X2 is -C(R7)(R8)-,
X3 is -C(R7)(R8)-;
R1, R2, R3, and R4 are hydrogen;
A is selected from the group consisting of benzo[c][1,2]oxaborol-
1(3H)-ol, 3,4-dihydro-
lHbenzo[c][1,2]oxaborinin-1-ol, and 2H-benzo[e][1,2]oxaborinin-2-ol, or a
derivative
thereof, such as a moiety selected from any one of A1-A6:
HO
HO
R14
k IR' 3
8
0
/8
A2,
0
Ft12
T:
64
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
OH P14
0,-- -----------^ - ---
,
412,
^ .--1--y3
L..i A R j2\:.,,
t 1
12 ,...--e". ....---"
".=,,,I,...--- fez
R =
12 IT
tV4
A4,
4.
k R1
I
1-10-,
.-=1 MD. 0 , N,
LI As, or
A6;
i -,..._ 12 .,õ.=-= ....
'''''',.. \ -:',
R -- R - ,----=- -
"R. =
i
k
R6 is selected from the group consisting of hydrogen, C1-6 alkyl,
C3-7 cycloalkyl, C1-6
alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7-cycloalkyl, -(C1-
3-
alkyl)-(C3-6-cycloalkyl), -(C2-3-alky(oxy)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-
6-
cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered
heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroary1), wherein the
above-
mentioned members of the R6 group, except hydrogen, may optionally be
substituted
independently of one another by one or more sub stituents selected from the
group
consisting of C1-6 alkyl and halogen, except halogen may not be adjacent to a
heteroatom;
R7 and R8 are independently selected from the group consisting of hydrogen and
C1-6 alkyl,
wherein C1-6 alkyl may optionally be substituted with one or more of halogen;
R9 and R" are independently selected from the group consisting of hydrogen, C1-
6 alkyl, C3-7
cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7-
cycloalkyl, -(C1-3-alkyl)-(C3-6-cycloalkyl), -(C2-3-alkyoxyl)-(C2-6-alkyl), -
(C2-3-
alkyl(oxy)-(C3-6-cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-
7-
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
membered heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroary1);
wherein the
last fourteen members of the above-mentioned R9 and Rl groups may optionally
be
substituted independently of one another by one or more halogen, or R9 and R1
may
be linked together to form a ring;
R11 is selected from the group consisting of hydrogen, C1-6
alkyl, C1-7 cycloalkyl, C1-6
al kyl(oxy), C3-7 cycloalkyl (oxy), -COO-Ci-6 alkyl, -COO-C3-7-cycloalkyl , -
(C1-3-
alkyl)-(C3-6-cycloalkyl), -(C2-3-alkyoxyl)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-
o-
cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered
heteroeyeloalkyl), -heteroaryl, and -(C1-3 -alkyl)-(heteroaryl), wherein the
last thirteen
members of the above-mentioned Rilgroup may optionally be substituted
independently of one another by one or more sub stituents selected from the
group
consisting of halogen and hydroxy, except that said optional substitution may
not be
geminal;
each R12 is independently selected from the group consisting of hydrogen,
halogen, C1-6 alkyl,
and C3-7 cycloalkyl, wherein the last two substituents may optionally be
substituted
independently of one another by one or more halogen;
1213 is hydrogen; and
each R14 is independently selected from the group consisting of hydrogen,
halogen, cyano, C1-6
alkyl, C3-7 cycloalkyl, and C1-6 alkyl(oxy), wherein the last three members of
the
above-mentioned R14 group may optionally be substituted independently of one
another by one or more halogen.
[0076] In one embodiment of the compound of formula (IV), (IVa), and (IV)b as
described
herein
Xi is selected from the group consisting of-O-, -N(R6)-, and -
C(R7)(R8)-;
X2 is -C(R7)(R8)-;
X3 is -C(R7)(R8)-;
RI-, R2, R3, and R4 are hydrogen;
A is selected from the group consisting of benzo[c][1,2]oxaborol-
1(3H)-ol, 3,4-dihydro-
lHbenzo[c][1,2]oxaborinin-1-ol, and 2H-benzo[e][1,2]oxaborinin-2-ol, or a
derivative
thereof, such as a moiety selected from any one of A1-A6:
66
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
HO R14
k H 0 1
ia
µh 1
P
I Ai, 0/
1 I
A2,
``,.....
12/
13 R tin
11
1412 OH R
1 i 11 OH
I R to
0,---
I
n12 -
A3, ". N.N. 1
A4,
12 -,' ,,,,,' ..,¨=-, õ...,--. N'Ne'''''''''
" rs
4,1
14
12
4 3
rii 4 Ri 4
HO .,.... 0
'---- ' --:.:---:¨'- .,.----'
I As, or
[ , ...,... 1.
A6;
f 2 [
R13 /
R -
R7 and R8 are independently selected from the group consisting of hydrogen and
C1-6 alkyl,
wherein C1-6 alkyl may optionally be substituted with one or more of halogen;
R9 and R1 are independently selected from the group consisting of hydrogen,
C1-6 alkyl, C3-7
cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7-
cycloalkyl, -(C1-3-alkyl)-(C3-6-cycloalkyl), -(C2-3-alkyoxyl)-(C2-6-alkyl), -
(C2-3-
alkyl(oxy)-(C3-6-cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-
7-
membered heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroary1);
wherein the
last fourteen members of the above-mentioned R9 and RI groups may optionally
be
67
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
substituted independently of one another by one or more halogen, or R9 and R1
may
be linked together to form a ring;
Rii is selected from the group consisting of hydrogen, C1-6
alkyl, C3-7 cycloalkyl, C1-6
alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7-cycloalkyl, -(C1-
3-
alkyl)-(C3-6-cycloalkyl), -(C2-3-alkyoxyl)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-
6-
cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered
heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroary1), wherein the
last thirteen
members of the above-mentioned RH group may optionally be substituted
independently of one another by one or more sub stituents selected from the
group
consisting of halogen and hydroxy, except that said optional substitution may
not be
geminal;
each R12 is independently selected from the group consisting of hydrogen,
halogen, C1-6 alkyl,
and C3-7 cycloalkyl, wherein the last two substituents may optionally be
substituted
independently of one another by one or more halogen;
R'3 is hydrogen; and
each R" is independently selected from the group consisting of hydrogen,
halogen, cyano, C1-6
alkyl, C3-7 cycloalkyl, and C1-6 alkyl(oxy), wherein the last three members of
the
above-mentioned R14 group may optionally be substituted independently of one
another by one or more halogen.
[0077] In one embodiment the compound according to the invention is a compound
selected
from the group consisting of Examples 1-57 as shown below:
Example Example
Structure Structure
Number Number
2
0
AL
HN' N ,e HN F -
-N.' ---\--1,.= '''.
1 1 NC 2 NC
F = 'µ.8-011 0
¨ oh
68
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
')/'-'\\,õµ,., 0 ,,P-'*\
\...._/- CN \..._ .
N-N .,4-..." = . 0.,s..õ011 N-t,4
,,...,.. .. .0,111,0H
4
m. . ....,,...,
O''''''' H
NII: NH
et¨N=
'.\., t-Cisi 0 s=
\.,, _,,,=>--ON
--A,
N-N ,.....-..-.., = ,.õ0OH
N-N ==,-,\?z-
--ti\,,
6
0 .NH
Uµ.___
-----N OH
NN ._:::::yIIs-Mil
7 = ==\ .31,, 1.,,,..., 1. 3 8 cak 11
...---=
.4.,=.--)
N'''.- -''''''''''NN'.. r N -
\-
11 H
0- = a.:--.5\:NH,,
NH..
= ,,,
\sõ,..<== CN 1-õ,,,,,
k
N-N ,..."%= µ -N .1
4
9 ).),, .,1il_ P io
,LI.I., _ .-- P
N . = 8 -4
611
0:04\ " etti 01-
.11Hz NH-,
kiL.s,,.)¨Ctki
\
OH
N.- N ..õ..---):::3:=: N -N 1-1.---\---13:,
11 <,,,..,..)=L ,sti,,,,,. f,õ 12
0=J, II w- --,
1 II. .='
..
iv. N11,
...,..._
ci
osi c,
\,_,...< F.
pi -N 6.;:.. 0,11.,011 N-N ,,,..õ-K,
,Cku..,01-1
13 =N 11, ,L,,,õ 1. ,,J 14
N...,,, .:.,. \r,
N.14...--kz.õ...õ.õ. ... = ..4.,.:0- =
0 ..NH.> 0'. "
'NH
-,.
69
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
NHz.
N-N ----' s .B-.
15 ji, 1 16 1 NC
H (11\s
O''* = = ..,. . ti
N Hz = -
C) \---CN
1 r4:7
7 ., . ,,, -=NN I \,õ ..-.) 18
It -1.....A.,.,,,. ...,-)õ,.....õ-
.)
NH .,
-1k
19 N -N 20
21 it
H ti
ao'NNI1 0' to..ii
./----N
21 S k =
22 ,Ici,r- '''=- N...--...se' -' (231 LI,
0-- N1-:% ,
;
/... 0 ,....-,
\
=i. ,.. - - CS
-...,µ
0 s
OH
117 OH
NC' 14. s=N r-,..z.r:, i ,4,--
23 µ .,1,L. 1, .,..,,,1 24
..,N,,,,,,-- -115.% - \
2 11.' 1 0
to, A
0 . NI-6
II 0_ OH
i
S
/ 1 ''' } y-k- 26
' \ '''.14 '''s "\ -=µ -
\\f
Fi
,
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
02_
\, CN 01¨\
1--Cli .. c F3
27 S.,=11, ,,,L, ,L. J 28
01' H
siNN19.2 = . 11
N1.4.,
Q
/-..õ-,
\)--CN
µµ. )
N,N F....:-..:.--"'s.v....Ø14,0H NCI -
29 4 11, J...,,,,..1,L..) 30
'i-- ,N ---- ----
coo-NNH,
,
õ,..." \
CL >---- CN ,.,.....,,
----\ N()'..'LC
?I -N r-,.., 0,6
31 4., ,,,L-N, 1 ,41 32
iLN
0k
NH 0=:-- N H ,.,
\,,....<1.-CN
NC' -
. N ,-N r....... OOH
33 / =
1
CN k)
0 OH
35 ,..)-1\ =\ 1 j 36 _.ms*---Nr14
y ill
= ==,----<:> 9ti
\.._?---c14 .
P OH
38 14 -14 .---
õ v=
=)-1,..= -,k,,, ' =P 4... It
.IN b
H . N112
,-
71
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
Nt,
_,./ \
.. .00H N-N ::-1.=µ' Iy
1.4
39 40 k Li
0'=X-
H H
=
p
H2N-Ax----\
: N
41 1 NC
42
Oh
'NH2:
.., ,
µ).--CN 0
\ \s_1---C14
-,,s1 . F
N. ---N
44 W-N
V\Isil'1' e) SAirsrlk) ,,,--)
J\ H ot 4
Nt o---\NIIH
L<
34-N e --0-13.-OH Ntki. ,,,N -
N,,,Trnr..0,9,011
45 'õ11,1,,,,,, 1 ,,,.j.,,,, 46 i 11.
1,..."*.1,,,,d
_ mt, Cr-WH
0 ,
1--CN
---A 0.\__\)---
CH
14- \ .11 K.,-,-- 0,13...-011 N-
N ..-----)r%Pli
47 L, kisr-, I .,-) 48
ti =-=
r
0 _.. cr-A.
Ni Nil.
72
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
L
rai \......4
\
N-N 50 rXi '.8-- "
49 Sik, 1 ,
Yls,tel,=,,,,,,i1..õz," -- N , \,,,..
.µ,..,- ,......-
H 1J ....,,, Crsktlft- NM,
.:: ..
NH,
'
/----.0µ
ttr-N-s-CN
iliN',4NP-V,1
'. I.
51 IN, )
lid
--$:-'''L1 l 52
\ IN, sjk\J'L.P
N --
( '\ NS 0' tizli
8-.
t
OH
0 \ 0 s
0CF2.
40 53 54 e i iz I
Cr 1\11i-- NH-
;
../-
0 7õ...cs ';'-",' UN1--CN
1
55 es.. il ... A 56
H
C' \---CN
\-...., /
57
t N ,
[0078] In one embodiment, the compound according to the invention is selected
from the group
consisting of Examples 1-57 and has trans relative stereochemistry as
represented in formula
(IVa) and (IVb):
73
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
X2 X2
Xi X3 Xi X3
R R R3
R3
IN 2
N \ N
..s;N
R4
R4
A A
\ / \ /
R4/
0 R4 R4/
0 R4
(IVa) and
(IVb).
[0079] In one embodiment, the compound according to the invention is selected
from the group
consisting of Examples 1-57 and has trans relative stereochemistry as
represented in formula
(IVb).
Definitions
[0080] Terms used herein will have their customary meaning in the art unless
specified
otherwise. The organic moieties mentioned in the definitions of the variables
of the compound of
formula (I), formula II, formula (III), formula (IV), (IVa), and (IVb) are -
like the term halogen ¨
collective terms for individual listings of the individual group members. The
prefix Cn-Cm (or
Cn-m) indicates, in each case, the possible number of carbon atoms in the
group.
[0081] The term "animal" as used herein includes all mammals, birds and fish
and also includes
all vertebrate animals. Animals include, but are not limited to, cats, dogs,
cattle, chickens, cows,
deer, goats, horses, llamas, pigs, sheep and yaks. It also includes an
individual animal in all
stages of development, including embryonic and fetal stages. In some
embodiments, the animal
will be a non-human animal.
[0082] By the term "enriched" is meant when the weight:weight ratio is at
least approximately
1.05 or higher in favor of the enantiomer that displays significant in vitro
and in vivo activity
(the eutomer).
[0083] In one embodiment, the compounds of the instant invention are selective
INK I inhibitors
relative to SAK 2. The determination of relative selectivity for a given
compound of AK I
74
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
inhibition is defined as the relative ratio of the (JAK2 EC5o value/JA.K1
EC:5o value). In one
embodiment, for a given compound, the relative ratio of the (JAK2 IC5o
value/JAM IC5o value)
is at least 2. In yet another embodiment, for a given compound, the relative
ratios of the JAK2
1C5o valueLiAKI 1C5o value) is at least 5. in another embodiment, the relative
ratios of the JAK2
1C501.IAKI IC5o are preferably at least 1Ø in one embodiment the ratios of
the JAK2 I.C.,WJAK1
1C,i0 are greater than 10.
[0084] The term "treatment" or "treating" includes alleviating, ameliorating,
relieving or
otherwise reducing the signs and symptoms associated with a disease or
disorder.
[0085] "Therapeutically effective amount" means that amount of a drug or
pharmaceutical agent
that will elicit the biological or medical response of a tissue, a system,
animal or human that is
being sought by a researcher, veterinarian, medical doctor or other clinician.
[0086] The term "composition", as in pharmaceutical composition, is intended
to encompass a
product comprising the active ingredient(s), and the inert ingredient(s)
(pharmaceutically acceptable excipients) that make up the carrier, as well as
any product which
results, directly or indirectly, from combination, complexation or aggregation
of any two or more
of the ingredients, or from dissociation of one or more of the ingredients, or
from other types of
reactions or interactions of one or more of the ingredients. Accordingly, the
pharmaceutical
compositions of the present invention encompass any composition made by
admixing a
compound of formula I, formula II, formula (III), formula (IV), (IVa), and
(IVb) or a mixture
thereof, and pharmaceutically acceptable excipients.
[0087] The term "optionally substituted" means "unsubstituted or substituted,"
and therefore, the
generic structural formulas described herein encompasses compounds containing
the specified
optional substituent as well as compounds that do not contain the optional
substituent.
[0088] When referring to the compounds disclosed herein, the following terms
have the
following meanings unless indicated otherwise. The following definitions are
meant to clarify,
but not limit, the terms defined. If a particular term used herein is not
specifically defined, such
term should not be considered indefinite. Rather, terms are used within their
accepted meanings.
[0089] As used herein, "alkyl" refers to monovalent saturated aliphatic
hydrocarbon groups
having from 1 to 20 carbon atoms, preferably 1-8 carbon atoms, preferably 1-6
carbon atoms.
The hydrocarbon chain may be either straight-chained or branched. Illustrative
alkyl groups
include methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, and tert-
butyl. Similarly, an
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
"alkenyl" group refers to an alkyl group having one or more double bonds
present in the chain,
and an "alkynyl" group refers to an alkyl group having one or more triple
bonds present in the
chain.
[0090] As used herein -halogen" or "halo" refers to a halogen. In some
embodiments, the
halogen is preferably Br, Cl, or F.
[0091] As used herein, "haloalkyl" refers to monovalent saturated aliphatic
hydrocarbon groups
having from 1 to 20 carbon atoms, preferably 1-8 carbon atoms, preferably 1-6
carbon atoms,
wherein at least one hydrogen atom is substituted by a halogen, including but
not limited to
perhalo groups where all hydrogen atoms are replaced with halogen atoms. The
haloalkyl chain
can be either straight-chained or branched. Illustrative alkyl groups include
trifluoromethyl,
trifluoroethyl, trifluoropropyl, trifluorobutyl, and pentafluoroethyl.
Similarly, a "haloalkenyl"
group refers to a haloalkyl group having one or more double bonds present in
the chain, and a
"haloalkynyl" group refers to a haloalkyl group having one or more triple
bonds present in the
chain.
[0092] Moreover, an "alkylene" linker group refers to a divalent alkyl group,
namely (CH2)x,
where x is 1 to 20, preferably 1 to 8, preferably 1 to 6, and more preferably
1 to 3.
[0093] As used herein, "hydroxyalkyl" refers to an alkyl group as herein
defined substituted with
one or more ¨OH group. Similarly, a "hydroxyalkenyl" group refers to a
haloalkyl group having
one or more double bonds present in the chain, and a "hydroxyalkynyl" group
refers to a
haloalkyl group having one or more triple bonds present in the chain.
[0094] As used herein, "aryl- refers to a substituted or unsubstituted
carbocyclic aromatic ring
system, either pendent or fused, such as phenyl, naphthyl, anthracenyl,
phenanthryl,
tetrahydronaphthyl, indane, or biphenyl. A preferred aryl group is phenyl.
[0095] As used herein, "cycloalkyl" refers to an unsaturated or partially
saturated hydrocarbon
ring, containing from 3 to 15 ring atoms. Illustrative cycloalkyl groups
include cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, as well as partially saturated versions
thereof, such as
cyclohexenyl, and cyclohexadienyl. Moreover, bridged rings, such as
adamantane, are included
within the definition of "cycloalkyl."
[0096] As used herein, the term "heterocycly1" refers to an unsaturated or
partially saturated
hydrocarbon ring, containing from 3 to 15 ring atoms, wherein one or more
carbon atom is
replaced with a heteroatom selected from 0, N, S, or Si, where each N, S, or
Si may be oxidized,
76
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
and where each N may be quarternized. A heterocyclyl group may be attached to
the remainder
of the molecule through a heteroatom. Heterocyclyl does not include
heteroaryl.
[0097] As used herein, the term "heteroaryl" or "heteroaromatic" refers to
aromatic ring groups
having 5 to 14 ring atoms selected from carbon and at least one (typically 1-
4, more typically 1
or 2) heteroatom (e.g., oxygen, nitrogen, sulfur, or silicon). They include
monocyclic rings and
polycyclic rings in which a monocyclic heteroaromatic ring is fused to one or
more other
carbocyclic aromatic or heteroaromatic rings. Examples of monocyclic
heteroaryl groups include
furanyl (e.g., 2-furanyl, 3-furanyl), imidazolyl (e.g., N-imidazolyl, 2-
imidazolyl, 4-imidazolyl, 5-
imidazolyl), isoxazolyl (e.g., 3-isoxazolyl, 4-isoxazolyl, 5-isoxazoly1),
oxadiazolyl (e.g., 2-
oxadiazolyl, 5-oxadiazoly1), oxazolyl (e.g., 2-oxazolyl, 4-oxazolyl, 5-
oxazoly1), pyrazolyl (e.g.,
3-pyrazolyl, 4-pyrazoly1), pyrrolyl (e.g., 1-pyrrolyl, 2-pyrrolyl, 3-
pyrroly1), pyridyl (e.g., 2-
pyridyl, 3-pyridyl, 4-pyridy1), pyrimidinyl (e.g., 2-pyrimidinyl, 4-
pyrimidinyl, 5-pyrimidinyl),
pyridazinyl (e.g., 3-pyridazinyl), thiazolyl (e.g., 2-thiazolyl, 4-thiazolyl,
5-thiazoly1), triazolyl
(e.g., 2-triazolyl, 5-triazoly1), tetrazolyl (e.g., tetrazoly1) and thienyl
(e.g., 2-thienyl, 3-thienyl.
Examples of monocyclic six-membered nitrogen-containing heteroaryl groups
include
pyrimidinyl, pyridinyl and pyridazinyl. Examples of polycyclic aromatic
heteroaryl groups
include carbazolyl, benzimidazolyl, benzothienyl, benzofuranyl, indolyl,
quinolinyl,
benzotriazolyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, isoquinolinyl,
indolyl, isoindolyl,
acridinyl, or benzisoxazolyl.
[0098] The terms "arylalkyl," "heteroarylalkyl," and "heterocyclylalkyl"
refers to those radicals
in which an aryl, heteroaryl, or heterocyclyl group is linked through an alkyl
group. Examples
includes benzyl, phenethyl, pyridylmethyl, and the like. The terms also
include alkyl linking
groups in which a carbon atom, for example, a methylene group, has been
replaced by, for
example, an oxygen atom. Examples include phenoxymethyl, pyrid-2-yloxymethyl,
3-(naphth-
l-yloxy)propyl, and the like. Similarly, the term "benzyl" as used herein is a
radical in which a
phenyl group is attached to a CH2 group, thus, a CH2Ph group. Benzyl groups
may be
substituted or unsubstituted. The term substituted benzyl refers to radicals
in which the phenyl
group or CH2 contains one or more sub stituents. In one embodiment, the phenyl
group may have
1 to 5 substituents, or in another embodiment 2 to 3 substituents.
[0099] As used herein "optionally substituted" refers to a substitution of a
hydrogen atom, which
would otherwise be present for the substituent. When discussing ring systems,
the optional
77
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
substitution is typically with 1, 2, or 3 substituents replacing the normally-
present hydrogen.
When referencing straight and branched moieties, however, the number of
substitutions may be
more, occurring wherever hydrogen is present. The substitutions may be the
same or different.
[0100] Illustrative substituents, which with multiple substituents can be the
same or different,
include halogen, haloalkyl, R', OR', OH, SH, SR, NO2, CN, C(0)R, C(0)(alkyl
substituted with
one or more of halogen, haloalkyl, NH2, OH, SH, CN, and NO2), C(0)0W, OC(0)W,
CON(R)2,
OC(0)N(R')2, NH2, NHR', N(R')2, NHCOR', NHCOH, NHCONH2, NHCONHR', NHCON(R')2,
NRCOR', NRCOH, NHCO2H, NHCO2R, NHC(S)NH2, NHC(S)NHRI, NHC(S)N(W)2, CO2R,
CO2H, CHO, CONH2, CONHR', CON(R')2, S(0)2H, S(0)2R', SO2NH2, S(0)H, S(0)R',
SO2NHR', SO2N(R)2, NHS(0)2H, NR'S(0)2H, NHS(0)2W, NR'S(0)2R, Si(R)3, where
each of
the preceding may be linked through a divalent alkylene linker, (CH2)x, where
x is 1, 2, or 3. In
embodiments where a saturated carbon atom is optionally substituted with one
or more
substituent groups, the substituents may be the same or different and also
include =0, =S,
=NNHR', =NNH2, =NN(R')2, =N-OR', =N-OH, =NNHCOR', =NNHCOH, =NNHCO2R',
=NNHCO2H, =NNHSO2R', =NNHSO2H, =N-CN, =NH, or =NR'. For each of the preceding,
each may be linked through an alkylene linker, (CH2)x, where x is 1, 2, or 3,
Each occurrence of
R' is the same or different and , in some embodiments, represents hydrogen,
alkyl, alkenyl,
alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, or, in some
embodiments,when two R' are
each attached to a nitrogen atom, they may form a saturated or unsaturated
heterocyclic ring
containing from 4 to 6 ring atoms.
[0042] As used herein, the phrase veterinary or veterinarily, or
pharmaceutical or
pharmaceutically acceptable salt refers to any salt of a compound disclosed
herein which retains
its biological properties and which is not toxic or otherwise undesirable for
veterinary or
pharmaceutical use. The general use of the terms pharmaceutical or
pharmaceutically is intended
to reach either veterinary or veterinarily, as well. The terms may be used
interchangeably as
context allows.
[0043] Such salts may be derived from a variety of organic and inorganic
counter-ions known in
the art. Such salts include acid addition salts formed with organic or
inorganic acids such as
hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, sulfamic, acetic,
trifluoroacetic,
trichloroacetic, propionic, hexanoic, cyclopentylpropionic, glycolic,
glutaric, pyruvic, lactic,
malonic, succinic, sorbic, ascorbic, malic, maleic, fumaric, tartaric, citric,
benzoic, 3-(4-
78
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
hydroxybenzoyl)benzoic, picric, cinnamic, mandelic, phthalic, lauric,
methanesulfonic,
ethanesulfonic, 1,2-ethane-disulfonic, 2-hydroxyethanesulfonic,
benzenesulfonic, 4-
chlorobenzenesulfonic, 2-naphthalenesulfonic, 4-toluenesulfonic, camphoric,
camphorsulfonic,
4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic, glucoheptonic, 3-
phenylpropionic,
trimethylacetic, tert-butylacetic, lauryl sulfuric, gluconic, benzoic,
glutamic, hydroxynaphthoic,
salicylic, stearic, cyclohexylsulfamic, quinic, muconic acid, and like acids.
[0101] Salts further include, by way of example only, salts of non-toxic
organic or inorganic
acids, such as halides, such as, chloride and bromide, sulfate, phosphate,
sulfamate, nitrate,
acetate, trifluoroacetate, trichloroacetate, propionate, hexanoate,
cyclopentylpropionate,
glycolate, glutarate, pyruvate, lactate, malonate, succinate, sorbate,
ascorbate, malate, maleate,
fumarate, tartarate, citrate, benzoate, 3-(4-hydroxybenzoyl)benzoate, picrate,
cinnamate,
mandelate, phthalate, laurate, methanesulfonate (mesylate), ethanesulfonate,
1,2-ethane-
disulfonate, 2-hydroxyethanesulfonate, benzenesulfonate (besylate), 4-
chlorobenzenesulfonate,
2-naphthalenesulfonate, 4-toluenesulfonate, camphorate, camphorsulfonate, 4-
methylbicyclo[2.2.2]-oct-2-ene- 1-carboxylate, glucoheptonate, 3-
phenylpropionate,
trimethylacetate, tert-butylacetate, lauryl sulfate, gluconate, benzoate,
glutamate,
hydroxynaphthoate, sali cyl ate, stearate, cyclohexylsulfamate, quinate,
muconate, and the like
[0102] Examples of inorganic bases that may be used to form base addition
salts include, but are
not limited to, metal hydroxides, such as lithium hydroxide, sodium hydroxide,
and potassium
hydroxide; metal amides, such as lithium amide and sodium amide; metal
carbonates, such as
lithium carbonate, sodium carbonate, and potassium carbonate; and ammonium
bases such as
ammonium hydroxide and ammonium carbonate.
[0103] Examples of organic bases that may be used to form base addition salts
include, but are
not limited to, metal alkoxides, such as lithium, sodium, and potassium
alkoxides including
lithium methoxide, sodium methoxide, potassium methoxide, lithium ethoxide,
sodium ethoxide,
potassium ethoxide, and potassium tert-butoxide; quaternary ammonium
hydroxides, such as
choline hydroxide; and amines including, but not limited to, aliphatic amines
(i.e., alkylamines,
alkenylamines, alkynylamines, and alicyclic amines), heterocyclic amines,
arylamines,
heteroarylamines, basic amino acids, amino sugars, and polyamines.
[0104] The base may be a quaternary ammonium hydroxide, wherein one or more of
the alkyl
groups of the quaternary ammonium ion are optionally substituted with one or
more suitable
79
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
substituents. Preferably, at least one alkyl group is substituted with one or
more hydroxyl groups.
Non-limiting examples of quaternary ammonium hydroxides that may be used in
accordance
with the present invention include choline hydroxide, trimethylethylammonium
hydroxide,
tetramethylammonium hydroxide, and is preferably choline hydroxide. An
alkylamine base may
be substituted or unsubstituted. Non-limiting examples of unsubstituted
alkylamine bases that
may be used in accordance with the present invention include methylamine,
ethylamine,
diethylamine, and triethylamine. A substituted alkylamine base may be
substituted with one or
more hydroxyl groups, and preferably one to three hydroxyl groups. Non-
limiting examples of
substituted alkylamine bases that may be used in accordance with the present
invention include
2-(diethylamino)ethanol, N,N-dimethylethanolamine (deanol), tromethamine,
ethanolamine, and
diolamine.
Stereoisoiners and po-Lynlorphic =forms
[0105] In certain cases, the depicted substituents may contribute to optical
isomers and/or
stereoisomerism. Compounds having the same molecular formula but differing in
the nature or
sequence of bonding of their atoms or in the arrangement of their atoms in
space are termed
"isomers." Isomers that differ in the arrangement of their atoms in space are
termed
"stereoisomers." Stereoisomers that are not mirror images of one another are
termed
"diastereomers" and those that are non-superimposable mirror images of each
other are termed
"enantiomers". When a compound has an asymmetric center, for example when it
is bonded to
four different groups, a pair of enantiomers is possible. A molecule with at
least one stereocenter
may be characterized by the absolute configuration of its asymmetric center
and is designated (R)
or (5) according to the rules of Cahn and Prelog (Cahn et at., 1966, Ans.,Tew.
Chem. 78: 413-447,
Angew. Chem., Mt. Ed Engl. 5: 385-414 (errata: Angel)). Chem., Mt. Ed. Engl.
5:511); Prelog
and Helmchen, 1982, Angew. Chem. 94: 614-631, Angew. Chem. Internat. Ed. Eng.
21: 567-583;
Mata and Lobo, 1993, Tetrahedron: Asymmetry 4: 657-668) or may be
characterized by the
manner in which the molecule rotates the plane of polarized light and is
designated
dextrorotatory or levorotatory (namely, as (-0- or (-)-isomers, respectively).
A chiral compound
may exist as either an individual enantiomer or as a mixture thereof. A
mixture containing equal
proportions of enantiomers is called a "racemic mixture".
[0106] In certain embodiments, the compounds disclosed herein may possess one
or more
asymmetric centers, and such compounds may therefore be produced as a racemic
mixture, an
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
enantiomerically enriched mixture, or as an individual enantiomer. Unless
indicated otherwise,
for example by designation of stereochemistry at any position of a formula,
the description or
naming of a particular compound in the specification and claims is intended to
include both
individual enantiomers and mixtures, racemic or otherwise, thereof. Methods
for determination
of stereochemistry and separation of stereoisomers are well-known in the art.
[0107] In certain embodiments, the compounds disclosed herein are
"stereochemically pure". A
stereochemically pure compound has a level of stereochemical purity that would
be recognized
as "pure" by those of skill in the art. Of course, this level of purity may be
less than 100%. In
certain embodiments, "stereochemically pure" designates a compound that is
substantially free,
i.e. at least about 85% or more, of alternate isomers. In particular
embodiments, the compound
is at least about 85%, about 90%, about 91%, about 92%, about 93%, about 94%,
about 95%,
about 96%, about 97%, about 98%, about 99%, about 99.5% or about 99.9% free of
other
isomers.
[0108] In addition, the compounds disclosed herein (active agents') may exist
as hydrates or
solvates, in which a certain stoichiometric amount of water or a solvent is
associated with the
molecule in the crystalline form. The compositions of the invention may
include hydrates and
solvates of the active agents. In some embodiments, the compositions of the
invention may
include up to 15% (w/w), up to 20% (w/w), or up to 30% (w/w) of a particular
solid form.
[0109] As used herein, the terms "subject" and "patient" may be used
interchangeably herein. In
one embodiment, the subject is a human. In one embodiment, the subject is a
companion animal
such as a dog or cat. In a further embodiment, the subject is an animal such
as a sheep, cow,
horse, goat, fish, pig, or domestic fowl (e.g., chicken, turkey, duck, or
goose). In another
embodiment, the subject is a primate such as a monkey such as a cynomolgous
monkey or a
chimpanzee.
[0110] In addition, a pharmaceutically acceptable prodrug of the compound
represented by the
formula (1), formula (11), and formula (11I) is also included in the present
invention. 'The
pharmaceutically acceptable prodrug refers to a compound having a group which
may be
converted into an amino group, a hydroxyl group, a carboxyl group, or the
like, by solvolysis or
under a physiological condition. Examples of the groups forming the prodrug
include those as
described in Prog. Med., 5, 2157-2161 (1985) or "Pharmaceutical Research and
Development"
(Hirokawa Publishing Company, 1990), vol. 7, Drug Design, 163-198. The term
prodrug is used
81
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
throughout the specification to describe any pharmaceutically acceptable form
of a compound
which, upon administration to a patient, provides the active compound.
Pharmaceutically
acceptable prodrugs refer to a compound that is metabolized, for example
hydrolyzed or
oxidized, in the host to form the compound of the present invention Typical
examples of
prodrugs include compounds that have biologically labile protecting groups on
a functional
moiety of the active compound. Prodrugs include compounds that may be
oxidized, reduced,
aminated, deaminated, hydroxyl ated, dehydroxylated, hydrolyzed, dehydrolyzed,
alkylated,
dealkylated, acylated, deacylated, phosphorylated, or dephosphorylated to
produce the active
compound.
[0111] The present invention includes all pharmaceutically acceptable
isotopically-labelled
compounds of the invention wherein one or more atoms are replaced by atoms
having the same
atomic number, but an atomic mass or mass number different from the atomic
mass or mass
number usually found in nature. Examples of isotopes suitable for inclusion in
the compounds of
the invention include isotopes of hydrogen, such as 21-1 and 3H, carbon, such
as 11C, '3C and "C,
chlorine, such as 36C1, fluorine, such as 18F, iodine, such as 123I and 1251,
nitrogen, such as 13N and
15N, oxygen, such as 150, 170 and 180, phosphorus, such as 32P, and sulfur,
such as 35S. Certain
isotopically-labelled compounds of the invention, such as those incorporating
a radioactive
isotope, may be useful in drug or substrate tissue distribution studies. The
radioactive isotopes
tritium, i.e. 3H, and carbon-14, i.e. 14C, are particularly useful for this
purpose in view of their
ease of incorporation and ready means of detection. Substitution with heavier
isotopes such as
deuterium, i.e. 2H, may afford certain therapeutic advantages resulting from
greater metabolic
stability, for example, increased in vivo half-life or reduced dosage
requirements, and hence may
be preferred in some circumstances. Substitution with positron emitting
isotopes, such as 11C,
18F, 150 and "3N, may be useful in Positron Emission Topography (PET) studies
for examining
substrate receptor occupancy. Isotopically-labeled compounds of the invention
may generally be
prepared by conventional techniques known to those skilled in the art or by
processes analogous
to those described in the accompanying Examples using an appropriate
isotopically-labeled
reagent in place of the non-labeled reagent previously employed.In one aspect,
the invention
provides a process for preparing a compound of any embodiment of formula (I),
formula (II),
formula (III), formula (IV), formula (IVa) and formula (IVb) as described
herein.
Compositions and Methods of Administration
82
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
[0112] The compounds of formula (I), formula (II), formula (III), formula
(IV), formula (IVa)
and formula (IVb) used in the methods disclosed herein may be administered in
certain
embodiments using veterinary or pharmaceutical compositions including at least
one compound
of formula (I), formula (II), formula (IV), formula (IVa) and formula (IVb),
if appropriate in the
salt form, either used alone or in the form of a combination with one or more
compatible and
veterinary or pharmaceutically acceptable carriers, such as diluents or
adjuvants, or with another
agent. There are provided compositions which comprise a derivative of a
compound of formula
(I), formula (II), formula (III), formula (IV), formula (IVa) and formula
(IVb) or a salt thereof,
and an acceptable excipient, carrier or diluent. The composition may also be
in a variety of
forms which include, but are not limited to, oral formulations, injectable
formulations, and
topical, dermal or subdermal formulations. The particular route selected by
the practitioner
depends upon factors such as the physicochemical properties of the
pharmaceutical or
therapeutic agent, the condition of the host and economics.
[0113] In one aspect, the invention provides for a method for treating a
patient having a disease
or disorder susceptible to modulation of JAK comprising administering a
therapeutically
effective amount of a compound as described herein, including any embodiment
of a compound
according formula (I), (II), (III), (IV), (IVa), or (IVb).
[0114] In one embodiment, the invention provides a method of treating a
patient having a
disease or disorder that can be ameliorated by the selective inhibition of a
Janus kinase JAK 1
relative to JAK 2.
[0115] In one embodiment, the invention provides for a method of treating a
patient having a
disease or disorder with a therapeutically effective amount of a compound
which is an
embodiment of formula (I), formula (II), formula (III), formula (IV), formula
(IVa) and formula
(IVb), wherein the disease or disorder is one or more of atopic dermatitis,
flea allergy dermatitis,
eczema, pruritus, psoriasis, psoriatic arthritis, Bechet's disease, pityriasis
rubra pilaris, alopecia
areata, discoid lupus erythematosus, vitiligo, palmoplantar pustulosis,
mucocutaneous disease
erythema multiforme, mycosis fungoides, graft-versus-host disease, cutaneous
lupus, rheumatoid
arthritis (RA), arthritis, ulcerative colitis, Crohn's disease, inflammatory
bowel disease (MD),
transplant rejection, systemic lupus erythematosus (SLE), dermatomyositis,
Sjogren's syndrome,
dry eye disease, secondary hypereosinophilic syndrome (HES), allergy, allergic
dermatitis,
asthma, vasculitis, multiple sclerosis, diabetic nephropathy, cardiovascular
disease,
83
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
artherosclerosis, and cancer.
[0116] In one embodiment, the invention provides a method of treating a
patient as described
above, wherein the the disease or disorder is one or more of atopic
dermatitis, flea allergy
dermatitis psoriasis, and rheumatoid arthritis.
[0117] According to one embodiment, the invention provides for a method of
treating a patient
having a disease or disorder susceptible to modulating of JAK and comprising
administering an
amount of a compound according to the invention in an amount to perturb an
immune regulatory
pathway in a cell. In one such embodiment, the perturbation results in an
effect on the JAK-
STAT pathway.
[0118] In one aspect, the invention provides a method of inhibiting JAI( in a
mammalian cell
comprising contacting the mammalian cell with a compound according to any
embodiment of
formula (I), (II), and (III), (IV), (IVa), or (IVb). In certain embodiments,
the mammalian cell is a
cell from a subject having an inflammatory condition.
[0119] In one aspect, the invention provides for a composition comprising a
compound
according to any embodiment of formula formula (I), formula (II), formula
(II), formula (IV),
formula (IVa) and formula (IVb) and a pharmaceutically or veterinary
acceptable carrier.
[0120] The composition may be in a form suitable for oral use, for example, as
dietary
supplements, troches, lozenges, chewables, tablets, hard or soft capsules,
emulsions, aqueous or
oily suspensions, aqueous or oily solutions, dispersible powders or granules,
syrups, or elixirs.
Compositions intended for oral use may be prepared according to any method
known in the art
for the manufacture of veterinary or pharmaceutical compositions and such
compositions may
contain one or more agents selected from the group consisting of sweetening
agents, bittering
agents, flavoring agents, coloring agents and preserving agents in order to
provide elegant and
palatable preparations. In certain cases, it is convenient and efficient to
administer veterinary
medicines orally by placing the therapeutic agent in a solid or liquid matrix
that is suitable for
oral delivery. These methods include chewable drug-delivery formulations. The
problem
associated with administering oral formulations to animals is that the
therapeutic agent often
provides an unpleasant taste, aroma, or texture, which causes the animals to
reject the
composition. This is further exacerbated by compositions that are hard and
difficult to swallow.
[0121] Oral veterinary compositions in the form of soft chewable compositions
("soft chews"),
or chewable tablets that are palatable are usually convenient to administer to
certain animals,
84
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
particularly cats and dogs, and may be used effectively to dose veterinary
medicine to these
animals. However, many oral compositions comprising active agents with a
bitter or unpleasant
taste are not well accepted by cats and dogs. Furthermore, when the
bioavailability of an active
agent from an oral dosage form is not sufficient or is variable, the required
exposure of the
animal to the active ingredient may not be sufficient to provide the desired
efficacy. Problems
such as these often lead to low or sub-optimal efficacy and control of
parasites.
[0122] Chewable dosage forms for drug delivery are well known to
pharmaceutical technology.
It is known in the pharmaceutical industry that the act of chewing increases
the surface area of
the available active ingredient and may increase the rate of absorption by the
digestive tract.
Chewable systems are also advantageous where it is desirable to make an active
ingredient
available topically to the mouth or throat areas for both local effects and/or
systemic absorption.
Further, chewable dosage forms are also utilized to ease drug administration
in pediatric and
geriatric patients. Examples of chewable dosage forms may be found in U.S.
Pat. Nos.
6,387,381; 4,284,652; 4,327,076; 4,935,243; 6,270,790; 6,060,078; 4,609,543;
and, 5,753,255,
all incorporated herein by reference.
[0123] Palatability and "mouth feel" are important characteristics to be
considered in providing a
dosage form, or matrix, for an active pharmaceutical or medicinal
Unfortunately, many
pharmaceuticals and other active ingredients have a bitter or otherwise
unpalatable taste, or an
unacceptable mouth feel, due to the grittiness or chalkiness of the compound,
or both. These
characteristics make it difficult to incorporate such active ingredients into
the current state of the
art for chewable dosage forms because the objectionable taste and/or mouth
feel make it less
likely to obtain compliance by the user. Oral veterinary dosage forms that are
not palatable to the
animal treated result in low acceptance of the medicament by the animal and a
low level of
compliance. Thus, there is a need for improved oral veterinary dosage forms
that are palatable
and well accepted by the treated animal.
[0124] Another challenge with oral veterinary compositions, particularly soft
chewable
compositions, is that the release and dissolution of the active agent from the
composition after it
is ingested by the animal can be variable and incomplete. This leads to
variability in the amount
of the drug that is absorbed from the digestive tract of the animal.
[0125] US Patent No. 7,955,632 (incorporated herein by reference) describes
palatable, edible
soft chewable medication vehicles for the delivery of pharmaceutically
acceptable active
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
ingredients to an animal and processes of making the same.
[0126] Furthermore, US 2004/0037869 Al, US 2004/0151759 Al, WO 2005/062782 and
WO
2004/016252 to Cleverly et al. (incorporated herein by reference) describe
chewable veterinary
formulations and tablets that contain at least one pharmaceutical active
agent, and
WO 2009/02451A2 and US 2011/0059988 to Heckeroth et al. describe various
compositions for
oral administration to animals (all incorporated herein by reference).
[0127] Traditionally, in veterinary formulations, palatability had been
achieved by the inclusion
of animal byproducts or flavors derived from animal sources into the
formulation. For example,
it is customary to include excipients, such as chicken powder, liver powder,
beef, ham, fish, or
rawhide-derived products in dog chews to make the chew attractive and
palatable to the dog.
See, e.g., U.S. Patent 6,086,940; U.S. Patent 6,093,441; U.S. Patent
6,159,516; U.S. Patent
6,110,521; U.S. Patent 5,827,565; U.S. Patent 6,093,427, all to Axelrod et at.
(all incorporated
herein by reference).
[0128] Exceptionally palatable soft chewable oral veterinary compositions that
provide high
bioavailability of active agent are described in U.S. Patent 9,259,417; U.S.
Patent 9,233,100;
U.S. Patent 9,931,320; U.S. Patent 10,596,156; all to So11 et al. (all
incorporated herein by
reference).
[0129] Lozenges are solid compositions containing one or more active
ingredients intended to
dissolve or disintegrate slowly in the oral cavity by passive incubation in
the oral cavity, or
actively by sucking or chewing. They may be used for systemic effect if the
drug is absorbed
through the buccal or esophageal lining or is swallowed. In particular, soft
lozenges may be
chewed or allowed to dissolve slowly in the mouth. These dosage forms have the
advantage of
being flavored and thus easy to administer to both human and animal patients;
have formulas that
are easy to change and may be patient specific; may deliver accurate amounts
of the active
ingredient to the oral cavity and digestive system; and allow for the drug to
remain in contact
with the oral or esophageal cavity for an extended period of time.
[0130] Tablets may contain the active ingredient in admixture with non-toxic,
pharmaceutically
acceptable excipients which are suitable for the manufacture of tablets. These
excipients may be,
for example, inert diluents, such as calcium carbonate, sodium carbonate,
lactose, calcium
phosphate or sodium phosphate; granulating and disintegrating agents, for
example, corn starch,
or alginic acid; binding agents, for example, starch, gelatin or acacia, and
lubricating agents, for
86
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
example, magnesium stearate, stearic acid or talc. The tablets may be uncoated
or they may be
coated by known techniques to delay disintegration and absorption in the
gastrointestinal tract
and thereby provide a sustained action over a longer period.
[0131] Formulations for oral use may be hard gelatin capsules, wherein the
active ingredient is
mixed with an inert solid diluent, for example, calcium carbonate, calcium
phosphate or kaolin.
Capsules may also be soft gelatin capsules, wherein the active ingredient is
mixed with water or
miscible solvents such as propylene glycol, PEGs and ethanol, or an oil
medium, for example,
peanut oil, liquid paraffin, or olive oil.
[0132] The compositions may also be in the form of oil-in-water or water-in-
oil emulsions. The
oily phase may be a vegetable oil, for example, olive oil or arachis oil, or a
mineral oil, for
example, liquid paraffin or mixtures of these. Suitable emulsifying agents may
be naturally-
occurring phosphatides, for example, soy bean, lecithin, and esters or partial
esters derived from
fatty acids and hexitol anhydrides, for example, sorbitan monoleate, and
condensation products
of the said partial esters with ethylene oxide, for example, polyoxyethylene
sorbitan monooleate.
The emulsions may also contain sweetening agents, bittering agents, flavoring
agents, and
preservatives.
[0133] In one embodiment of the formulation, the composition is in the form of
a
microemulsion. Microemulsions are well suited as the liquid carrier vehicle.
Microemulsions
are quaternary systems comprising an aqueous phase, an oily phase, a
surfactant and a
cosurfactant. They are translucent and isotropic liquids. Microemulsions are
composed of stable
dispersions of microdroplets of the aqueous phase in the oily phase or
conversely of
microdroplets of the oily phase in the aqueous phase. The size of these
microdroplets is less than
200 nm (1000 to 100,000 nm for emulsions). The interfacial film is composed of
an alternation
of surface-active (SA) and co-surface-active (Co-SA) molecules which, by
lowering the
interfacial tension, allows the microemulsion to be formed spontaneously. In
one embodiment of
the oily phase, the oily phase may be formed from mineral or vegetable oils,
from unsaturated
polyglycosylated glycerides or from triglycerides, or alternatively from
mixtures of such
compounds. In one embodiment of the oily phase, the oily phase comprises of
triglycerides; in
another embodiment of the oily phase, the triglycerides are medium-chain
triglycerides, for
example, Cs-Cio caprylic/capric triglyceride. In another embodiment, the oily
phase will
represent a % v/v range selected from the group consisting of about 2 to about
15%; about 7 to
87
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
about 10%; and about 8 to about 9% v/v of the microemulsion. The aqueous phase
includes, for
example, water or glycol derivatives, such as propylene glycol, glycol ethers,
polyethylene
glycols or glycerol. In one embodiment of the glycol derivatives, the glycol
is selected from the
group consisting of propylene glycol, diethylene glycol monoethyl ether,
dipropylene glycol
monoethyl ether and mixtures thereof. Generally, the aqueous phase will
represent a proportion
from about 1 to about 4% v/v in the microemulsion. Surfactants for the
microemulsion include
diethylene glycol monoethyl ether, dipropylene glycol monomethyl ether,
polyglycolyzed Cg-Cio
glycerides or polyglycery1-6 dioleate. In addition to these surfactants, the
cosurfactants include
short-chain alcohols, such as ethanol and propanol. Some compounds are common
to the three
components discussed above, for example, aqueous phase, surfactant and
cosurfactant.
However, it is well within the skill level of the practitioner to use
different compounds for each
component of the same formulation. In one embodiment, for example, for the
amount of
surfactant/cosurfactant, the cosurfactant to surfactant ratio may be from
about 1/10 to about 1/2.
In another embodiment for the amount of cosurfactant, there will be from about
25 to about 75%
v/v of surfactant and from about 10 to about 55% v/v of cosurfactant in the
microemulsion.
[0134] Oily suspensions may be formulated by suspending the active ingredient
in a vegetable
oil, for example, atachis oil, olive oil, sesame oil or coconut oil, or in
mineral oil such as liquid
paraffin. The oily suspensions may contain a thickening agent, for example,
beeswax, hard
paraffin or cetyl alcohol. Sweetening agents such as sucrose, saccharin or
aspartame, bittering
agents, and flavoring agents may be added to provide a palatable oral
preparation. These
compositions may be preserved by the addition of an anti-oxidant such as
ascorbic acid, or other
known preservatives.
[0135] Aqueous suspensions may contain the active material in admixture with
excipients
suitable for the manufacture of aqueous suspensions. Such excipients are
suspending agents, for
example, sodium carboxymethylcellulose, methylcellulose,
hydroxypropylmethylcellulose,
sodium alginate, polvinylpyrrolidone, gum tragacanth and gum acacia;
dispersing or wetting
agents may be a naturally-occuring phosphatide, for example, lecithin, or
condensation products
of an alkylene oxide with fatty acids, for example, polyoxyethylene stearate,
or condensation
products of ethylene oxide with long chain aliphatic alcohols, for example,
heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with
partial esters
derived from fatty acids and a hexitol such as polyoxyethylene sorbitol
monooleate, or
88
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
condensation products of ethylene oxide, with partial esters derived from
fatty acids and hexitol
anhydrides, for example, polyethylene sorbitan monooleate. The aqueous
suspensions may also
contain one or more preservatives, for example, ethyl, or n-propyl, p-
hydroxybenzoate, one or
more coloring agents, one or more flavoring agents, and one or more sweetening
agents and/or
bittering agents, such as those set forth herein.
[0136] Dispersible powders and granules suitable for preparation of an aqueous
suspension by
the addition of water provide the active ingredient in admixture with a
dispersing or wetting
agent, suspending agent and one or more preservatives. Suitable dispersing or
wetting agents
and suspending agents are exemplified by those already mentioned above.
Additional excipients,
for example, sweetening, bittering, flavoring and coloring agents, may also be
present.
[0137] Syrups and elixirs may be formulated with sweetening agents, for
example, glycerol,
propylene glycol, sorbitol or sucrose. Such formulations may also contain a
demulcent, a
preservative, flavoring agent(s) and coloring agent(s).
[0138] The compositions may be in the form of a sterile injectable aqueous or
oleaginous
suspension. This suspension may be formulated according to the known art using
those suitable
dispersing or wetting agents and suspending agents which have been mentioned
above The
sterile injectable preparation may also be a sterile injectable solution or
suspension in a non-toxic
parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-
butane diol. Among
the acceptable vehicles and solvents that may be employed are water, Ringer's
solution and
isotonic sodium chloride solution. Cosolvents such as ethanol, propylene
glycol or polyethylene
glycols may also be used. Preservatives, such as phenol or benzyl alcohol, may
be used.
[0139] In addition, sterile, fixed oils are conventionally employed as a
solvent or suspending
medium. For this purpose, any bland fixed oil may be employed including
synthetic mono- or
diglycerides. In addition, fatty acids such as oleic acid find use in the
preparation of injectables.
[0140] Topical, dermal and subdermal formulations may include emulsions,
creams, ointments,
gels or pastes.
[0141] Organic solvents that may be used in the invention include but are not
limited to:
acetyltributyl citrate, fatty acid esters such as the dimethyl ester,
diisobutyl adipate, acetone,
acetonitrile, benzyl alcohol, butyl diglycol, dimethylacetami de,
dimethylformamide, dipropylene
glycol n-butyl ether, ethanol, isopropanol, methanol, ethylene glycol
monoethyl ether, ethylene
glycol monomethyl ether, monomethylacetamide, dipropylene glycol monomethyl
ether, liquid
89
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
polyoxyethylene glycols, propylene glycol, 2-pyrrolidone (e.g. N-
methylpyrrolidone), diethylene
glycol monoethyl ether, ethylene glycol and diethyl phthalate, or a mixture of
at least two of
these solvents.
[0142] As vehicle or diluent, compositions of the present invention may
include plant oils such
as, but not limited to soybean oil, groundnut oil, castor oil, corn oil,
cotton oil, olive oil, grape
seed oil, sunflower oil, etc.; mineral oils such as, but not limited to,
petrolatum, paraffin,
silicone, etc.; aliphatic or cyclic hydrocarbons or alternatively, for
example, medium-chain (such
as Cs-C12) triglycerides.
[0143] Dosage forms may contain from about 0.5 mg to about 5 g of an active
agent.
[0144] In one embodiment of the invention, the active agent is present in the
formulation at a
concentration of about 0.05 to 10% weight/volume.
[0145] A compound of formula (I), formula (II), formula (III), formula (IV),
formula (IVa) and
formula (IVb) may be employed as such or in the form of their preparations or
formulations as
combinations.
[0146] A compound of formula (I), formula (II), formula (III), formula (IV),
formula (IVa) and
formula (IVb) according to the invention may be combined with one or more
agents having the
same sphere of activity, for example, to increase activity, or with substances
having another
sphere of activity, for example, to broaden the range of activity. As an
example, a combination
of a compound of formula (I) (or of a compound of formula (I), formula (II),
formula (IV),
formula (IVa) and formula (IVb)) with one or more of an additional JAK
inhibitor or a
JAK/Signal Transducer and Activator of Transcription (JAK/STAT) modulator may
offer
therapeutic advantage. Examples of JAK inhibitors that may be useful as
combination agents
include Baricitinib, Ruxolitinib, Filgotinib, CYT387, Upadacitinib,
Fedratinib, Peficitinib,
Lestaurtinib, Pacritinib, Oclacitinib, Cerdulatinib, and Tofacitinib.
[0147] The compounds of formula (I), formula (II) or formula (III) according
to the invention
may be combined with one or more additional active agents. further additional
active agents
which may be used in the methods provided herein in combination with a
compound of formula
(I), (II) or (III) include, but are not limited to, disease-modifying anti-
rheumatic drugs
(DMARDs such as cyclosporine A and methotrexate), anti-inflammatory agents
such as
nonsteroidal anti-inflammatory drugs (NSAIDs), immnunosuppressants,
mycophenolate mofetil,
biologic agents, TNF'-a inhibitors (such as etanercept), Cox-2 inhibitors
(such as firocoxib), and
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
analgesics. These agents may include but are not limited to cyclosporin A,
e.g. Sandimmune
or Neoral , rapamycin, FK-506 (tacrolimus), leflunomide, deoxyspergualin,
mycophenol ate,
e.g., Cellcept , azathioprine, e.g. Imuran , daclizumab, e.g. Zenapax , OKT3,
e.g.
Orthocolone , AtGam, aspirin, acetaminophen, ibuprofen, naproxen, piroxicam,
and anti-
inflammatory steroids, e.g. prednisolone or dexamethasone.
[0148] In some embodiments, the second active agents may include, but are not
limited to, anti-
inflammatories such as NSAIDs including, but not limited to, diclofenac (e.g.,
ARTHROTECO),
diflunisal (e.g., DOLOBIDca"), etodolac (e.g., LODINE ), fenoprofen (e.g.,
NALFON ),
ibuprofen (e.g., ADVIL , CHILDREN'S ADVIL/MOTRIN ,1VIEDIPREN , MOTRIN ,
NUPRIN , or PEDIACARE FEVER ), indomethacin (e.g., ARTHREXINg), ketoprofen
(e.g.,
ORUVAIL ), ketorolac (e.g., TORADOLC), fosfomycin tromethamine (e.g., MONURAL
),
meclofenamate (e.g. , MECLOMEN'), nabumetone (e.g., RELAFENO), naproxen (e.g.,
ANAPROX , ANAPROX DS, EC-NAPROSYN , NAPRELAN or NAPROSYN ),
oxaprozin (e.g., DAY PRO ), piroxicam (e.g., FELDENES), sulindac (e.g.,
CLINORILO), and
tolmetin (e.g., TOLECTIN DS or TOLECTINO).
[0149] In other embodiments, the second active agents may include, but are not
limited to,
disease-modifying antirheumatic drugs (e.g., DMARDs) or immnunosuppressants
such as, but
not limited to, methotrexate (e.g., RHEUMATREX ), sulfasalazine (e.g.,
AZULFIDINE ), and
cyclosporine (e.g., SANDIMMUNE1) or NEROALS; and including cyclosporine A).
[0150] In other embodiments, the second active agents may include, but are not
limited to,
mycophenolate mofetil (e.g., CellCepe)), an immunosuppressive agent widely
used in organ
transplantation and gaining favor in treating autoimmune and inflammatory skin
disorders.
[0151] In further embodiments, the second active agents may include, but are
not limited to,
biologic agents such as etanercept (e.g., ENBREL ), infliximab (e.g., REMICADE
) and
adalimumab (e.g., HUMIRAC).
[0152] In further embodiments of interest, the second active agents may
include, but are not
limited to Cox-2 inhibitors such as celecoxib (e.g., CELEBREX ), firocoxib
(e.g.
PREVICOX*)), valdecoxib (e.g., BEXTRAg) and meloxicam (e.g.,
MOBIC*,1VIETACAM*).
[0153] In further embodiments, the second active agents may include veterinary
therapeutic
agents that are well-known in the art (see e.g. Plumb's Veterinary Drug
Handbook, 5th Edition,
ed. Donald C. Plumb, Blackwell Publishing, (2005) or The Merck Veterinary
Manual, 9th
91
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
Edition, (January 2005)) and include but are not limited to acarbose,
acepromazine maleate,
acetaminophen, acetazolamide, acetazolamide sodium, acetic acid,
acetohydroxamic acid,
acetylcysteine, acitretin, acyclovir, albendazole, albuterol sulfate,
alfentanil, allopurinol,
alprazolam, altrenogest, amantadine, amikacin sulfate, aminocaproic acid,
aminopentamide
hydrogen sulfate, aminophylline/theophylline, amiodarone, amitriptyline,
amlodipine besylate,
ammonium chloride, ammonium molybdenate, amoxicillin, clavulanate potassium,
amphotericin
B desoxycholate, amphotericin B lipid-based, ampicillin, amprolium, antacids
(oral), antivenin,
apomorphione, apramycin sulfate, ascorbic acid, asparaginase, aspiring,
atenolol, atipamezole,
atracurium besylate, atropine sulfate, aurnofin, aurothioglucose, azaperone,
azathioprine,
azithromycin, baclofen, barbituates, benazepril, betamethasone, bethanechol
chloride, bisacodyl,
bismuth sub salicylate, bleomycin sulfate, boldenone undecylenate, bromides,
bromocriptine
mesylate, budenoside, buprenorphine, buspirone, busulfan, butorphanol
tartrate, cabergoline,
calcitonin salmon, calcitrol, calcium salts, captopril, carbenicillin indanyl
sodium, carbimazole,
carboplatin, carnitine, carprofen, carvedilol, cefadroxil, cefazolin sodium,
cefixime, clorsulon,
cefoperazone sodium, cefotaxime sodium, cefotetan disodium, cefoxitin sodium,
cefpodoxime
proxetil, ceftazidime, ceftiofur sodium, ceftiofur, ceftiaxone sodium,
cephalexin, cephalosporins,
cephapirin, charcoal (activated), chlorambucil, chloramphenicol, chlordi
azepoxi de,
chlordiazepoxide, clidinium bromide, chlorothiazide, chlorpheniramine maleate,
chlorpromazine,
chlorpropamide, chlortetracycline, chorionic gonadotropin (HCG), chromium,
cimetidine,
ciprofloxacin, cisapride, cisplatin, citrate salts, clarithromycin, clemastine
fumarate, clenbuterol,
clindamycin, clofazimine, clomipramine, claonazepam, clonidine, cloprostenol
sodium,
clorazepate dipotassium, clorsulon, cloxacillin, codeine phosphate,
colchicine, corticotropin
(ACTH), cosyntropin, cyclophosphamide, cyclosporine, cyproheptadine,
cytarabine,
dacarbazine, dactinomycin/actinomycin D, dalteparin sodium, danazol,
dantrolene sodium,
dapsone, decoquinate, deferoxamine mesylate, deracoxib, deslorelin acetate,
desmopressin
acetate, desoxycorticosterone pivalate, detomidine, dexamethasone,
dexpanthenol, dexraazoxane,
dextran, diazepam, diazoxide (oral), dichlorphenamide, diclofenac sodium,
dicloxacillin,
diethylcarbamazine citrate, diethylstilbestrol (DES), difloxacin, digoxin,
dihydrotachy sterol
(DHT), diltiazem, dimenhydrinate, dimercaprol/BAL, dimethyl sulfoxide,
dinoprost
tromethamine, diphenylhydramine, disopyramide phosphate, dobutamine,
docusate/DSS,
dolasetron mesylate, domperidone, dopamine, doramectin, doxapram, doxepin,
doxorubicin,
92
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
doxycycline, edetate calcium disodium.calcium EDTA, edrophonium chloride,
enalapril/enalaprilat, enoxaparin sodium, enrofloxacin, ephedrine sulfate,
epinephrine,
epoetin/erythropoietin, eprinomectin, epsiprantel, erythromycin, esmolol,
estradiol cypionate,
ethacrynic acid/ethacrynate sodium, ethanol (alcohol), etidronate sodium,
etodolac, etomidate,
euthanasia agents w/pentobarbital, famotidine, fatty acids (essential/omega),
felbamate, fentanyl,
ferrous sulfate, filgrastim, finasteri de, fipronil, fi orfeni col,
fluconazole, flucytosine,
fludrocortisone acetate, flumazenil, flumethasone, flunixin meglumine,
fluorouracil (5-FU),
fluoxetine, fluticasone propionate, fluvoxamine maleate, fomepizole (4-M13),
furazolidone,
furosemide, gabapentin, gemcitabine, gentamicin sulfate, glimepiride,
glipizide, glucagon,
glucocorticoid agents, glucosamine/chondroitin sulfate, glutamine, glyburide,
glycerine (oral),
glycopyrrolate, gonadorelin, grisseofulvin, guaifenesin, halothane, hemoglobin
glutamer-200
(OXYGLOBINg), heparin, hetastarch, hyaluronate sodium, hydrazaline,
hydrochlorothiazide,
hydrocodone bitartrate, hydrocortisone, hydromorphone, hydroxyurea,
hydroxyzine, ifosfamide,
imidacloprid, imidocarb dipropinate, impenem-cilastatin sodium, imipramine,
inamrinone
lactate, insulin, interferon alfa-2a (human recombinant), iodide
(sodium/potassium), ipecac
(syrup), ipodate sodium, iron dextran, isoflurane, isoproterenol,
isotretinoin, isoxsuprine,
itraconazole, ivermectin, kaolin/pectin, ketamine, ketoconazole, ketoprofen,
ketorolac
tromethamine, lactulose, leuprolide,levamisole, levetiracetam, levothyroxine
sodium, lidocaine,
lincomycin, liothyronine sodium, lisinopril, lomustine (CCNU), lufenuron, ly
sine, magnesium,
mannitol, marbofloxacin, mechlorethamine, meclizine, meclofenamic acid,
medetomidine,
medium chain triglycerides, medroxyprogesterone acetate, megestrol acetate,
melarsomine,
melatonin, meloxi can, melphalan, meperidine, mercaptopurine, meropenem,
metformin,
methadone, methazolami de, methenamine mandelate/hippurate, methimazole,
methionine,
methocarbamol, methohexital sodium, methotrexate, methoxyflurane, methylene
blue,
methylphenidate, methylprednisolone, metoclopramide, metoprolol,
metronidaxole, mexiletine,
mibolerlone, midazolam milbemycin oxime, mineral oil, minocycline,
misoprostol, mitotane,
mitoxantrone, morphine sulfate, moxidectin, naloxone, mandrolone decanoate,
naproxen,
narcotic (opiate) agonist analgesics, neomycin sulfate, neostigmine,
niacinamide, nitazoxanide,
nitenpyram, nitrofurantoin, nitroglycerin, nitroprusside sodium, nizatidine,
novobiocin sodium,
nystatin, octreotide acetate, olsalazine sodium, omeprozole, ondansetron,
opiate antidiarrheals,
orbifloxacin, oxacillin sodium, oxazepam, oxibutynin chloride, oxymorphone,
oxytretracycline,
93
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
oxytocin, pamidronate di sodium, pancreplipase, pancuronium bromide,
paromomycin sulfate,
parozetine, pencillamine, general information penicillins, penicillin G,
penicillin V potassium,
pentazocine, pentobarbital sodium, pentosan polysulfate sodium,
pentoxifylline, pergolide
mesylate, phenobarbital, phenoxybenzamine, pheylbutazone, phenylephrine,
phenypropanolamine, phenytoin sodium, pheromones, parenteral phosphate,
phytonadi one/vitamin K-1, pimobendan, piperazine, pirlimycin, piroxi cam,
polysulfated
glycosaminoglycan, ponazuril, potassium chloride, pralidoxime chloride,
prazosin,
prednisolone/predni sone, primidone, procainamide, procarbazine,
prochlorperazine,
propantheline bromide, propionibacterium acnes injection, propofol,
propranolol, protamine
sulfate, pseudoephedrine, psyllium hydrophilic mucilloid, pyridostigmine
bromide, pyrilamine
maleate, pyrimethamine, quinacrine, quinidine, raniti dine, rifampin, s-
adenosyl-methionine
(SAMe), saline/hyperosmotic laxative, selamectin, selegiline /1-deprenyl,
sertraline, sevelamer,
sevoflurane, silymarin/milk thistle, sodium bicarbonate, sodium polystyrene
sulfonate, sodium
stibogluconate, sodium sulfate, sodum thiosulfate, somatotropin, sotalol,
spectinomycin,
spironolactone, stanozolol, streptokinase, streptozocin, succimer,
succinylcholine chloride,
sucralfate, sufentanil citrate, sulfachlorpyridazine sodium,
sulfadiazine/trimethroprim,
sulfamethoxazole/trimethoprim, sulfadimentoxine, sulfadimethoxine/ormetoprim,
sulfasalazine,
taurine, tepoxaline, terbinafline, terbutaline sulfate, testosterone,
tetracycline, thiacetarsamide
sodium, thiamine, thioguanine, thiopental sodium, thiotepa, thyrotropin,
tiamulin, ticarcilin
di sodium, tiletamine /zolazepam, tilmocsin, tiopronin, tobramycin sulfate,
tocainide, tolazoline,
telfenamic acid, topiramate, tramadol, trimcinolone acetonide, trientine,
trilostane, trimepraxine
tartrate w/prednisolone, tripelennamine, tylosin, urdosiol, valproic acid,
vanadium, vancomycin,
vasopressin, vecuronium bromide, verapamil, vinblastine sulfate, vincristine
sulfate, vitamin
E/selenium, warfarin sodium, xylazine, yohimbine, zafirlukast, zidovudine
(AZT), zinc
acetate/zinc sulfate, and zonisamide and mixtures thereof.
[0154] These one or more additional active agents may be administered as part
of the same or
separate dosage forms, via the same or different routes of administration, and
on the same or
different administration schedules according to standard pharmaceutical
practice known to one
skilled in the art.
[0155] The pharmaceutical preparation comprising the compounds of formula (I),
(II), (III),
(IVa), (IVb), and (IV) for delivery to a human or other mammal, is preferably
in unit dosage
94
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
form, in which the preparation is subdivided into unit doses containing an
appropriate quantity of
the active component. The unit dosage form may be a packaged preparation
containing discrete
quantities of the preparation, such as packaged tablets, capsules, and powders
in vials or
ampoules. Also, the unit dosage form may be a capsule, tablet or lozenge
itself, or it may be an
appropriate number of any of these in packaged form.
[0156] The quantity of active component in a unit dose preparation may be
varied or adjusted
from about 0.1 mg to about 1000 mg, according to the particular application
and the potency of
the active component. The composition may, if desired, also contain other
compatible
therapeutic agents.
[0157] In therapeutic use for the treatment or alleviation of inflammation,
auto-immune diseases,
and cancer in a human or other mammal, the compounds utilized in the method of
treatment are
administered at an initial dosage of about 0.1 mg/kg to about 100 mg/kg per
interval, about 0.1
mg/kg to about 50.0 mg/kg per interval, about 0.1 mg/kg to about 10.0 mg/kg
per interval, about
0.1 mg/kg to about 5.0 mg/kg per interval, about 0.1 mg/kg to about 2.5 mg/kg
per interval,
about 0.1 mg/kg to about 2.0 mg/kg per interval, about 0.1 mg/kg to about 1.0
mg/kg per
interval, about 0.4 mg/kg to about 1.0 mg/kg per interval, or about 0.4 mg/kg
to about 0.6 mg/kg
per interval. Preferred intervals may be daily, weekly, monthly, quarterly,
semi-annually, or
annually. The dosages may be varied depending on the requirements of the
patient, for example,
the size of the human or mammal being treated, the severity of the condition
being treated, the
route of administration, and the potency of the compound(s) being used.
Determination of the
proper dosage and route of administration for a particular situation is within
the skill of the
practitioner. Generally, the treatment will be initiated with smaller dosages,
which are less than
the optimum dose of the compound, which may be increased in small increments
until the
optimum effect under the particular circumstances of the condition is reached.
For convenience,
the total daily dosage may be divided and administered in portions during the
day if desired.
[0158] In therapeutic use, the compounds of formula (I), (11), (111), (IVa),
(IV b), and (IV) are
useful in manufacture of a medicament for a method of the treating any
indication where
inhibition of JAK would be desirable, including but not limited to cancer,
neuroinflammation,
inflammatory airway diseases, ankylosing spondylitis, inflammatory bowel
diseases, rheumatoid
arthritis, psoriasis, and atopic dermatitis. In one or more embodiments, one
or more of a
compound of formula (I), (II), (III), (IVa), (IVb), and (IV) is useful in the
treatment of one or
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
more of atopic dermatitis, psoriasis, psoriatic arthritis, Bechet's disease,
pityriasis rubra pilaris,
alopecia areata, discoid lupus erythematosus, vitiligo, palmoplantar
pustulosis, mucocutaneous
disease erythema multiforme, mycosis fungoides, graft-versus-host disease,
cutaneous lupus,
rheumatoid arthritis (RA), arthritis, ulcerative colitis, Crohn's disease,
inflammatory bowel
disease (MD), transplant rejection, systemic lupus erythematosus (SLE),
dermatomyositis,
Sjogren's syndrome, dry eye disease, secondary hypereosinophilic syndrome
(HES), allergy,
asthma, vasculitis, multiple sclerosis, diabetic nephropathy, cardiovascular
disease,
artherosclerosis, and cancer. One route of administration may be oral. One
route of
administration may be topical.
[0159] In one aspect, the invention of the present disclosure provides for a
method of treating
one or more diseases or disorders of inflammation, auto-immune dysfunction,
and cancer
comprising administering to a subject in need thereof an effective amount of a
compound that is
an embodiment herein of formula (I), (II), (III), (IV), (IVa) or (IVb).
[0160] In one embodiment, the invention of the present disclosure provides a
method of treating
atopic dermatitis, flea allergy dermatitis, psoriasis, or rheumatoid arthritis
comprising
administering to a subject in need thereof an effective amount of a compound
that is an
embodiment of formula (I), (II), (III), (IV), (IVa) or (IVb). In one
embodiment, the compound is
administered orally; in one embodiment, the compound is administered
parenterally; in one
embodiment, the compound is administered topically.
[0161] In one embodiment, the invention of the present disclosure provides for
a method for
treating one or more diseases or disorders of inflammation, auto-immune
dysfunction, and cancer
comprising administering to a subject in need thereof an effective amount of a
compound
according to any embodiment herein of formula (I), (II), (III), (IV), (IVa) or
(IVb) wherein the
subject is a mammal.
[0162] In one embodiment, the invention of the present disclosure provides for
method for
treating one or more diseases or disorders of inflammation, auto-immune
dysfunction, and cancer
comprising administering to a subject in need thereof an effective amount of a
compound
according to any embodiment herein of formula (I), (II), (III), (IV), (IVa) or
(IVb) wherein the
subject is selected from one or more of livestock mammals, domestic mammals,
and companion
animals. In one embodiment, the mammal is one or more of humans, cattle,
sheep, goats, llamas,
alpacas, pigs, horses, donkeys, dogs, and cats. In one embodiment, the mammal
is a human, a
96
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
dog, or a cat.
[0163] In one aspect, the invention of the present disclosure provides a
compound for use in
medicine, wherein the compound is an embodiment of formula (I), (II), (III),
(IV), (IVa), or
(IVb) herein
[0164] In another aspect, the invention of the present disclosure provides for
use of a compound
according to any embodiment herein of any of formula (I), (II) (III), (IV),
(IVa), and (IVb) for
the manufacture of a medicament for the treatment of one or more diseases or
disorder of
inflammation, auto-immune dysfunction, and cancer.
[0165] In one embodiment, the invention of the present disclosure provides for
use of a
compound according to any embodiment herein of formula (I), (II), (III) (IV),
(IVa), or (IVb) for
the manufacture of a medicament for the treatment of a disease or disorcer
that can be be
ameliorated by the selective inhibition of a Janus kinase JAK 1 relative to
JAK 2. In one
embodiment, the disease or disorder is atopic dermatitis, flea allergy
dermatitis, psoriasis, or
rheumatoid arthritis.
[0166] In one aspect, the invention provides for use of a compound according
to an embodiment
of formula (I), (II), (III), (IV), (IVa) or (IVb) herein and a second active
agent in the manufacture
of a medicament for the treatment of a disease or a disorder that can be
ameliorated by the
selective inhibition of a Janus kinase JAK 1 relative to JAK 2.
[0167] In one aspect, the invention provides for use of a compound according
to an embodiment
of formula (I), (II), and (III), (IV), (IVa), or (IVb) herein for the
treatment of one or more
diseases or disorders of inflammation, auto-immune dysfunction, and cancer. In
one
embodiment, the disease or disorder is atopic dermatitis, flea allergy
dermatitis, psoriasis, or
rheumatoid arthritis.
[0168] The present invention explicitly encompasses compounds described
herein, including salt
forms thereof, and salt forms thereof The present invention also encompasses
those compounds
presented herein, including stereoisomers thereof. The compounds encompassed
by the present
invention include, in some embodiments, compounds selected from Compound Lists
1 and 2 as
described herein.
97
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
[0169] Compound List 1
Structure IUPAC Name
f- 1-(trans-4-eyanotetrahydro-2H-
pyran-3-y1)-3-((1-
,4
f <
....P.
:\ . hydroxy-1,3-di hydroben zo [el [1,2]oxaborol-6-
f .
/
)vm......(: \
..-::::.... / yl)amino)-1H-pyrazole-4-carboxamide
='= 'Id
1 fr?
.49.
= =:=== A
11,
\ 1
c17H18BN504
Example 16 herein
1-(trans-4-eyanotetrahydro-2H-pyran-3-y1)-3-((1 -
fl. hydroxy-1,3-dihydrobenzo [el
[1,2]oxaborol-5-
j(
et¨O\ yl)amino)-1H-pyrazole-4-carboxamide
I >...... ,
e
, ,/
i \ ...
N.., ......
WI,- to
e%11.7 ,,,,;=,1-.: ==,,
I I
(
4'''s-----g=,.
'OH
C17F118BN504
Example 41 herein
it.
1 -(trans-4-ey an otetrah ydro-2H-pyran-3 -y1)-3 -44-
.i
fluoro-l-hydroxy-1,3-
µ,-----=1,`
i= \
i N.A.....s. \ dihydrobenzo[e][1,21oxaborol-6-yl)amino)-
1H-
RN"'
pyrazole-4-carboxamide
.1
: ,=
e
1 I
C17F117BFN304
Example 1 herein
98
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
1-(trans-4-cyanotetrahydro-2H-pyran-3-y1)-3-((2-
,,k
hydroxy-2H-benzo[e][1,210xaborinin-6-
3-
)00,00c.
yl)amino)-1H-pyrazolc-4-carboxamide
1
6*1
C181-118BN504
Example 51 herein
1-(trans-4-cyanotetrahydro-2H-pyran-3-y1)-3-((2-
o
hydroxy-2H-benzo[e][1,21oxaborinin-7-
,k
yl)amino)-1H-pyrazole-4-carboxamide
/
/
1
=
"It
1,, = EL,
C181-118BN504
Example 2 herein
1-(trans-4-cyanotetrahydro-2H-pyran-3-y1)-342-
,...-A.
\
hydroxy-4-methy1-2H-benzo[e] [1,2]oxaborinin-6-
z
yl)amino)-1H-pyrazole-4-carboxamide
*1.
c?
A
A
-
C19H20BN504
Example 3 herein
99
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
o _____________________________________________ 3-((7-chloro-1-hydroxy-1,3-
.-X---, ..-.0;' -. i= dihydrobenzo[c][1,21oxaborol-5-
yl)amino)-1-
,t,v
(trans-4-cyanotctrahydro-2H-pyran-3-y1)-1H-
., .
K4
\ I"
w pyrazole-4-carboxamide
\ *,,.
I' ---1:-.1
/ I
C171-117BCIN504
Example 52 herein
c.,
1-(trans-4-cyanotetrahydro-2H-pyran-3-y1)-3((2-
,::!;-;\
N4z.N1; I hydroxy-3,4-dimethy1-2H-
1
':,..õ
1 benzo[e][1,21oxaborinin-6-yl)amino)-1H-
WS
,==''''''' 'IP
le
g4 pyrazole-4-carboxamide
</
,
. .õ1.
%
\
'i
e..
i
C20H22BN504
Example 4 herein
0 1-(trans-4-cyanotetrahydro-2H-
pyran-3-y1)-342-
¶, i
hydroxy-3-methy1-2H-benzo[e][1,21oxaborinin-6-
',/
t yl)amino)-1H-pyrazole-4-carboxamide
gl
;;:-
*IN/ ?fi
\
N
er---s
N 1.Z,..
/
/ ti
'L 2>
-e
/
/ \
bn
c19H20BN504
Example 5 herein
100
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
o _____________________________________________________________________
11 1-(trans-4-eyanotetrahydro-2H-pyran-3-y1)-3-
((1-
,...
\ =:::
hydroxy-7-methyl-1,3-
...--4 :.= x l i
I - s,
i
i dihydrobenzo[c J [ 1 ,2] oxab
o rol -5 -yl)amino)- 1H-
....-------/
Mr
i e pyrazole-4-carboxamide
1 ,...,-.
to""" sil W
0
'OH
C18H20BN504
Example 6 herein
1-(trans-4-eyanotetrahydro-2H-pyran-3-y1)-3-((1-
/ ;
1 i õ ,
"---, ..:.:,- ..
4:4
. ., ---f- - ,401.0(\ I hydroxy-3,4-dihydro-1H-
.,, 1
k e
1 benzo[e][1,21oxaborinin-7-
yl)amino)-1H-
..-,
13N. N
; 0 pyrazole-4-carboxamide
µ).... N
: )
C18H2oBN504
Example 42 herein
li 1-(trans-4-cyanotetrahydro-2H-pyran-3-y1)-3-
((1-
,
e \ c. hydroxy-3,4-dihydro-1H-
ii,4 '''. ..=,,,,,..0%,
\õ
benzo[c][1,21oxaborinin-6-yl)amino)-1H-
õ,.,,:=,:sw,
pyrazole-4-carboxamide
1..,, .1
..:,
1
..,'`'',,-= ..,-,
1
Z i
.iL
C18H20BN504
Example 7 herein
101
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
[0170] Compound List 2
O - \
\,......./"'"
,.
1. OH
i4,14
\ t
A., L 1-' ,A
...r.õ..
o- xti--- - ----
14
Ci 11 0
01' /..4 H
t4H2
µ2
Example 43 herein Prophetic Example
'
- ''''--N
, ....2N
\--if F pH k......,,.::.
i,i` õsti .0-..., . ,0 =..
8 _OH
.... N .õ---,...õ..õ. -,...
0.--" to42 Br
Example 38 herein Prophetic Example
102
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
[0171] A composition comprising a therapeutically acceptable amount of any of
the compounds
described herein is within the scope of the invention. The composition may
further comprise a
pharmaceutically or veterinary acceptable excipient, diluent, carrier, or
mixture thereof. Such a
composition may be administered to a subject in need thereof to treat or
control a disease or
disorder mediated, in whole or in part, directly or indirectly, by JAK. The
composition may
further comprise an additional active agent, as described herein.
EXAMPLES
Experimental Procedures.
[0172] The following examples provide a more detailed description of the
process conditions for
preparing compounds of the present invention. It is to be understood, however,
that the
invention, as fully described herein and as recited in the claims, is not
intended to be limited by
the details of the following schemes or modes of preparation.
Certain abbreviations may be used in describing the examples of the present
disclosure. The
abbreviations are believed to be used consistently within commonly accepted
use of those skilled
in the art.
CHEMISTRY EXAMPLE S
[0173] In the following schemes, general substituent groups are represented
with assignments
that may not align with the formulae of the present disclosure. The following
schemes provide a
key for such sub stituent groups that should be followed for the schemes and
not applied to the
formulae of the present disclosure.
SYNTHETIC EXAMPLES
[0174] Following the general and specific synthetic teaching of the present
disclosure, the
compounds listed have been synthesized and characterized as set forth herein:
103
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
Preparation of intermediate A
H2N
0-'sr NH
1). TMSCN, TMSOTf, DCM H2N
...,0., ¨14 3
.....C.))
0-20 C, 8 h =-=-='.'0 H 2N
0
-"-=r
N
_--,.,,) _____
--Tr 2). pyridine, POCI3, DCM NC DBU, Et0H
0
70 C, 20 h 90 C, 48 h H2N
NC
int.A
Preparation of 3,6-dihydro-2H-pyran-4-carbonitri(e
0,_ 1). TMSCN, TMSOTf, DCM
(0-20 C, 8 h
2). pyridine POCI3 DCM, , Tr ..-
NC''..-Ss*"..j-...
0 70 C, 20 h
To a mixture of 'TMSCN (142 g, 1.44 mol, 180 mL, 1.2 eq) in DCM (600 mL) was
added
tetrahydropyran-4-one (120 g, 1.20 mol, 100 mL, 1 eq) and TMSOTf (13.3 g, 59.9
mmol, 9.0 mL,
0.05 eq) dropwise at 0 C and stirred at 20 C for 8 h. Then added pyridine (979
g, 12.3 mol, 10.3
eq), followed by P0C13 (551 g, 3.60 mol, 3 eq) dropwise. The resulting mixture
was heated and
stirred at 70 C for 20 h under N2 atmosphere. TLC showed the reaction was
completed. The
reaction mixture was poured into 5 L of ice water and adjusted pH to 7 by HC1
(2 N). The black
solid was filtered out. The filtrate was extracted with Et0Ac (2 L x 2). The
combined organic
layers were washed with brine (2 L x 2), dried over Na2SO4, filtered and
concentrated under
reduced pressure to give a residue. The residue was purified by column
chromatography (SiO2,
Petroleum ether/Ethyl acetate=15/1 to 5/1) to give 3,6-dihydro-2H-pyran-4-
carbonitrile (100 g,
76.4% yield) as red oil. IH NMR (CDC13, 400 MHz) 6 6.66-6.63 (m, 1H), 4.26 (q,
J = 2.8 Hz,
2H), 3.82 (t, J = 5.6 Hz, 2H), 2.38-2.33 (m, 2H).
[0175]
Preparation of 3-amino-1-[(trans)-4-cyanotetrahydro-2H-pyran-3-yllpyrazole-4-
carboxamide
104
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
H2N
ONH _________________________________________________ ON
H2N
HN
).=
NC DBU, Et0H ¨14 1\16
90 C, 48 h H2N
int.A
To a mixture of 3-amino-1H-pyrazole-4-carboxamide (15.0 g, 118 mmol, 1 eq) and
3,6-dihydro-
2H-pyran-4-carbonitrile (26.0 g, 237 mmol, 2 eq) in ethanol (600 mL) was added
DBU (41.7 g,
273 mmol, 41.2 mL, 2.3 eq) dropwise at 20 C. The resulting mixture was heated
and stirred at
90 C for 48 h under N2 atmosphere. LCMS showed the reaction was completed and
desired MS
observed. The reaction mixture was concentrated in vacuum to give a residue.
The residue was
purified by column chromatography (SiO2, Ethyl acetate/Me0H =1/0 to 20/1) to
give 3-amino-1-
(4-cyan otetrahydro-2H-pyran-3-y1) pyrazol e-4-carboxami de (5.4 g, 19.3%
yield) as a white solid.
1H NMIt (DMSO-d6,400 MHz) 6 8.04(s, 1H), 7.36 (br s, 1H), 6.83 (br s, 1H),
5.50 (s, 2H), 4.39-
4.33 (m, 1H), 3.94-3.89 (m, 2H), 3.56-3.37 (m, 2H), 3.38-3.32 (m, 1H), 2.12-
2.09 (m, 1H), 1.95-
1.91 (m, 1H).
[0176]
Preparation of Intermediate DI
07;2
NI-12 C?""ZEN
Cr o OH
). CN __________
1
TMSCN, DMSO, H20 pyridine, POCI:, ______ CN
DBU, Et0H N -N .),LNH
2
20 C, 0.5 h 0 C-100 C, 2 h 20 C-100 C, 16 h
0
NH2
Dl
Preparation of 1-hydroxycyclohexaneearbonitrile
IT
OH
r
TMSCN, DMSO, H20 C:t
20 C, 0.5 h
To a mixture of cyclohexanone (968 mmol, 100 mL, 1 eq) in DMSO (950 mL) and
H20 (175 mL)
was added TMSCN (1.26 mol, 157.4 mL, 1.3 eq) drop-wise at 20 C under N2. The
mixture was
stirred at 20 C for 0.5 h. TLC showed the reaction was completed. The mixture
was poured into
ice-water (w/w = 1/1) (2 L) and stirred for 10 min. The aqueous phase was
extracted with ethyl
acetate (500 mL x 3). The combined organic phase was washed with brine (300 mL
x 2), dried
105
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
with anhydrous Na2SO4, filtered and concentrated in vacuum to give a residue.
The residue was
purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=10/1 to
4/1) to give 1-
hydroxycyclohexanecarbonitrile (100 g, 82.5% yield) as a yellow oil.
[0177]
Preparation of cyclohexene-1-carbonitrile
OH
OLCN ______________________________________________ 31- CN
Pyridine, POCI3
0 C-100 C, 2 h
To a mixture of 1-hydroxycyclohexanecarbonitrile (50.0 g, 399 mmol, 1 eq) in
pyridine (6.39 mol,
516 mL, 16 eq) was added P0C13 (799 mmol, 74.2 mL, 2 eq) drop-wise at 0 C
under Nz. The
mixture was heated to 100 C and stirred for 2 h. TLC showed the reaction was
completed. The
mixture was poured into ice-water (w/w = 1/1) (2.5 L) and stirred for 10 min.
The aqueous phase
was extracted with ethyl acetate (1 Lx 3). The combined organic phase was
washed with brine (1
L x 2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to
give a residue. The
residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl
acetate=10/1 to 5/1)
to give cyclohexene-l-carbonitrile (29.0 g, 67.7% yield) as a yellow oil. '1-1
N1V1R (CDC13-d6, 400
MHz) 5 6.62-6.59 (m, 1H), 2.20-2.16 (m, 4H), 1.67-1.63 (m, 4H).
[0178]
Preparation of 3-amino-1-((trans)-2-cyanocyclohexyl)-1H-pyrazole-4-
earboxarnide
Ocx:r1H2
H, N 2 Qieee¨ZZ¨N
/
HN-N
=CN
DBU, Et0H NH2
20 C-100 C, 16 h NH2
D1
To a mixture of cyclohexene-1-carbonitrile (11.2 g, 104 mmol, 2.2 eq) and 3-
amino-1H-pyrazole-
4-carboxamide (6.0 g, 47.5 mmol, 1 eq) in Et0H (100 mL) was added DBU (114
mmol, 17.2 mL,
2.4 eq) drop-wise at 20 C under Nz. LCMS showed the reaction was completed and
desired MS
observed. The mixture was heated to 100 C and stirred for 16 h. The reaction
mixture was
concentrated in vacuum to give a residue. The residue was purified by column
chromatography
(5i02, Ethyl acetate/methanol =1/0 to 10/1) to give 3-amino-1-((trans)-2-
cyanocyclohexyl)-1H-
106
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
pyrazole-4-carboxamide (3.0 g, 27.0% yield) as a white solid. 1H NMR (DMSO-d6,
400 Wiz) 6
7.99 (s, 1H), 7.31 (br s, 1H), 6.79 (br s, 1H), 5.44 (s, 2H), 4.20-4.13 (m,
1H), 3.15-3.08 (m, 1H),
2.15-2.12 (m, 1H), 1.89-1.86 (m, 1H), 1.77-1.65 (m, 4H), 1.43-1.26 (m, 2H).
[0179]
Preparation of intermediate D2
HN¨N
Q.....N
0 NH2
CN
TMSCN NC OH POCI3, Pyridine
)_e_tiss¨N
DMSO, H20 0-100 C, 3 h [1:5. DBU, Et0H
NH
2
50 C, 12 h 90 C, 20 h
0
NH2
Preparation of 1-hydroxycyclopentanecarbonitrile
0 NC OH
TMSCN
DMSO, H20
50 C, 12 h
To a mixture of cyclopentanone (83.0 g, 986 mmol, 87.3 mL, 1 eq) in DMSO (800
mL) and H20
(160 mL) was added dropwise TMSCN (127 g, 1.28 mol, 160 mL, 1.3 eq) at 0 C.
The mixture
was heated and stirred at 50 C for 12 h. TLC showed the reaction was
completed. The reaction
was poured into ice: H20 = (1:1, 500 mL) and extracted with Et0Ac (500 mL x
3). The combined
organic layers were washed with brine (500 mL x 2), dried over anhydrous
Na2SO4, filtered and
concentrated under reduced pressure to give a residue. The residue was
purified by flash silica gel
chromatography (ISCOR; 330 g SepaFlashe Silica Flash Column, Eluent of 0-10%
Ethyl
acetate/Petroleum ether gradient @ 150 mL/min) to give 1-
hydroxycyclopentanecarbonitrile (50.0
g, 45.5% yield) as colorless oil. 1H NMR (CDC13, 400 MHz) 6 3.56-3.40 (m, 1H),
2.18-2.05 (m,
4H), 1.97-1.79 (m, 4H).
[0180]
Preparation of cyclopentene-1-carbonitrile
OH CN
POCI3, Pyridine
0-100 C, 3 h
To a mixture of 1-hydroxycyclopentanecarbonitrile (50.0 g, 449 mmol, 1 eq) in
pyridine (500 mL)
was added dropwise P0C13 (137 g, 899 mmol, 83.6 mL, 2 eq) at 0 C under N2. The
mixture was
107
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
heated and stirred at 100 C for 3 h. TLC showed the reaction was completed.
The reaction was
poured into ice: H20 = (1:1, 1000 mL) and extracted with Et0Ac (500 mL x 3).
The combined
organic layers were washed with brine (500 mL x 2), dried over anhydrous
Na2SO4, filtered and
concentrated under reduced pressure to give a residue. The residue was
purified by flash silica gel
chromatography (ISCO ; 330 g SepaFlash Silica Flash Column, Eluent of 0-5%
Ethyl
acetate/Petroleum ether gradient @ 150 mL/min) to give cyclopentene-l-
carbonitrile (18.0 g, 42.9%
yield) as yellow oil. 1H NMIR (CDC13, 400 MHz) 6 6.66 (q, J = 2.0 Hz, 1H),
2.61-2.52 (m, 4H),
2.04-1.98 (m, 2H).
[0181]
Preparation of Rae-3-amino-1-(2-cyanocyclopentyl)pyrazole-4-earboxamide
HN--N
NH2
CN 0 N-
NH2
DBU, Et0H
NH2
90 C, 20 h NH2
02
To a mixture of cyclopentene-1 -carbonitrile (7.38 g, 71.3 mmol, 90% purity,
1.5 eq) and 3-amino-
1H-pyrazole-4-carboxamide (6.00 g, 47.5 mmol, 1 eq) in Et0H (100 mL) was added
DBU (14.4
g, 95.1 mmol, 14.3 mL, 2 eq) in one portion at 20 C. The mixture was heated
and stirred at 90 C
for 20 h. TLC showed the reaction was completed. The reaction mixture was
concentrated under
reduced pressure to give a residue. The residue was purified by flash silica
gel chromatography
(ISCOC; 220 g SepaFlash Silica Flash Column, Eluent of 0-10% Me0H/Ethyl
Acetate gradient
@ 150 mL/min) to give 3-amino-1-(trans-2-cyanocyclopentyl)pyrazole-4-
carboxamide (6.00 g,
57.5% yield) as a white solid. 1H NAIR (DMSO-d6, 400 MHz) 6 8.03 (s, 1H), 7.30
(br s, 1H), 6.79
(br s, 1H), 5.49 (s, 2H), 4.71 (q, J= 8.0 Hz, 1H), 3.26 (q, J= 8.8 Hz, 1H),
2.26-2.09 (m, 2H), 1.96-
1.72 (m, 4H).
108
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
[0182]
Examples:
1. Preparation of Ntrans-4-cyanotetrahydro-2H-pyran-3-y11-3-1(4-fluoro-1-
hydroxy-3H -2,1-
benzoxaborol-6-yl)aminolpyrazole-4-earboxamide
N
N
Br Br Br
= 0 Mel, K2CO3 4.110 HBPin,
Ir(OMe)2(C00)2 t/M Na104, NH40Ac
OH DMF, 25 C, 2 h Wo 2-MeTHF,0-80 C, 16 h
e
-o' 0 THF/H20, 25
C, 5 h
0
0
H2N)IX--\-N Br H2N H2N-
IrN¨C
(H0)2B le 0
Cu(OAc)2, Pyridine HN N
NC B2Pin2, Pd(PPh3)2C12,
KOAc HN NNC=
0 DCM, 25 C, 15 h dioxane, 25-80 C, 15
h
B 0
Br
0 0
0 0
0
0
NaBH4 H2NN)
HN N s:
NC
THF/Me0H, 0 C, 0.5 h
B-OH
[0183]
1.1 Preparation of methyl 2-bromo-6-fluoro-benzoate
Br Br
0 Mel, K2CO3
0
OH DMF, 25 C, 2 h
0
To a mixture of 2-bromo-6-fluoro-benzoic acid (15.00 g, 68.5 mmol, 1 eq) and
K2CO3 (9.47 g,
68.5 mmol, 1 eq) in DMF (100 mL) was added iodomethane (14.58 g, 102 mmol, 6.4
mL, 1.5 eq)
dropwi se at 25 C under N2, the resulting mixture was stirred at 25 C for 2 h.
H20 (150 mL) was
added into the above reaction mixture, which was extracted with PE (50 mL x
3). The combined
organic layers were washed by brine (50 mL x 2), dried over Na2SO4, filtered
and concentrated in
vacuo to give a residue. The residue was purified by flash silica gel
chromatography (ISCOO;
120 g SepaFlash Silica Flash Column, Eluent of 5-6% Ethyl acetate/Petroleum
ether gradient @
109
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
120 mL/min) to give methyl 2-bromo-6-fluoro-benzoate (12.00 g, 51.5 mmol,
75.18% yield) as
colorless oil. 1H NMR (CDC13, 400 MHz) 6 7.36 (d, J= 8.0 Hz, 1H), 7.25 (dd, J=
8.0, 6.4 Hz,
1H), 7.06 (t, J= 8.0 Hz, 1H), 3.95 (s, 3H).
[0184]
1.2 Preparation of methyl 2-bromo-6-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)
benzoate
I
.,...
I
N /
Br Br
= 0 HBPin, Ir(0Me)2(COD)
2 _____________________________________________________ -0,B 0
0 2-MeTHF,0-80 C, 16 h __ -0' W 0
F' F"
To a mixture of methyl 2-bromo-6-fluoro-benzoate (4.00 g, 17.2 mmol, 1 eq),
Ir(OMe)2(COD)2
(228 mg, 343 [tmol, 0.02 eq) and 4-tert-butyl-2-(4-tert-butyl-2-
pyridyl)pyridine (138 mg, 515
umol, 0.03 eq) in 2-MeTHF (30 mL) was added 4,4,5,5-tetramethy1-1,3,2-
dioxaborolane (3.30 g,
25.8 mmol, 3.74 mL, 1.5 eq) dropwise at 0 C under N2 atmosphere, the resulting
mixture was
stirred at 80 C for 16 h. The reaction mixture was filtered, and the filtrate
was concentrated in
vacuo to give a residue. The residue was purified by flash silica gel
chromatography (ISCOO;
40g SepaFlash Silica Flash Column, Eluent of 0-10% Ethyl acetate/Petroleum
ether gradient @
100 mL/min) to give methyl 2-bromo-6-fluoro-4-(4,4,5,5-tetramethy1-1,3,2-
dioxaborolan -2-
yl)benzoate (2.80g, 5.46 mmol, 31.81% yield, 70% purity) as colorless oil. 1H
NMR (CDC13, 400
MHz) 6 7.80 (s, 1H), 7.48 (d, J= 8.8 Hz, 1H), 3.98 (s, 3H), 1.35 (s, 12H).
[0185]
1.3 Preparation of (3-bromo-5-fluoro-4-methoxycarbonyl-phenyl)boronic acid
Br Br
0 Na104, N11-140Ac
0
B __________________________________________________ ) __ (H0)2B
-0' 0 THF/H20, 25 C, 5 h 0
F/ F"
To a mixture of methyl 2-bromo-6-fluoro-4-(4,4,5,5-tetramethy1-1,3,2-
dioxaborolan-2-y1)
benzoate (2.80 g, 5.46 mmol, 70% purity, 1 eq) in THF (15 mL) and H20 (20 mL)
was added
NaI04 (4.67 g, 21.8 mmol, 1.21 mL, 4 eq) and ammonium acetate (1.68 g, 21.8
mmol, 4 eq) in one
portion at 25 C under N2 atmosphere, the resulting mixture was stirred at 25 C
for 5 h. H20 (10
mL) was added into the above mixture, the resulting mixture was extracted with
Et0Ac (10 mL x
110
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
2). The combined organic layers were washed by brine (10 mL x 2), dried over
Na2SO4, filtered
and concentrated in vacuo to give a residue. The residue was purified by flash
silica gel
chromatography (ISCOO; 40 g SepaFlash Silica Flash Column, Eluent of 5-15%
Ethyl
acetate/Petroleum ether gradient @ 90 mL/min) to give (3-bromo-5-fluoro-4-
methoxycarbonyl -
phenyl)boronic acid (1.20 g, 4.33 mmol, 79.39% yield) as a white solid. 1H NMR
(DMSO-d6, 400
MHz) 6 8.58 (s, 2H), 7.89 (s, 1H), 7.64 (d, J= 9.6 Hz, 1H), 3.91 (m, 3H).
[0186]
1.4 Preparation of methyl 2-brorno-4-[[4-carbamoyl-1-[trans-4-cyanotetrahydro-
2H-pyran -3-
yllpyrazol-3-yllaming-6-fluoro-benzoate
0
H2N fir H2N-A
s 0
rN Br Ne-
(H0)2B 0
Cu(OAc)2, Pyridine
DCM, 25 C, 15 h HN
0
Ne
11110
Br
0 0
To a mixture of (3-bromo-5-fluoro-4-methoxycarbonyl-phenyl)boronic acid (565
mg, 2.04 mmol,
1.2 eq) and 3-amino-l-[rans-4-cyanotetrahydro-2H-pyran-3-yl]pyrazole-4-
carboxamide (400
mg, 1.70 mmol, 1 eq) in DCM (50 mL) was added pyridine (673 mg, 8.50 mmol, 5
eq) and
Cu(OAc)2 (772 mg, 4.25 mmol, 2.5 eq) in one portion at 25 C under N2
atmosphere, the resulting
mixture was stirred at 25 C for 15 h. Then the reaction mixture was filtered,
the filtrate was
concentrated in vacuo to give a residue. The residue was purified by flash
silica gel
chromatography (ISCOg; 20 g SepaFlash Silica Flash Column, Eluent of 75-85%
Ethyl
acetate/Petroleum ether gradient @90 mL/min) to give methyl 2-bromo-4-[[4-
carbamoy1-1-[trans-
4-cyanotetrahydro-2H-pyran-3-yl]pyrazol-3-yl]amino]-6-fluoro-benzoate (200 mg,
429 umol,
12.61% yield) as a white solid. 1H NMIR (DMSO-do, 400 MHz) 6 9.60 (s, 1H),
8.36 (s, 1H), 7.81
(br s, 1H), 7.69-7.65 (m, 2H), 7.31 (br s, 1H), 4.66-4.61 (m, 1H), 4.08-4.06
(m, 1H), 4.05-4.03 (in,
1H), 3.85 (s, 3H), 3.68-3.65 (m, 2H), 3.49-3.48 (m, 1H), 2.17-2.14 (m, 1H),
2.00-1.90 (m, 1H).
111
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
[0187]
1.5 Preparation of methyl 4-114-carbamoy1-1-Itrans-4-cyanotetrahydro-2H-pyran-
3-yll pyrazol-
3-yllamino]-2-fluoro-6-(4, 4,5, 5-tetramethy1-1,3 ,2-dioxaborolan-2-
yl)benzoate
H2N H2N-j4rN_N/¨os)
HN N HN N
NC B2Pin2, Pd(PPh3)2C12,
KOAc NC.
Olt dioxane, 25-80 C 15 h
B-0
Br F "IP
o 0 o o
To a mixture of methyl 2-bromo-4-[[4-carbamoy1-1-[trans-4-cyanotetrahydropyran-
3-yl] pyrazol-
3-yl]amino]-6-fluoro-benzoate (100 mg, 214 pmol, 1 eq) and 4,4,5,5-tetramethy1-
2 -(4,4,5,5-
tetramethy1-1,3,2-dioxaborolan-2-y1)-1,3,2-dioxaborolane (272 mg, 1.07 mmol, 5
eq) in dioxane
(5 mL) was added KOAc (53 mg, 536 pmol, 2.5 eq) and Pd(PPh3)2C12 (15 mg, 21
pmol, 0.1 eq) in
one portion at 25 C under N2 atmosphere, the resulting mixture was stirred at
80 C for 15 h. Then
the reaction mixture was filtered, the filtrate was concentrated in vacuo to
give a residue. The
residue was purified by flash silica gel chromatography (ISCOV; 12 g SepaFlash
Silica Flash
Column, Eluent of 70-90% Ethyl acetate/Petroleum ether gradient @ 75 mL/min)
to give methyl
4- [[4-carbamoyl -1 -[trans-4-cyanotetrahy dro-2H-pyran-3 -yl] .. pyrazol-3 -
y1 ] amino]-2-fluoro-6-
(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)benzoate (200 mg, 234 pmol,
54.50% yield, 60%
purity) as a white solid. 1H NMR (CDC13, 400 MHz) 6 9.23 (s, 1H), 7.82 (s,
1H), 7.64 (d, J= 9.2
Hz, 1H), 7.1 (dõI = 2 Hz, 1H), 5.53 (br s, 2H), 4.26-4.23 (m, 1H), 4.18-4.16
(m, 1H), 4.07-4.04
(m, 3H), 3.92 (s, 3H), 3.66-3.65 (m, 1H), 2.17-2.15 (m, 1H), 2.05-2.03 (m,
1H), 1.42 (s, 12H).
[0188]
1.6 Preparation of Ntrans-4-eyanotetrahydro-2H-pyran-3-y11-3-[(4-fluoro-1-
hydroxy-311 -2,1-
benzoxaborol-6-yl)aminolpyrazole-4-earboxamide
H2N
H2N-jLX---"\-
NC
HN N
NaBH4 HN
NC
THF/Me0H, 0 C, 0.5 h
411
B---
0 0
To a mixture of methyl 4-[[4-carbamoy1-14trans-4-cyanotetrahydropyran-3-
yl]pyrazol -3-
yl]amino1-2-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate
(200 mg, 234 pmol,
112
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
60% purity, 1 eq) in THF (1 mL) and Me0H (0.1 mL) was added NaBH4 (44 mg, 1.17
mmol, 5
eq) in portions at 0 C under N2 atmosphere, the resulting mixture was stirred
at 0 C for 0.5 h.
The reaction was quenched with addition of H20 (3 mL) at 0 C, pH of the
resulting mixture was
adjusted to 2-3 with 2N HC1, the mixture was extracted with Et0Ac (5 mL x 4).
The combined
organic layers were washed by brine (3 mL x 2), dried over Na2SO4, filtered
and concentrated in
vacuo to give a residue. The residue was purified by prep-HPLC (column: Welch
Xtimate C18
100*25mm*3um; mobile phase: [water (0.05%HC1)-ACN];B%: 5%-35%,8min) to give 1-
[trans-
4-cyanotetrahydropyran-3-y1]-3-[(4-fluoro-1-hydroxy-3H-2,1-benzoxaborol-6-
y1)amino]pyrazole-4-carboxamide (35.6 mg, 89 imol, 38.25% yield, 96.75%
purity) as a white
solid. 11-I NMR (DMSO-d6, 400 MHz) 69.42 (s, 1H), 9.32 (s, 1H), 8.32 (s, 1H),
7.76 (br s, 1H),
7.71 (d, J= 12.4 Hz, 1H), 7.44 (s, 1H), 7.25 (br s, 1H), 5.01 (s, 2H), 4.60
(dd, J= 12.0, 4.4 Hz,
1H), 4.06-4.02 (m, 1H), 3.91-3.89 (m, 1H), 3.72-3.67 (m, 2H), 3.52-3.48 (m,
1H), 2.18-2.15 (m,
1H), 2.01-1.97 (m, 1H). MS (ESI): mass calculated for C17H17BFN504, 385.14,
m/z found 386.2
[M-41]+. Purity by HPLC: 96.75% (220 nm), 99.38% (254 nm).
[0189]
2. Preparation of 1-[trans-4-cyanotetrahydro-2H-pyran-3-y1]-3-1(2-hydrav-1,2-
benzoxaborinin -7-yl)aininolpyrazole-4-carboxantide
o
Br
Br
411 OH LDA, PMDTA
Br OH tris[2-(2-
pyridyl)phenyl]iridium
,
CH3CN, 25 C, 15 h
0 THE, 0 C, 1 h
\ B.,OH
NH2 NH2
H2N 0>
/¨
N -
Nes HN
NC
KOAc, Pd2(dba)3, t-BuXPhos
i-PrOH, 25-80 C, 0.5 h 40
113
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
[0190]
2.1 Preparation of (E)-5-bronto-2-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)vinyl) phenol
Br >Si"
40 ____________________________________________
= OH Bb
OH LDA, PMDTA Br
THE, 0 C, 1 h
To a mixture of LDA (2 M, 37.3 mL, 3 eq) in THF (50 mL) was added 4,4,5,5-
tetramethyl -2-
[(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)methyl]-1,3,2-dioxaborolane
(20.00 g, 74.6 mmol,
3 eq) and N'[2-(dimethylamino)ethy1]-N,N,NI-trimethyl-ethane-1,2-diamine (8.62
g, 49.7 mmol,
10.4 mL, 2 eq) dropwise at 0 C under N2 atmosphere, the resulting mixture was
stirred at 0 C for
20 min. To the above mixture was then added a solution of 4-bromo-2-hydroxy-
benzaldehyde
(5.00 g, 24.8 mmol, 1 eq) in THF (50 mL) at 0 C, and the resulting mixture was
stirred for 1 h at
0 C. The reaction was quenched with sat. aq NH4C1 (100 mL), extracted with
Et0Ac (50 mL x
2). The combined organic layers were washed by brine (100 mL x 2), dried over
Na2SO4, filtered
and concentrated in vacuo to give a residue. The residue was purified by flash
silica gel
chromatography (ISCO ; 80 g SepaFlash Silica Flash Column, Eluent of 10-15%
Ethyl
acetate/Petroleum ether gradient @100mL/min) to give (E)-5-bromo-2-(2-(4,4,5,5
-tetramethyl-
1,3,2-dioxaborolan-2-yl)vinyl)phenol (5.00 g, 15.38 mmol, 61.85% yield) as
yellow oil. 1-1-1 NMR
(CDC13, 400 MHz) 6 7.56 (d, J= 18.4 Hz, 1H), 7.33 (d, J= 8.4 Hz, 1H), 7.05 (d,
J= 8.4 Hz, 1H),
7.00 (s, 1H), 6.16 (d, J= 18.4 Hz, 1H), 5.49 (br d, 1H), 1.29 (s, 12H).
[0191]
2.2 Preparation of 7-bromo-2-hydroxy-1,2-benzoxaborittine
Br
OH p tris[2-(2-pyridyl)phenyl]iridium
Br
CH3CN, 25 C, 15 h
B-OH
To a mixture of 5-bromo-2-[(Z)-2-(4,4,5,5-tetram ethyl - 1,3,2-dioxab orol an-
2-yl)vinyl ]phenol (500
mg, 1.54 mmol, 1 eq) in CH3CN (10 mL) was added tris[2-(2-
pyridyl)phenyl]iridium (10 mg, 15
iLunol, 0.01 eq) in one portion at 25 C under N2 atmosphere, the resulting
mixture was stirred and
irradiated using 34W blue LED lamps for 15 h. The mixture was filtered, and
the filtrate was
concentrated in vacuo to give a residue. The residue was purified by prep-HPLC
(column: Waters
Xbridge Prep OBD C18 150*40mm*10um; mobile phase: [water (10mM NH4HC 03)-ACN];
B%:
114
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
30%-60%,8min) to give 7-bromo-2-hydroxy-1,2 ¨benzoxaborinine (240 mg, 1.07
mmol, 23.13%
yield) as a white solid. 1H NMR (DMSO-d6, 400 MHz) 6 9.17 (s, 1H), 7.78 (d, J=
12.0 Hz, 1H),
7.47 (d, J' 8.0 Hz, 1H), 7.45 (d, J= 2.0 Hz, 1H), 7.33 (dd, J= 8, 2 Hz, 1H),
6.17 (d, J= 12.0 Hz,
1H).
[0192]
2.3 Preparation of 1-[trans-4-cyanotetrahydro-211-pyran-3-ylk34(2-hydroxy-1,2-
benzoxaborinin -7-y0aminolpyrazole-4-earboxamide
NH, NE-I2
C)
Br
00 n H2N N /¨
NC HN
Nd
KOAc, Pd2(dba)3, t-BuXPhos
B4OH i-PrOH, 25-80 C, 0.5 h
B4OH
To a mixture of 3-amino-l-[rans-4-cyanotetrahydropyran-3-yl]pyrazole-4-
carboxamide (276
mg, 1.17 mmol, 1.1 eq) and 7-bromo-2-hydroxy-1,2-benzoxaborinine (240 mg, 1.07
mmol, 1 eq)
in i-PrOH (4 mL) was added AcOK (157 mg, 1.60 mmol, 1.5 eq), Pd2(dba)3 (49 mg,
53 p,mol,
0.05 eq) and t-BuXPhos (45 mg, 107 [imol, 0.1 eq) in one portion at 25 C under
N2 atmosphere,
the resulting mixture was stirred at 80 C for 0.5 h. The mixture was filtered,
and the filtrate was
concentrated in vacuo to give a residue. The residue was purified by prep-HPLC
(column:
Welch Xtimate C18 100*25mm*3um; mobile phase: [water (0.05%HC1)-ACN]; B%:10%-
40%,
8min) to give 1-[trans-4-cyanotetrahydro-2H-pyran-3-y1]-3-[(2-hydroxy-1,2-
benzoxaborinin-7-
yl)amino] pyrazole-4-carboxamide (150.9 mg, 398 37.28% yield, 95.11%
purity) as a
white solid. IHNMIt (DMSO-d6, 400 MHz) 6 9.42 (s, 1H), 8.80 (s, 1H), 8.33 (s,
1H), 7.77 (br s,
1H), 7.69 (d, J= 11.6 Hz, 1H), 7.54 (d, J = 2.0 Hz, 1H), 7.35 (d, J= 8.4 Hz,
1H), 7.24 (br s, 1H),
7.11 (d, J = 8.4, 2.0 Hz, 1H), 5.87 (d, J = 11.6 Hz, 1H), 4.63-4.58 (m, 1H),
4.08-4.04(m, 1H),
3.92-3.90 (m, 1H), 3.71-3.65 (m, 2H), 3.52-3.50(m, 1H), 2.19-2.17 (m, 1H),
2.02-1.99 (m, 1H).
MS (ESI): mass calculated for C18H18BN504, 379.15, m/z found 380.2[M-41]+.
Purity by HPLC:
95.11% (220 nm), 98.39% (254 nm).
[0193]
3. Preparation of 1-ftrans-4-eyanotetrahydro-2H-pyran-3-y11-3-1(2-hydroxy-4-
methy1-1,2-
benzoxaborinin-6-yl)aminolpyrazole-4-earboxamide
115
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
0 OH )720r-'017-1(73Z< Am OH
1r(PPY)3 n
0
0 _________________________________ -
Br LDA, PMDTA, THF .. Br 'IP
6 MeCN, 25'0, 16h Br B111W
0-25 C, 1 h
N
0
0 int A NI-1\1 0 BõOH
Pd2dba3, tButyl-XPhos, KOAc, i-PrOH Si
25-95 C, 2411 1\1
0
NH2
[0194]
3.1 Preparation of 4-bromo-2-1(E)-1-methyl-2-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan -2-
yl)vinyll phenol
op OH 0 0 An OH
0
0 ____________ Br 41*IIIIP 131.<
Br LDA, PMDTA, THF
0-25 C, 1 h
To a mixture of LDA (2 M, 25.6 mL, 2.2 eq) in THF (40 mL) was added N'42-
(dimethylamino)ethy1]-N,N,N'-trimethyl-ethane-1,2-diamine (8.06 g, 46.5 mmol,
9.7 mL, 2 eq)
and a solution of 4,4,5,5-tetramethy1-2-[(4,4,5,5-tetramethy1-1,3,2-
dioxaborolan-2-y1) methy1]-
1,3,2-dioxaborolane (12.4 g, 46.5 mmol, 2 eq) in THF (30 mL) at 0 C under N2.
The reaction was
stirred at 0 C for 20 min. Then added a solution of 1-(5-bromo-2-hydroxy-
phenyl)ethanone (5.0
g, 23.3 mmol, 1 eq) in THF (30 mL) at 0 C. The reaction mixture was stirred at
25 C for another
40 min. TLC showed the reaction was completed. The mixture was quenched with
sat. aq. NH4C1
(100 mL), adjusted pH to 6 with 2 N HC1 and then extracted with Et0Ac (50 mL x
3). The
combined organic layers were washed with brine (80 mL x 2), dried over Na2SO4,
filtered and
concentrated under reduced pressure to get the residue. The residue was
purified by flash silica
gel chromatography (ISCOg; 80 g SepaFlashe Silica Flash Column, Eluent of 0-
15%
Ethylacetate/Petroleum ether gradient @ 100 mL/min) to give 4-bromo-2-[(E)-1-
methy1-2-
(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)vinyl]phenol (5 g, 80% purity) as
yellow oil.
[0195]
3.2 Preparation of6-bromo-2-hydroxy-4-methy1-1,2-benzoxaborinine
116
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
OH
0,B4OH
Ir(PPY)3
___________________________________________________ >
Br
MeCN, 25 C, 16h Br
0
To a mixture of 4-bromo-2-[(E)-1-methy1-2-(4,4,5,5-tetramethy1-1,3,2-
dioxaborolan-2-yl)vinyl]
phenol (2.50 g, 5.9 mmol, 80% purity, 1 eq) in CH3CN (30 mL) was added tris[2-
(2-
pyridyl)phenyl]iridium (39 mg, 59 umol, 0.01 eq) in one portion at 25 C under
N2. The reaction
was stirred and irradiated using 34W blue LED lamps for 16 h. LCMS showed the
reaction was
completed and desired MS observed. 2 parallel reactions were combined for work
up. The mixture
was concentrated under reduced pressure to give the residue. The residue was
purified by flash
silica gel chromatography (ISCOe; 40g SepaFlashe Silica Flash Column, Eluent
of 0-15% Ethyl
acetate/Petroleum ether gradient @ 100 mL/min) to give 6-bromo-2-hydroxy-4-
methy1-1,2-
benzoxaborinine (2.50 g) as a yellow solid. I-H NMR (CDC13, 400 MHz) 6 8.95
(s, 1H), 7.74 (d, I
= 2.4 Hz, 11-1), 7.55 (dd, 2.4, 8.4 Hz, 1H), 7.18 (d, J= 8.8 Hz, 1H), 5.99
(s, 1H), 2.35 (s, 3H).
[0196]
3.3 Preparation of 1-[trans-4-cyanotetrahydro-2H-pyran-3-y11-3-[(2-hydroxy-4-
methyl-1,2-
benzoxaborinin-6-ypaminolpyrazole-4-carboxamide
40 .-
0, B
OH
Int.A N-N
0
Br Pd2dba3, tButyl-XPhos, KOAc, i-PrOH N
25-95 C, 24h
0
NH2
A mixture of 6-bromo-2-hydroxy-4-methyl-1,2-benzoxaborinine (500 mg, 2.1 mmol,
1 eq) and 3-
amino-1-(trans-4-cyanotetrahydro-2H-pyran-3-yl)pyrazole-4-carboxamide (542 mg,
2.3 mmol,
1.1 eq) in i-PrOH (10 mL) was added Pd2(dba)3 (19 mg, 21 umol, 0.01 eq) , t-Bu
Xphos (178 mg,
419 umol, 0.2 eq) and KOAc (411 mg, 4.2 mmol, 2 eq) at 25 C under N2. Then
reaction was stirred
at 95 C for 24 h. LCMS showed the reaction was completed and desired MS
observed. 4 parallel
reactions were combined for work up. The reaction mixture was filtered and
concentrated in
vacuum to give a residue. The residue was quenched with H20 (60 mL), adjusted
pH to 6 with
2H HC1 at 0 C, and then extracted with Et0Ac (30 mL x 3). The combined organic
layers were
washed with brine (40 mL x 3), dried over Na2SO4, filtered and concentrated
under reduced
pressure to give a residue. The residue was purified by flash silica gel
chromatography (ISCOO;
117
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
20g SepaFlashe Silica Flash Column, Eluent of 0-100% Ethyl acetate/Petroleum
ether gradient
@ 50 mL/min) to give 1-(trans-4-cyanotetrahydro-2H-pyran-3-y1)-3-[(2-hydroxy-
1,2-
benzoxaborinin-6-yl)amino]pyrazole-4-carboxamide (800 mg) as an off-white
solid. The product
was separated by SFC (column: DA10EL CHIRALPAK AD(250mm*30mm,lOurn); mobile
phase:
[Neu-ETOH];B%: 53%-53%,5min) to give 1-[trans-4-cyanotetrahydro-2H-pyran-3-y1]-
3-[(2-
hydroxy-4-methy1-1,2-benzoxaborinin -6-yl)amino]pyrazole-4-carboxamide
(stereoisomer one)
(365.7 mg, 96.7% purity, 99.3% ee, first peak, Rt = 1.330 min) as an off-white
solid. 1H NMR
(DMSO-d6, 400 MHz) 69.06 (s, 1H), 8.63 (s, 1H), 8.29 (s, 1H), 7.93 (d, J= 2.8
Hz, 1H), 7.69 (br
s, 1H), 7.50 (dd, J= 2.8, 8.8 Hz, 1H), 7.12 (d, J= 8.8 Hz, 2H), 5.93 (s, 1H),
4.60-4.54 (m, 1H),
4.06 (dd, J = 4.4, 11.6 Hz, 1H), 3.95-3.92 (m, 1H), 3.72-3.65 (m, 2H), 3.46-
3.33 (m, 1H), 2.40 (s,
3H), 2.18-2.14 (m, 1H), 2.01-1.96 (m, 1H). MS (ESI): mass calculated for
C19H20BN504 393.16;
m/z found 392.1 [M-H]-. HPLC: 96.72% (220 nm), 99.74% (254 nm). and 1-[trans-4-
cyanotetrahydropyran-3 -yl] -3 -[(2-hydroxy-4-methyl-1,2-b enzoxab orinin-6-
yl)amino]pyrazol e-4-
carboxamide (stereoisomer two) (365.4 mg, 98.0% purity, 99.4% ee, second peak,
Rt = 1.548) as
an off-white solid. 1H NMR (DMSO-d6,400 MHz) 69.06 (s, 1H), 8.63 (s, 1H), 8.29
(s, 1H), 7.93
(d, .1 = 2.8 Hz, 1H), 7.69 (hr s, 1H), 7.50 (dd, .1 = 2.8, 8.8 Hz, 1H), 7.17-
7.11 (m, 2H), 5.93 (s, 1H),
4.58-4.53 (m, 1F1), 4.06 (dd, J= 4.4, 11.2 Hz, 111), 3.95-3.92 (m, 1H), 3.72-
3.65 (m, 2H), 3.46-
3.33 (m, 1H), 2.41 (s, 3H), 2.18-2.15 (m, 1H), 2.01-1.93 (m, 1H). MS (ESI):
mass calculated for
C19H2oBN504 393.16, m/z found 392.1 [M-H]. HPLC: 98.00% (220 nm), 99.88% (254
nm).
[0197]
118
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
4. Preparation of 1-(trans-4-eyanotetrahydro-2H-pyran-3-A-342-hydroxy-3,4-
dimethyl-2H-
benzok][1,21oxaborinin-6-Aandno)-1H-pyrazole-4-earboxamide
al OH
0
0, Br
0,13,0H
B B¨C) Mel, LiTMP B B-27-'z< ____________
6 6
THF, 0-20 C, 2 h O (1, LDA, PMDTA Br
0 C, THF ,1.5 h
NsL;NrH2
0 NH 02
0
N¨N
Pd2(dba)3, tBuXPhos, KOAc
i-PrOH, 25-80 C, 50 h
0
NH2
[0198]
4.1 Preparation of 4,4,5,5-tetramethy1-2-11-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-y0 ethyl7-
1,3,2-dioxaborolane
0
B B- Mel, LiTMP
B
6 6
THF, 0-20 C, 2 h 6 6
To a mixture of 2,2,6,6-tetramethylpiperidine (2.90 g, 20.5 mmol, 3.5 mL, 1.1
eq) in THF (30 mL)
was added n-BuLi (2.5 M, 8.2 mL, 1.1 eq) dropwise at 0 C under N2 atmosphere,
the resulting
mixture was stirred at 0 C for 30 min. Then a solution of 4,4,5,5-tetramethy1-
24(4,4,5,5 -
tetramethy1-1,3,2-dioxaborolan-2-yemethy11-1,3,2-dioxaborolane (5.00 g, 18.66
mmol, 1 eq) in
THF (30 mL) was added to the above mixture dropwise at 0 C, the reaction
mixture was stirred
for 30 min at 0 C. Mel (2.91 g, 20.5 mmol, 13 mL, 1.1 eq) was added dropwise
to reaction mixture
at 0 C, the resulting mixture was stirred for 30 min at 20 C. The mixture was
poured into sat. aq
NH4C1 (50 mL), and stirred for 5 min. The aqueous phase was extracted with
ethyl acetate (30
mL x 3). The combined organic phase was washed with brine (30 mL x 2), dried
with anhydrous
Na2SO4, filtered and concentrated in vacuo to give a residue. The residue was
purified by flash
silica gel chromatography (ISCO , 80g SepaFlashe Silica Flash Column, Eluent
of 5-12% Ethyl
acetate/Petroleum ether gradient @ 120 mL/min) to give 4,4, 5,5-tetramethy1-2-
[1-(4,4,5,5-
tetramethy1-1,3,2-dioxaborolan-2-y1)ethyl]-1,3,2-dioxaborolane (3.60 g, 12.77
mmol, 68.42%
yield) as colorless oi1.1H NMR (CDC13, 400 MHz) 6 1.22 (s, 24H), 1.05 (d, J=
7.2 Hz, 3H), 0.74
119
CA 03201606 2023- 6-7
WO 2022/133420
PCT/US2021/072885
(q, J= 7.2 Hz, 1H).
[0199]
4.2 Preparation of 6-bromo-2-hydroxy-3,4-dimethyl-1,2-benzoxaborinine
At OH
0
Br µ111. 0õOH
O.,
3
LDA, PMDTA Br
0 C, THF ,1.5 h
To a mixture of 4,4,5,5-tetramethy1-2-[1-(4,4,5,5-tetramethy1-1,3,2-
dioxaborolan-2-y1)ethyl]-
1,3,2-dioxaborolane (2.62 g, 9.30 mmol, 2 eq) and LDA (2 M, 4.70 mL, 2 eq) in
TIIF (15 mL)
was added N'42-(dimethylamino)ethyll-N,N,N-trimethyl-ethane-1,2-diamine (1.21
g, 6.98 mmol,
1.5 mL, 1.5 eq) dropwise at 0 C under N2 atmosphere, the resulting mixture was
stirred for 30 min
at 0 C. To the above mixture was added a solution of 1-(5-bromo-2-hydroxy-
phenyl) ethanone (1
g, 4.65 mmol, 1 eq) in THF (5 mL) dropwise at 0 C, the resulting mixture was
stirred for 1 h at
0 C. The mixture was poured into sat. aq. NH4C1 (10 mL), the pH of the
resulting mixture was
adjusted to 5-6 with HC1 (2N) at 0 C. The mixture was extracted with Et0Ac (10
mL x 2), the
combined organic layers were washed by brine (10 mL x 2), dried over Na2SO4,
filtered and
concentrated in vacuo to give a residue. The residue was purified by flash
silica gel
chromatography (ISCOg; 80 g SepaFlash Silica Flash Column, Eluent of 5-7%
Ethyl
acetate/Petroleum ether gradient @ 100 mL/min) to give 6-bromo-2-hydroxy-3,4-
dimethy1-1,2-
benzoxaborinine (500 mg, 1.91 mmol, 41.04% yield, 96.53% purity) as a white
soli d.1H NMR
(DMSO-d6, 4001VIHz) 6 8.89 (s, 1H), 7.74 (d, J= 2.4 Hz, 1H), 7.47 (dd, J= 8.8,
2.4 Hz, 1H), 7.14
(d, J= 8.8 Hz, 1H), 2.23 (s, 3H), 1.97 (s, 3H). MS (ESI): mass calculated for
C1oH1oBBr02, 252.00,
m/z found 251.1[M-H]-. Purity by HPLC: 96.53% (220 nm), 99.57% (254 nm).
[0200]
4.3 Preparation of 1-(trans-4-eyanotetrahydro-211-pyran-3-y1)-342-hydroxy-3,4-
dimethyl-211-
benzote][1,21oxaborinin-6-Aamino)-1H-pyrazole-4-earboxamide
N NH2
0,B4OH
N¨N
Br Pd2(dba)3, tBuXPhos, KOAc
i-PrOH, 25-80 C, 50 h
0
NH2
120
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
To a mixture of 6-bromo-2-hydroxy-3,4-dimethy1-1,2-benzoxaborinine (130 mg,
514 umol, 1 eq)
and 3 -amino-1-(trans-4-cy anotetrahy dropyran-3 -yl)pyrazol e-4-carb oxami de
(145 mg, 617 pm ol ,
1.2 eq) in i-PrOH (3 mL) was added Pd2(dba)3 (24 mg, 26 Imo', 0.05 eq), t-Bu
Xphos (22 mg, 51
[Imo', 0.1 eq) and KOAc (76 mg, 771 pmol, 1.5 eq) in one portion at 25 C under
N2 atmosphere,
the resulting mixture was stirred at 80 C for 50 h. To the above mixture was
added H20 (0.1 mL)
at 25 C, the resulting mixture was concentrated in vacuo to give a residue.
The residue was
purified by prep-HPLC (column: Waters Xbridge BEH C18 100*30mm*10um; mobile
phase:
[water (10mM NH4HC 03)-ACN] ; B%: 25%-55%,10min) to give 1 -(trans-4-cy
anotetrahy dro-2H-
pyran-3 -y1)-3 -((2-hydroxy-3,4-dimethy1-2H-b enzo[e] [1,2] oxaborinin-6-y1
)amino)-1H-pyrazole-
4-carboxamide (96 mg, 228.64 umol, 14.83% yield, 96.99% purity) as a yellow
solid. 1H N1VIR
(DMSO-do, 400 MHz) 6 9.04 (s, 1H), 8.56 (s, 1H), 8.29 (s, 1H), 7.94 (d, J= 2.8
Hz, 1H), 7.69 (br
s, 1H), 7.42 (dd, J= 8.4, 2.8 Hz, 1H), 7.15 (br s, 1H), 7.08 (d, J = 8.4 Hz,
1H), 4.58-4.55 (m, 1H),
4.08-4.04 (m, 1H), 3.97-3.94 (m, 1H), 3.72-3.67 (m, 2H), 3.46-3.40 (m, 1H),
2.32 (s, 3H), 2.29-
2.25 (m, 1H), 2.05-1.99 (m, 1H), 1.98 (s, 3H). MS (ESI): mass calculated for
C2oH22BN504,
407.18, m/z found 408.2[M+1-11 . Purity by HPLC: 96.99% (220 nm), 98.08% (254
nm).
[0201]
S. Preparation of 1-(trans-4-eyanotetrahydro-2H-pyran-3-y1)-342-hydroxy-3-
methy1-2H-
benzok][1,2Joxaborinin-6-Aamino)-1H-pyrazole-4-earboxamide
.0N1
N NHz
\o-/-N;NH,
OH 40 0 OH 0 N_N ORN
0,5....OH
RP/ Br LDA, PMDTA Br Pd2(dba)3, tBuXPhos,
KOAc
THF, 0 C, 1.5 h 1-PrOH, 25-80 C, 50 h
0
NH2
[0202]
5.1 Preparation of 6-bromo-2-hydroxy-3-tnethyl-1,2-benzoxaborinine
411
40 OH 03OH
LDA, PMDTA
Br Br
THF, 0 C, 1.5 h
To a mixture of LDA (2 M, 12.4 mL, 2 eq) in THF (15 mL) was added 4,4,5,5-
tetramethy1-2- [1-
(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)ethyl]-1,3,2-dioxaborolane (5.96
g, 21.1 mmol, 1.7
121
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
eq) and N'42-(dimethylamino)ethy1]-N,N,N'-trimethyl-ethane-1,2-diamine (3.23
g, 18.66 mmol,
3.9 mL, 1.5 eq) dropwise at 0 C under N2 atmosphere, the resulting mixture was
stirred at 0 C for
20 min. Then 5-bromo-2-hydroxy-benzaldehyde (2.5 g, 12.44 mmol, 1 eq) in THF
(10 mL) was
added into the mixture above, the reaction mixture was stirred at 0 C for
additional 1 h. The
reaction was quenched with sat. aq NH4C1 (20 mL), extracted with Et0Ac (20 mL
x 2). The
combined organic layers were washed with brine (10 mL x 2), dried over Na2SO4,
filtered and
concentrated in vacuo to give a residue, which was purified by prep-HPLC
(column: Phenomenex
Gemini-NX 80*40mm*3um; mobile phase: [water(lOmM NH4HCO3)-ACN], B%: 25%-55%,
8min) to give 6-bromo-2-hydroxy-3- methyl-1,2-benzoxaborinine (600 mg, 2.48
mmol, 19.97%
yield, 98.86% purity) as a white solid.11-1NM_R (DMSO-d6, 400 MHz) 6 9.09 (s,
1H), 7.65 (d, J =
2.4 Hz, 1H), 7.45-7.42 (m, 2H), 7.14 (d, J= 8.8 Hz, 1H), 2.01 (s, 3H). MS
(ESI): mass calculated
for C9H8BBr02, 237.98, m/z found 237.1[M-H]. Purity by HPLC: 98.86% (220 nm),
99.14% (254
nm).
[0203]
12 Preparation of 1-(trans-4-eyanotetrahydro-211-pyran-3-y0-342-hydroxy-3-
tnethyl-21-1-
benzok][1,21oxaborinin-6-y0amino)-1H-pyrazole-4-earboxamide
\N1N;12 H2
0-1¨
0,B4OH 0 " abh 0,B4OH
Pd2(dba)3, tBuXPhos, KOAc
5N
Br
i-PrOH, 25-80 C, 50 h
0
NH2
To a mixture of 6-bromo-2-hydroxy-3-methyl-1,2-benzoxaborinine (400 mg, 1.00
mmol, 1 eq)
and 3-amino-1 -(trans-4-cy anotetrahydropyran-3-yl)pyrazole-4-carboxamide (282
mg, 1.20 mmol,
1.2 eq) in i-PrOH (10 mL) was added Pd2(dba)3 (45.8 mg, 50.0 mol, 0.05 eq),
AcOK (147 mg,
1.50 mmol, 1.5 eq) and t-Bu Xphos (42.5 mg, 100 mol, 0.1 eq) in one portion at
25 C under N2
atmosphere, the resulting mixture was stirred at 80 C for 50 h. The reaction
mixture was poured
into H20 (0.2 mL), filtered and concentrated in vacuo to give a residue, which
was purified by
prep-HPLC (column: Welch Xtimate C18 100*25mm*3um; mobile phase: [water
(0.05%HC1)-
ACN]; B%: 30%-50%,8min) to give 1-(trans-4-cyanotetrahydro-2H-pyran-3-y1)-3-02-
hydroxy-3-
methy1-2H-b enzo[e] [1,2] oxaborinin-6-yl)amino)-1H-pyrazole-4-carboxamide
(50.1 mg, 121
mol, 12.1% yield, 94.9% purity) as an off-white solid. 1H NMR (DMSO-d6, 400
MHz) 6 9.06 (s,
122
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
1H), 8.76 (s, 1H), 8.28 (s, 1H), 7.65 (br s, 1H), 7.60 (d, J= 2.8 Hz, 1H),
7.48 (s, 1H), 7.46 (dd, J
= 8.8, 2.8 Hz, 1H), 7.13 (br s, 1H), 7.08 (d, J= 8.8 Hz, 1H), 4.57-4.54 (m,
1H), 4.03 (dd, J= 11.2,
4.4 Hz, 1H), 3.92-3.87 (m, 1H), 3.72-3.67 (m, 2H), 3.52-3.49 (m, 1H), 2.17-
2.14 (m, 1H), 2.07 (s,
3H), 2.06-1.97 (m, 1H). MS (ESI): mass calculated for Ci9H2oBN504, 393.16, m/z
found 392.1[M-
H]. Purity by HPLC: 94.87% (220 nm), 99.83% (254 nm).
[0204]
6. Preparation of 1-(trans-4-cyanotetrahydro-2H-pyran-3-yl)-3-[(1-hydroxy-7-
methyl-3H-2,1-
benzoxaborol-5-y0aminokyrazole-4-earboxamide
0
A Br
H2N-Ar- N-(=,
Br HBPin Na104, NH40Ac Br
NC
il,
H2N N _,/
riiki IWP aim
Ir(OM &IV 0-y e)2(COD)2 . Y --'3
CO2Me THF H20 HO, 1111V
B CO2Me
Cu(OAc)2, TEA, CMS
1111" CO2Me
2-Me-THF, 90 C, 72 h 0-25 C, 4 h IN
25 C, 12 h
OR'¶CN 0QN 0 0QN
pH
Br B2(neoP)2 N..., NaBH4
N-N
B
yi,_N MI Y y
CO2Me Pd(dppf)O12, KO CO2Me
Ac, dioxane' THF, Me0H ipN WI s '
N
0 0 0 u
NH2 NH2 . m. .2
[0205]
6.1 Preparation of methyl 2-bromo-3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan -2-
yl)benzoate
0.,B AI Br
Al Br HBPin
_________________________________________________ .-
'WI
InOMe)2(COD)2 , dtPPY
) CO2Me
114" .
CO2Me ¨c1:,
2-Me-THF, 90 C, 72 h
To a mixture of methyl 2-bromo-3-methyl-benzoate (1.00 g, 4.37 mmol, 1 eq) and
4,4,5,5-
tetramethy1-1,3,2-dioxaborolane (3.35 g, 26.19 mmol, 3.80 mL, 6 eq) in 2-MeTHF
(30 mL) was
added 4-tert-butyl-2-(4-tert-butyl-2-pyridyl)pyri dine (117 mg, 436 umol, 0.1
eq) and
Ir(OMe)2(COD)2 (58 mg, 87.5 pmol, 0.02 eq) dropwise at 20 C, the resulting
mixture was stirred
at 90 C for 72 h under N2 atmosphere. The combined reaction mixture was
concentrated in vacuo
to give a residue, which was purified by column chromatography (SiO2,
Petroleum ether/Ethyl
acetate=0/1 to 10/1) to give methyl 2-bromo-3-methy1-5-(4,4,5,5-tetramethy1-
1,3,2-dioxaborolan-
2-yl)benzoate (1.27 g, 3.57 mmol, 81.73% yield) as yellow oi1.1H NAAR (CDC13,
400 MHz) 6 7.87
(s, 1H), 7.76 (s, 1H), 3.93 (s, 3H), 2.47 (s, 3H), 1.35 (s, 12H).
123
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
[0206]
6.2 Preparation of (4-bromo-3-methoxycarbonyl-5-methyl-phenyl)boronic acid
Br
Na104, NH40Ac Br
0,B
CO2Me
THF, H20 HOõ
CO2Me
O-25 C, 4 h OH
To a mixture of methyl 2-bromo-3-methy1-5-(4,4,5,5-tetramethy1-1,3,2-
dioxaborolan-2-y1)
benzoate (3.80 g, 10.70 mmol, 1 eq) in H20 (20 mL) and THF (20 mL) was added
NaI04 (9.16 g,
42.81 mmol, 2.37 mL, 4 eq) and NH40Ac (3.30 g, 42.81 mmol, 4 eq) in small
portions at 0 C, the
resulting mixture was stirred at 25 C for 4 h under N2 atmosphere. Then the
reaction mixture was
partitioned between Et0Ac (20 mL) and H20 (20 mL). The organic phase was
separated, washed
with brine (20 mL x 2), dried over Na2SO4, filtered and concentrated in vacuo
to give a residue,
which was purified by column chromatography (Si02, Petroleum ether/Ethyl
acetate=1/0 to 2/1)
to give (4-bromo-3-methoxycarbony1-5-methyl-phenyl)boronic acid (2.4 g, 8.79
mmol, 82.17%
yield) as yellow solid.1H NM_R (DMSO-do, 400 MHz) 6 8.29 (s, 2H), 7.86 (s,
1H), 7.83 (s, 1H),
3.85 (s, 3H), 2.40 (s, 3H).
[0207]
6.3 Preparation of methyl 2-bromo-544-carbamoyl-1-(trans-4-cyanotetrahydro-2H-
pyran-3-
yl)-1H-pyrazol-3-y0amino)-3-methylbenzoate
0
0Q-CN
is Br H21\I
N_N Br
HO,B CO2Me Cu(OAc)2, TEA, DMS0
CO2Me
OH 25 C. 12 h
0
NH2
To a mixture of 3-amino-1-(trans-4-cyanotetrahydropyran-3-yl)pyrazole-4-
carboxamide (1.00 g,
4.25 mmol, 1 eq) and (4-bromo-3-methoxycarbony1-5-methyl-phenyl)boronic acid
(1.16 g, 4.25
mmol, 1 eq) in DMSO (20 mL) was added TEA (2.15 g, 21.25 mmol, 2.96 mL, 5 eq),
Cu(OAc)2
(155 mg, 851 [tmol, 0.2 eq) and 4A molecular sieve (500 mg, 4.25 mmol, 1 eq)
at 25 C, the
resulting mixture was stirred at 25 C for 12 h under 02 atmosphere. The
reaction mixture was
poured into sat. NI-14C1 (20 mL), the resulting precipitates were removed by
filtration, the filtrate
was extracted with DCM (20 mL x 3). The combined organic layers were washed
with brine (20
124
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
mL x 2), dried over Na2SO4, filtered and concentrated in vacuo to give a
residue, which was
purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=10/1 to
1/2) to give
methyl 2-bromo-5-((4-carbamoy1-1-(trans-4-cyanotetrahydro-2H-pyran-
3-y1)-1H-pyrazol-3-
yl)amino)-3-methylbenzoate (840 mg, 1.82 mmol, 42.74% yield) as a yellow
solid. 1H NMR
(DMSO-do, 400 MHz) 6 9.29 (s, 1H), 8.32 (s, 1H), 7.78 (d, .1 = 2.4 Hz, 1H),
7.76 (br s, 1H), 7.67
(d, J= 2.4 Hz, 1H), 7.25 (br s, 1H), 4.62-4.59 (m, 1H), 4.09-4.06 (m, 1H),
3.97-3.94 (m, 1H), 3.86
(s, 3H), 3.68-3.62 (m, 2H), 3.49-3.45 (m, 1H), 2.39 (s, 3H), 2.20-2.16 (m,
1H), 2.06-1.96 (m, 1H).
[0208]
6.4 Preparation of methyl 54[4-carbamoyl-1-(trans-4-eyanotetrahydro-2H-pyran-3-
yOpyrazol-
3-yllaminol-2-(5,5-dimethy(-1,3,2-dioxaborinan-2-y1)-3-methyl-benzoate
Q"CN OQ'"CN
N-N An Br B2(neoP)2
N-N
N CO2Me Pd(dppf)Cl2, KOAc, dioxane
N µ1.1111 CO2Me
70 C. 6 h
NH2 NH2
A mixture of 2-(5,5 -dimethyl- 1,3,2-dioxaborinan-2-y1)-5, 5-dimethyl -1,3,2-
di oxaborinane (157
mg, 693 [tmol, 2 eq), methyl 2-bromo-5-((4-carbamoy1-1-(trans-4-
cyanotetrahydro-2H-pyran-3-
y1)-1H-pyrazol-3-yl)amino)-3-methylbenzoate (160 mg, 346.10 umol, 1 eq), KOAc
(51 mg, 519
urnol, 1.5 eq) and Pd(dppf)C12 (13 mg, 18 timol, 0.05 eq) in dioxane (10 mL)
was degassed and
purged with N2 for 3 times, the resulting mixture was stirred at 70 C for 6 h
under N2 atmosphere.
The reaction mixture was filtered, the filtrate was concentrated in vacuo to
give a residue, which
was purified by column chromatography (SiO2, Petroleum ether/Ethyl
acetate=10/1 to 1/1) to give
methyl 5- [ [4-carb am oyl -1-(tran s-4-cyanotetrahydro-2H-pyran-3-y1) pyrazol
-3 -yl] amino] -2-(5,5 -
dimethy1-1,3,2-dioxaborinan-2-y1)-3-methyl -benzoate (600 mg, 1.21 mmol,
70.00% yield) as a
yellow solid. 1H NMIR (DMSO-d6, 400 MHz) 6 9.23 (s, 1H), 8.32 (s, 1H), 7.97
(d, J= 2.0 Hz, 1H),
7.74 (br s, 1H), 7.49 (d, .1= 2.0 Hz, 1H), 7.23 (br s, 1H), 4.60-4.57 (m, 1H),
4.10-4.06 (m, 1H),
3.96-3.93 (m, 1H), 3.87 (s, 3H), 3.68 (s, 4H), 3.66-3.62 (m, 2H), 3.52-3.48
(m, 1H), 2.35 (s, 3H),
2.20-2.17 (m, 1H), 2.06-1.96 (m, 1H), 1.06 (s, 6H).
125
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
[0209]
6.5 Preparation of 1-[trans-4-cyanotetrahydropyran-3-341-3-[(1-hydroxy-7-
methy1-3H-2,1-
benzoxaborol-5-yl)aminolpyrazole-4-earboxamide
oQ".CN
OH
N--N B,o NaBH4 N-N
THF, 0 C, h
0
N CO2Me N
0 0
NI-I2 NH2
To a mixture of methyl 5-[[4-carbamoy1-1-[trans-4-cyanotetrahydropyran-3-
yl]pyrazol-3-
yllamino]-2-(5,5-dimethyl-1,3,2-dioxaborinan-2-y1)-3-methyl-benzoate (1.00 g,
2.02 mmol, 1 eq)
in TI-IF (20 mL) was added NaBH4 (382 mg, 10.1 mmol, 5 eq) in portions at 0 C
under N2. The
mixture was stirred at 0 C for 1 h. LCMS showed the reaction was completed and
desired MS
observed. 2 parallel reactions were combined for work up. The mixture was
added H20 (15 mL),
adjusted pH=5 with HC1 (2N) and extracted with Et0Ac (10 mL x 2). The combined
organic
layers were washed by brine (10 mL x 2), dried over Na2SO4, filtered and
concentrated under
reduced pressure to get a residue. The residue was purified by prep-HPLC
(column: Phenomenex
luna C18 (250*70mm,15 urn); mobile phase: [water (0.04%HC1)-ACN];B%: 17%-
47%,20min) to
give 1-(trans-4-cy anotetrahy dropyran-3-y1)-3-[(1 -hy droxy-7-
methyl -3H-2, 1-b enzoxab orol-5-
yl)amino]pyrazole-4-carboxamide (543 mg, 34.0% yield, 96.4% purity). The
product (543 mg,
96.4% purity) was purified by SFC (column: DAICEL CHIRALPAK IG
(250mm*30mm,10um);
mobile phase: [Neu-IPA]; B%: 40%-40%,6min) to give 1-[trans-4-
cyanotetrahydropyran-3-y1]-3-
[(1-hydroxy-7-methy1-3H-2,1-benzoxaborol-5-y1) amino] pyrazole-4-carboxamide
(stereoisomer
one) (243 mg, 99.6% purity, 99.4% ee, first peak, Rt = 2.153 min) as a white
solid. 11-1 NMR
(DMSO-d6, 400 MHz) 39.33 (s, 1H), 8.59 (s, 1H), 8.31 (s, 1H), 7.73 (br s, 1H),
7.46 (s, 1H), 7.21
(br s, 1H), 7.07 (s, 1H), 4.90 (s, 2H), 4.58-4.55 (m, 1H), 4.07-4.02 (m, 1H),
3.92-3.87 (m, 1H).
3.71-3.64 (m, 2H), 3.52-3.48 (m, 1H), 2.40 (s, 3H), 2.18-2.14 (m, 1H), 2.02-
1.97 (m, 1H),.MS
(ESI): mass calculated for C18H2oBN504 381.16, m/z found 382.3 [M+H]t.HPLC:
99.65% (220
nm), 100% (254 nm). and 1-[trans-4-cyano tetrahydropyran-3-y1]-3-[(1-hydroxy-7-
methy1-3H-
2,1-benzoxaborol-5-yl)amino]pyrazole-4-carboxamide (stereoisomer two) (233 mg,
99.4% purity,
97.1% ee, second peak, Rt = 2.533 min) as a white solid. 11-1 NIVIR (DMSO-d6,
400 MHz) 6 9.33
( s, 1H), 8.60 (s, 1H), 8.30 (s, 1H), 7.73 (br s, 1H), 7.46 (s, 1H), 7.21 (br
s, 1H), 7.07 (s, 1H), 4.90
(s, 2H), 4.58-4.55 (m, 1H), 4.07-4.02 (m, 1H), 3.92-3.87 (m, 1H). 3.71-3.64
(m, 2H), 3.52-3.48
126
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
(m, 1H), 2.40 (s, 3H), 2.18-2.14 (m, 1H), 2.02-1.97 (m, 1H),.MS (EST): mass
calculated for
C18H20BN504 381.16, m/z found 382.2 [M+H]+. HPLC: 99.43% (220 nm), 100% (254
nm).
[0210]
7. Preparation of 1-(trans-4-cyanotetrahydro-2H-pyran-3-y1)-341-hydroxy-3,4-
dihydro-1H-
benzok][1,2Joxaborinin-6-y0amino)-1H-pyrazole-4-carboxamide
ro.N._40
is
N- NH2 Qõõ_--,N >cob_p<
e
NH2 0 0 Br a- N-N Br
0 ___________________________________________________________________________
,
CO2Me \,....)1,.
(H0)2B Cu(0Ac)2, TEA, DMSO CO2Me
Pd(PPh3)2C12, KOAc
N
40 C, 12 h H dioxane,
120 C, 1 h
0 NH2
0 Q N
r''JL Ogõõ_-,N
53H
N-N 40 B--0 NaBH4 __ ).- N-N B.,o
I
CO2Me THF, Me0H
N N
0-25 C, 1 h H
0.----I'H
0-).1 1411)
NH2 NI-12
[0211]
7.1 Preparation of methyl 2-(2-bromo-544-carhamoy1-1-(trans-4-cyanotetrahydro-
21-1-pyran-
3-y1)-1H-pyrazol-3-Aamino)phenyl)acetate
(00
N--r----( NH2
¨N
40
NH2 Br N-N
(H0)2B
____________________________________________________ ).-
CO2Me y Cu(OAc)2, TEA, DMSO N
140 Br CO2Me
40 C, 12 h H
0
NH2
To a solution of 3 -amino-1-(tran s-4-cyanotetrahydro-2H-pyran-3 -y1)-1H-
pyrazole-4-carb oxami de
(948 mg, 4.03 mmol, 1.1 eq) in DMSO (15 mL) was added Cu(0Ac)2 (1.66 g, 9.16
mmol, 2.5 eq),
[4-bromo-3-(2-methoxy-2-oxo-ethyl)phenyl]boronic acid (1 g, 3.66 mmol, 1 eq)
and TEA (1.85
g, 18.3 mmol, 2.6 mL, 5 eq) at 25 C, the resulting mixture was stirred at 40 C
for 12 h under 02
atmosphere. The reaction mixture was cooled to r.t., filtered with celite, the
filtrate was diluted
with H20 (20 mL), extracted with Et0Ac (10 mL x 3). The combined organic
layers were washed
with brine (20 mL), dried over Na2SO4, filtered and concentrated in vacuo to
give a residue. The
residue was purified by flash silica gel chromatography (ISCOg; 12 g SepaFlash
Silica Flash
Column, Eluent of 0-50% Ethyl acetate/Petroleum ether gradient @ 50 mL/min) to
give methyl
127
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
2-(2 -bromo-5 -((4-carb amoyl -1 -(trans-4-cy anotetrahy dro-2H-pyran-3 -y1)-
1H-pyraz ol-3 -
yl)amino)phenyl)acetate (1.20 g, 2.60 mmol, 70.83% yield) as a yellow solid.
11-1NMIR (DMSO-
d6, 400 MHz) 6 9.25(s, 1H), 8.31 (s, 1H), 7.75 (s, 1H), 7.54-7.50 (m, 1H),
7.76-7.43 (m, 2H), 7.25
(s, 1H), 4.59-4.56 (m, 1H), 4.03-4.02 (m, 2H), 3.79-3.78 (m, 1H), 3.70 (s,
2H), 3.69-3.68 (m, 1H),
3.66 (s, 3H), 3.63-3.62 (m, 1H), 2.14-2.08 (m, 1H), 1.99-1.98 (m, 1H).
[0212]
7.2 Preparation of methyl 2-(544-carbamoy1-1-(trans-4-cyanotetrahydro-2H-pyran-
3-y1)-1H-
pyrazol-3-y0amino)-2-(5,5-dirnethyl-1,3,2-dioxaborinan-2-yl)phenyl)acetate
ogõõ-_,N
Br
>B-BP,
N--N 0 0
NNN 13-0
CO2Me Pd(PPh3)20I2, KOAc I N SCO2Me
dioxane, 120 C, 1 h
0 0
NH2 NH2
A mixture of 2-(5,5-dimethy1-1,3,2-dioxaborinan-2-y1)-5,5-dimethy1-1,3,2-
dioxaborinane (855
mg, 3.79 mmol, 2.5 eq), methyl 2-(2-bromo-5-((4-carbamoy1-1-(trans-4-
cyanotetrahydro-2H-
pyran-3-y1)-1H-pyrazol-3-yl)amino)phenyl)acetate (700 mg, 1.51 mmol, 1 eq),
KOAc (372 mg,
3.79 mmol, 2.5 eq) and Pd(PPh3)2C12 (106 mg, 151 pmol, 0.1 eq) in dioxane (20
mL) was degassed
and purged with N2 for 3 times, the resulting mixture was stirred at 120 C for
1 h under N2
atmosphere. The reaction mixture was filtered, the filtrate was concentrated
in vacuo to give a
residue. The crude product was triturated with MTBE (5 mL) at 25 C for 10 min
to give methyl
2-(5-((4-carbamoy1-1-(trans-4-cyanotetrahydro-2H-pyran-3-y1)-1H-pyrazol-3-
yl)amino)-2-(5,5-
dimethyl-1,3,2-dioxaborinan-2-y1)phenyl)acetate (500 mg, crude) as a brown
solid, which was
used directly without further purification.
[0213]
7.3 Preparation of 1-(trans-4-cyanotetrahydro-2H-pyran-3-yl)-341-hydroxy-3,4-
dihydro-1H-
benzold[1,21oxaborinin-6-y0amino)-1H-pyrazole-4-carboxamide
¨N OH
NaBH4 N¨N N¨N 6,0 13---
0
õIL
CO2Me THE, Me0H
0-25 C, 1 h
0 0
NH2 NH2
To a solution of methyl 2-(5-((4-carbamoy1-1-(trans-4-cyanotetrahydro-2H-pyran-
3-y1)-1H-
pyrazol-3-yl)amino)-2-(5,5-dimethy1-1,3,2-dioxaborinan-2-yl)phenyl)acetate
(500 mg, 1.01
128
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
mmol, 1 eq) in THF (5 mL) and Me0H (1 mL) was added NaBH4 (191 mg, 5.05 mmol,
5 eq) in
portions at 0 C, the resulting mixture was stirred at 25 C for 1 h. The
reaction was quenched with
2N HC1, partitioned between H20 (10 mL) and Et0Ac (10 mL), and the aqueous
layer was
extracted with Et0Ac (10 mL x 2) The combined organic phase was washed with
brine (10 mL
x 3), dried with anhydrous Na2SO4, filtered and concentrated in vacuo to give
a residue. The
residue was purified by Prep-HPLC (column: Phenomenex luna C18 80*40mm*3 urn;
mobile
phase: [water (0.04%HC1)-ACN]; B%: 15%-35%,7min) to give 1-(trans-4-
cyanotetrahydro-2H-
pyran-3 -y1)-3 -((1-hydroxy-3,4-dihy dro-1H-benzo [c][1,2] oxaborinin-6-
yl)amino)-1H-pyrazole-4-
carboxamide (58 mg, 152.15 [rmol, 15.07% yield) as a white solid. 41 NMIR
(DMSO-d6, 400 MHz)
6 9.31 (s, 1H), 8.31 (s, 1H), 8.16 (s, 1H), 7.72 (s, 1H), 7.58 (d, J = 8.4 Hz,
1H), 7.36 (dd, J = 1.6,
8.0 Hz, 1H), 7.33 (s, 1H), 7.21 (s, 1H), 4.61-4.55 (m, 1H), 4.06-4.02 (m, 3H),
3.93-3.90 (m, 1H),
3.71-3.65 (m, 2H), 3.52-3.46 (m, 1H), 2.86-2.81 (m, 2H), 2.18-2.14 (m, 1H),
2.04-1.93 (m, 1H).
MS (ESI): mass calculated for C18H2oBN504, 381.16, m/z found 382.2 [M+H] .
Purity by HPLC:
93.88% (220 nm), 92.24 (254 nm).
[0214]
8. Preparation of 1-(trans-2-cyanocyclopenty1)-3-[(2-hydroxy-1,2-
benzoxaborinin-6-yi)
amino]pyrazole-4- earboxamide
0õOH
QBr .... 401
0õ
N-N 40 BOH
NH2 5
Pd2(dba)3, KOAc, t-Bu Xphos
N
0 i-PrOH, 80 C, 24 h 0
NH2 NH2
To a mixture of 3-amino-1-(2-cyanocyclopentyl)pyrazole-4-carboxamide (130 mg,
533 umol,
90% purity, 1.2 eq) and 6-bromo-2-hydroxy-1,2-benzoxaborinine (100 mg, 444
umol, 1 eq) in i-
PrOH (2 mL) was added Pd2(dba)3 (20 mg, 22.2 umol, 0.05 eq), KOAc (65 mg, 667
umol, 1.5 eq)
and t-Bu Xphos (19 mg, 44.4 umol, 0.1 eq) in one portion at 20 C under N2. The
mixture was
heated to 80 C and stirred for 24 h. LCMS showed the reaction was completed
and desired MS
observed. The reaction mixture was quenched with H20 (0.5 mL), filtered and
concentrated under
reduced pressure to give a residue. The residue was purified by prep-I-IPLC
(column: Waters
Xbridge BEH C18 100*30mm*10um; mobile phase: [water(lOmM NH4HCO3)-ACN];B%: 15%-
45%,8min) to give 1-(trans-2-cyano cycl opentyl )-3 -[(2-hydroxy-1,2-b enzox
ab ori ni n-6-
yl)amino]pyrazole-4-carboxamide (74 mg, 22.9% yield, 95.0% purity) as a white
solid. 1H NMR
129
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
(DMSO-d6, 400 MHz) 6 9.06 (s, 1H), 8.79 (s, 1H), 8.27 (s, 1H), 7.79 (d, J= 2.8
Hz, 1H), 7.76 (d,
J= 11.6 Hz, 1H), 7.61 (br s, 1H), 7.49 (dd, J= 2.8, 8.8 Hz, 1H), 7.20-7.10 (m,
2H), 6.10 (d, J=
12.0 Hz, 1H), 4.87 (q, J= 8.0 Hz, 1H), 3.42 (q, J= 8.8 Hz, 1H), 2.35-2.29 (m,
1H), 2.26-2.19 (m,
1H), 2.12-2.03 (m, 1H), 2.01-1.84 (m, 3H). MS (ES!): mass calculated for
C18H18BN503, 363.15,
m/z found 362.2 [M-H]". HPLC: 95.09% (220 nm), 99.68% (254 nm).
[0215]
9. Preparation of 1-(trans-2-eyanocyclohexyl)-3-1(1-hydroxy-3H-2,1-
benzoxaborol-6-y1)
uminolpyrazole-4-earboxamide
NH2
iNH2
0
Br F12804 I Br (H0)2B Br
Cr. N"\\ i-PrMgCI, B(OMe)3 Di
CO2H Me0H, 80 C, 8 h CO2Me THF.15-0 C, 1.5 h CO2Me
Cu(OAc)2, TEA, THF, DMA
25 C, 24 h
" " N
N--N CO2Me B2PIn2
N¨N C 2" NaB1-14
N¨N
N yC
¨0 THE Me0H
N "11111.47"
0 Br Pd(PPh3)2I2, KOAc dioxane, 80 C, 3 h B4.. o
0-20 C, 1 h
NH2 0 OH
NH, 0 NH2
[0216]
9.1 Preparation of methyl 2-bromo-4-iodo-benzoate
401 Br I Br
H2B04
CO2H Me0H, 80 C, 8 h CO2Me
To a mixture of 2-bromo-4-iodo-benzoic acid (5.00 g, 15.3 mmol, 1 eq) in Me0H
(100 mL) was
added H2SO4 (7.65 g, 76.5 mmol, 4.2 mL, 98% purity, 5 eq) in one portion at 20
C. The mixture
was heated to 80 C and stirred at 80 C for 8 h. TLC showed the reaction was
completed. The
reaction mixture was concentrated under reduced pressure to give a residue.
The residue was
poured into ice H20 (50 mL) and adjusted pH = 7 by addition of sat.aq. Na2CO3.
The mixture was
extracted with Et0Ac (40 mL x 3). The combined organic layers were washed with
brine (40 mL
x 2), dried over anhydrous Na2SO4, filtered and concentrated under reduced
pressure to give
130
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
methyl 2-bromo-4-iodo-benzoate (5.00 g, 95.9% yield) as a brown solid. 1H NMR
(CDC13, 400
MHz) 6 8.06 (d, J= 1.6 Hz, 1H), 7.71 (dd, J= 1.6, 8.0 Hz, 1H), 7.53 (d, J =
8.4 Hz, 1H), 3.93 (s,
3H).
[0217]
9.2 Preparation of (3-bromo-4-methoxycarbonyl-phenyl)boronic acid
I Br (H0)2B Br
i-PrMgCI, B(OMe)3
THF,15-0 C, 1.5 h
CO2Me CO2Me
To a mixture of 2-[2-(dimethylamino)ethoxy]-N,N-dimethyl-ethanamine (4.51 g,
28.2 mmol, 1.2
eq) in THF (80 mL) was added i-PrMgC1 (2 M, 14.1 mL, 1.2 eq) drop-wise at 15 C
under N2. The
mixture was stirred for 0.5 hat 15 C. Methyl 2-bromo-4-iodo-benzoate (8.00 g,
23.5 mmol, 1 eq)
was added drop-wise to the reaction mixture and the resulting mixture was
stirred at 25 C for 10
min. Then B(OMe)3 (4.88 g, 46.9 mmol, 5.3 mL, 2 eq) was added drop-wise at 0 C
and stirred
for 1 h. LCMS showed the reaction was completed and desired MS observed. The
reaction
mixture was quenched with sat.aq. NH4C1 (80 mL) at 0 C and adjusted pH = 5
with HC1 (2 N).
Then the mixture was extracted with Et0Ac (80 mL x 4). The combined organic
layers were
washed with brine (80 mL x 3), dried over Na2SO4, filtered and concentrated
under reduced
pressure to give a residue. The residue was purified by flash silica gel
chromatography (ISCOO;
120g SepaFlash Silica Flash Column, Eluent of 0-100% Ethyl acetate/Petroleum
ether gradient
@ 100 mL/min) to give (3-bromo-4-methoxycarbonyl-phenyl)boronic acid (3.50 g,
57.6% yield)
as a white solid. 1H NMR (DMSO-d6, 400 MHz) 6 8.04 (s, 1H), 7.80 (dd, J= 0.8,
7.6 Hz, 1H),
7.69 (d, J= 7.6 Hz, 1H), 3.83 (s, 3H).
[0218]
9.3 Preparation of methyl 2-bronto-4-114-carbarnoyl-1-(trans-2-
cyanocyclohexyl)pyrazol -3-
yllaminolbenzoate
131
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
NH2
N < NH2
0
(H0)2B Br
D1 NN 401 CO2Me
CO2Me cu(OAc)2, TEA, THF, DMA SN Br
25 C, 24 h
0
NH2
To a mixture of (3-bromo-4-methoxycarbonyl-phenyl)boronic acid (800 mg, 3.09
mmol, 1 eq) and
3-amino-1-(2-cyanocyclohexyl)pyrazole-4-carboxamide (865 mg, 3.71 mmol, 1.2
eq) in TI-IF (20
mL) and DMA (5 mL) was added TEA (1.56 g, 15.4 mmol, 2.15 mL, 5 eq), Cu(0Ac)2
(1.40 g,
7.73 mmol, 2.5 eq) and 4A molecular sieve (1.5 g) in one portion at 25 C under
02. The mixture
was stirred at 25 C for 24 h. LCMS showed the reaction was completed and
desired MS observed.
The reaction mixture was filtered and the filtrate was concentrated under
reduced pressure to give
a residue. The residue was purified by flash silica gel chromatography
(ISCOOD; 40 g SepaFlash
Silica Flash Column, Eluent of 0-100% Ethyl acetate/Petroleum ether gradient @
50 mL/min) to
give methyl 2-bromo-4-[[4-carbamoy1-1-(trans-2-cyanocyclohexyl)pyrazol-3-
yl]amino]benzoate
(600 mg, 43.5% yield) as yellow oil. 1H NMR (DMSO-d6, 400 Wiz) 6 11.95 (br s,
1H), 9.58 (s,
1H), 8.30 (s, 1H), 7.99 (d, J¨ 2.0 Hz, 1H), 7.80 (d, J¨ 8.8 Hz, 1H), 7.77 (br
s, 1H), 7.58 (dd, J ¨
2.4, 8.8 Hz, 1H), 7.28 (br s, 1H), 4.44 (dt, .1=4.4, 11.2 Hz, 1H), 3.80 (s,
3H), 3.26-3.20 (m, 1H),
2.20-2.17(m, 1H), 1.86-1.73 (m, 5H), 1.49-1.27 (m, 2H).
[0219]
9.4 Preparation of methyl 44[4-earbamoy1-1-(trans-2-eyanocyclohexyl)pyrazol-3-
yllamino] -2-
(4,4,5,5-tetramethyl -1,3,2-dioxaboro1an-2-yObenzoate
N--N CO2Me B2PIn2
N-N 401 CO2Me
____________________________________________________ JD-
-
Br Pd(PPh3)2Cl2, KOAc
dioxane, 80 C, 3 h
B40<.
0 0
NH2 NH2
To a mixture of methyl 2-bromo-4-[[4-carbamoy1-1-(trans-2-
cyanocyclohexyl)pyrazol-3-
yl]amino] benzoate (430 mg, 963 umol, 1 eq) and 4,4,5,5-tetramethy1-2-(4,4,5,5-
tetramethyl-
1,3,2- dioxaborolan-2-y1)-1,3,2-dioxaborolane (489 mg, 1.93 mmol, 2 eq) in
dioxane (5 mL) was
added KOAc (284 mg, 2.89 mmol, 3 eq) and Pd(dppf)C12 (35 mg, 48.1 umol, 0.05
eq) in one
132
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
portion at 25 C under N2. The mixture was stirred at 80 C for 3 h. LCMS showed
the reaction
was completed and desired MS observed. The reaction mixture was filtered and
the filtrate was
concentrated under reduced pressure to give a residue. The residue was
purified by flash silica gel
chromatography (ISCO ; 40 g SepaFlash Silica Flash Column, Eluent of 0-100%
Ethyl
acetate/Petroleum ether gradient @ 50 mL/min) to give methyl 44[4-carbamoy1-1-
(trans-2-
cyanocyclohexyl)pyrazol-3-yl]amino]-2-(4,4,5,5-tetramethy1-1,3,2- di oxaborol
an -2-y1 )b enzoate
(300 mg, 63.1% yield) as a yellow solid. 1H NMR (DMSO-do, 400 MHz) 6 9.52 (s,
1H), 8.28 (s,
1H), 7.87 (d, J= 8.8 Hz, 1H), 7.80 (d, J= 8.8 Hz, 1H), 7.76 (br d, J = 2.0 Hz,
1H), 7.62 (d, J = 8.8
Hz, 1H), 7.48 (dd, J= 2.0, 8.4 Hz, 1H), 7.25 (br s, 1H), 4.43 (dt, J = 4.0,
11.2 Hz, 1H), 3.80 (s,
3H), 3.27-3.17 (m, 1H), 2.17 (br d, J = 11.6 Hz, 1H), 1.87-1.69 (m, 5H), 1.51-
1.23 (m, 14H).
[0220]
9.5 Preparation of 1-(trans-2-eyanocyclohexyl)-3-[(1-hydroxy-3H-2,1-
benzoxaborol-6-yl)
aminolpyrazole-4-earboxamide
N-N CO2Me NaBH4
N-N
y THF Me0H BP
0-20 C, 1 h
0 OH
NH2 0
NH2
To a mixture of methyl 4[[4-carbamoy1-1-(2-cyanocyclohexyl)pyrazol-3-yl]amino]
-2-(4,4,5,5-
tetramethy1-1,3,2-dioxaborolan-2-yl)benzoate (300 mg, 608 umol, 1 eq) in TFIF
(10 mL) and
Me0H (0.5 mL) was added NaBH4 (69 mg, 1.82 mmol, 3 eq) in portions at 0 C. The
mixture was
stirred at 25 C for 1 h. LCMS showed the reaction was completed and desired MS
observed. The
reaction mixture was added water (10 mL) at 0 C. The resulting mixture was
adjusted pH to 5
with HC1 (2 N) and stirred for 10 min at 0 C. The solution was diluted with
Et0Ac (5 mL) and
extracted with Et0Ac (10 mL x 3). The combined organic layers were washed with
brine (15 mL
x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to
give a residue. The
residue was purified by prep-HPLC (column: Welch Xtimate C18 100*25mm*3um;
mobile phase:
[water (0.04%HC1)-ACN];B%: 10%-40%,8min) to give 1-(trans-2-cyanocyclohexyl)-3-
[(1-
hydroxy-3H-2,1-benzoxaborol-6-y1) amino]pyrazole-4-carboxamide (133 mg, 60.1%
yield, 100%
purity) as a white solid. 1H NMR (DMSO-d6, 400 MHz) 6 9.23 (s, 11-1), 9.09(s,
1H), 8.23 (s, 1H),
7.75 - 7.70 (m, 1H), 7.73-7.70 (m, 1H), 7.67 (br s, 1H), 7.29 (d, J= 8.4 Hz,
1H), 7.16 (Ur s, 1H),
4.92 (s, 2H), 4.38 (dt, J = 3.6, 10.8 Hz, 1H), 3.30-3.27 (m, 1H), 2.19 (br d,
J= 10.0 Hz, 1H), 2.00-
133
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
1.97 (m, 1H), 1.90-1.70 (m, 4H), 1.52-1.29 (m, 2H). MS (ESI): mass calculated
for C181120BN503,
365.17, m/z found 366.2 [M H]. HPLC: 100.00% (220 nm), 100.00 (254 nm).
[0221]
10. Preparation of 1-(trans-2-eyanocyclopenty1)-3-[(1-hydroxy-3H-2,1-
benzoxaborol-6-
Aamino] pyrazole-4-carboxamide
0
H2N)1TNN--0
_14
H2N jfl
(H0)2B Br D2 N N¨N 40 CO2Me B2Pin2 N_N
40 CO2Me
002Me Br ___________ .
Cu (0Ac)2, TEA, THF Pd(PPh3)2Cl2, KOAc N
25 C, 16 h H dioxane, 80 C, 3 h a
0 NH, NH,
NaBH4
THE, Me0H N ION BP
0-25 C, 1 H OH
0
NH,
[0222]
10.1 Preparation of methyl 2-bromo-44[4-carbamoy1-1-(trans-2-
cyanocyclopentyl)pyrazol-3-yll
amino]benzoate
H2N)L r
H2N
(H0)2B 000 Br 02 N-N CO,Me
Cu (0Ac),, TEA, THF N
CO,Me Br
25 C, 16 h
0
NH2
To a mixture of (3-bromo-4-methoxycarbonyl-phenyl)boronic acid (600 mg, 2.32
mmol, 1 eq) and
3-amino-1-(trans-2-cyanocyclopentyl)pyrazole-4-carboxamide (509 mg, 2.32 mmol,
1 eq) in THF
(10 mL) was added TEA (1.17 g, 11.6 mmol, 1.6 mL, 5 eq), Cu(0Ac)2 (1.05 g,
5.80 mmol, 2.5 eq)
and 4A molecular sieve (1 g) at 25 C under 02. The mixture was stirred at 25 C
for 16 h. LCMS
showed the reaction was completed and desired MS observed. The reaction
mixture was filtered
and the filtrate was concentrated under reduced pressure to give a residue.
The residue was
purified by flash silica gel chromatography (ISCOS; 40 g SepaFlash Silica
Flash Column, Eluent
of 0-100% Ethyl acetate/Petroleum ether gradient @ 50 mL/min) to give methyl 2-
bromo-44[4-
carbamoy1-1-(trans-2-cyanocyclopentyppyrazol-3-yl]amino]benzoate (0.36 g,
35.9% yield) as a
134
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
yellow solid. 1H NAAR (DMSO-do, 400 MHz) 6 9.57 (s, 1H), 8.34 (s, 1H), 8.06
(d, J= 2.0 Hz, 1H),
7.79 (d, J= 8.8 Hz, 1H), 7.73 (br s, 1H), 7.54 (dd, J= 2.0, 8.4 Hz, 1H), 7.28
(br s, 1H), 4.96 (q, J
= 8.0 Hz, 1H), 3.79 (s, 3H), 3.43-3.35 (m, 1H), 2.33-2.21 (m, 2H), 2.14-2.05
(m, 1H), 1.98-1.87
(m, 5H).
[0223]
10.2 Preparation of methyl 4[14-carbamoy1-1-(trans-2-cyanocyclopentyl)pyrazol-
3-yllaminok
2- (4,4,5,5-tetramethy1-1,3,2- dioxaboro1an-2-yObenzoate
g,..,
N-N CO2Me B2PIn2 N-N CO2Me
SN 111111"1
6-.
Br Pd(PPh3)2Cl2, KOAc N
Bfr1111111"
dioxane, 80 C, 3 h
0 0
NH2 NH2
To a mixture of methyl 2-bromo-4-[[4-carbamoy1-1-(trans-2-
cyanocyclopentyl)pyrazol-3-yl]
amino]benzoate (360 mg, 832 umol, 1 eq) and 4,4,5,5-tetramethy1-2-(4,4,5,5-
tetramethyl -1,3,2-
dioxaborolan-2-y1)-1,3,2-dioxaborolane (B2Pin2, 423 mg, 1.67 mmol, 2 eq) in
dioxane (5 mL) was
added KOAc (246 mg, 2.50 mmol, 3 eq) and Pd(dppf)C12 (31 mg, 41.6 umol, 0.05
eq) in one
portion at 20 C under N2. The mixture was heated to 80 C and stirred at 80 C
for 3 h. LCMS
showed the reaction was completed and desired MS observed. The reaction
mixture was filtered
and the filtrate was concentrated under reduced pressure to give a residue.
The residue was
purified by flash silica gel chromatography (ISCOR; 40 g SepaFlash Silica
Flash Column, Fluent
of 0-100% Ethyl acetate/Petroleum ether gradient @ 50 mL/min) to give methy14-
[[4-carbamoyl-
1-(trans-2-cy anocycl op entyl)pyraz 01-3 -yl]ami no] -2-(4,4,5,5 -tetramethyl-
1,3,2- dioxab orol an-2-
yl)benzoate (0.3 g, 75.1% yield) as a yellow solid. 1H NMR (DMSO-d6, 400 MHz)
6 9.55 (d, J=
14.8 Hz, 1H), 8.32 (d, J= 0.8 Hz, 1H), 7.86 (d, J= 8.8 Hz, 1H), 7.80 (d, J=
8.8 Hz, 0.5H), 7.72
(br s, 0.5H), 7.68 (d, J= 2.0 Hz, 0.5H), 7.64-7.62 (m, 1H), 7.52 (dd, J= 2.0,
8.4 Hz, 0.5H), 7.25
(br s, 1H), 4.99-4.92(m, 1H), 3.79 (d, J= 1.6 Hz, 3H), 3.46-3.38 (m, 1H), 2.31-
2.23 (m, 2H), 2.14-
2.05 (m, 1H), 1.97-1.82 (m, 3H), 1.33 (s, 6H).
[0224]
10.3 Preparation of 1-(trans-2-eyanocyclopenty1)-3-[(1-hydroxy-3H-2,1-
benzoxaborol-6-
yl)amino] pyrazole-4-carboxamide
135
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
CO2Me
N-N Nal3H4
N-N
SN
1361.0
THF, Me0H
0-25 C, 1 h OH
0 m,
NH2
To a mixture of methyl 44[4-carbamoy1-1-(trans-2-cyanocyclopentyppyrazol-3-
ydamino]-2 -
(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)benzoate (300 mg, 625 umol, 1 eq)
in THE (10 mL)
and Me01-1 (0.5 mL) was added NaBH4 (72 mg, 1.88 mmol, 3 eq) in portions at 0
C. The reaction
was allowed to warm to 25 C and stirred at 25 C for 1 h. LCMS showed the
reaction was
completed and desired MS observed. The reaction mixture was quenched with H20
(10 mL) at
0 C, adjusted pH to 5 with HC1 (2 N) and stirred for 10 min at 0 C. The
mixture was extracted
with Et0Ac (10 mL x 3). The combined organic layers were washed with brine (15
mL x 2), dried
over Na2SO4, filtered and concentrated under reduced pressure to give a
residue. The residue was
purified by prep-HPLC (column: Welch Xtimate C18 100*25mm*3um; mobile phase:
[water
(0.04%HC1)-ACN];B%: 10%-40%,8min) to give 1-(trans-2-cyanocyclopenty1)-3-[(1-
hydroxy-
3H-2,1-benzoxaborol-6-y1) amino] pyrazole-4-carboxamide (73.6 mg, 33.5% yield,
100% purity)
as a white solid. 1H NMR (DMSO-d6, 400 MHz) 6 9.21 (s, 1H), 9.04 (s, 1H), 8.28
(s, 1H), 7.75-
7.71 (m, 2H), 7.64 (br s, 1H), 7.29 (d, J= 8.0 Hz, 1H), 7.16 (br s, 1H), 4.92
(s, 2H), 4.91-4.87(m,
1H), 3.47-3.40 (m, 1H), 2.32-2.28 (m, 1H), 2.25-2.17 (m, 1H), 2.14-2.04 (m,
1H), 2.01-1.84 (m,
3H). MS (EST): mass calculated for C17H18BN503, 351.15, m/z found 352.2 [M+H].
HPLC: 100.00% (220 nm), 100.00 (254 nm).
[0225]
11. Preparation of 1-(trans-2-cyanocyclohexyl)-341-hydroxy-1,3-
dihydrobenzo[cffl,21
oxaborol-5-yl)amino)-1H-pyrazole-4-carboxamide
136
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
0
2[2-(dimethylamino)ethoxy] H2N )1r
N-0
-N,N-dimethyl-ethanamine, -II
z
2N H
0 Br H2SO4, Me0H 0 Br
_________________________ J.- i PrMgCI, B(OMe)3, THF
__________________________________________________ 0." HO.B 1110/ Br D1 N
CO2Me ________ ).-
I COOH 0 C-80 C, 3 h I CO2Me 0 C-25 C, 1 h OH
Cu(0Ae)2, TEA, 4A MS,
02, DMA, THF, 20 C, 16 h
c>18.oZ-ZN i
B2n QirZ-ZN
eoP2, Pd(dppf)ci2, "E7----N
?
pH
Br KOAc, dioxane g NaBH4,
Me0H, THF
N-N 0 N, N-N lio '0 ___________ ).- N-N
....õ.....11.. CO2Me 25 C-85 C, 16 h
\,.....11....
,y..... 0
N N CO2Me 0 C, 1 h N
H H H
0 0 0
NH2 NH2 NH2
[0226]
11.1 Preparation of methyl 2-bromo-5-iodo-benzoate 1
Br H2SO4, Me0H Br
0 0
I COOH 0 0-80 C, 3 h I CO2Me
To a solution of 2-bromo-5-iodo-benzoic acid (10.0 g, 30.5 mmol, 1 eq) in Me0H
(150 mL) was
added drop-wise a solution of H2SO4 (4.89 mL, 91.7 mmol, 3 eq) at 0 C over a
period of 5 mins
under N2. The reaction was heated and stirred at 80 C for 3 h. TLC showed the
reaction was
completed. The reaction mixture was adjusted pH to 7 with sat.aq. Na2CO3 (100
mL) at 0 C, and
extracted with ethyl acetate (100 mL x 3). The combined organic phase was
washed with brine
(100 mL x 2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum
to give a residue.
The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl
acetate=10/1
to 5/1) to give methyl 2-bromo-5-iodo-benzoate (10.0 g, 95.8% yield) as a
yellow solid. 1-1-1 NMR
(CDC13-d6, 400 MHz) 6 8.10 (s, 11-1), 7.63 (dd, J= 8.4 Hz, 2.0 Hz, 1H), 7.38
(d, J= 8.4 Hz, 1H),
3.94 (s, 3H).
[0227]
11.2 Preparation of (4-brorno-3-me1hoxycarbonyl-phenyl)boronic acid
2-[2-(dimethylamino)ethoxy]
-N,N-dimethyl-ethanamine,
0 Br
0 Br i-PrMgCI, B(0Me)3, THF
__________________________________________________ J. HO.
B CO2Me
I CO2Me 0 C-25 C, 1 h
OH
To a solution of 2-[2-(dimethylamino)ethoxy]-N,N-dimethyl-ethanamine (2.82 g,
17.6 mmol, 1.2
137
CA 03201606 2023- 6-7
WO 2022/133420
PCT/US2021/072885
eq) in THF (60 mL) was added i-PrMgC1 (2 M, 8.80 mL, 1.2 eq) at 15 C. The
mixture was stirred
at 15 C for 20 min. Then methyl 2-bromo-5-iodo-benzoate (5.00 g, 14.6 mmol, 1
eq) was added
drop-wise to the reaction mixture at 15 C. The resulting mixture was allowed
to warm to 25 C
and continue stirred at 25 C for 10 min. Trimethyl borate (3.31 mL, 29.3 mmol,
2 eq) was added
drop-wise at 0 C. The reaction mixture was stirred at 0 C for 1 h. TLC showed
the reaction was
completed. The reaction mixture was quenched by addition of sat. aq. NH4C1
(100 mL) at 0 C,
then extracted with ethyl acetate (40 mL x 3). The combined organic layers
were washed with
brine (90 mL x 3), dried over Na2SO4, filtered and concentrated under reduced
pressure to give a
residue. The residue was purified by column chromatography (SiO2, Petroleum
ether/Ethyl
acetate=1/1 to 0/1) to give (4-bromo-3-methoxycarbonyl-phenyl)boronic acid
(2.00 g, 52.6% yield)
as a yellow solid. 1H NMR (DMSO-d6, 400 MHz) 6 8.35 (s, 1H), 8.14-8.13 (m,
1H), 7.90-7.87 (m,
1H), 7.77-7.73 (m, 1H), 3.89-3.86 (m, 3H).
[0228]
11.3 Preparation of methyl 2-bromo-5((4-carbamoy1-1-(trans-2-cyanocyclohexyl)-
1H- pyrazol-
3-yl)amino)benzoate
N-C=>
los Br H2N 4
D1 N ___________________________________________________ N-N so Br
HO. B CO2Me Cu(OAc)2, TEA, 4A MS,
OH CO2Me
02, DMA THE, 20 C, 16 h H
0
NI-I2
To a mixture of 3-amino-141S,2S)-2-cyanocyclohexyl)-1H-pyrazole-4-carboxamide
(793 mg,
3.40 mmol, 1.1 eq) and (4-bromo-3-methoxycarbonyl-phenyl)boronic acid (800 mg,
3.09 mmol,
1 eq) in THF (30 mL) and DMA (5 mL) was added Cu(0Ac)2 (1.40 g, 7.73 mmol, 2.5
eq), 4A
molecular sieve (1.5 g) and TEA (1.56 g, 15.4 mmol, 2.15 mL, 5 eq) in one
portion at 20 C under
02. The mixture was stirred at 20 C for 16 h. LCMS showed the reaction was
completed and
desired MS observed. The reaction mixture was filtered and the filtrate was
concentrated under
reduced pressure to give a residue. The residue was purified by column
chromatography (SiO2,
Ethyl acetate/Methano1=1/0 to 5/1) to give methyl 2-bromo-5-((4-carbamoy1-1-
(trans-2-
cyanocyclohexyl)-1H-pyrazol-3-yl)amino)benzoate (1.2 g, 87.0% yield) as a
yellow solid. 1H
NMR (DMSO-d6, 400 MHz) 6 12.50 (s, 1H),9.89 (s, 1H), 8.14 (s, 1H), 8.55 (d, J=
2.8 Hz, 1H),
8.25 (dd, J= 8.8 Hz, 3.2 Hz, 1H), 8.11 (d, J= 8.8 Hz, 1H), 7.77 (br s, 1H),
4.99-4.93 (m, 1H), 4.40
138
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
(s, 3H), 3.82-3.74 (m, 1H), 2.72-2.65 (m, 1H), 2.57-2.53 (m, 1H), 2.39-2.26
(m, 4H), 2.00-1.99
(m, 1H), 1.87-1.86 (m, 1H).
[0229]
11.4 Preparation of methyl 5((4-carbamoy1-1-(trans-2-cyanocyclohexyl)-1I1-
pyrazol-3-y1)
amino)-2-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)henzoate
C?'flN B2neop2, Pd(dppf)C12,
Br KOAc, dioxane
N -N N -N B.0
25 C-85 C, 16 h
CO2Me N µµI'V CO2Me
0 0
NH2 NH2
To a mixture of methyl 2-bromo-5-04-carbamoy1-1-((1S,2S)-2-cyanocyclohexyl) -
1H-pyrazol-3-
yl)amino)benzoate (1.0 g, 1.34 mmol, 60% purity, 1 eq) in dioxane (20 mL) was
added KOAc
(395 mg, 4.03 mmol, 3 eq), Pd(dppf)C12 (98.3 mg, 135 umol, 0.1 eq) and
4,4,4',4',5,5,5',5'-
octamethy1-2,2'-bi(1,3,2-dioxaborolane) (853 mg, 3.36 mmol, 2.5 eq) in one
portion at 25 C under
N2, then the mixture was heated to 85 C and stirred for 16 h. LCMS showed the
reaction was
completed and desired MS observed. The reaction mixture was filtered and the
filtrate was
concentrated in vacuum to give a residue. The residue was purified by column
chromatography
(SiO2, Ethyl acetate/Methanol= 1/0 to 10/1) to give methyl 54(4-carbamoy1-1-
(trans-2-
cyanocycl ohexyl)-1H-pyrazol-3-y1)amino)-2-(4,4,5,5- tetram ethyl-1,3, 2-
di oxab orol an-2-
yl)benzoate (500 mg, crude) as brown oil. 1H NMR (DMSO-d6, 400 MHz) 6 9.37 (s,
1H), 8.27 (s,
1H), 7.97 (d, J= 2.4 Hz, 1H), 7.77 (dd, 1= 8.4 Hz, 2.4 Hz, 114), 7.71 (hr s,
1H), 7.40 (d, J' 8.0
Hz, 1H), 7.22 (hr s, 1H), 4.45-4.38 (m, 1H), 3.82 (s, 3H), 3.27-3.20 (m, 1H),
2.21-2.17 (m, 1H),
2.03-1.98 (m, 1H), 1.96 (m, 12H), 1.83-1.72 (m, 4H), 1.49-1.32 (m, 2H).
[0230]
11.5 Preparation of 1-(trans-2-eyanoeyelohexyl)-341-hydroxy-1,3-
dihydrobenzokl[1,21
oxaborol-5-y1)amino)-1H-pyrazole-4-carboxamide
0
OH
6_ NaBH4, Me0H, THF
N N N 0 N -N 14,0
CO2Me 0 C, 1 h
0 0
NH2 NH2
139
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
To a mixture of methyl 5-((4-carbamoy1-1-((1S,2S)-2-cyanocyclohexyl)-1H-
pyrazol-3-y1)
amino)-2-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)benzoate (500 mg, 1.01
mmol, 1 eq) in
THF (10 mL) was added Me0H (12.3 mmol, 0.5 mL, 12.1 eq) and NaBH4 (115 mg,
3.04 mmol, 3
eq) in portions at 0 C under N2. The mixture was stirred at 0 C for 1 h. LCMS
showed the reaction
was completed and desired MS observed. The mixture was poured into ice-water
(w/w = 1/1) (20
mL). The reaction mixture was adjusted pH to 4-5 with HO (2 N) at 0 C. The
aqueous phase was
extracted with ethyl acetate (10 mL x 3). The combined organic phases was
washed with brine
(10 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to
give a residue. The
residue was purified by prep-HPLC (column. Phenomenex luna C18 80*40mm*3
um,mobile
phase: [water (0.04%HC1)-ACN];B%: 27%-45%,7min) to give 1-(trans-2-
cyanocyclohexyl)-3-
((1-hydroxy-1,3-dihydrobenzo [c][1,2]oxaborol-5-yl)amino)-1H-pyrazole-4-
carboxamide (107
mg, 28.8% yield, 99.7% purity) as a white solid. 1H NMR (DMSO-do, 400 MHz) 6
9.39 (s, 1H),
8.88 (s, 1H), 8.26 (s, 1H), 7.70 (br s, 1H), 7.60-7.57 (m, 2H), 7.38 (d, J=
8.0 Hz, 1H), 7.19 (br s,
1H), 4.93 (s, 2H), 4.43-4.36 (m, 1H), 3.30-3.24 (m, 1H), 2.19-1.98 (m, 2H),
1.85-1.72 (m, 4H),
1.45-1.36 (m, 2H). MS (ESI): mass calculated for C48H20BN503 365.17, m/z found
366.2 [M+H]t.
HPLC: 99.79% (220 nm), 100% (254 nm).
[0231]
12. Preparation of 1-(trans-2-cyanocyclopentyl)-3((1-hydroxy-1,3-
dihydrobenzo[c]
[1,21oxaborol-5-y0amino)-1H-pyrazole-4-carboxamide
0
AI 'N
Br
H2N '(;) V B2neop2, Pd(cIPPOCl2,
H2N
D2 N Br KOAc, dioxane
HO,
13 CO2Me
Cu(OAc)2, TEA, 4A MS, \ N CO2Me 25 C-85 C, 16 h
N 411119. CO2Me
0'1-1
02, DMA, THF, 20 0, 16h 0 0
NH2 NH2
OH
NaBH4, Me0H, THF
N - N 14,0
===õ,,
0 C-15 C, 1 h N 411111-.VIF
0
NH2
[0232]
12.1 Preparation of methyl 2-bromo-5((4-earbamoyl-1-(trans-2-eyanoeyelopentyl)
-1H-
140
CA 03201606 2023- 6-7
WO 2022/133420
PCT/US2021/072885
pyrazol-3-yl)amino)benzoate
1-12N)Lr N-0
N
Ai Br H2N Ill
D2 N Br
HO. B 1141" CO2Me N-N 1/00
y=L
0.1-1 Cu(OAc)2, TEA, 4A MS, N CO2Me
02, DMA, THE, 20 C, 16 h 0
NH2
To a mixture of 3-amino-1-(trans-2-cyanocyclopenty1)-1H-pyrazole-4-carboxamide
(700 mg, 3.19
mmol, 1 eq) and (4-bromo-3-methoxycarbonyl-phenyl)boronic acid (826 mg, 3.19
mmol, 1 eq) in
THF (50 mL) was added Cu(0Ac)2 (1.45 g, 7.98 mmol, 2.5 eq) ,4A molecular sieve
(1.5 g) and
TEA (15.9 mmol, 2.22 mL, 5 eq) in one portion at 20 C under 02. The mixture
was stirred at 20 C
for 16 h. The reaction mixture was filtered and the filtrate was concentrated
under reduced pressure
to give a residue. The residue was purified by column chromatography (Si02,
Ethyl
acetate/Methano1=1/0 to 10/1) to give methyl 2-bromo-5- ((4-carbamoy1-1-(trans-
2-
cyanocyclopenty1)-1H-pyrazol-3-yl)amino)benzoate (600 mg, 1.39 mmol, 43.4%
yield) as a
yellow solid. 1H NMR (DMSO-d6, 400 MHz) 6 9.34 (s, 1H), 8.31 (s, 1H), 8.12 (d,
J= 2.8 Hz, 1H),
7.67 (br s, 1H), 7.62-7.58 (m, 3.2 Hz, 1H), 7.56-7.53 (m, 1H), 7.21 (br s,
1H), 4.97-4.90 (m, 1H),
3.84 (s, 3H), 3.41-3.34 (m, 1H), 2.32-2.23 (m, 2H), 2.07-1.96 (m, 1H), 1.94-
1.92 (m, 1H), 1.92-
1.88 (m, 2H).
[0233]
12.2 Preparation of methyl 5((4-earbamoy1-1-(trans-2-eyanocyclopenty1)-1H-
pyrazol-3-y1)
amino)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate
B2neop2, Pd(dPPDCI2,
N-N Br KOAc, dioxane NN B -0
y-LN 4111111)..." CO2Me 25 C-85 C. 16 h CO2Me
0 0
NH2 NH2
To a mixture of methyl 2-brom o-5-((4-carbam oyl -1-(tran s-2-cy an ocycl
opentyl ) -114-pyraz ol -3 -
yl)amino)benzoate (500 mg, 1.16 mmol, 1 eq) in dioxane (10 mL) was added KOAc
(340 mg, 3.47
mmol, 3 eq), Pd(dppf)C12 (84.6 mg, 115 umol, 0.1 eq) and 4,4,4',4',5,5,5',5'-
octamethy1-2,2'-
bi(1,3,2-dioxaborolane) (734 mg, 2.89 mmol, 2.5 eq) in one portion at 25 C
under N2. The mixture
was heated to 85 C and stirred for 16 h. The reaction mixture was filtered and
the filtrate was
concentrated in vacuum. The residue was purified by prep-TLC (Si02,
Ethyl
141
CA 03201606 2023- 6- 7
WO 2022/133420 PCT/US2021/072885
acetate/Methano1=1/0 to 10/1) to give methyl 5-((4-carbamoy1-1-(trans-2-
cyanocyclopenty1)-1H-
py razol-3 -yl)amin o)-2-(4,4,5, 5 -tetram eth y1-1,3 ,2-di oxab orol an-2-
yl)b enzoate (500 mg, 90.1%
yield) as a brown solid.
[0234]
12.3 Preparation of 1-(trans-2-cyanocyclopenty1)-3-((1-hydroxy-1,3-
dihydrobenzolel
[1,21oxaborol-5-yl)amino)-11-1-pyrazole-4-earboxamide
cION
OH
NaBH4, Me0H, THF
N-N th 0 _______________________________________________ N-N 13,0
N CO2Me CPC-15 C, 1 h N
0 0
NH2 NH2
To a mixture of methyl 5-((4-carbamoy1-1-(trans-2-cyanocyclopenty1)-1H-pyrazol-
3-y1) amino)-
2-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)benzoate (500 mg, 1.04 mmol, 1
eq) in THF (10
mL) was added Me0H (12.3 mmol, 0.5 mL, 11.8 eq) and NaBH4 (119 mg, 3.13 mmol,
3 eq) in
portions at 0 C under N2. The mixture was stirred at 15 C for 1 h. LCMS showed
the reaction
was completed and desired MS observed. The mixture was poured into ice-water
(w/w = 1/1) (20
mL) and the aqueous phase was adjusted pH to 5-6 with HC1 (2N). The aqueous
phase was
extracted with ethyl acetate (10 mL x 3). The combined organic phases was
washed with brine
(10 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to
give a residue. 'The
residue was purified by prep-HPLC (column: Phenomenex luna C18 80*40mm*3 urn;
mobile
phase: [water (0.04%HC1)-ACN];B%: 25%-43%,7min) to give 1-(trans-2-
cyanocyclopenty1)-3-
((1 -hydroxy-1, 3-dihydrob enzo[c] [1,2]oxaborol-5-yl)amino)-1H-pyrazole-4-
carboxamide (119
mg, 31.7% yield, 97.0% purity) as a white solid.IHNMR (DMSO-d6, 400 MHz) 5
9.37 (s, 1H),
8.88 (s, 1H), 8.30 (s, 1H), 7.66 (s, 2H), 7.58 (d, J= 8.0 Hz, 1H), 7.35 (d, J
8.0 Hz, 1H), 7.19 (br
s, 0.5H), 4.93-4.86 (m, 3H), 3.43-3.36 (m, 1H), 2.31-2.21 (m, 2H), 2.09-1.87
(m, 4H).
MS (ESI): mass calculated for C17H18BN503 351.15, m/z found 352.1 [M+H].
FlPLC: 97.07%
(220 nm), 100% (254 nm).
[0235]
13. Preparation of 3((8-ehloro-2-hydroxy-2H-benzok][1,21oxaborinin-6-Aamino)-1-
(trans-
4-eyanotetrahydro-2H-pyran-3-yI)-1H-pyrazole-4-carboxamide
142
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
CI
ci OH
>/> II
co
NBS, PEG-400 rat IPPY)3
OH _______________________________ OH _________
0 MeCN 25
C, 16h
111111111
,-0 15 C-20 C, 2 h Br PTDMA, LDA, THF Br
0 C-20 C, 1.5 h
N-N
yNH2
CI CI
NH2 A 0õOH
0,B_OH ___________________________________ N---N 410 B
Pd2(dba)3, t-Bu Xphos,
Br KOAc, i-PrOH,
0
25 C-80 C, 16 h NH2
[0236]
13.1 Preparation of 5-bromo-3-ehloro-2-hydroxy-benzaldehyde
CI CI
NBS, PEG-400
OH _____________________________________________________ OH
4In ,0 15 C-20 C, 2 h Br
To a mixture of 3-chloro-2-hydroxy-benzaldehyde (4.50 g, 28.7 mmol, 1 eq) in
PEG-400 (70 mL)
was added NBS (5.37 g, 30.2 mmol, 1.05 eq) in portions at 15 C. The mixture
was stirred at 20 C
for 2 h TLC showed the reaction was completed The mixture was poured into ice-
water (w/w =
1/1) (100 mL). The aqueous phase was extracted with ethyl acetate (50 mL x 3).
The combined
organic phase was washed with brine (50 mL), dried with anhydrous Na2SO4,
filtered and
concentrated in vacuum to give a residue. The residue was purified by column
chromatography
(SiO2, Petroleum ether/Ethyl acetate=10/1 to 5/1) to give 5-bromo-3-chloro-2-
hydroxy-
benzaldehyde (5.50 g, 81.2% yield) as a white solid. 1H NMR (DMSO-do, 400 MHz)
6 11.20 (s,
1H), 10.11 (s, 1H), 7.98 (s, 1H), 7.83 (s, 1H).
[0237]
13.2 Preparation of 4-bronto-2-ehloro-6-[(E)-2-(4,4,5,5-tetramethy1-1,3,2-
dioxaborolan-2-y1)
vinyllphenol
CI
CI >5c6 OH
401 OH _____
¨0
B
,0 PTDMA, LDA, THE Br
Br
0 C-20 C, 1 5 h
143
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
To a solution of LDA (2 M, 10.6 mL, 2.5 e q) in THF (10 mL) was added
N'12-
(dimethylamino)ethy1]-N,N,N'-trimethyl-ethane-1,2-diamine (3.68 g, 21.2 mmol,
4.43 mL, 2.5 e q)
drop-wise at 0 C. Then, added 4,4,5,5 -tetramethy1-2- [(4,4,5, 5-tetram ethyl-
1,3 ,2-di oxab orol an-2 -
yl)methy11-1,3,2-dioxaborolane (4.55 g, 16.7 mmol, 2 e q) in THF (5 mL) at 0
C. After addition,
the mixture was stirred at 0 C for 30 min, and then to this was added 5-bromo-
3-chloro-2-hydroxy-
benzaldehyde (2.00 g, 8.49 mmol, 1 e q) in THF (5 mL) at 0 C. The reaction was
allowed to warm
to 20 C and stirred at 20 C for 1 h. TLC showed the reaction was completed.
The mixture was
poured into sat. aq. NH4C1 (50 mL). The aqueous phase was extracted with ethyl
acetate (20 mL
x 3). The combined organic phase was washed with brine (10 mL x 2), dried with
anhydrous
Na2SO4, filtered and concentrated in vacuum to give a residue. The residue was
purified by column
chromatography (SiO2, Petroleum ether/Ethyl acetate=10/1 to 5/1) to give 4-
bromo-2-chloro-6-
[(E)-2- (4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)vinyl]phenol (2 g, 5.56
mmol, 65.5% yield)
as yellow oil.
[0238]
13.3 Preparation of 6-bromo-8-chloro-2-hydroxy-1,2-benzoxaborinine
CI
CI
OH Ir(PPY)3
0,B4OH
Br
MeCN, 25 C, 16 h
ot Br
To a mixture of 4-b romo-2-chl oro-6- [(E)-2-(4,4,5, 5-tetram ethyl-
1,3 ,2-di oxab orol an-2-y1)
vinyl]phenol (1.0 g, 2.78 mmol, 1 e q) in CH3CN (11 mL) was added tris[2-(2-
pyridyl)phenyl]iridium (18.2 mg, 27.8 umol, 0.01 e q) in one portion at 25 C
under N2. The
reaction was stirred and irradiated using 34W blue LED lamps for 16 h. TLC
showed the reaction
was completed. The mixture was filtered and concentrated to give the residue.
The residue was
purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=5/1 to
4/1) to give 6-
bromo-8-chloro-2-hydroxy-1,2-benzoxaborinine (225 mg, 31.1% yield) as a white
solid.
1H NMR (DMSO-d6, 400 MHz) 6 9.45 (s, 1H), 7.81-7.77(m, 3H), 6.27 (d, .1= 11.6
Hz, 1H).
MS (ESD: mass calculated for C8H5BBrC102 257.93, m/z found 257.0 [M-H]. HPLC:
98.95%
(220 nm), 97.82% (254 nm).
144
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
[0239]
13.4 Preparation of 3-[(8-chloro-2-hydroxy-1,2-benzoxaborinin-6-yl)atninok1-
[trans-4-
eyanotetrahydr-2H-opyran-3-ylkyrazole-4-earboxamide
()._NN.,..r NH2
CI 0 '--AsprNH2 0Qõõz¨__N ci
A 0 0õOH
0.B.-OH _______________________________________________ N-N B
B Pd2dba3, tBuXPhos, KOAc, iPrOH,
r
25 C-80 C, 16 h
0
NH2
To a mixture of 6-bromo-8-chloro-2-hydroxy-1,2-benzoxaborinine (500 mg, 1.93
mmol, 1 eq) and
3 -am i n o-1 -(trans-4-cy an otetrahy dro-2H-pyran-3 -yl )- 1H-pyrazol e-4-
carb ox am i de (454 mg, 1.93
mmol, 1 eq) in i-PrOH (20 mL) was added Pd2(dba)3 (177 mg, 193 umol, 0.1 eq),
t-Bu Xphos (164
mg, 386 umol, 0.2 eq) and KOAc (379 mg, 3.86 mmol, 2 eq) in one portion at 25
C. The mixture
was heated and stirred at 80 C for 16 h. LCMS showed the reaction was
completed and desired
MS observed. 2 parallel reactions were combined for work up. The reaction
mixture was filtered,
and the filtrate was concentrated under reduced pressure to give a residue.
The residue was purified
by prep-HPLC (column: Phenomenex luna C18 (250*70mm,15 urn); mobile phase:
[water (HCI)-
ACN];B%: 14%-44%,20min) to give 3-[(8-chloro-2-hydroxy-1,2-benzoxaborinin-6-
y1) amino]-1-
[trans-4-cyanotetrahydro-2H-pyran-3-yl]pyrazole-4-carboxamide (590 mg) and
then separated by
SFC (column: DAICEL CHIRALPAK IC (250mm*30mm,10um); mobile phase: [Neu-
IPA];B%:
50%-50%,10min). to give 3-[(8-chloro-2-hydroxy-1,2-benzoxaborinin-6-y1) amino]-
1-[trans-4-
cyanotetrahydro-2H-pyran-3-yl]pyrazole-4-carboxamide (stereoisomer one) (197.5
mg, 24.7%
yield, 97.1% purity, 100% ee, first peak, Rt = 1.262 min) as a white solid. 1H
NIVIR (DMSO-d6,
400 IVIElz) 6 9.17 (s, 1H), 9.14 (s, 1H), 8.32 (s, 1H), 7.84 (d, J = 10.4 Hz,
1H), 7.80 (d, J 2.8 Hz,
1H), 7.74 (br s, 0.5H), 7.68 (d, J= 2.8 Hz, 1H), 7.22 (br s, 0.5H), 6.20 (d, J
= 12.0 Hz, 1H), 4.62-
4.58 (m, 1H), 4.09-4.04 (m, 1H), 3.95-3.91 (m, 1H), 3.72-3.69 (m, 2H), 3.67-
3.50 (m, 1H), 2.20-
2.15 (m, 1H), 2.03-1.99 (m, 1H). MS (ESI): mass calculated for Cistli7BC1N504
413.11, m/z found
414.2 [M+H]. HPLC: 97.10% (220 nm), 99.78% (254 nm). and 3-[(8-chloro-2-
hydroxy-1,2-
benzoxaborinin-6-yl)amino]-1-[trans-4- cyanotetrahydro-2H-pyran-3 -y1
]pyrazole-4- carb oxami de
(stereoisomer two) (176 mg, 22.0% yield, 98.1% purity, 99.2% ee, second peak,
Rt = 1.431 mm)
as a white solid. 1H NMR (DMSO-d6, 400 MI-lz) 6 9.17 (s, 1H), 9.14(s, 1H),
8.32(s, 1H), 7.84(d,
J= 10.4 Hz, 1H), 7.80 (d, J= 2.8 Hz, 1H), 7.74 (br s, 0.5H), 7.68 (d, J = 2.8
Hz, 1H), 7.22 (br s,
145
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
0.5H), 6.20 (d, J= 12.0 Hz, 1H), 4.62-4.56 (m, 1H), 4.09-4.04 (m, 1H), 3.95-
3.92 (m, 1H), 3.72-
3.66 (m, 2H), 3.51-3.50 (m, 1H), 2.20-2.16 (m, 1H), 2.03-1.98 (m, 1H). MS
(ESI): mass calculated
for C18H17BC1N504413.11, m/z found 414.1 [M+H]t HPLC: 98.18% (220 nm), 99.83%
(254 nm).
[0240]
14. Preparation of 1-('trans-4-eyanotetrahydro-211-pyran-3-y0-34('8-fluoro-2-
hydroxy-3-
methyl-1,2 -benzoxaborinin-6-Aaminolpyrazole-4-earboxamide
N NH2
>"
gib OH
t" abh OH Ir(PPY)3 0., B4OH A 0
e ,0 LDA PMDTA, THF Br 1111111111 M CN, 25 C, 167-
Pcl,c1ba,, tBuXPhos, KOAc iPrOH
Br 0 C, 1 h 130f< Br
80 C, 12 h
F
OOH
N e
0 NH2
[0241]
14.1 Preparation of 4-hromo-2-fluoro-6-[(E)-2-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-y1)
prop-1-enyllphenol
OH
OH
LDA, PMDTA, THF Br
Br
0 C, 1 h
To a solution of LDA (2 M, 6.85 mL, 3 eq) in THF (5 mL) was added dropwise
N'42-
(dimethylamino)ethy1]-N,N,N'-trimethyl-ethane-1,2-diamine (PMDTA, 1.58 g, 9.13
mmol, 1.9
mL, 2 eq) and 4,4,5,5-tetramethy1-2-[1-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-
2-y1) ethy1]-1,3,2-
dioxaborolane (3.22 g, 11.4 mmol, 2.5 eq) at 0 C under N2. The mixture was
stirred at 0 C for 30
min. A solution of 5-bromo-3-fluoro-2-hydroxy-benzaldehyde (1.00 g, 4.57 mmol,
1 eq) in THF
(5 mL) was added dropwise to the reaction at 0 C. The reaction mixture was
stirred for 0.5 h at
20 C. TLC showed the reaction was completed. The reaction mixture was added
water (30 mL)
146
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
at 0 C, and then the resulting mixture was adjusted pH to 5 with HC1 (2 N).
The solution was
diluted with Et0Ac (10 mL) and extracted with Et0Ac (20 mL x 3). The combined
organic layers
were washed with brine (30 mL x 2), dried over Na2SO4, filtered and
concentrated under reduced
pressure to give a residue. The residue was purified by flash silica gel
chromatography (ISCO ,
40 g SepaFlashe Silica Flash Column, Eluent of 0-10% Ethyl acetate/Petroleum
ether gradient @
50 mL/min) to give 4-b rom o-2-fluoro-6- [(E)-2-(4,4, 5,5 -tetram
ethyl-1,3 ,2-di ox ab orol an-2-
yl)prop-1-enyl]phenol (1.1 g, 67.5% yield) as a yellow solid. 1H NMR (DMSO-do,
400 MHz) 6
10.01 (s, 1H), 7.40 (dd, = 2.4, 10.4 Hz, 1H), 7.19 (s, 1H), 7.15 (d, J= 1.6
Hz, 1H), 1.80(s, 3H),
1.25 (s, 12H).
[0242]
14.2 Preparation of 6-bromo-8-fluoro-2-hydroxy-3-methy1-1,2-benzoxaborinine
OH
I r(P PY)3 O. B_OH
-0
Br B MeCN, 25 C, 16 h
Br
To a mixture of 4-bromo-2-fluoro-6-[(E)-2-(4,4,5,5-tetramethy1-1,3,2-
dioxaborolan-2-y1) prop-1-
enyl]phenol (600 mg, 1.68 mmol, 1 eq) in CH3CN (7 mL) was added tris[2-(2-
pyridyl)phenyl]iridium (Ir(PPY)3, 11.00 mg, 16.8 umol, 0.01 eq) in one portion
at 25 C under N2.
The reaction mixture was stirred at 25 C and irradiated using 34W blue LED
lamps for 16 hrs.
LCMS showed the reaction was completed and desired MS observed. The reaction
mixture was
concentrated under reduced pressure to give a residue. The residue was
purified by flash silica gel
chromatography (ISCOg; 20 g SepaFlash Silica Flash Column, Eluent of 0-10%
Ethyl
acetate/Petroleum ether gradient @ 50 mL/min) to give 6-bromo-8-fluoro-2-
hydroxy-3-methyl-
1,2-benzoxaborinine (350 mg, 81.1% yield, 99.3% purity) as a white solid. 1H
NMR (DMSO-do,
400 MHz) 6 9.39 (s, 1H), 7.56-7.53 (m, 1H), 7.52 (s, 1H), 7.47 (s, 1H), 2.02
(s, 3H).
MS (ESI): mass calculated for C9H713BrF02, 255.97, m/z found 255.0 [M-11]-.
HPLC: 99.33%
(220 nm), 99.43 (254 nm).
[0243]
14.3 Preparation of 1-(trans-4-eyanotetrahydro-2H-pyran-3-y0-34(8-fluoro-2-
hydroxy-3-
1 47
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
methyl- 1,2-benzoxaborinin-6-Aaminolpyrazole-4-earboxamide
0 " NH2
0,BõOH A 0
0,B4OH
Pd2dba3, tBuXPhos, KOAc, iPrOH
Br 30 C, 12 h
0
NH2
To a mixture of 6-bromo-8-fluoro-2-hydroxy-3-methyl-1,2-benzoxaborinine (500
mg, 1.95 mmol,
1 eq) and 3 -amino-1-(trans-4-cy anotetrahy dropyran-3 -yl)pyrazol e-4-carb
oxami de (550 mg, 2.34
mmol, 1.2 eq) in i-PrOH (10 mL) was added KOAc (478 mg, 4.87 mmol, 2.5 eq), t-
Bu Xphos (165
mg, 389 umol, 0.2 eq) and Pd2(dba)3 (178 mg, 195 umol, 0.1 eq) in one portion
at 20 C under N2.
The mixture was heated and stirred at 80 C for 12 h. LCMS showed the reaction
was completed
and desired MS observed. 5 parallel reactions were combined for work up. The
reaction mixture
was filtered and concentrated under reduced pressure. The residue was purified
by prep-HPLC
(column: Phenomenex luna C18 250mm*10Omm*10um; mobile phase: [water (HC1)-
ACN];B%:
0%-12%,20min) to give 1-(trans-4-cyanotetrahy dro-2H-pyran-3 -y1)-3 - [(8-
fluoro-2-hy droxy-3-
methyl -1,2-benzoxaborinin-6-yl)amino]pyrazole-4-carboxamide (510 mg, 12.7%
yield) as a
yellow solid. 1H NMR (DMSO-d6, 400 MHz) 6 9.15 (s, 1H), 9.10 (br s, 1H), 8.30
(s, 1H), 7.72
(br s, 1H), 7.61 (dd, J= 2.4, 13.6 Hz, 1H), 7.49 (s, 1H), 7.30 (d, J= 1.2 Hz,
1H), 7.20 (br s, 1H),
4.57 (dt, J = 4.4, 10.4 Hz, 1H), 4.04 (dd, J = 4.4, 11.2 Hz, 1H), 3.91 (d, J =
10.4 Hz, 1H), 3.74-
3.66 (m, 2H), 3.54-3.48 (m, 1H), 2.17 (br d, J= 9.6 Hz, 1H), 2.02 (d, J= 1.2
Hz, 3H), 2.00-1.95
(m, 1H).further separated by SFC (column:
Phenomenex-Cellulose-2
(250mm*30mm,10um);mobile phase: [Neu-Me0H];B%: 45%-45%,8min) to give 1-[trans-
4-
cyanotetrahy dro-2H-pyran-3 -y1]-3 - [(8-fluoro-2-hydroxy-3 -methy1-1,2-b enz
oxab orinin-6-
yl)amino]pyrazole-4-carboxamide (stereoisomer one) (232 mg, 97.1% purity,
99.5% ee, first peak,
Rt = 1.458 min) as a white solid. 11-1NMR (DMSO-d6, 400 MHz) 6 9.15 (s, 1H),
9.11 (s, 1H), 8.29
(s, 1H), 7.74 (br s 1H), 7.61 (dd, J= 13.6 Hz, 2.8 Hz, 1H), 7.49 (s, 1H), 7.31
(s, 1H), 7.20 (br s,
1H), 4.57 (td, J= 14.4 Hz, 1H), 4.03 (dd, J= 11.2 Hz, 4.4 Hz, 1H), 3.95-3.88
(m, 1H) 3.73-3.65
(m, 2H), 3.55-3.49 (m, 1H), 2.20-2.13 (m, 1H), 2.02 (s, 3H), 2.00-1.93 (m,
1H). MS (ESI): mass
calculated for Ci9H19BFN504 411.15; m/z found 412.2 [M+H]t HPLC: 9717% (220
nm), 99.28%
(254 nm). and 1-[trans-4-cyanotetrahydro-2H-pyran-3-y1]-3- [(8-fluoro-2-
hydroxy-3-methy1-1,2-
1 4 8
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
benzoxaborinin-6-yl)amino]pyrazole-4-carboxamide (stereoisomer two) (160 mg,
97.4% purity,
96.0% ee, second peak, Rt = 1.646 min) as a white solid. 1H NMIR (DMSO-d6, 400
MHz) 6 9.15
(s, 1H), 9.11 (s, 1H), 8.29 (s, 1H), 7.74 (br s 1H), 7.61 (d, J= 13.2 Hz, 1H),
7.49 (s, 1H), 7.31 (s,
1H), 7.20 (br s, 1H), 4.64-4.51 (m, 1H), 4.08-4.00 (m, 1H), 3.96-3.87 (m, 1H)
3.75-3.63 (m, 2H),
3.54-3.48 (m, 1H), 2.19-2.12 (m, 1H), 2.02 (s, 3H), 1.99-1.90 (m, 1H). MS
(EST): mass calculated
for C19f119BFN504 411.15; m/z found 412.2 [M+H]t. HPLC: 97.45% (220 nm),
98.86% (254 nm).
[0244]
15. Preparation of 1-(trans-2-eyanoeyelopentyl)-3-[(8-fluoro-2 -hydroxy-3-
tnetizyl-1,2-
benzoxaborinin-6-y0aminolpyrazole-4-earboxamide
To a mixture of 6-bromo-8-fluoro-2-hydroxy-3-methyl-1,2-benzoxaborinine (100
mg, 389 umol,
1 eq) and 3-amino-1-(trans-2-cyanocyclopentyppyrazole-4-carboxamide (103 mg,
467 umol, 1.2
eq) in i-PrOH (5 mL) was added KOAc (96 mg, 973 umol, 2.5 eq), t-Bu Xphos (33
mg, 77.9 umol,
0.2 eq) and Pd2(dba)3 (36 mg, 38.9 umol, 0.1 eq) in one portion at 20 C under
N2. The mixture
was heated and stirred at 80 C for 12 h. LCMS showed the reaction was
completed and desired
MS observed.
\ I
NH2
0 0õOH
0,,CH NH2 N-N
Br Pd2dba3, tBuXPhos, KOAc, iPrOH
80 C, 12h 0
NH2
The reaction mixture was filtered and concentrated under reduced pressure to
give a residue. The
residue was purified by prep-HPLC (column: Phenomenex Gemini-NX 80*40mm*3um;
mobile
phase: [water (10mM NH4HCO3)-ACN];B%: 15%-45%,8min) to give 1-(trans-2-
cyanocy clopenly1)-3 -[(8-fl uoro-2-hy droxy -3 -methyl-1,2-b enzoxaborinin-6-
yl)amino]pyrazole-4-
carb oxamide (18.5 mg, 12.0% yield, 91.9% purity) as a yellow solid.
1H NMR (DMSO-d6, 400 MHz) 6 9.12 (s, 1H), 9.09 (s, 1H), 8.29 (s, 1H), 7.62
(dd, J= 2.4, 13.2
Hz, 2H), 7.45 (s, 1H), 7.34 (d, J= 1.2 Hz, 1H), 7.15 (s, 1H), 4.88 (q, J= 8.0
Hz, 1H), 3.43-3.36
(m, 1H), 2.35-2.29 (m, 1H), 2.27-2.19 (m, 1H), 2.12-2.05 (m, 1H), 2.01 (s,
3H), 1.97-1.84 (m,
3H). MS (ESI): mass calculated for C19H19BFN503, 395.16, m/z found 396.2
[M+H]t HPLC:
149
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
91.94% (220 nm), 97.67% (254 nm).
[0245]
16. Preparation of 1-(trans-4-cyanotetrahydro-2H-pyran-3-y1)-341-hydroxy-1,3-
dihydrobenzolcf11,21oxaborol-6-Aamino)-1H-pyrazole-4-carboxamide
0 NH2
B(OH)2 1-1N-J(X" .N _CC)
/-0\
I Br H2SO4, Me0H I ilth Br PrMgC1, B(OMe),
40 N N
HN N
NC
CO2H 80 C, 6 h CO2Me THF, 0-25 C, 1.5 h Br
Cu(0Ac)2, TEA, DMA,
CO,Me 40 C, 12 h
Br
002 Me
NH2
NH2
0
HN N
B2Pin2 NaBH
ND ________________________________________________________ HN N
Fd(dppf)C12, KOAc 140 R THF, Me0H, 0-20 C, 2 h NC
IF
dioxane, 80 C, 12 h 134-0(
B¨OH
0 0
[0246]
16.1 Preparation of methyl 2-bromo-4-iodo-benzoate
I 40 Br H2SO4, Me0H I 40 Br
CO2H 80 C, 6 h CO2Me
To a solution of 2-bromo-4-iodo-benzoic acid (25.0 g, 76.5 mmol, 1 eq) in Me0H
(250 mL) was
added H2SO4 (38.2 g, 382 mmol, 20.8 mL, 98% purity, 5 eq) in one portion at 20
C. The mixture
was heated to 80 C and stirred at 80 C for 6 h. TLC showed the reaction was
completed. The
reaction mixture was concentrated under reduced pressure to give a residue.
The residue was
poured into ice-water (200 mL), adjusted pH = 7 by sat.aq.Na2C 03 and then
extracted with Et0Ac
(200 mL x 3). The combined organic layers were washed with brine (200 mL x 2),
dried over
anhydrous Na2SO4, filtered and concentrated under reduced pressure to give
methyl 2-bromo-4-
iodo-benzoate (24.5 g, 93.9% yield) as a yellow solid. 1H NIVIR (CDC13, 400
MHz) 6 8.06 (s, 1H),
7.71 (dd, J = 1.6, 8.4 Hz, 1H), 7.52 (d, J = 8.0 Hz, 1H), 3.93 (s, 3H).
[0247]
16.2 Preparation of (3-bromo-4-methoxycarbonyl-phenyl)boronic acid
150
CA 03201606 2023- 6-7
WO 2022/133420
PCT/US2021/072885
B(OH)2
I Br iPrMgCI, B(OMe)3
-
CO2Me THF, 0-25 C, 1.5 h
Br
CO2Me
To a mixture of 2-[2-(dimethylamino)ethoxy]-N,N-dimethyl-ethanamine (5.64 g,
35.2 mmol, 1.2
eq) in THF (100 mL) was added i-PrMgC1 (2 M, 17.6 mL, 1.2 eq) at 15 C under
N2. The resulting
mixture was stirred for 0.5 hat 15 C. Methyl 2-bromo-4-iodo-benzoate (10.0 g,
29.3 mmol, 1 eq)
was added dropwise to the reaction mixture, and the mixture was stirred at 25
C for 10 min.
B(OMe)3 (6.10 g, 58.6 mmol, 6.6 mL, 2 eq) was added to the reaction mixture
dropwise at 0 C
and stirred for 1 h. LCMS showed the reaction was completed and desired MS
observed. The
reaction was quenched by addition of sat. aq. NH4C1 (100 mL) at 0 C, adjusted
pH = 5 by HC1
(2N) and extracted with Et0Ac (30 mL x 3). The combined organic layers were
washed with brine
(100 mL x 3), dried over Na2SO4, filtered and concentrated under reduced
pressure to give a
residue The residue was purified by flash silica gel chromatography (ISCOR;
120 g SepaFla.shig
Silica Flash Column, Eluent of 0-25% Ethyl acetate/Petroleum ether gradient @
50 mL/min) to
give (3-bromo-4-methoxy carbonyl-phenyl)boronic acid (5.00 g, 65.8% yield) as
a yellow solid.
1H NMR (DMSO-d6, 400 MHz) 58.04 (s, 1H), 7.81 (d, J = 7.6 Hz, 1H), 7.69 (d, J
= 7.6 Hz, 1H),
3.83 (s, 3H).
[0248]
16.3 Preparation of methyl 2-bromo-4-0-carbamoy1-1-(trans-4-cyanotetrahydro-2H-
pyran-3-
y1)-1H-pyrazol-3-yl)amino)benzoate
0 NH2
B(01-02 H2NAr\-- '""C)
40 H2N --1\1
HN
N16-
Br Du(OAc)2, TEA, DMA;
CO2Me 40 C, 12 h Br
CO2Me
To a solution of (3-bromo-4-methoxycarbonyl-phenyl)boronic acid (1.00 g, 3.86
mmol, 1 eq) in
DMA (15 mL) was added 3 -ami no-1-(trans-4-cy anotetrahydropyran-3 -
yl)pyraz ol e-4-
carb oxamide (817 mg, 3.47 mmol, 0.9 eq), Cu(OAc)2 (1.75 g, 9.65 mmol, 2.5
eq), 4A molecular
sieve (1 g, 1.00 eq) and TEA (1.95 g, 19.3 mmol, 2.7 mL, 5 eq) at 25 C. The
mixture was heated
to 40 C and stirred at 40 C for 12 h. TLC showed the reaction was completed. 4
parallel reactions
151
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
were combined for work up. The reaction mixture was filtered. The filtrate was
quenched by
addition H20 (40 mL), then extracted with Et0Ac (40 mL x 3). The combined
organic layers were
washed with brine (40 mL x 3), dried over Na2SO4, filtered and concentrated
under reduced
pressure to give a residue. The residue was purified by flash silica gel
chromatography (ISCO ,
120 g SepaFlash Silica Flash Column, Eluent of 0-60% Ethyl acetate/Petroleum
ether gradient
@ 100 mL/min) to give methyl -2-brom o-4-[ [4-carb am oyl -1-(tran s-4-cy an
otetrahydropyran-3 -
yl)pyrazol-3 -yl]amino]b enzoate (4 g, 57.8% yield) as a white solid. 1H N1VIR
(DMSO-d6, 400
MHz) 6 9.60 (s, 1H), 8.36 (s, 1H), 7.94 (d, J= 2.0 Hz, 1H), 7.81 (d, J= 8.8
Hz, 2H), 7.61 (dd, J=
2.0, 8.8 Hz, 1H), 7.30 (s, 1H), 4.67-4.58 (in, 1H), 4.08-3.98 (m, 3H), 3.92
(br d, J= 10.8 Hz, 1H),
3.70-3.61 (m, 2H), 3.50-3.45 (m, 1H), 2.17 (br d, J = 10.0 Hz, 1H), 1.99 (s,
3H), 1.57-1.48 (m,
2H).
[0249]
16.4 Preparation of methyl 444-earbamoyl-1-(trans-4-eyanotetrahydro-2H-pyran-3-
yl)-1H-
pyrazol-3-yl)amino)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate
NH2
NH2
0
N¨e>
HN
--
132Pin2
N
HN
N5
-
IS Br Pd(dppf)C12, KOAc 40
dioxane, 80 C, 12 h
CO2Me 0 0
A mixture of methyl 2-b rom o-4-[ [4-carb am oyl-1 -(trans-4-cy
anotetrahy dro-2H-pyran-3 -
yl)pyrazol-3-yl]amino]benzoate (1.00 g, 2.23 mmol, 1 eq), 4,4,5,5-tetramethy1-
2-(4,4,5,5-
tetramethy1-1,3,2-dioxaborolan-2-y1)-1,3,2-dioxaborolane (1.13 g, 4.46 mmol, 2
eq), KOAc (656
mg, 6.69 mmol, 3 eq) and Pd(dppf)C12 (81.6 mg, 111 umol, 0.05 eq) in dioxane
(20 mL) was
degassed and purged with N2 for 3 times. The mixture was heated and stirred at
80 C for 12
h under N2 atmosphere. LCMS showed the reaction was completed and desired MS
observed. 4
parallel reactions were combined for work up. The reaction mixture was
filtered and the filtrate
was concentrated under reduced pressure to give a residue. The residue was
purified by flash silica
gel chromatography (ISCO , 120 g SepaFlash Silica Flash Column, Eluent of 0-
70% Ethyl
acetate/Petroleum ether gradient @, 100 mL/min) to give methyl 44(4-carbamoy1-
1-(trans-4-
cyan otetrahy dro-2H-py ran-3 -y1)-1H-pyraz ol -3 -yl )am in o)-2-(4,4, 5,5-
tetram ethyl -1,3,2-
152
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
dioxaborolan-2-yl)benzoate (3.00 g, 67.8% yield) as a white solid. 1H-NMR
(DMSO-d6, 400 MHz)
6 9.54 (s, 1H), 8.34 (s, 1H), 7.83-7.80 (m, 2H), 7.66 (s, 1H), 7.55-7.53 (m,
1H), 7.33-7.32 (m, 1H),
4.64-4.61 (m, 1H), 4.08-4.05 (m, 2H), 4.03-4.01 (m, 1H), 3.92-3.90 (m, 1H),
3.79 (s, 3H), 3.68-
3.61 (m, 2H), 3.42-3.40 (m, 1H), 2.16-2.14 (m, 1H), 1.34 (s, 12H).
[0250]
16.5 Preparation of 1-(trans-4-cyanotetrahydro-2H-pyran-3-y)-341-hydroxy-1,3-
dihydrobenzok][1,2Joxaborol-6-y9amino)-1H-pyrazole-4-carboxamide
NH2
NH2
HN N
NaBH4
_oNC ___________________________________ . HN N
THF, Me0H; 0-20 C, 2 h NC.
411
B¨OH
0 0
To a solution of methyl 4-[[4-carbamoy1-1-(trans-4-cyanotetrahydro-2H-pyran-3-
yl)pyrazol-3-
yl] amino]-2-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)benzoate (3.00 g,
6.06 mmol, 1 eq) in
THF (30 mL) was added NaBH4 (1.49 g, 39.4 mmol, 6.5 eq) in portions at 0 C.
The mixture
was stirred at 20 C for 2 h. LCMS showed the reaction was completed and
desired MS
observed. The reaction was poured into ice-water (30 mL), adjusted pH = 6 by
HC1 (2N) and
extracted with Et0Ac (30 mL x 3). The combined organic layers were washed with
brine (30
mL x 2), dried over anhydrous Na2SO4, filtered and concentrated under reduced
pressure to give
a residue. The residue was purified by prep-HPLC (column: Phenomenex luna C18
(250*70mm,15 um); mobile phase: [water (0.05%HC1)-ACN];B%: 10%-40%,30min) to
give 1-
(trans-4-cyanotetrahydro-2H-pyran-3-y1)-3-((1-hydroxy-1,3-
dihydrobenzo[c][1,2]oxaborol-6-
yl)amino)-1H-pyrazole-4-carboxamide (600 mg, yield 30%, purity 99.8%) as a
white solid,
which was further separated by SFC (column: DAICEL CHIRALPAK
IC(250mm*30mm,10um); mobile phase: [Neu-IPA];B%: 50%-50%,9min) to give 1-
(trans-4-
cyanotetrahydro-2H-pyran-3-y1)-3-((1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-
6-yl)amino)-
1H-pyrazole-4-earboxamide (stereoisomer one) (243 mg, 97.5% purity, 100% ee,
first peak, Rt =
2.279 min) as a white solid 1H NMR (DMSO-do, 400 MHz) 6 9.25 (s, 1H), 9.11 (s,
1H), 8.30 (s,
1H), 7.74 (s, 1H), 7.69 (dd, J= 2.0, 8.0 Hz, 2H), 7.30 (d, J= 8.0 Hz, 1H),
7.20 (br s, 1H), 4.93
153
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
(s, 2H), 4.59-4.55 (m, 1H), 4.03 (dd, J= 4.0, 11.2 Hz, 1H), 3.92 (br d, J=
10.8 Hz, 1H), 3.74-
3.66 (m, 2H), 3.52-3.47(m, 1H), 2.16 (br d, J= 10.0 Hz, 1H), 2.04-1.94 (m,
1H). MS (ESI): mass
calculated for C17H18BN504, 367.15, m/z found 368.2 [M+H]t. HPLC: 97.53% (220
nm), 99.74
(254 nm). and 1-(trans-4-cyanotetrahydro-2H-pyran-3-y1)-3-((1-hydroxy-1,3-
dihydrobenzo[c][1,2]oxaborol-6-yl)amino)-1H-pyrazole-4-carboxamide
(stereoisomer two) (239
mg, 99.4% purity, 100% ee, second peak, Rt = 2.804 min) as a white solid. 1H
NMR (DMSO-d6,
400 MHz) 6 9.25 (s, 1H), 9.11 (s, 1H), 8.30 (s, 1H), 7.74 (d, J= 1.6 Hz, 1H),
7.69 (dd, J= 2.4,
8.4 Hz, 2H), 7.30 (d, J= 8.0 Hz, 1H), 7.20 (br s, 1H), 4.93 (s, 2H), 4.60-4.54
(m, 1H), 4.03 (dd, J
= 4.0, 11.2 Hz, 1H), 3.92 (br d, J= 10.4 Hz, 1H), 3.74-3.67 (m, 2H), 3.50-3.45
(m, 1H), 2.16 (br
d, .J = 10.0 Hz, 1H), 2.04-1.97 (m, 1H). MS (ESI): mass calculated for
C17H18BN504, 367.15,
m/z found 368.2 [M+H]t HPLC: 99.47% (220 nm), 100.00% (254 nm).
[0251]
17. Preparation of 1-(trans-4-eyanotetrahydro-211-pyran-3-A-3-(0-hydroxy-5-
methyl-2H-
benzok][1,21oxaborinin-6-y1)amino)-1H-pyrazole-4-carboxamide.
c),,c) 1 (:)..,c) Aisit. OH
Br2 BBr3 Pine13Pin
_______________________________________________________ 1.= I o
Fe, CHCI3, -10 C Br 111111"11 DCM, 0 C, 1.5 hs Br
LDA, PMDTA, THF).-
25 C, 1 h
OH Ir(PPY)3 013
Op õOH
NH N2 H2
Pd2dba3, tBuXPhos
________________________________ J.-
Br BPin MeCN, 25 C, 16h Br
KOAc, iPrOH,MW
100 0, 2 hs
0
0õOH
N¨N g
0
NH2
[0252]
17.1 Preparation of 3-bromo-6-methoxy-2-methylbenzaldehyde
154
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
O
0 0
Br2
Fe, CHCI3, -10 C Br
To a solution of 2-methoxy-6-methylbenzaldehyde (8 g, 53 mmol, 1 eq) in
chloroform (150 mL)
was added Fe (150 mg, 2.69 mmol, 0.05 eq) in one portion at -10 C. After
addition, the mixture
was stirred at -10 C for 10 mins, and then a solution of bromine (1.3 g, 8.0
mmol, 1.2 eq) in DCM
(3 mL) was added drop-wise at -10 C in 10 minutes. The resulting mixture was
stirred at -10 C
for 1 hour. TLC showed the reaction was completed. Then the result solution
was poured into
water (250 mL). The organic layer was washed with sodium thiosulfate solution
(2 x 250 mL),
water (250 mL) and brine solution (250 mL). The organic layer was dried over
sodium sulfate and
concentrated under reduced pressure to give light yellow solid which was used
in next step directly
without purification. 3-bromo-6-methoxy-2-methylbenzaldehyde (12 g, 52.4 mmol)
was obtained
as light-yellow solid. 1H NMilt (400 MHz, CDC13) 5 7.67 (d, J= 9.2 Hz, 1H),
6.76 (d, J= 8.8 Hz,
1H), 3.90 (s, 3H), 2.65 (s, 3H).
[0253]
17.2 Preparation of 3-bromo-6-hydroxy-2-methylbenzaldehyde
O OH
BBr3
Br DCM, 0 C, 1.5 hs Br
A solution of boron tribromide (13.1 g, 52.4 mmol, 5.1 mL, 1 eq) in
dichloromethane (5 ml) was
added to a stirred solution of 3-bromo-6-methoxy-2-methyl-benzaldehyde (12 g,
52.4 mmol, 1 eq)
in DCM (150 mL) under nitrogen at 0 C. The reaction mixture was stirred for
1.5 hours at
0 C.TLC showed the reaction was completed. Water (400 mL) was added cautiously
at 0 C and
the mixture was continue stirred for 15 min. TLC showed the reaction was
completed.
The organic layer was washed with sodium bicarbonate aqueous (200 mL), water
(200 mL) and
brine (200 mL), then the organic layer was dried over sodium sulfate and
concentrated under
reduced pressure to give the crude product as brown solid which was purified
by silica gel column
chromatography (Petroleum ether/Ethyl acetate=100:1 to 50:1) to afford 3-bromo-
6-hydroxy-2-
methyl-benzaldehyde (11 g, 97.6% yield) as yellow solid. 111 NMR (400 MHz,
CDC13) 6 12.07 (s,
1H), 10.37 (s, 1H), 7.64 (d, J= 8.8 Hz, 1H), 6.75 (d, J= 8.8 Hz, 1H), 2.69 (s,
3H).
155
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
[0254]
17.3 Preparation of (E)-4-bromo-3-methyl-2-(2-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-
yl)vinyl)phenol
OH OH
Pinr--ThPin
õAD
Br LDA, PMDTA, THF Br BIDin
25 C, 1 h
To a solution of N'-[2-(dimethylamino)ethy1]-N,N,N'-trimethylethane-1,2-
diamine (PMDTA, 4.8
g, 28 mmol, 5.8 mL, 2 eq) in THF (20 mL) was added LDA (2 M, 17.5 mL, 2.5 eq)
and a solution
of 4,4,5,5 -tetram ethyl -2-[(4,4, 5,5-tetram ethy1-1,3,2-di ox ab orol an-2-
yl)methy1]-1,3 ,2-
dioxaborolane (B1, 7.5 g, 27.9 mmol, 2 eq) in THE (10 mL) at 0 C under Na. The
mixture was
stirred at 0 C for 20 min. Then to this reaction was added drop-wise a
solution of 3-bromo-6-
hydroxy-2-methyl-benzaldehyde (3 g, 13.9 mmol, leg) in THF (6 mL) at 25 'C.
The mixture was
stirred at 25 C for 40 min. LCMS showed the reaction was completed and desired
MS observed.
NH4C1 aqueous (30 mL) was added to the reaction solution and adjusted the pH=5-
6 with HC1
(2N) at 0 C. The suspension was extracted with Et0Ac (50 mL x 2). The combined
organic layers
were washed by brine (50 mL x 2), dried over Na2SO4, filtered and concentrated
under reduced
pressure to get yellow gum which was purified by flash silica gel
chromatography (ISC00; 80 g
SepaFlash Silica Flash Column, Eluent of 5-7% Ethyl acetate/Petroleum ether
gradient @ 100
mL/min) to give
4-b rom o-3 -m ethy1-2- [(E)-2-(4,4,5, 5-tetram ethyl-1,3 ,2-di oxab
orol an-2-
yl)vinyl]phenol (1.56 g, 33% yield) as yellow gum. 11-INMIt (400 MHz, DMSO-d6)
6 987 (s, 1H),
7.38 - 7.27 (m, 2H), 6.69 (d, J= 8.4 Hz, 1H), 5.93 (d, J= 14.4 Hz, 1H), 2.34
(s, 3H), 1.24 (s, 12H).
[0255]
17.4 Preparation of 6-bromo-5-methyl-2H-benzok111,21oxaborinin-2-o!
OH 0õOH
Ir(PPY)3
Br BPin MeCN, 25 C, 16h Br
To
a mixture of 4-brom o-3 -m ethy1-2- [(E)-2-(4,4,5, 5-tetram ethyl-1,3
,2-di oxab orol an-2-
yl)vinyl]phenol (2 g, 5.90 mmol, 1 eq) in MeCN (20 mL) was added tris[2-(2-
pyridyl)phenyl]iridium (Ir(PPY)3,193 mg, 295 umol, 0.05eq) in one portion at
25 C under N2. The
156
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
reaction mixture was stirred at 25 C and irradiated using 34W blue LED lamps
for 16 hrs. TLC
showed the reaction was completed. The reaction mixture was concentrated to
give yellow solid
which was purified by silica gel chromatography (Petroleum ether/Ethyl
acetate=1/1) to afford 6-
bromo-2-hydroxy-5-methy1-1,2-benzoxaborinine (0.9 g, 64% yield) as a yellow
solid. III NMR
(400 MHz, DMSO-do) 6 9.07 (br s, 1H), 8.09 (d, .1= 12.4 Hz, 1H), 7.58 (d, .1=
8.8 Hz, 1H), 7.04
(d, J= 8.8 Hz, 1H), 6.21 (d, J= 12.0 Hz, 1H), 2.54 (s, 3H).
[0256]
17.5 Preparation of 1-(trans-4-eyanotetrahydro-2H-pyran-3-y1)-342-hydroxy-5-
methyl-2H-
benzoleff1,2Joxaborinin-6-y0amino)-1H-pyrazole-4-carboxamide
0
0õOH (// Pd2dba3, tBuXPhos
N NH2
0,13'0H
___________________________________________________________ >
N¨N
Br
KOiAoco,ociP,r2OhHs,MW
NH2
0
0
0
NH2
A
To a mixture of 6-bromo-2-hydroxy-5-methyl-1,2-benzoxaborinine (1.5 g, 6.3
mmol, leq) and 3-
amino-1-[trans-4-cy anotetrahy dropy ran-3 -yl]py razol e-4-c arb oxami de
(1.48 g, 6.3 mmol, 1 eq) in
propan-2-ol (20 mL) added Pd2(dba)3 (280 mg, 314 umol, 0.05 eq) di-tert-butyl-
[2-(2,4,6-
triisopropylphenyl)phenyl]phosphine (260 mg, 630 umol, 0.1 eq) and KOAc (1.23
g, 12.5 mmol,
2eq) at 20 C under N2. The mixture was stirred at 100 C for 2 h under
microwave. LCMS showed
the reaction was completed and desired MS observed. The mixture was cooled to
25 C, and Et0Ac
(40 mL) was added to the result mixture. The mixture filtered and the solution
was concentrated
under reduced pressure to get yellow gum which was purified by silica gel
column chromatography
(Petroleum ether/Ethyl acetate=1:1) to afford crude product. Then the crude
product was further
purified by Prep-HPLC (column: Phenomenex luna C18 (250*70mm,10 um); mobile
phase:
[water (HC1)-ACN];B%: 15%-45%,25min) to give desired product (0.95 g) as a
white solid. 1H
NMR (400 MHz, DMSO-d6) 6 9.26 (s, 1H), 8.78 (s, 1H), 8.30 (s, 1H), 8.27 (d, J=
8.8 Hz, 1H),
8.17 (d, J= 12.4 Hz, 1H), 7.75 (br s, 1H), 7.17 (br s, 1H), 7.08 (d, J¨ 9.2
Hz, 1H), 6.15 (d, J-
12.4 Hz, 1H), 4.62 -4.49 (m, 1H), 4.06 -3.97 (m, 1H), 3.94- 3.86 (m, 1H), 3.72
-3.60 (m, 2H),
3.53 - 3.44 (m, 1H), 2.39 (s, 3H), 2.20 - 2.10 (m, 1H), 2.04 - 1.90 (m, 1H).
MS (ESI): mass
calculated for Ci9H20BN504, 393.16, m/z found 394.2[M+H]t. HPLC: 99.57% (220
nm), 99.24%
(254 nm).
157
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
845 mg was further separated by SFC (column: REGIS(S,S)WHELK-
01(250mm*25mm,10um);
mobile phase: [Neu-IPA];B%: 50%-50%,9min) to give two isomers:
1- [trans-4-cy anotetrahy dro-2H-pyran-3 -yl] -3- [(2-hydroxy-5 -methyl-1,2-b
enzoxab orinin-6-
yl)amino]pyrazole-4-carboxamide (stereoisomer one) (374.3 mg, 15.1% yield,
100% ee, first peak,
Rt = 1.329 min) as a white solid; 11-1NMR (400 MHz, DMSO-d6) 6 9.25 (s, 1H),
8.79 (s, 1H), 8.30
(s, 1H), 8.27 (d, = 8.8 Hz, 1H), 8.17 (d, 1= 12.4 Hz, 1H), 7.75 (br s, 1H),
7.17 (br s, 1H), 7.08
(d, J= 8.8 Hz, 1H), 6.15 (d, J= 12.0 Hz, 1H), 4.62 - 4.49 (m, 1H), 4.06- 3.97
(m, 1H), 3.94 - 3.86
(m, 1H), 3.72 - 3.60 (m, 2H), 3.53 - 3.44 (m, 1H), 2.39 (s, 3H), 2.20 - 2.10
(m, 1H), 2.04 - 1.90
(m, 1H). MS (ESI). mass calculated for C19H20BN504, 393.16, m/z found
394.2[M+H]t HPLC:
99.90% (220 nm), 100% (254 nm) and 1-[trans-4-cyanotetrahydropyran-3-y1]-3-[(2-
hydroxy-5-
methy1-1,2-benzoxaborinin-6-yl)amino]pyrazole-4-carboxamide (stereoisomer two)
(280 mg,
11.1% yield, 99.44% cc, second peak, Rt = 1.543 min) (BN-203940-02) as a white
solid. 1-11 NIV1R
(400 MHz, DMSO-d6) 6 9.21 (s, 1H), 8.75 (s, 1H), 8.26 (s, 1H), 8.23 (d, J= 9.2
Hz, 1H), 8.13 (d,
J= 12.4 Hz, 1H), 7.71 (br s, 1H), 7.12 (br s, 1H), 7.04 (d, J= 8.8 Hz, 1H),
6.12 (d, J= 12.4 Hz,
1H), 4.62 -4.49 (m, 1H), 4.06 -3.97 (m, 1H), 3.94 -3.86 (m, 1H), 3.72 - 3.60
(m, 2H), 3.53 - 3.44
(m, 1H), 2.35 (s, 3H), 2.20 -2.10 (m, 1H), 2.04 - 1.90 (m, 1H). MS (ESI): mass
calculated for
C19H2oBN504, 393.16, m/z found 394.2[M+H]+. HPLC: 99.95% (220 nm), 99.93% (254
nm).
[0257]
18. Preparation of 1-(trans-2-eyanocyclohexyl)-3-1(2-hydroxy-1,2-
benzoxaborinin-6-
Aaminolpyrazole-4-earboxamide
N-N
NH2
0 PinBBPin NH2
ti=11,1 it,h. OH,=0 0 OH
0õOH
-Er N¨I\1
B
Br LDA, PMDTA Br
PcI2(dba) 0111 3, t-Bu XPhos, KOAc N
THF, 0 C, 1 h i-PrOH, 25-85 C, 30 h
NH2
[0258]
18.1 Preparation of 6-brotno-2-hydroxy-1,2-benzoxaborinine
OH PinBBPin BõOH
41P11
Br 4" LDA, PMDTA Br
THF, 0 C, 1 h
158
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
To a solution of LDA (2 M, 18.7 mL, 2.5 eq) in THF (50 mL) was added 4,4,5,5-
tetramethy1-2-
[(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)methyl]-1,3,2-dioxaborolane
(10.0 g, 37.3 mmol,
2.5 eq) and N'[2-(dimethylamino)ethy1]-N,N,N'-trimethyl-ethane-1,2-diamine
(PMDTA, 7.76 g,
44.8 mmol, 9.4 mL, 3 eq) dropwise at 0 C under N2. The mixture was stirred at
0 C for 20 min.
To the resulting mixture was added a solution of 5-bromo-2-hydroxy-
benzaldehyde (3.00 g, 14.9
mmol, 1 eq) in TI-IF (10 mL) dropwi se at 0 C. The mixture was continue
stirred for 1 h at 0 C.
LCMS showed the reaction was completed and desired MS observed. The mixture
was quenched
by addition of sat. aq. NH4C1 (30 mL) and extracted with Et0Ac (30 mL x 2).
The combined
organic layers were washed by brine (30 mL x 2), dried over Na2SO4, filtered
and concentrated
under reduced pressure to get a residue. The residue was purified by flash
silica gel
chromatography (ISCO , 40 g SepaFlash Silica Flash Column, Eluent of 20-40%
Ethyl
acetate/Petroleum ether gradient @ 75 mL/min) to get 6-bromo-2-hydroxy-1,2-
benzoxaborinine
(500 mg, 14.9% yield) as a white solid. 1H NMR (CDC13, 400 MHz) 6 7.69 (d, J =
12.0 Hz, 1H),
7.55 (d, J = 2.4 Hz, 1H), 7.46 (dd, J = 8.8, 2.4 Hz, 1H), 7.14 (d, J= 8.8 Hz,
1H), 6.28 (d, J= 12.0
Hz, 1H).
[0259]
18.2 Preparation of 1-(trans-2-eyanoeyelohexy0-34(2-hydroxy-1,2-benzoxaborinin-
6-
y0aminolpyrazole-4-earboxamitle
N-N
NH2
0
NH2
.-
0,13__OH
N-N ita,h 0,B4OH
Br Pd2(dba)3, t-Bu XPhos, KOAc
i-PrOH, 25-85 C, 30 h
0
NH2
To a mixture of 3-amino-1-(trans-2-cyanocyclohexyl)pyrazole-4-calboxamide (143
mg, 611 umol,
1.1 eq) and 6-bromo-2-hydroxy-1,2-benzoxaborinine (125 mg, 556 umol, 1 eq) in
i-PrOH (10 mL)
was added AcOK (82 mg, 834 umol, 1.5 eq), Pd2(dba)3 (26 mg, 27.8 umol, 0.05
eq) and t-Bu
Xphos (24 mg, 55.6 umol, 0.1 eq) in one portion at 25 C under N2. The mixture
was heated to
85 C and stirred at 85 C for 30 h. LCMS showed the reaction was completed and
desired MS
observed. The mixture was added H20 (0.1 mL) at 25 C, filtered and the
filtrate was concentrated
159
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
under reduced pressure to give a residue. The residue was purified by prep-
HPLC (column:
Phenomenex Gemini-NX 80*40mm*3um; mobile phase: [water (10mM NH4HCO3)-
ACN];13%:
15%-45%,8min) to get 1-(trans-2-cyanocyclohexyl)-3-[(2-hydroxy-1,2-
benzoxaborinin-6-
yl)amino]pyrazole-4-carboxamide (34.9 mg, 90.8% purity) as an off-white solid.
NMR
(DMSO-do, 400 MHz) 6 9.07 (s, 1H), 8.80 (s, 1H), 8.23 (s, 1H), 7.79 (d, .1=
12.0 Hz, 1H), 7.68 (d,
= 2.8 Hz, 1H), 7.5 (hr s, 1H), 7.57 (dd, 1= 8.8, 2.8 Hz, 1H), 7.14-7.11 (m,
2H), 6.10 (d, = 12.0
Hz, 1H), 4.39-4.33 (m, 1H), 3.32-3.29 (m, 1H), 2.21-2.18 (m, 1H), 1.98-1.96
(m, 1H), 1.84-1.71
(m, 4H), 1.45-1.37 (m, 2H). MS (ESI): mass calculated for C19H2oBN503 377.17,
m/z found 378.2
[M-FEI]t HPLC. 90.87% (220 urn), 96.68% (254 urn).
[0260]
19. Preparation of 3-1(3-tert-butyl-2-hydroxy-1,2-benzoxaborinin-6-yl)amino]-1-
(trans-4-
eyanotetrahydro-2H-pyran-3-Apyrazole-4-earboxamide
OH
Br
TsNHNH2 B2pin2, NaH
>,.
0, ¨0 ..74
Me0H, 25 C, 3 '1 NNHTs 71-
toluene, 0-1100C, 10 h LDA, PMDTA
0 0
THF, 0 C, 1 h
0
H2N)?N¨C3 0QCN
0,13'0H H2N N
NC
N¨N
Br Pd2(dba)3, t-Bu XPhos, KOAc BOH
i-PrOH, 25-85 C, 30 h
0
NH2
[0261]
19.1 Preparation of N-(2,2-dimethylpropylideneamino)-4-methyl-
benzenesulfonamide
TsNHNH2
>=0 ...,40.õ
Me0H, 25 C, 3 h NNHTs
To a mixture of 2,2-dimethylpropanal (10.0 g, 116 mmol, 12.8 mL, 1 eq) in Me0H
(100 mL) was
added 4-methylbenzenesulfonohydrazide (21.6 g, 116 mmol, 1 eq) in one portion
at 25 C under
N2. The mixture was stirred at 25 C for 3 h. TLC showed the reaction was
completed.
160
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
The mixture was concentrated under reduced pressure to give N-(2,2-
dimethylpropylideneamino)-
4-methyl-benzenesulfonamide (20.0 g, crude) as a white solid.
[0262]
19.2 Preparation of 2-12,2-dimethy1-1-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-
2-yl)propylk
4,4,5,5-tetramethy1-1,3,2-dioxaborolane
B2pin2, NaH
0- -0
>NNHTs ___________________________________________
toluene, 0-110 C, 1071
To a mixture of N-[2,2-dimethylpropylideneamino]-4-methyl-benzenesulfonamide
(10.0 g, 39.3
mmol, 1 eq) in toluene (250 mL) was added NaH (1.89 g, 47.2 mmol, 60% purity,
1.2 eq) in
portions at 0 C under N2. The reaction was allowed to warm to 25 C and stirred
at 25 C for 0.5
h. To the reaction mixture was added 4,4,5,5-tetramethy1-2-(4,4,5,5-
tetramethy1-1,3,2-
dioxaborolan-2-y1)-1,3,2-dioxaborolane (11.9 g, 47.2 mmol, 1.2 eq) at 25 C.
The resulting
mixture was heated to 110 C and stirred at 110 C for 9.5 h. TLC showed the
reaction was
completed. The mixture was quenched with H20 (100 mL) at 0 C and extracted
with Et0Ac (100
m1, x 2) The combined organic layers were washed by brine (100 mT, x 2), dried
over Na2SO4,
filtered and concentrated under reduced pressure to get a residue. The residue
was purified by
flash silica gel chromatography (ISCOg; 120 g SepaFlashe Silica Flash Column,
Eluent of 10-20%
Ethyl acetate/Petroleum ether gradient @ 120 mL/min) to get 2-[2,2-dimethy1-1-
(4,4,5,5-
tetram ethyl-1,3 ,2-di oxab orol an-2-yl)propyl] -4,4,5,5 -tetramethyl- 1,3 ,2-
di ox ab orolane (8.20 g,
64.4% yield) as colorless oil. 1H NMR (CDC13, 400 MHz) 6 1.24 (s, 12H), 1.23
(s, 12H), 1.07 (s,
9H), 0.78 (s, 1H).
[0263]
19.3 Preparation of 6-bromo-3-tert-bu4'1-2-hydroxy-1,2-benzoxaborinine
10"o
0, OH
Br 13'
6 LDA, PMDTA Br
THF, 0 C, 1 h
To a mixture of LDA (2 M, 2.5 mL, 2 eq) in THF (10 mL) was added 2-[2,2-
dimethy1-1-(4,4,5,5-
161
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
tetramethyl-1,3 ,2-di oxaborolan-2-yl)propyl] -4,4,5,5-tetramethyl- 1,3 ,2-
dioxab orolane (1.61 g,
4.97 mmol, 2 eq) and N'42-(dimethylamino)ethy1]-N,N,N'-trimethyl-ethane-1,2-
diamine
(PMDTA, 1.08 g, 6.22 mmol, 1.3 mL, 2.5 eq) dropwise at 0 C under N2. The
mixture was stirred
at 0 C for 0.5 h. Then added a solution of 5-bromo-2-hydroxy-benzaldehyde (500
mg, 2.49 mmol,
1 eq) in THF (10 mL) at 0 C. The resulting mixture was stirred at 0 C for 0.5
h. LCMS showed
the reaction was completed and desired MS observed. The mixture was quenched
by addition of
sat. aq. N1H4C1 (30 mL) and extracted with Et0Ac (20 mL x 2). The combined
organic layers were
washed by brine (30 mL x 2), dried over Na2SO4, filtered and concentrated
under reduced pressure
to get a residue. The residue was purified by flash silica gel chromatography
(ISCOe; 20 g
SepaFlash Silica Flash Column, Eluent of 20-25% Ethyl acetate/Petroleum ether
gradient g 60
mL/min) to get the crude product. The crude product was triturated by
Petroleum ether (3 mL)
and filtered to give 6-bromo-3-tert-butyl-2-hydroxy-1,2-benzoxaborinine (200
mg, 99.2% purity)
as a white solid. 1H NMR (DMSO-d6, 400 MHz) 6 9.14 (s, 1H), 7.74 (d, J= 2.4
Hz, 1H), 7.47-7.43
(m, 2H), 7.12 (d, J= 8.8 Hz, 1H), 1.24 (s, 9H). MS (ESI): mass calculated for
C12H14BBrO2 280.03;
m/z found 279.1 [M-H]-. LIPLC: 99.26% (220 nm), 100% (254 nm).
[0264]
19.4 Preparation of 3-1(3-tert-butyl-2-hydroxy-1,2-benzoxaborinin-6-Aaminal-1-
(trans-4-
cyanotetrahydro-2H-pyran-3-Apyrazole-4-carboxamide
0
H2N
N_C3 0Q,õCN
0,BõON H2N N '
N¨N
Br Pd2(dba)3, t-Bu XPhos, KOAc BON
i-PrOH, 25-85 C, 30 h
0
NH2
To a mixture of 3-amino-1-(4-cyanotetrahydropyran-3-yl)pyrazole-4-carboxamide
(201 mg, 854
umol, 1.2 eq) and 6-bromo-3-tert-butyl-2-hydroxy-1,2-benzoxaborinine (200 mg,
712 umol, 1 eq)
in i-PrOH (10 mL) was added AcOK (105 mg, 1.07 mmol, 1.5 eq), Pd2(dba)3 (33
mg, 35.6 umol,
0.05 eq) and t-Bu Xphos (30 mg, 71 umol, 0.1 eq) in one portion at 25 C under
N2. The mixture
was heated to 85 C and stirred at 85 C for 30 h. LCMS showed the reaction was
completed and
desired MS observed. The mixture was quenched with H20 (0.1 mL), filtered and
concentrated
under reduced pressure to get a residue. The residue was purified by prep-HPLC
(column: Waters
162
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
Xbridge BEH C18 100*30mm*10um; mobile phase: [water (10mM NH4HCO3)-ACN];B%:
20%-50%,10min) to get 3-[(3-tert-buty1-2-hydroxy-1,2-benzoxaborinin-6-yDamino]-
1-(trans-4-
cyanotetrahydro-2H-pyran-3-y1)pyrazole-4-carboxamide (85 mg, 99.5% purity) as
a yellow solid.
1H-NMR (DMSO-d6, 400 MHz) 6 9.07 (s, 1H), 8.83 (s, 1H), 8.28 (s, 1H), 7.68 (hr
s, 1H), 7.60-
7.58 (m, 1H), 7.57-7.54 (m, 1H), 7.42 (s, 1H), 7.12 (hr s, 1H), 7.08 (d, .1=
7.6 Hz, 1H), 4.59-4.53
(m, 1H), 4.07-4.02 (m, 1H), 3.93-3.90 (m, 1H), 3.72-3.66 (m, 2H), 3.50-3.48
(m, 1H), 2.16-2.14
(m, 1H), 2.01-1.99 (m, 1H), 1.25 (s, 9H). MS (ESI): mass calculated for
C22H26BN504435.21; m/z
found 436.3 [M-41] . HPLC: 99.51% (220 nm), 98.07% (254 nm).
[0265]
20. Preparation of 3-1(3-tert-butyl-2-hydroxy-1,2-benzoxaborinin-6-yl)aminol-1-
(trans-2-
cyanocyclopentyl)pyrazole-4-carboxamide
NH2
0
Br Pd2(dba)3, t-Bu XPhos. KOAc N¨N
BOH
i-PrOH, 25-85 C, 30 h
0
NH2
To a mixture of 3-amino-1-(trans-2-cyanocyclopentyl)pyrazole-4-carboxamide
(93.6 mg, 427
umol, 1.2 eq) and 6-bromo-3-tert-butyl-2-hydroxy-1,2-benzoxaborinine (100 mg,
355 umol, 1 eq)
in i-PrOH (5 mL) was added AcOK (52.4 mg, 533 umol, 1.5 eq), Pd2(dba)3 (16.3
mg, 17.8 umol,
0.05 eq) and t-Bu Xphos (15.1 mg, 35.6 umol, 0.1 eq) in one portion at 25 C
under N2. The
mixture was heated and stirred at 85 C for 30 h. LCMS showed the reaction was
completed and
desired MS observed. The mixture was quenched with H20 (0.3 mL), filtered and
concentrated
under reduced pressure to get a residue. The residue was purified by prep-HPLC
(column: Waters
Xbridge BEH C18 100*30mm*10um; mobile phase: [water (10mM NH4HCO3)-ACN];B%:
25%-55%,10min) to get 3-[(3-tert-buty1-2-hydroxy-1,2-benzoxaborinin-6-yDamino]-
1-(trans-2-
cyanocyclopentyl)pyrazole-4-carboxamide (34.6 mg, 22.7% yield, 98.2% purity)
as a yellow solid.
1H-NMR (DMSO-d6, 400 MHz) 6 9.03 (s, 1H), 8.81 (s, 1H), 8.27 (s, 1H), 7.77 (s,
1H), 7.60-7.58
(hr s, 1H), 7.46-7.43 (m, 2H), 7.13-7.10 (hr s, 1H), 7.06 (d, ./= 8.4 Hz, 1H),
4.89-4.83 (m, 1H),
3.39-3.31 (m, 1H), 2.30-2.28 (m, 2H), 2.07-1.88 (m, 4H),1.24 (s, 9H).
163
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
[0266]
21. Preparation of 3-1(3-tert-buty1-2-hydroxy-1,2-benzoxaborinin-6-yl)anzinok1-
(trans-2-
eyanoeyelohexyl)pyrazole-4-earboxamide
0
H2NAX.- N_O
Q"".CN
H2N zz
0,13,0H NC
N-N 0,13,0H
Br Pdz(dba)3, t-Bu XPhos, KOAc >,1L
i-PrOH, 25-85 C, 30 h
NI-12
To a mixture of 3-amino-1-(2-cyanocyclohexyppyrazole-4-carboxamide (149 mg,
640 umol, 1.2
eq) and 6-bromo-3-tert-butyl-2-hydroxy-1,2-benzoxaborinine (150 mg, 533 umol,
1 eq) in i-PrOH
(10 mL) was added AcOK (78.6 mg, 800 umol, 1.5 eq), Pd2(dba)3 (24.5 mg, 26.7
umol, 0.05 eq)
and t-Bu Xphos (22.7 mg, 53.4 umol, 0.1 eq) in one portion at 25 C under N2.
The mixture was
heated and stirred at 85 C for 30 h. LCMS showed the reaction was completed
and desired MS
observed. The mixture was quenched with H20 (0.1 mL), filtered and the
filtrate was concentrated
under reduced pressure to get a residue. The residue was purified by prep-HPLC
(column: Waters
Xbridge BEH C18 100*30mm*10um; mobile phase: [water (10mM NI-14HCO3)-ACN];1%.
35%-65%,10min) to give 3-[(3-tert-buty1-2-hydroxy-1,2-benzoxaborinin-6-
yl)amino]-1-(2-
cyanocyclohexyl)pyrazole-4-carboxamide (55.9 mg, 23.9% yield, 99.1% purity) as
a yellow solid.
1H-N1VIR (DMSO-d6, 400 MHz) 6 9.05 (s, 1H), 8.82 (s, 1H), 8.23 (s, 1H), 7.68
(br s, 1H), 7.61
(dd, J = 8.8, 2.8 Hz, 1H), 7.54 (d, J = 2.8 Hz, 1H), 7.41 (s, 1H), 7.12 (br s,
1H), 7.08 (d, J= 8.8
Hz, 1H), 4.38-4.35 (m, 1H), 3.28-3.27 (m, 1H), 2.23-2.18 (m, 1H), 2.09-2.06
(m, 1H), 1.83-1.71
(m, 4H), 1.51-1.48 (m, 1H), 1.36-1.31 (m, 1H), 1.25 (s, 9H). MS (ESI): mass
calculated for
C23H28BN503 433.23; m/z found 432.3 [M-H]-. HPLC: 99.19% (220 nm), 99.85% (254
nm).
[0267]
22. 1-1trans-4-cyanooxan-3-yli-342-hydroxy-3-(2-hydroxyethyl)-2H-1,2-
benzoxaborinin-6-
yllatninol-1H-pyrazole-4-carboxamide
164
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
OH
BPin Br0.. _OH
n-DuLl, I ITMP, TI ir, TBSO BPIB LDA, PMDTA, THF, 0 C, 1 h
Br OTBS
0-25 C, 4 h
/ NH,
¨N
0B
N¨N HCI (1N) 0,B
N
Pc12(dba)3, t-Bu XPhos, KOAc, clioxane THF,25 C, 1 h
OTBS OH
25 C-85 C, 30 h
NH2 0
NH2
[0268]
22.1 Preparation of 3,3-bis(4,4,5,5-tetraine1hy1-1,3,2-dioxaborolan-2-
y0propoxy-tert-butyl-
dimethyl-silane
BPin
TBSO
TBSO¨/ (BPi n
n-BuLi, HTMP, THF, 0-25 C, 4 h
To a mixture of 2,2,6,6-tetramethylpiperidine (HTMP, 2.90 g, 20.5 mmol, 3.48
mL, 1.1 eq) in THF
(60 mL) was added n-BuLi (2.5 M, 8.21 mL, 1.1 eq) dropwise at 0 C under N2.
The mixture was
stirred at 0 C for 30 min. To the reaction mixture was added a solution of
4,4,5,5-tetramethy1-2-
[(4,4,5,5-tetram ethyl -1,3,2-di oxaborol an-2-yl)methy1]-1,3,2-dioxaborol ane
(5.00 g, 18.6 mmol, 1
eq) in THF (30 mL) dropwise at 0 C. The reaction mixture was stirred for 30
min at 0 C. Then a
solution of 2-bromoethoxy-tert-butyl-dimethyl-silane (11.1 g, 46.6 mmol, 2.5
eq) in THF (30 mL)
was added dropwise to the above mixture at 0 C. The resulting reaction mixture
was stirred for 3
h at 20 C. TLC showed the reaction was completed. The mixture was poured into
sat. aq. NH4C1
(50 mL) and extracted with ethyl acetate (30 mL x 3). The combined organic
phase was washed
with brine (30 mL x 2), dried over Na2SO4, filtered and concentrated in vacuum
to give a residue.
The residue was purified by flash silica gel chromatography (ISCO ; 80 g
SepaFlash Silica
Flash Column, Eluent of 5-10% Ethyl acetate/Petroleum ether gradient g 100
mL/min) to give
3,3 -bi s(4, 4,5,5 -tetramethyl-1,3 ,2-dioxaborol an-2-yl)propoxy-tert-butyl-
dimethyl-silane (4.7 g,
59.0% yield) as colorless oil. 1-11 NMR (CDC13, 400 MHz) 6 3.55 (t, J= 7.2 Hz,
2H), 1.82-1.77 (m,
2H), 1.22 (s, 24H), 0.91 (s, 9H), 0.87 (t, J= 6.8 Hz, 1H), 0.04 (s, 6H).
165
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
[0269]
22.2 Preparation of 2-(6-bromo-2-hydroxy-1,2-benzoxaborinin-3-yl)ethoxy-tert-
butyl-dintethyl-
silane
OH
Rip ,0
0
BPin Br
i
\ =
TBSO¨/ BPin LDA, PMDTA, THF, 0 C, 1 h Br OTBS
To a mixture of LDA (2 M, 5.47 mL, 2.2 eq) in THF (20 mL) was added 3,3-
bis(4,4,5,5-
tetramethy1-1,3,2-dioxaborolan-2-yl)propoxy-tert-butyl-dimethyl-silane (4.67
g, 10.9 mmol, 2.2
eq) and N'-[2-(dimethylamino)ethy1]-N,N,N'-trimethy1-ethane-1,2-diamine (2.16
g, 12.4 mmol,
2.60 mL, 2.5 eq) dropwise at 0 C under N2. The mixture was stirred at 0 C for
30 min, and then
to the mixture was added a solution of 5-bromo-2-hydroxy-benzaldehyde (1.00 g,
4.97 mmol, 1
eq) in TI-IF (20 mL). The resulting mixture was stirred for 0.5 h at 0 C. LCMS
showed the reaction
was completed and desired MS observed. The mixture was quenched with sat. aq.
NH4C1 (50 mL)
and extracted with Et0Ac (50 mL x 2). The combined organic layers were washed
by brine (30
mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure
to get a residue. The
residue was purified by flash silica gel chromatography (ISCOg; 40 g SepaFlash
Silica Flash
Column, Eluent of 15-25% Ethyl acetate/Petroleum ether gradient @ 75 mL/min)
to give 2-(6-
bromo-2-hydroxy-1,2-benzoxaborinin-3-yl)ethoxy-tert-butyl-dimethyl-silane
(2.00 g, 31.4%
yield, 30% purity) as colorless oil.
1E1 NMR (DMSO-d6, 400 MHz) 6 9.07 (s, 1H), 7.66 (d, J = 2.4 Hz, 1H), 7.47-7.45
(m, 2H), 7.14
(d, .1 = 8.8 Hz, 1H), 3.75 (t, .1 = 7.2 Hz, 2H), 2.66-2.65 (m, 2H), 0.85 (s,
9H), 0.01 (s, 6H).
[0270]
22.3 Preparation of 3-113-p-Itert-butyl(dimethy)silygoxyethyll-2-hydroxy-1,2-
benzoxaborinin-
6-yllaminol-Htrans-4-cyanotetrahydro-2H-pyran-3-yllpyrazole-4-carboxamide
oQ
0,B_OH 0,B_OH
N¨N
Br OTBS Pd2(dba)3, t-Bu XPhos, KOAc, dioxane
OTBS
25 C-85 C, 30 h
0
NH2
To a mixture of 3 - amino-1-(tran s-4-cy anotetrahydropyran-3 -yl)pyraz ol e-4-
carb oxami de (235 mg,
1.00 mmol, 1.2 eq) and 2-(6-bromo-2-hydroxy-1,2-benzoxaborinin-3-yl)ethoxy-
tert-butyl-
166
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
dimethyl-silane (800 mg, 835 umol, 40% purity, 1 eq) in i-PrOH (10 mL) was
added AcOK (122
mg, 1.25 mmol, 1.5 eq), Pd2(dba)3 (38.2 mg, 41.8 umol, 0.05 eq) and t-Bu Xphos
(35.5 mg, 83.5
umol, 0.1 eq) in one portion at 25 C under N2. The mixture was stirred at 85 C
for 30 h. LCMS
showed the reaction was completed and desired MS observed. The mixture was
added H20 (0.5
mL), filtered and the filtrate was concentrated under reduced pressure to get
a residue. The residue
was purified by flash silica gel chromatography (ISCO ; 20 g SepaFlash Silica
Flash Column,
Eluent of 70-85% Ethyl acetate/Petroleum ether gradient @ 60 mL/min) to give
34[342-[tert-
butyhdimethyl)silyl]oxyethy1]-2-hydroxy-1,2-benzoxaborinin-6-yl]amino]-1-
(trans-4-cyano
tetrahydropyran-3-yl]pyrazole-4-carboxamide (200 mg, 22.2% yield) as a white
solid. NMR
(DMSO-d6, 400 MHz) 6 9.08 (s, 1H), 8.76 (s, 1H), 8.30 (s, 1H), 7.72 (br s,
1H), 7.64 (d, J = 2.8
Hz, 1H), 7.51 (s, 1H), 7.48 (dd, J= 8.8, 2.8 Hz, 1H), 7.17 (br s, 1H), 7.11
(d, J = 8.8 Hz, 1H),
4.59-4.56 (m, 1H), 4.07-4.03 (m, 1H), 4.01-3.98 (m, 1H), 3.78-3.76 (m, 2H),
3.75-3.73 (m, 2H),
3.58-3.55 (m, 1H), 2.58-2.56 (m, 2H), 2.23-2.19 (m, 1H), 2.01-1.98 (m, 1H),
0.85 (s, 9H), 0.02 (s,
6H).
[0271]
22.4 Preparation of 1-[trans-4-eyanooxan-3-y11-342-hydroxy-3-(2-hydroxyethyl)-
211-1,2-
benzoxaborinin-6-Raminol-1H-pyrazole-4-carboxamide
ocI
THF,25 C, 1 h
OTBS N OH
NH2 0
NH2
To a mixture of 34[342-[tert-butyhdimethyl)silydoxyethyl]-2-hydroxy-1,2-
benzoxaborinin-6-
yl]amino]-1-[trans-4-cyanotetruhydropyran-3-yl]pyrazole-4-carboxamide (100 mg,
186 umol, 1
eq) in TI-IF (1 mL) was added HC1 (1 M, 1.12 mL, 6 eq) in one portion at 25 C
under N2. The
mixture was stirred at 25 C for 1 h. LCMS showed the reaction was completed
and desired MS
observed. The mixture was concentrated under reduced pressure to give a
residue. The residue
was purified by prep-HPLC (column: Waters Xbridge BEH C18 100*30mm*10um;
mobile phase:
[water (10mM NH4HCO3)-ACN];B%: 5%-35%,10min) to give 1-[trans-4-cyanooxan-3-
y1]-3-
{ [2-hydroxy-3-(2-hydroxyethyl)-2H-1,2-benzoxaborinin-6-yl]amino]-1H-pyrazole-
4-
carboxamide (65 mg, 39.3% yield, 95.3% purity) as a white solid. 1H NMR (DMSO-
d6, 400 MHz)
167
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
9.07 (s, 1H), 8.79 (s, 1H), 8.28 (s, 1H), 7.71 (br s, 1H), 7.61 (d, J= 2.4 Hz,
1H), 7.49-7.45 (m, 2H),
7.15 (br s, 1H), 7.09 (d, J= 8.8 Hz, 1H), 4.68 (t, J= 5.2 Hz, 1H), 4.56-4.54
(m, 1H), 4.05-4.03 (m,
1H), 3.95-3.89 (m, 1H), 3.73-3.70 (m, 2H), 3.60-3.55 (m, 3H), 2.56-2.53 (m,
2H), 2.18-2.15 (m,
1H), 2.01-1.99 (m, 1H). MS (ESI): mass calculated for C20H22BN505 423.17; m/z
found 422.2 [M-
H]. HPLC: 95.37% (220 nm), 97.68% (254 nm).
[0272]
23. Preparation of 1-(trans-4-cyanotetrahydropyran-3-y1)-3-[(2-hydroxy-3,4,8-
trimethyl-1,2-
benzoxaborinin-6-yl)aminokyrazole-4-carboxamide
0- 6
arrir. OH CA' akin AlC13 OH -7Lic
a&. 0, OH
IP RP
Br 0 Pyridine, DCM MI 0 140 C, 4 h Br
LDA, PMDTA, THF Br
N NH2
co,
0 40 0õOH
Pd2dba3, tButyl-XPhos
KOAc,iPrOH
0
NH,
[0273]
23.1 Preparation of (4-bromo-2-methyl-phenyl) acetate
OH C1)1. ethil
Pyridine, DCM 11
Br Br
25 C, 2 h
To a solution of 4-bromo-2-methyl-phenol (3.00 g, 16 mmol, 1 eq) and pyridine
(2.50 g, 32.1
mmol, 2.6 mL, 2 eq) in DCM (20 mL) was dropwise added acetyl chloride (1.26 g,
16 mmol, 1.1
mL, 1 eq) at 0 C. The resulting mixture was stirred at 25 C for 2 h. TLC
showed the reaction
was completed. The reaction mixture was concentrated under reduced pressure to
remove DCM.
The reaction was quenched with H20 (30 mL), adjust pH=6 with 2N HC1 and
extracted with
Et0Ac (10 mL x 3). The combined organic layers were washed with brine (20 mL),
dried over
with Na2SO4, filtered and concentrated under reduced pressure to give (4-bromo-
2-methyl-phenyl)
acetate (3.30 g, 89.8% yield) as yellow liquid. 11-1 NMR (CDC13, 400 MHz) 6
7.39 (d, J= 2.4 Hz,
1H), 7.35 - 7.29 (m, 1H), 6.90 (d, J' 8.4 Hz, 1H), 2.33 (s, 3H), 2.17 (s, 3H).
168
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
[0274]
23.2 Preparation of 1-(5-bromo-2-hydroxy-3-methyl-phenyl)ethanone
ay).- 3
OH
0-140 C Br
0
Br
4 h
To a solution of (4-bromo-2-methyl-phenyl) acetate (3.30 g, 14.4 mmol, 3.4 mL,
1 eq) was added
A1C13 (4.80 g, 36.0 mmol, 2.5 eq) at 0 C. After addition, the resulting
mixture was heated and
stirred at 140 C for 4 h. TLC showed the reaction was completed. The reaction
mixture was
quenched by addition H20 (100 mL) at 0 C and then extracted with DCM (100 mL x
3). The
combined organic layers were washed with brine (200 mL), dried over with
Na2SO4, filtered and
concentrated under reduced pressure to give a residue. The residue was
purified by flash silica gel
chromatography (TSC0a); 120 g SepaFlash Silica Flash Column, Fluent of 0-10%
Ethyl
acetate/Petroleum ether gradient @ 100 mL/min) to give 1-(5-bromo-2-hydroxy -3-
methyl-
phenypethanone (3.00 g, 90.9% yield) as a yellow solid. 1H NMR (CDC13, 400
MHz) 6 12.48 (s,
1H), 7.69 (d, J= 2.3 Hz, 1H), 7.46 - 7.44 (m, 1H), 2.62 (s, 3H), 2.25 (s, 3H).
[0275]
23.3 Preparation of 6-bromo-2-hydroxy-3,4,8-trimethy1-1,2-benzoxaborinine
OH >>µ..0 0 0õOH
0
Br LDA, PMDTA, THE Br
To a solution of LDA (2 M, 6.6 mL, 3 eq) in THE (10 mL) was dropwise added
N'42-
(dimethylamino)ethy1]-N,N,N'-trim ethyl-ethane-1,2-diamine (1.51 g, 8.7 mmol,
1.8 mL, 2 eq) and
4,4,5,5 -tetram ethy1-2-[ 1 -(4,4,5,5 -tetram ethy1-1,3,2-di oxab orolan-2-
yl)ethyl] -1,3,2-
dioxaborolane (2.46 g, 8.7 mmol, 2 eq) at 0 'C. After addition, the mixture
was stirred at 0 C for
30 min and then 1-(5-bromo-2-hydroxy-3-methyl-phenyl)ethanone (1.00 g, 4.4
mmol, 1 eq) in
THF (3 mL) was added dropwise at 0 C. The resulting mixture was stirred at 0 C
for another 1 h.
LCMS showed the reaction was completed and desired MS observed. The reaction
mixture was
quenched by sat. NH4C1 (50 mL), adjust pH=7 with 1N HC1 and extracted with
Et0Ac (20 mL x
169
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
3). The combined organic layers were washed with brine (50 mL), dried over
Na2SO4, filtered and
concentrated under reduced pressure to give a residue. The residue was
purified by flash silica gel
chromatography (ISCOO; 40 g SepaFlash Silica Flash Column, Eluent of 0-30%
Ethyl
acetate/Petroleum ether gradient @ 100 mL/min) to give crude product. Then the
crude product
was triturated with Petroleum ether (10 mL) at 25 C for 10 min to give 6-bromo-
2-hydroxy -3,4,8-
trimethy1-1,2-benzoxaborinine (0.7 g, 60.0% yield) was as a yellow solid. 1H
NMR (DMSO-d6,
400 MHz) 6 8.81 (s, 1H), 7.56 (d, J= 2.4 Hz, 1H), 7.40 (d, J= 2.0 Hz, 1H),
2.33 (s, 3H), 2.21 (s,
3H), 1.97 (s, 3H). MS (ESI): mass calculated for C1tH12BBr02, 266.01, m/z
found 266.9 EM-Hr.
HPLC: 98.91% (220 nm), 99.83% (254 rim).
[0276]
23.4 Preparation of 1-(trans-4-cyanotetrahydropyran-3-y1)-3-[(2-hydroxy-3,4,8-
trimethyl-1,2-
benzoxaborinin-6-yl)aminolpyrazole-4-carboxamide
0,B4OH de/..NN- NH,
0
N//
0,B4OH
Br
Pd2c1ba3, tButyl-XPhos
KOAc, iPrOH, 80 C, 24 h
0 NI-12
To a solution of 3-amino-1-(trans-4-cyanotetrahydro-2H-pyran-3-yl)pyrazole-4-
carboxamide
(264 mg, 1.12 mmol, 1.5 eq) in i-PrOH (5 mL) was added KOAc (147 mg, 1.5 mmol,
2 eq), 6-
bromo-2-hydroxy-3,4,8-trimethy1-1,2-benzoxaborinine (200 mg, 749 umol, 1 eq),
Pd2(dba)3 (69
mg, 75 umol, 0.1 eq) and t-Bu Xphos (64 mg, 150 umol, 0.2 eq) under N2. The
resulting mixture
was heated and stirred at 80 C for 48 h. LCMS showed the reaction was
completed and desired
MS observed. 9 parallel reactions were combined for work up. The reaction
mixture was filtered
and the filtrate was concentrated under reduced pressure to give a residue.
The residue was
purified by prep-HPLC (column: Welch Xtimate C18 250*70mm#10um; mobile phase:
[water(lOmM NH4HCO3)-ACN];B%: 30%-60%,20min) to give 1-(trans-4-
cyanotetrahydro-2H-
py ran-3 -y1)-3 -[(2-hy droxy-3,4,8-trimethy1-1,2-b enzoxab orinin-6-y1)
amino]pyrazole-4-
carboxamide (550 mg, yield 19.3%, purity 97%) as a yellow solid, 1H NMR (DMSO-
d6, 400 MHz)
6 8.97 (s, 1H), 8.47 (s, 1H), 8.28 (s, 1H), 7.91 (d, J= 2.4 Hz, 1H), 7.69 (s,
1H), 7.2 (d, J= 2.0 Hz,
1H), 7.16 (s, 1H), 4.58-4.55 (m, 1H), 4.08 (dd, J= 10.8, 4 Hz, 1H), 3.94 (d,
J= 9.6 Hz, 1H), 3.72-
3.63 (m, 2H),3.42-3.32 (m, 1H), 2.34 (s, 3H), 2.29 (s, 3H), 2.17-2.16 (m, 1H),
2.16-1.98 (m, 4H).
170
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
MS (ESI): mass calculated for C21H24BN504, 421.19, m/z found 420.1 [M-H]-.
HPLC: 95.14%
(220 nm), 99.3 (254 nm). which was further separated by SFC (condition:
column: DAICEL
CHIRALCEL 04250mm*30mm,10um);mobile phase: [Neu-ETOH];B%: 50%-50%,5min) to
give 1- [trans-4-cyanotetrahy dro-211-pyran-3 -yl] -3- [(2-
hy droxy-3,4,8-trimethy1-1,2 -
benzoxaborinin-6-yl)amino]pyrazole-4-carboxamide (stereoisomer one) (211 mg,
7.43% yield,
100% ee, first peak, Rt = 1.497 min) as a yellow solid 1H NIVIR (DMSO-d6, 400
MHz) 6 8.97 (s,
1H), 8.47 (s, 1H), 8.28 (s, 1H), 7.91 (d, J= 2.4 Hz, 1H), 7.69 (s, 1H), 7.2
(d, J= 2.0 Hz, 1H), 7.16
(s, 1H), 4.58-4.55 (m, 1H), 4.08 (dd, J= 10.8, 4 Hz, 1H), 3.94 (d, J= 9.6 Hz,
1H), 3.72-3.63 (m,
2H),3.42-3.32 (m, 1H), 2.34 (s, 3H), 2.29 (s, 3H), 2.17-2.16 (m, 1H), 2.16-
1.98 (m, 4H). MS (ESI):
mass calculated for C21H24BN504, 421.19, m/z found 420.1 [M-Hr. HPLC: 97.32%
(220 nm),
99.27% (254 nm) and 1-[trans-4-cyanotetrahydro-2H-pyran-3-y1]-3-[(2-hydroxy-
3,4,8-trimethyl-
1,2-benzoxaborinin-6-y1) amino]pyrazole-4-carboxamide (stereoisomer two)
(222.5 mg, 7.83%
yield, 99.4% ee, second peak, Rt = 1.650 min) as a yellow solid. 1H NMR (DMSO-
d6, 400 MHz)
6 8.97 (s, 1H), 8.47 (s, 1H), 8.28 (s, 1H), 7.91 (d, J= 2.4 Hz, 1H), 7.69 (s,
1H), 7.2 (d, J= 2.0 Hz,
1H), 7.16 (s, 1H), 4.58-4.55 (m, 1H), 4.08 (dd, J= 10.8, 4 Hz, 1H), 3.94 (d,
J= 9.6 Hz, 1H), 3.72-
3.63 (m, 2H),3.42-3.32 (m, 1H), 2.34 (s, 3H), 2.29 (s, 3H), 2.17-2.16 (m, 1H),
2.16-1.98 (m, 4H).
MS (ESI): mass calculated for C21H24BN504, 421.19, m/z found 420.1 [M-H].
HPLC: 97.32%
(220 nm), 99.27% (254 nm).
[0277]
24. Preparation of 1-(trans-2-eyanocyclopenty1)-3-[(2-hydroxy-3,4,8-trimethyl-
1,2-
benzoxaborinin-6-yl)aminolpyrazole-4-carboxamide
NA'eNH2
0,B4OH N-
NH2
0,B4OH
N-N
Br
Pd2dba3, tButyl-XPhos
KOAc, iPrOH, 80 C, 24 h
0
NH2
To a solution of 3-amino-1-(trans-2-cyanocyclopentyl)pyrazole-4-carboxamide
(185 mg, 843
umol, 1.5 eq) in i-PrOH (3 mL) was added KOAc (110 mg, 1.12 mmol, 2 eq) , 6-
bromo-2-hydroxy-
3,4,8-trimethy1-1,2-benzoxaborinine (150 mg, 562 umol, 1 eq), Pd2(dba)3 (26
mg, 28.1 umol, 0.05
eq) and t-Bu Xphos (24 mg, 56.2 umol, 0.1 eq) at 25 C. The resulting mixture
was stirred at 80 C
171
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
for 24 h. LCMS showed the reaction was completed and desired MS observed. The
reaction
mixture was filtered, and the filtrate was concentrated under reduced pressure
to give a residue.
The residue was purified by prep-HPLC column: Waters Xbridge BEH C18
100*30mm*10um;
mobile phase: [water (10mM NH4HCO3)-ACN];EM: 30%-60%,10min) to give 1-(trans-2-
cyanocyclopentyl) -3- [(2-hydroxy-3 ,4, 8-trim ethy1-1,2-b enzoxab orinin-6-
yl)amino] pyraz ol e-4-
carboxamide (20.6 mg, 9.05% yield) as a yellow solid. 1H NMR (DMSO-d6, 400
MHz) 6 9.98 (s,
1H), 8.46 (s, 1H), 8.27 (s, 1H), 7.88 (d, J= 2.4 Hz, 1H), 7.60 (s, 1H), 7.25
(d, J= 2.0 Hz, 1H),
7.11 (s, 1H), 4.92 (q, J= 8.0 Hz, 1H), 3.40 (q, J= 8.6 Hz, 1H), 2.33 (s, 3H),
2.31 -2.27 (m, 1H),
2.27 - 2.20 (m, 4H), 2.17 - 2.06 (m, 1H), 1.97 (s, 3H), 1.94 - 1.85 (m, 3H) MS
(ESI): mass
calculated for C21H24BN503, 405.20, m/z found 404.1 [M-11]-. HPLC: 99.37% (220
nm), 99.67%
(254 nm).
[0278]
25. Preparation of 1-(trans-2-cyanoeyelohexyl)-3-[(2-hydroxy-3,4,8-trimethyl-
1,2-
benzoxaborinin-6-y1)aminokyrazole-4-carboxamide
0,13,0H NH2
B ,OH
QT
Br
Pd2dba3, tButyl-XPhos
KOAc, iPrOH, 80 C, 12 h
NH2
To a solution of 3-amino-1-(trans-2-cyanocyclohexyl)pyrazole-4-carboxamide
(105 mg, 450 umol,
1.2 eq) in i-PrOH (5 mL) was added KOAc (74 mg, 749 umol, 2 eq), 6-bromo-2-
hydroxy-3,4,8-
trimethy1-1,2-benzoxaborinine (100 mg, 374 umol, 1 eq), Pd2(dba)3 (34 mg, 37
umol, 0.1 eq) and
t-Bu Xphos (32 mg, 75 umol, 0.2 eq) at 25 C. The resulting mixture was heated
and stirred at
80 C for 12 h. LCMS showed the reaction was completed and desired MS observed.
The reaction
mixture was filtered, and the filtrate was concentrated under reduced pressure
to give a residue.
The residue was purified by prep-HPLC (column: Waters Xbridge BEH C18
100*30mm*10um;
mobile phase: [water (10mM NH4HCO3)-ACN];B%: 30%-60%,10min) to give 1-(trans-2-
cyanocyclohexyl)-3-[(2- hydroxy-3,4,8-trimethy1-1,2-benzoxaborinin-6-yl)amino]
pyrazole-4-
carboxamide (16.2 mg, 10.3% yield) as a yellow solid. HI NMR (DMSO-d6, 400
MIIz) 6 8.95 (s,
1H), 8.47 (s, 1H), 8.22 (s 1H), 7.94 (d, J= 2.4 Hz, 1H), 7.64 (s, 1H), 7.21
(d, J= 2.4 Hz, 1H), 7.11
172
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
(s, 1H), 4.42 - 4.33 (m, 1H), 3.32 - 3.24 (m, 1H), 2.33 (s, 3H), 2.27 (s, 3H),
2.22 -2.15 (m, 1H),
2.05 - 1.99 (m, 1H), 1.97 (s, 3H), 1.91 - 1.69 (m, 4H), 1.52 - 1.40 (m, 1H),
1.34 - 1.30 (m, 1H).
MS (ESI): mass calculated for C22H26BN503, 419.21, m/z found 418.2 [M-11]-.
HPLC: 93.91%
(220 nm), 98.62% (254 nm).
[0279]
26. Preparation of 1-ftrans-2-eyanoeyelohexy11-3-[(2-hydroxy-3-methy1-1,2-
benzoxaborinin-6-
yl)aminolpyrazole-4-carboxamide
OH
Mel B -
/13--
ID*
0 0
LiTMP, THF, 0-25 C, 2 h I L Br DA, PMDTA Br
0 OH
THF, 0 C, 1.5 h
N-N
H2
0
NH2
dol. 0,B...0H
Pd2(dba)3, t-Bu XPhos, KOAc >)Th\J
i-PrOH, 25-85 C 30 h
0
NH2
[0280]
26.1 Preparation of 4,4,5,5-tetramethy1-2-11-(4,4,5,5-tetraniethyl-1,3,2-
dioxaborolan-2-
yl)ethyll-1,3,2-dioxaborolane
n-BuLi, HTMP, THF, 0-25 C, 2h 0
To a mixture of 2,2,6,6-tetramethylpiperidine (HTMP, 8.70 g, 61.6 mmol, 10.5
mL, 1.1 eq) in THE
(100 mL) was added n-BuLi (2.5 M, 24.6 mL, 1.1 eq) drop-wise at 0 C under N2.
The mixture
was stirred at 0 C for 30 min. To the reaction mixture was added a solution of
4,4,5,5-tetramethy1-
2-[(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)methyl]-1,3,2-dioxaborolane
(15 g, 56.0 mmol, 1
eq) in THF (50 mL) dropwise at 0 C. The reaction mixture was stirred for 30
min at 0 C. Then
Mel (8.74 g, 61.6 mmol, 3.8 mL, 1.1 eq) was added dropwise to above mixture at
0 C. The
173
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
resulting reaction mixture was stirred at 25 C for 1 h. TLC showed the
reaction was completed.
The mixture was poured into sat. aq. NH4C1 (50 mL) and stirred for 10 min. The
aqueous phase
was extracted with ethyl acetate (50 mL x 3). The combined organic phase was
washed with brine
(30 mL x 2), dried over Na2SO4, filtered and concentrated in vacuum to give a
residue. The residue
was purified by flash silica gel chromatography (ISCOS; 120 g SepaFlash
Silica Flash Column,
Eluent of 5-15% Ethyl acetate/Petroleum ether gradient @ 120 mL/min) to get
4,4,5,5-
tetram ethy1-2-[1-(4, 4, 5,5-tetram ethyl-1,3 ,2-di oxab orol an-2-yl)ethy1]-
1,3 ,2-di oxab orol ane (10.0 g,
63.3% yield) as colorless oil. 1FINMR (CDC13, 400 MHz) 6 1.24 (s, 24H), 1.05
(d, J= 7.2 Hz, 3H),
0.73-0.70 (m, 1H).
[0281]
26.2 Preparation of 6-bromo-2-hydroxy-3-methy1-1,2-benzoxaborinine
AI OH
Br 4111"
6 40
LDA, PMDTA Br
THF, 0 C, 1.5 h -
To a mixture of LDA (2 M, 16.4 mL, 2.2 eq) in THE (50 mL) was added 4,4,5,5-
tetramethy1-2-[1-
(4,4,5,5-tetram ethyl -1,3,2-di oxaborol an-2-ypethy1]-1,3,2-dioxaborol ane
(8.42 g, 29.8 mmol, 2 eq)
and N'[2-(dimethylamino)ethy1]-N,N,NI-trimethyl-ethane-1,2-diamine (PMDTA,
5.17 g, 29.8
mmol, 6.2 mL, 2 eq) dropwise at 0 C under N2. The mixture was stirred at 0 C
for 30 min. To
the reaction mixture was added a solution of 5-bromo-2-hydroxy-benzaldehyde
(3.00 g, 14.9 mmol,
1 eq) in THF (10 mL) at 0 C. The resulting mixture was stirred at 0 C for 1 h.
LCMS showed
the reaction was completed and desired MS observed. The mixture was quenched
by addition of
sat. aq. NH4C1 (50 mL) and extracted with Et0Ac (30 mL x 2). The combined
organic layers were
washed by brine (50 mL x 2), dried over Na2SO4, filtered and concentrated
under reduced pressure
to get a residue. The residue was purified by flash silica gel chromatography
(ISCOe; 80 g
SepaFlash Silica Flash Column, Eluent of 30-40% Ethyl acetate/Petroleum ether
gradient @
100 mL/min) to get 6-bromo-2-hydroxy-3-methyl-1,2-benzoxaborinine (400 mg,
11.2% yield) as
a white solid. 1-1-1 NMR_ (DMSO-d6, 400 MHz) 6 9.08 (s, 1H), 7.65 (d, J = 2.4
Hz, 1H), 7.46-7.43
(m, 2H), 7.14 (d, J= 8.4 Hz, 1H), 2.01 (s, 3H).
174
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
[0282]
26.3 Preparation of Htrans-2-eyanoeyelohexy1J-3-[(2-hydroxy-3-methy1-1,2-
benzoxaborinin-
6-Aamino]pyrazole-4-earboxamide
N-N
yk,NH2
0 mõ
12
14111
B4OOH
N""-N datki 0,13,0 H
Br Pd2(dba)3, t-Bu XPhos, KOAc
i-PrOH, 25-85 C, 30 h
0
NH2
To a mixture of 3-amino-1-(trans-2-cyanocyclohexyl)pyrazole-4-carboxamide (100
mg, 429 umol,
1 eq) and 6-bromo-2-hydroxy-3-methyl-1,2-benzoxaborinine (102 mg, 429 umol, 1
eq) in i-PrOH
(10 mL) was added AcOK (63 mg, 643 umol, 1.5 eq), Pd2(dba)3 (20 mg, 21 umol,
0.05 eq) and t-
Bu Xphos (18 mg, 43 umol, 0.1 eq) in one portion at 25 C under N2. The mixture
was heated to
85 C and stirred at 85 C for 30 h. LCMS showed the reaction was completed and
desired MS
observed. The mixture was quenched with H20 (0.5 mL), filtered and
concentrated under reduced
pressure to get a residue. The residue was purified by prep-HPLC (column:
Waters Xbridge BEH
C18 100*30mm*10um; mobile phase: [water (NH4HCO3)-ACN];B%: 25%-55%, 10min) to
get
1- [trans-2-cyanocyclohexyl]-3 -[(2-hydroxy-3-methyl-1,2-benzoxaborinin-6-
yl)amino] pyrazole-
4-carboxamide (42.2 mg, 24.2% yield, 96.3% purity) as a gray solid. 1-H NMR
(DMSO-d6, 400
MHz) 6 9.04 (s, 1H), 8.76 (s, 1H), 8.22 (s, 1H), 7.65 (br s, 1H), 7.59 (d, J=
2.8 Hz, 1H), 7.49-7.45
(m, 2H), 7.11( br s, 1H), 7.08 (d, J= 7.2 Hz, 1H), 4.39-4.32 (m, 1H), 3.31-
3.28 (m, 1H), 2.21-2.19
(m, 1H), 2.01 (s, 3H), 1.99-1.96 (m, 1H), 1.83-1.69 (m, 4H), 1.44-1.37 (m,
2H). MS (ESI): mass
calculated for C2oH22BN503 391.18; m/z found 392.2 [M+Ht HPLC: 96.33% (220
nm), 98.83%
(254 nm).
[0283]
27. Preparation of Htrans-4-eyanotetrahydro-2H-pyran-3-y11-3-1(2-hydroxy-8-
methyl-1,2-
benzoxaborinin-6-yl)aminokyrazole-4-earboxamide
175
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
aim OH Br2, AcOH Am OH B 13 Ir(PPY)3
140 /-
0,130
WrBr
H
---- -fr.. U 2,0 0-20 C, 2 h LDA, PMDTA, TI-IF
O MeCN, 25 C, 16'h- Br
0-20 C, 1 h
N
0
013-
, OH
N-N 0
0
>,,.11.,_
N
Pd2dba2, tBuXPhos, KOAc H 0
i-PrOH, 80 C, 12 h NH2
[0284]
27.1 Preparation of 5-bromo-2-hydroxy-3-methyl-benzaldehyde
0 OH Br2, AcOH 0 OH
---0 0-20 C, 2 h 0
Br
To a mixture of 2-hydroxy-3-methyl-benzaldehyde (25.0 g, 183 mmol, 1 eq) in
AcOH (200 mL)
was added dropwise Br2 (33.7 g, 211 mmol, 10.8 mL, 1.15 eq) at 0 C. The
mixture was stirred at
20 C for 2 h. LCMS showed the reaction was completed and desired MS observed.
The reaction
mixture was quenched by addition H20 (250 mL) at 0 C and the resulting
suspension was filtered.
The filter cake was dissolved in Et0Ac (200 mL). Then the organic layer was
washed with
sat.aq.Na2S03 (150 mL x 3), dried over Na2SO4, filtered and concentrated under
reduced pressure
to give 5-bromo-2-hydroxy-3-methyl-benzaldehyde (20.0 g, 50.6% yield) as a
yellow solid. 1H
NMR (CDC13, 400 MHz) 5 11.18 (s, 1H), 9.80 (s, 1H), 7.49 (d, ./ = 2.0 Hz, 2H),
2.25 (s, 3H).
[0285]
27.2 Preparation of 4-bromo-2-methy1-6-[(E)-2-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-y1)
vinyllphenol
0--g-'13--C)
S
OH
>$\_.-0 OH
0 I
_________________________________________________ .-- -
Br ..--- il O\7
,-0 Br LDA, PMDTA, THE
0
0-20 C, 1 h
To a mixture of LDA (2 M, 62.78 mL, 3 eq) in THF (30 mL) was added dropwise
N'42-
(dimethylamino)ethy1]-N,N,N-trimethyl-ethane-1,2-diamine (14.5 g, 83.7 mmol, 2
eq) and
4,4,5,5-tetramethy1-2-[(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-y1)
methyl]-1,3,2-
176
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
dioxaborolane (28.0 g, 104 mmol, 2.5 eq) at 0 C under N2. The mixture was
stirred at 0 C for 30
min. And then a solution of 5-bromo-2-hydroxy-3-methyl-benzaldehyde (9 g, 41.8
mmol, 2.65
mL, 1 eq) in THE (30 mL) was added dropwise to the reaction mixture at 0 C and
stirred at 20 C
for 30 min. TLC showed the reaction was completed. The reaction mixture was
added H20 (100
mL) at 0 C, adjusted pH to 5 with HC1 (2 N) and stirred for 10 min at 0 C. The
solution was and
extracted with Et0Ac (100 mL x 3). The combined organic layers were washed
with brine (100
mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure
to give a residue.
The residue was purified by flash silica gel chromatography (ISCOO; 120 g
SepaFlashe Silica
Flash Column, Eluent of 0-5% Ethyl acetate/Petroleum ether gradient a 100
mL/min) to give 4-
b rom o-2-m ethyl -6- [(E)-2-(4,4,5,5 -tetram ethyl -1,3 ,2-di oxab orol an -2-
yl)vinyl]phenol (15.0 g,
crude) as yellow oil. 1H NMR (DMSO-d6, 400 MHz) 6 9.01 (s, 1H), 7.76 (s, 1H),
7.61 (d, J= 18.8
Hz, 1H), 7.58-7.45 (m, 2H), 7.25 (d, J= 2.4 Hz, 1H), 6.04 (d, J= 18.4 Hz, 1H),
2.17 (s, 3H), 1.24
(s, 12H).
[0286]
27.3 Preparation of 6-bromo-2-hydroxy-8-methyl-1,2-benzoxaborinine
gib OH
Ir(PPY)3 ask. 0B
õ _OH
Br µ1111111 13'17 MeCN, 25 C, 16 h 14,
Br
0
To a mixture of 4-bromo-2-methyl-6-[(E)-2-(4,4,5,5-tetramethy1-1,3,2-
dioxaborolan-2-y1)
vinyl]phenol (5.00 g, 14.7 mmol, 1 eq) in MeCN (30 mL) was added tris[2-(2-
pyridyl)phenyl]iridium (97 mg, 147 umol, 0.01 eq) in one portion at 20 C under
N2. The reaction
was stirred and irradiated using 34W blue LED lamps for 16 h. TLC showed the
reaction was
completed. The reaction mixture was filtered and the cake was washed with
Et0Ac (20 mL x 2).
And then the filter cake was dried in vacuo to afford 6-bromo-2-hydroxy-8-
methy1-1,2-
benzoxaborinine (3.00 g, 28.3% yield) as a yellow solid. 1H NMR (DMSO-d6, 400
MiElz) 6 9.09
(s, 1H), 7.74 (d, J= 11.6 Hz, 1H), 7.56 (d, J = 2.4 Hz, 1H), 7.44 (d, J= 2.0
Hz, 1H), 6.17 (d, J =
12.0 Hz, 1H), 2.33 (s, 3H).
177
CA 03201608 2023- 6- 7
WO 2022/133420
PCT/US2021/072885
[0287]
27.4 Preparation of Htrans-4-eyanotetrahydro-2H-pyran-3-y11-34(2-hydroxy-8-
tnethyl-1,2-
benzoxaborinin-6-yl)aminolpyrazole-4-earboxamide
p ,NH2
0_B r
,OH 0 NH2
0,B_OH
0 N¨N
Br
Pd2dba3, tBuXPhos, KOAc
i-PrOH, 80 C, 12 h 0
NH2
To a mixture of 6-bromo-2-hydroxy-8-methyl-1,2-benzoxaborinine (500 mg, 2.09
mmol, 1 eq)
and 3 -amino-1-[trans-4-cyanotetrahy dropyran-3 -yl]pyrazole-4-carb oxami de
(591 mg, 2.51 mmol,
1.2 eq) in i-PrOH (10 mL) was added Pd2(dba)3 (192 mg, 209 umol, 0.1 eq),
ditert-buty142-(2,4,6-
triisopropylphenyl)phenyl]phosphine (178 mg, 418 umol, 0.2 eq) and potassium
acetate (514 mg,
5.23 mmol, 2.5 eq) in one portion at 20 C under N2. The mixture was heated and
stirred at 80 C
for 12 h. LCMS showed the reaction was completed and desired MS observed. 4
parallel reactions
were combined for work up. The reaction mixture was filtered and the filtrate
was concentrated
under reduced pressure to give a residue. The residue was purified by prep-
HPLC (column:
Phenomenex C18 250*70mm 10u,mobile phase: [water(NH4HCO3)-ACN],13%. 25%-50% to
give 1-[trans-4-cy anotetrahy dro-2H-pyran-3 -y1]-3 - [(2-hy droxy-8 -methyl-
1,2- benzoxab orini n-6-
yl)amino]pyrazole-4-carboxamide (1.00 g, yield 28%, purity 95.1%) as a white
solid, which was
further separated by SFC (condition: column: DAICEL CHIRALPAK
IC (250mm*3 0mm,10um);mobil e phase: [Neu-Me0H];13%: 40%-40%,10min) to give 1 -
[trans-4-
cyanotetrahy dropyran-3 -yl] -3 -[(2-hydroxy -8-m ethy1-1,2-b enzoxab orinin-6-
yl)amino]py razol e-4-
carboxamide (stereoisomer one) (237 mg, 7.20% yield, 98.6% purity, 99.7% ee,
first peak, Rt =
1.381 min ). 1H NMR (DMSO-d6, 400 MHz) 6 9.01 (s, 1H), 8.77 (s, 1H), 8.28 (s,
1H), 7.80 (dõI
= 12.0 Hz, 1H), 7.69 (s, 1H), 7.64 (d, .1 = 2.4 Hz, 1H), 7.30 (d, .1= 2.4 Hz,
1H), 7.16 (s, 1H), 6.10
(d, J = 12.0 Hz, 1H), 4.55-4.52 (m, 1H), 4.08-4.05 (m, 1H), 4.03-4.02 (m, 2H),
3.72-3.70 (m, 1H),
3.50 (t, J= 2.0 Hz, 1H), 2.34 (s, 3H), 2.16-2.15 (m, 1H), 2.07-1.98 (m, 1H),.
MS (ESI): mass
calculated for C19H2oBN504, 393.16, m/z found 394.2 [M+H]t HPLC: 98.66% (220
nm), 99.73%
(254 nm) and 1 -[trans-4-cy anotetrahy dropyran-3 -y1]-3 -
[(2-hy droxy -8-m ethyl-1,2-
benzoxaborinin-6-yl)amino]pyrazole-4-carboxamide (stereoisomer two) (225 mg,
6.83% yield,
97.4% purity, 99.6% ee , second peak, Rt = 1.517 min) as a white solid. 1H NMR
(DMSO-d6, 400
MHz) 6 9.01 (s, 1H), 8.78 (s, 1H), 8.28 (s, 1H), 7.80 (d, J= 12.0 Hz, 1H),
7.69 (s, 1H), 7.64 (d, J
178
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
= 2.4 Hz, 1H), 7.30 (d, J= 2.4 Hz, 1H), 7.16 (s, 1H), 6.10 (d, J= 12.0 Hz,
1H), 4.55-4.53 (m, 1H),
4.03-4.02 (m, 1H), 3.72-3.70 (m, 1H), 3.69-3.66 (m, 2H), 3.50 (t, J= 2.0 Hz,
1H), 2.34 (s, 3H),
2.16-2.15 (m, 1H), 2.07-1.98 (m, 1H),. MS (ESI): mass calculated for
C19H2oBN504, 393.16, m/z
found 394.2 [M+H]t HPLC: 97.42% (220 nm), 99.22% (254 nm).
[0288]
28. 14trans-4-cyanotetrahydro-2H-pyran-3-y11-34[2-hydroxy-8-
(trifluoromethyl)-1,2-
benzoxaborinin-6-yllaminokyrazole-4-carboxamitle
Pin13"--'13Pin
CF3 CF3 CF3 CF3
40 OH (HCHO)n, MgC12 TEA
OH NBS OH LDA, PMDTA
OH
1
THF, 75 C, 12 h abh
CH3CN, 0 C, 1 h 401
Br
THF, 0 C, 30 min
Br BPin
NEl2
1r(PPY)3 40 B ________________________
0õOH KOAc,
t:XPAhos,0PdN2(Hd2
OgE
N-
ba)3 0õOH
CF3 N CF3
N B
MeCN, 25 C, 16 h Br i-PrOH, 85 C, 12 h
0 NH2
[0289]
28.1 Preparation of 2-hydroxy-3-(trifluoromethyobenzaldehyde
CF3 c3
OH (HCHO)n, MgC12, TEA OH
_
THF, 75 C, 12 h
To a solution of 2-(trifluoromethyl)phenol (14 g, 86.3 mmol, 1 eq) in THF (300
mL) was
added paraformaldehyde (20.7 g, 690 mmol, 8 eq), MgCl2 (12.3 g, 129 mmol, 1.5
eq) and TEA
(30.5 g, 302 mmol, 3.5 eq). The mixture was heated and stirred at 75 C for 12
h. TLC showed
the reaction was completed. The reaction mixture was quenched by addition H20
(200 mL) at 0 C,
and extracted with Et0Ac (50 mL x 3). The combined organic layers were washed
with brine (50
mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure
to give a residue.
The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl
acetate = 20/1
to 5/1) to give 2-hydroxy-3-(trifluoromethyl)benzaldehyde (10.7 g, 65.1%
yield) as yellow oil.
179
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
1H NMR (CDC13, 400 MHz) 6 11.74 (s, 1 H), 9.97 (s, 1 H), 7.84 (d, J = 8.0 Hz,
1 H), 7.78 (d, J =
7.6 Hz, 1 H), 7.13 (t, J = 7.6 Hz, 1 H).
[0290]
28.2 Preparation of 5-bromo-2-hydroxy-3-(trifluoromethyl)benzaldehyde
CF3 CF3
OH NBS OH
is
CH3CN, 0 C, 1 hi- 410:1
Br
To a solution of 2-hydroxy-3-(trifluoromethyl)benzaldehyde (10.7 g, 56.3 mmol,
1 eq) in CH3CN
(150 mL) was added NBS (12.0 g, 67.5 mmol, 1.2 eq) at 0 C. The mixture was
stirred at 0 C for
1 h. TLC showed the reaction was completed. The reaction mixture was quenched
by
addition H20 (100 mL) at 0 C, and extracted with Et0Ac (50 mL x 3). The
combined organic
layers were washed with brine (50 mL x 3), dried over Na2SO4, filtered and
concentrated under
reduced pressure to give a residue. The residue was purified by column
chromatography (SiO2,
Petroleum ether/Ethyl acetate = 1/0 to 10/1) to give 5 -b rom o-2-hydroxy-3-
(trifluoromethyl)benzaldehyde (10 g, 66.0% yield) as brown oil. 1H NMR (CDC13,
400 MHz) 6
11.63 (s, 1 H), 9.91 (s, 1 H), 7.93 (d, J = 2.4 Hz, 1 H), 7.89 (d, J = 2.4 Hz,
1 H).
[0291]
28.3 Preparation of 4-bromo-2-f(E)-2-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-
yl)viny11-6-
(trifluoroinethAphenol
CF3 CF3
OH LDA, PMDTA * OH
o THF, 0 C, 30 min
Br Br BPin
To a solution of LDA (2 M, 40.9 mL, 2.2 eq) in THF (50 mL) was added dropwise
N'42-
(dimethylamino)ethy1]-N,N,N'-trimethyl-ethane-1,2-diamine (12.8 g, 74.3 mmol,
15.5 mL, 2
eq) and 4,4,5,5-tetramethy1-2-[(4,4,5, 5-tetramethy1-1,3,2-diox aborol an-2-
yl)methyl] -1,3,2-
dioxaborolane (19.9 g, 74.3 mmol, 2 eq) at 0 C. The mixture was stirred at 0 C
for 20 min, and
then a solution of 5-bromo-2-hydroxy-3-(trifluoromethyl)benzaldehyde (10 g,
37.1 mmol, 1
eq) in TUT (50 mL) was added dropwise at 0 C. The resulting mixture was
continue stirred at
0 C for 10 min. LCMS showed the reaction was completed and desired MS
observed. The
reaction mixture was quenched by addition H20 (70 mL), and extracted with
Et0Ac (50 mL x 3).
180
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
The combined organic layers were washed with brine (50 mL x 3), dried over
Na2SO4, filtered and
concentrated under reduced pressure to give a residue. The residue was
purified by column
chromatography (SiO2, Petroleum ether/Ethyl acetate = 1/0 to 3/1) to give 4-
bromo-2-[(E)-2-
(4,4,5,5 -tetram ethyl -1,3 ,2-di oxab orol an-2-yl)vinyl] -6-(trifluorom
ethyl)phenol (11.5 g, 78.7%
yield) as yellow oil.
[0292]
28.4 Preparation of 6-bromo-2-hydroxy-8-(trifluoromethyl)-1,2-benzoxaborinine
cF, cF3
OH I r(PPY)3
0, B__OH
MeCN, 25 C, 16 h 40
Br BPin Br
To a solution of 4-bromo-2-[(E)-2-(4,4, 5,5-tetramethy1-1,3 ,2-dioxab
orolan-2-yl)viny1]-6-
(trifluoromethyl)phenol (5.65 g, 14.4 mmol, 1 eq) in CH3CN (20 mL) was added
tris[2-(2-
pyridyl)phenyl]iridium (94 mg, 143 umol, 0.01 eq). The reaction was stirred
and irradiated using
34 W blue LED lamps at 25 C for 16 h. TLC showed the reaction was completed.
The reaction
mixture was filtered and concentrated under reduced pressure to give a
residue. The residue was
purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate = 10/1
to 1/1) to give 6-
bromo-2-hydroxy-8-(trifluoromethyl)-1,2-benzoxaborinine (4.4 g, 52.2% yield)
as yellow oil.
1H NMR (CDC13, 400 MHz) 6 7.75 (s, 1 H), 7.72 (d, J = 2.0 Hz, 1 H), 7.70 (s, 1
H), 7.67 (s, 1 H),
6.40 (d, J = 12.0 Hz, 1 H).
[0293]
28.5 Preparation of 1-firans-4-cyanotetrahydro-2H-pyran-3-y1J-3-112-hydroxy-8-
(trifluorornethyl)-1,2-benzoxaborinin-6-yliaminolpyrazole-4-earboxamide
_______________________________________________ N NH2
C F3 A 0 CF3
õOH
0..B _OH KOAc, t-Bu XPhos, Pd2(dba)3 N-N 0
5:1
i-PrOH, 85 C, 12 h N1
Br
0
NH2
A mixture of 6-bromo-2-hydroxy-8-(trifluoromethyl)-1,2-benzoxaborinine (1 g,
3.41 mmol, 1 eq),
3-amino-1-(trans-4-cyanotetrahydropyran-3-yl)pyrazole-4-carboxamide (803 mg,
3.41 mmol, 1
181
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
eq), KOAc (503 mg, 5.12 mmol, 1.5 eq), t-Bu XPhos (72 mg, 170 umol, 0.05 eq)
and Pd2(dba)3
(313 mg, 341 umol, 0.1 eq) in i-PrOH (15 mL) was degassed and purged with N2
for 3 times. Then
mixture was heated and stirred at 85 C for 12 h under N2. The reaction mixture
was filtered and
concentrated under reduced pressure to give a residue. The residue was
purified by prep-HPLC
(column: Phenomenex Luna 80 x 30 mm x 3 um; mobile phase: [water (HC1)-ACN];
B%: 20%-
50%, 8 min) to give 1 -(tran s-4-cy an otetrahy dro-2H-
pyran-3 -y1)-3 -[[2-hy droxy-8 -
(trifluoromethyl)-1,2-benzoxaborinin-6-yl] amino]pyrazole-4-carboxamide (580
mg, 97.5% purity)
as a white solid. 111 NMR (DMSO-d6, 400 MHz) 6 9.25 (s, 1 H), 9.19 (s, 1 H),
8.32 (s, 1 H), 7.99
(dd, J= 2.4, 14.0 Hz, 2 H), 7.88 (d, J= 12.0 Hz, 1 H), 7.74 (s, 1 H), 7.22 (s,
1 H), 6.23 (d, J= 11.6
Hz, 1 H), 4.60 (td, J = 4.8, 10.4 Hz, 1 H), 4.07 (dd, J = 4.4, 11.2 Hz, 1 H),
3.93 (d, J = 12.0 Hz, 1
H), 3.71-3.60 (m, 2 H), 3.46 (t, J= 12.0 Hz, 1 H), 2.18 (d, J= 10.0 Hz, 1 H),
2.05-1.94 (m, 1 H).
MS (ESI): mass calculated for C19H17BF3N504 447.13; m/z found 446.1 [M-H]-.
HPLC: 97.56%
(220 nm), 99.92% (254 nm). The product (543 mg) was further separated by SFC
(column:
DAICEL CHIRALPAK IC (250 mm x 30 mm, 10 um); mobile phase: [Neu-IPA]; B%: 36%-
36%,
7 min) to give 1-[trans-4-cyanotetrahydro-2H-pyran-3-y1]-3-[[2-hydroxy-8-
(trifluoromethyl)-1,2-
benzoxaborinin-6-yllamino]pyrazole-4-carboxamide (stereoisomer one) (206.8 mg,
13.5% yield,
97.6% purity, 100% ee, first peak, Rt = 1.083 min) as an off-white solid. 1H
NMR (DMSO-d6, 400
MHz) 6 9.26 (s, 2 H), 8.33 (s, 1 H), 8.00 (dd, J= 2.0, 13.6 Hz, 2 H), 7.89 (d,
J = 12.0 Hz, 1 H),
7.75 (s, 1 H), 7.24 (s, 1 H), 6.24 (d, J = 12.0 Hz, 1 H), 4.60 (td, J= 4.4,
10.0 Hz, 1 H), 4.08 (dd, J
= 4.4, 11.2 Hz, 1 H), 3.94 (d, .1= 11.2 Hz, 1 H), 3.72-3.61 (m, 2H), 3.47
(t,./= 11.2 Hz, 1 H), 2.18
(d, J= 10.4 Hz, 1 H), 2.06-1.94 (m, 1 H). MS (ESI): mass calculated for
C19H17BF3N504 447.13;
m/z found 446.0 [M-H]. HPLC: 97.66% (220 nm), 99.26% (254 nm). and 1-[trans-4-
cyanotetrahy dro-2H-py ran-3 -y1]-3 -[ [2-hy droxy-8-(tri fluorom ethyl)-1,2-b
enzoxab orini n-6-
yl]amino]pyrazole-4-carboxamide (stereoisomer two) (204 mg, 13.3% yield, 97.2%
purity, 100%
cc, second peak, Rt = 1.205 min) as a white solid. 1H N1V1R (DMSO-d6, 400 MHz)
I5 9.26 (s, 2 H),
8.33 (s, 1 H), 8.00 (dd, J= 2.8, 14.0 Hz, 2 H), 7.89 (d, J= 12.0 Hz, 1 H),
7.76 (s, 1 H), 7.23 (s, 1
H), 6.24 (d, J= 12.0 Hz, 1 H), 4.60 (td, J= 4.4, 10.0 Hz, 1 H), 4.08 (dd, J =
4.4, 11.2 Hz, 1 H),
3.94 (d, .1= 10.4 Hz, 1 H), 3.72-3.60 (m, 2 H), 3.49 (t, .1= 11.6 Hz, 111),
2.18 (d, .1= 9.6 Hz, 1 H),
2.06-1.94 (m, 1 H). MS (ESI): mass calculated for C19111713F3N504 447.13; m/z
found 446.1 [M-
H]. HPLC: 97.26% (220 nm), 99.42% (254 nm).
182
CA 03201608 2023- 6- 7
WO 2022/133420
PCT/US2021/072885
[0294]
29. 1-(trans-4-cyanotetrahydro-211-pyran-3-y1)-3-[(7-fluoro-2-hydroxy-1,2-
benzoxaborinin-6-
Aaminolpyrazole-4-carboxamide
F OH Br2 OH PinBBPin OH I
r(PPY)3
O CHCI3, 25 C, 1611 Br LDA, PMDTA, THF, Br 411 Bpin
MeCN, 25 C, 16 h
0 C, 1h
N,,NH2
B_OH
0 Int.A
F 0,B4OH
Br Pd2dba3, tBuXPhos, K2CO3,
100 C, 2h, M.W.dioxane
NH2
[0295]
29.1 Preparation of 5-bromo-4-fluoro-2-hydroxybenzaldehyde
F too OH Br2 OH
410 ,.0
.õ0 cHc13, __ 25 C, 16h Br
To a solution of 4-fluoro-2-hydroxy-benzaldehyde (1 g, 7.14 mmol, 1 eq) in
CH3C1 (10 mL) was
added Br2 (1.1 8,6.78 mmol, 0.95 eq) dropwise at 0 C. The reaction was allowed
to warm to 25 C
and stirred at 25 C for 16 h. TLC showed the reaction was completed. The
reaction mixture was
quenched with H20 (20 mL) and extracted with Et0Ac (10 mL x 3). The combined
organic layers
were washed with brine (10 mL), dried over anhydrous Na2SO4, filtered and
concentrated under
reduced pressure to give a residue. The residue was purified by silica gel
column chromatography
(Petroleum ether: Et0Ac = 100:1 to 10:1) to give 5-bromo-4-fluoro-2-hydroxy-
benzaldehyde (1
g, 63.9% yield) as a yellow solid.
[0296]
29.2 Preparation of (E)-4-bromo-5-fluoro-2-(2-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-
yl)vinyl)phenol
183
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
F OH PinB BPin OH
Br LDA, PMDTA, THE, Br BPin
0 C, 1h
To a mixture of LDA (2 M, 22.8 mL, 2.5 eq) in TI-IF (5 mL) was added N'42-
(dimethylamino)ethy1]-N,N,N'Arimethyl-ethane-1,2-diamine (7.9 g, 45.6 mmol, 2
eq) and a
solution of 4,4,5,5 -tetramethy1-2-[(4,4, 5,5-tetramethy1-1,3,2-dioxab orolan-
2-yl)methy1]-1,3,2 -
dioxaborolane (9.80 g, 36.5 mmol, 2 eq) in TI-IF (5 mL) at 0 C under N2. The
mixture was stirred
at 0 C for 20 min. Then dropwise added a solution of 5-bromo-4-fluoro-2-
hydroxy-benzaldehyde
(4 g, 18.3 mmol, 1 eq) in THF (5 mL) at 25 C. The reaction was continue
stirred at 25 C for 40
min. TLC showed the reaction was completed. The reaction mixture was quenched
with aq.NH4C1
(100 mL) and extracted with Et0Ac (50 mL x 3). The combined organic layers
were washed with
brine (50 mL), dried over anhydrous Na2SO4, filtered and concentrated under
reduced pressure to
give a residue. The residue was purified by silica gel column chromatography
(Petroleum ether:
Et0Ac = 100:1 to 5:1) to give 4-brom o-5-fluoro-2- [(E)-2-(4,4,5,5-tetram
ethyl-1,3,2-
dioxab orolan-2-yl)vinyl]phenol (5 g, 79.8% yield) as a yellow solid. MS:
(M+1):174.1
[0297]
29.3 Preparation of 6-bromo-7-fluoro-2H-benzofel[1,21oxaborinin-2-ol
OH F 0,B4OH
I r(PPY)3
Br gpin MeCN, 25 C, 16 h Br
To a mixture of 4-bromo-5-fluoro-2-[(E)-2-(4,4,5,5-tetramethy1-1,3,2-
dioxaborolan-2-y1)
vinyl]phenol (3 g, 8.75 mmol, 1 eq) in MeCN (20 mL) was added tris[2-(2-
pyridyl)phenyl]iridium
(Ir(PPY)3,143 mg, 218 umol, 0.025 eq) in one portion at 25 C under N2. The
reaction was stirred
and irradiated using 34W blue LED lamps for 16 h. TLC showed the reaction was
completed. 3
parallel reactions were combined for work up. The reaction mixture was
filtered and the filter
cake was washed with MeCN (5 mL) and dried in vacuum to give a residue (1 g).
The residue
was purified by silica gel column chromatography (Petroleum ether: Et0Ac =
100:1 to 1:1) to give
(1,5 g, 70.6% yield) as a yellow solid.
[0298]
29.4 Preparation of 1-(trans-4-cyanotetrahydro-2H-pyran-3-y1)-3-((77fluoro-2-
hydroxy-2H-
1 84
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
benzole][1,21oxaborinin-6-v!)-1H-pyrazole-4-earboxamide
ocII 'N
N NH2
Nix -3-c
0 N l H2 eo
0,B.-OH i nt.A N-N F 0,8-1DH
0
Br ../ Pd2dba3, tBuXPhos, K2CO3,
100 C, 2h, M.W.dioxane 0 NH2
A mixture of 6-bromo-7-fluoro-2-hydroxy-1,2-benzoxaborinine (155 mg, 638 umol,
1.5 eq), 3-
amino-1-(trans-4-cyanotetrahydro-2H-pyran-3-yl)pyrazole-4-carboxamide (100 mg,
425 umol, 1
eq), Pd2(dba)3 (38.9 mg, 42.5 umol, 0.1 eq), t-Bu Xphos (36.0 mg, 85.0 umol,
0.2 eq) and K2CO3
(117 mg, 850 umol, 2 eq) in i-PrOH (5 mL) was degassed and purged with N2 for
3 times. The
mixture was heated and stirred at 100 C for 2 h under N2 atmosphere. LCMS
showed the reaction
was completed and desired MS observed. The reaction mixture was quenched with
H20 (20 mL)
and extracted with Et0Ac (10 mL x 3). The combined organic layers were washed
with brine (10
mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced
pressure to give a
residue. The residue was purified by prep-HPLC (column: Phenomenex luna C18
80*40mm*3
um;mobile phase: [water (1-1C1)-ACN];B%: 20%-40%,7min) to give 1-(trans-4-
cyanotetrahydro-
2H-pyran-3 -y1)-3 - [(7-fluoro-2-hydroxy-1,2-benzoxaborinin-6-
yl)amino]pyrazole-4-carboxamide
(67.2 mg, 39.8% yield) as an off-white solid. '14 NMR (DMSO-da, 400 MHz) 6 =
9.35 (d, J= 2.4
Hz, 1H), 8.93 (br d, J= 16.8 Hz, 1H), 8.38 (d, J= 9.6 Hz, 1H), 8.32 (s, 1H),
7.89 (d, J= 12.0 Hz,
1H), 7.83-7.69 (m, 1H), 7.19 (d, J= 12.4 Hz, 2H), 6.09 (d, J= 12.0 Hz, 1H),
4.59 (dt, J= 4.4, 10.2
Hz, 1H), 4.05 (dd, J= 4.4, 11.2 Hz, 1H), 3.97-3.89 (m, 1H), 3.84-3.66 (m, 2H),
3.57-3.49 (m, 1H),
2.17 (br d, J = 9.6 Hz, 1H), 2.05-1.94 (m, 1H). MS (ESI): mass calculated for
C18H17BFN504,
397.14, m/z found 396.1[M-H]. HPLC: 100.00% (220 nm), 99.88% (254 nm).
[0299]
30. Preparation of Htrans-4-cyanotetrahydro-2H-pyran-3-y11-3-[(2-hydroxy-4-
isopropyl-1,2-
benzoxaborinin-6-y1)aminolpyrazole-4-carboxarnide
185
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
0
OH
i-PrMgCI 1OH >5c0
0,,OH
Br CN THF, 0-25 C, 2 h Rr 0 LDA, PMDTA, THE
Br
(0-Nalr_N- NEIN:H2
NJ 0B'
, OH
Pd2dba3, tButyl-XPhos NH
KOAc, iPrOH, 80 C, 12 h 0 NH2
[0300]
30.1 Preparation of 1-(5-bromo-2-hydroxy-phenyl)-2-methyl-propan-1-one
isOH i-PrMgCI OH
Br CN THF,0-25 C, 2 h Br 0
To a solution of 5-bromo-2-hydroxy-benzonitrile (10 g, 50.5 mmol, 6.7 mL, 1
eq) in THE (200
mL) was added i-PrMgCI (2 M, 75.7 mL, 3 eq) at 0 C. The reaction was allowed
to warm to 25 C
and stirred at 25 C for 2 h. LCMS showed the reaction was completed and
desired MS observed.
The reaction mixture was quenched by H20 (100 mL) at 0 C, and then extracted
with Et0Ac (80
mL x 3). The combined organic layers were washed with brine (50 mL), dried
over Na2SO4,
filtered and concentrated under reduced pressure to give a residue. The
residue was purified by
column chromatography (Petroleum ether/Ethyl acetate=10/1 to 3/1) to give 1-(5-
bromo-2-
hydroxy-pheny1)-2-methyl-propan- 1 -one (10 g, 81.4% yield) as a white solid.
[0301]
30.2 Preparation of 6-bromo-2-hydroxy-4-isopropy1-1,2-benzoxaborinine
0
OH >5c0 0,B4OH
0
Br LDA, PMDTA, THF Br
To a solution of LDA (2 M, 15.4 mL, 5 eq) in THE (20 mL) was added dropwise
N'42-
(dimethylamino)ethyll-N,N,N'-trimethyl-ethane-1,2-diamine (PMDTA, 4.28 g, 24.7
mmol, 5.2
mL, 4 eq) and 4,4,5,5-tetramethy1-2-[(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-
y1)methyl] -1,3,2-
186
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
dioxaborolane (6.61 g, 24.7 mmol, 4 eq) at 0 C. The mixture was stirred at 0 C
for 30 min. Then
a solution of 1-(5-bromo-2- hydroxy-phenyl)-2-methyl-propan- 1-one (1.50 g,
6.2 mmol, 1 eq) in
THF (10 mL) was added dropwise at 0 C. The reaction was continue stirred at 0
C for 1 h. LCMS
showed the reaction was completed and desired MS observed. The reaction
mixture was quenched
by sat. aq. NH4C1 (100 mL), and adjusted pH=7 with 1N HC1, then extracted with
Et0Ac (50 mL
x 3). The combined organic layers were washed with brine (100 mL), dried over
with Na2SO4,
filtered and concentrated under reduced pressure to give a residue. The
residue was purified by
flash silica gel chromatography (ISCO , 40 g SepaFlash Silica Flash Column,
Eluent of 0-30%
Ethyl acetate/Petroleum ether gradient @ 100 mL/min) to give crude product.
The crude product
was triturated with Petroleum ether (10 mL) at 25 C for 10 min to give 6-bromo-
2-hydroxy-4-
isopropyl-1,2-benzoxaborinine (0.9 g, 3.37 mmol, 54.6% yield) as off-white
solid. 1H NMR
(DMSO-d6, 400 MHz) 6 8.96 (s, 1H), 7.84 (d, J = 2.3 Hz, 1H), 7.55 (dd, J =
2.4, 8.8 Hz, 1H), 7.84
(d, J = 8.8 Hz, 1H), 6.03 (s, 1H), 3.26 - 3.23 (m, 1H), 1.19 (d, J= 6.8 Hz,
6H)
MS (ESI): mass calculated for C11ll12BBrO2, 266.01, m/z found 265.1 [M-H].
HPLC: 99.71% (220 nm), 99.70 (254 nm).
[0302]
30.3 Preparation of 1-frans-4-eyanotetrahydropyran-3-y11-3-1(2-hydroxy-4-
isopropy1-1,2-
benzoxaborinin-6-y0aminokyrazole-4-earboxamide
2
0,B4OH H2
0-0 NI \--OcN NHN rHO
0,B"OH
0 N¨N
Br
Pd2dba3, tButyl-XPhos NH
KOAc iPrOH, 80 C, 12 h 0
NH2
To a solution of 6-bromo-2-hydroxy-4-isopropyl-1,2-benzoxaborinine (0.5 g,
1.87 mmol, 1 eq), 3-
amino-1-(trans-4-cyanotetrahydropyran-3-yl)pyrazole-4-carboxamide (396 mg,
1.69 mmol, 0.9
eq), t-Bu Xphos (159 mg, 374 umol, 0.2 eq), Pd2(dba)3 (171 mg, 187 umol, 0.1
eq) and KOAc
(367 mg, 3.75 mmol, 2 eq) in i-PrOH (10 mL) was degassed and purged with N2
for 3 times. Then
the mixture was heated and stirred at 80 C for 12 h under N2 atmosphere. LCMS
showed the
reaction was completed and desired MS observed. 3 parallel reactions were
combined for work
up. The reaction mixture was filtered and the filtrate was concentrated under
reduced pressure to
give a residue. The residue was purified by column chromatography (SiO2,
Petroleum ether/Ethyl
187
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
acetate=1/1 to 0/1) to give desired compound (980 mg, yield 59%, purity 94.9%)
as a white solid,
which was further separated by SFC (condition: column: DAICEL CHIRALPAK
IC(250mm*30mm,10um);mobile phase: [Neu-Me0H];13%: 50%-50%,5min) to give 1-
[trans-4-
cyanotetrahy dro-2H-pyran-3 -y1]-3 -[(2-hy droxy-4-i sopropy1-1,2-b enz oxab
orinin-6-
yl)amino]pyrazole-4-carboxamide (stereoisomer one) (404.6 mg, 51.2% yield,
99.5% ee, first
peak, Rt = 1.288 min ) 1H N1VIR (DMSO-d6, 400 MHz) 6 9.08 (s, 1H), 8.64 (s,
1H), 8.29 (s, 1H),
8.22- 8.21 (m, 1H) 7.72 (s, 1H), 7.37- 7.34 (m, 1H), 7.16 - 7.12 (m, 2H), 5.97
(s, 1H), 4.59 - 4.56
(m, 1H), 4.09 - 4.06 (m, 1H), 3.72 - 3.69 (m, 1H), 3.60 - 3.56 (m, 1H), 3.49 -
3.42 (m, 1H), 3.42 -
3.36 (m, 1H), 3.30 - 3.28 (m, 1H), 2.21 - 2.19 (m, 1H), 2.03 - 1.99 (m, 1H),
1.28 (t, 1 = 6.8 Hz,
6H). MS (ESI): mass calculated for C21H24BN504, 421.19, m/z found 422.2 [M+Hr.
HPLC: 97.80%
(220 nm), 99.26% (254 nm). and 1-[trans-4-cyanotetrahydro-2H-pyran-3-y11-3-[(2-
hydroxy-4-
isopropyl-1,2-benzoxaborinin-6-yl)amino]pyrazole-4-carboxamide (stereoisomer
two) (427.1 mg,
54.1% yield, 97.4% purity, 99.2% ee , second peak, Rt = 1.401 mm) as a white
solid. 1H NMR
(DMSO-d6, 400 MHz) 6 9.08 (s, 1H), 8.65 (s, 1H), 8.30 (s, 1H), 8.22 - 8.21 (m,
1H) 7.72 (s, 1H),
7.37 - 7.34 (m, 1H), 7.16 - 7.12 (m, 2H), 5.97 (s, 1H), 4.59 - 4.56 (m, 1H),
4.09 - 4.06 (m, 1H),
3.72- 3.69 (m, 1H), 3.60 - 3.56 (m, 1H), 3.49 - 3.42 (m, 1H), 3.42 -3.36 (m,
1H), 3.30 -3.28 (m,
1H), 2.21 -2.19 (m, 1H), 2.03 - 1.99 (m, 1H), 1.28 (t, I= 6.8 Hz, 6H) MS
(EST): mass calculated
for C21H24BN504, 421.19, m/z found 422.3 [M+H]. HPLC: 97.82% (220 nm), 99.31%
(254 nm).
[0303]
31. Preparation of 1-(trans-2-eyanoeyelopenty1)-3-1(2-hydroxy-8-methyl-1,2-
benzoxaborinin-
6-y1)aminolpyrazole-4-earboxantide
N
//I
z. .5 C5 NH2 ¨..N'N-----
N H2 _----N
0 0,,,B4OH 0 N_N AI OOH
Br Br
.
Pd2dba3, tBuXPhos, KOAc
N
i-PrOH, 80 C, 12 h CH
NH2
A mixture of 6-bromo-2-hydroxy-8-methyl-1,2-benzoxaborinine (100 mg, 418 umol,
1 eq), 3-
amino-1-(2-cyanocyclopentyl)pyrazole-4-carboxamide (110 mg, 502 umol, 1.2 eq),
t-Bu Xphos
(36 mg, 83 umol, 0.2 eq), Pd2(dba)3 (77 mg, 83 umol, 0.2 eq) and KOAc (82.1
mg, 837 umol, 2
eq) in i-PrOH (6 mL) was degassed and purged with N2 for 3 times, and then the
mixture was
188
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
heated to 80 C and stirred at 80 C for 12 h under N2 atmosphere. LCMS showed
the reaction was
completed and desired MS observed. The reaction mixture was filtered and the
filtrate was
concentrated under reduced pressure. The residue was purified by prep-HPLC
(column:
Phenomenex Gemini-NX C18 75*30mm*3um; mobile phase: [water (10mM NH4HCO3)-
ACN];B%: 25%-45%,8min) to give 1-(trans-2-cyanocyclopenty1)-3-[(2-hydroxy-8-
methyl-1,2-
benzoxaborinin-6-y1)amino]pyrazole-4-carboxamide (18 mg, 11.4% yield) as a
white solid. 1H
NMR (DMSO-do, 400 MHz) 6 8.99 (s, 1H), 8.76 (s, 1H), 8.27 (s, 1H), 7.74 (d, J=
12.0 Hz, 1H),
7.67 (d, J= 2.8 Hz, 1H), 7.59 (brs, 1H), 7.36 (s, 1H), 7.13 (brs, 1H), 6.08
(d, J= 11.6 Hz, 1H),
4.87 (q, J = 8.0 Hz, 1H), 3.41-3.33 (m, 1H), 2.31 (s, 3H), 2.26-2.24 (m, 1H),
2.18-2.13 (m, 1H),
1.95-1.84 (m, 4H) MS (ESI): mass calculated for Ci9H2oBN503, 377.17, m/z found
378.2 [M+Hr.
HPLC: 92.03% (220 nm), 97.51% (254 nm).
[0304]
32. Preparation ofHtrans-4-cyanotetrahydro-2H-pyran-3-y11-34(2-hydroxy-3,8-
dimethyl-1,2-
benzoxaborinin-6-Aaminokyrazole-4-carboxamide
.0N
N ;;; NH2
OH Br2, AcOH abb OH 4,11b.. 0 R OH 0 N-N
0- _OH
0-20 C, 2 h p ,0 LDA, PMDTA THF 11.1
Br Pd2dba3
tBuXPhos, KOAc
0-20 C, 1 h
i-PrOH, 80 C, 12 h
NH2
[0305]
32.1 Preparation of 5-bromo-2-hydroxy-3-methyl-benzaldehyde
OH Br2, AcOH OH
0-20 C, 2 h
Br
To a mixture of 2-hydroxy-3-methyl-benzaldehyde (10 g, 73.4 mmol, 1 eq) in
AcOH (300 mL)
was added Br2 (13.5 g, 84.5 mmol, 1.15 eq) at 25 C under N2. The mixture was
stirred at 25 C
for 2 h. TLC showed the reaction was completed. The reaction mixture was
quenched by addition
H20 (100 mL), then solid was precipitate out. The precipitate was filtered to
give 5-bromo-2-
hydroxy-3-methyl-benzaldehyde (10 g, 63.3% yield) as a white solid.
189
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
[0306]
32.2 Preparation of 6-bromo-2-hydroxy-3,8-dintethyl-1,2-benzoxaborinine
0,6,OH
LDA, PMDTA, THF
Br Br
0-20 C, 1 h
To a mixture of LDA (2 M, 5.1 mL, 2.2 eq) in THF (30 mL) was added N42-
(dimethylamino)ethy1]-N,N,N'-trimethyl-ethane-1,2-diamine (PMDTA, 1.6 g, 9.30
mmol, 1.94
mL, 2 eq) and a solution of 4,4,5,5-tetramethy1-241-(4,4,5,5-tetramethy1-1,3,2-
dioxaborolan-2-
y1)ethyl]-1,3,2-dioxaborolane (2.9 g, 10.2 mmol, 2.2 eq) in THE' (30 mL) at 0
C for 30 min. Then
added 5-bromo-2-hydroxy-3-methyl-benzaldehyde (1 g, 4.65 mmol, 1 eq) at 0 C
under N2. The
reaction was allowed to warm to 20 C and stirred at 20 C for 1 h. LCMS showed
the reaction was
completed and desired MS observed. The reaction mixture was quenched by sat.
aq. NH4C1 (50
mL), extracted with Et0Ac (30 mL x 3). The combined organic layers were washed
with brine
(20 mL x 2), dried over Na2SO4, filtered and concentrated under reduced
pressure to give a residue.
The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl
acetate=10/1
to 5/1) to give 6-bromo-2-hydroxy-3,8-dimethy1-1,2-benzoxaborinine (0.55 g,
46.7% yield) as a
white solid. 1H NMR (DMSO-d6, 400 MHz) 6 9.03 (s, 1H), 7.48 (s, 1H), 7.43 (s,
1H), 7.37 (s, 1H),
2.33 (s, 3H), 2.02 (s, 3H).
[0307]
32.3 Preparation of 1-Itrans-4-eyanotetrahydro-2H-pyran-3-yll-3-1(2-hydroxy-
3,8-dimethyt-
1,2-benzoxaborinin-6-y0aminokyrazole-4-earboxamide
N NH2
NH2
<
0 ¨N
0,B4OH 0,B4OH
0 N-N
Br Pd2dba3, tBuXPhos, KOAc
i-PrOH, 80 C, 12 h 0 NH2
To a mixture of 6-bromo-2-hydroxy-3,8-dimethy1-1,2-benzoxaborinine (0.2 g, 790
umol, 1 eq)
and 3 -am i n o-lttran s-4-cy an otetrahy dro-2H-pyran -3 -yl] pyrazol e-4-c
arb ox am i de (223 mg, 949
umol, 1.2 eq) in i-PrOH (8 mL) was added Pd2(dba)3 (36 mg, 39.5 umol, 0.05
eq), KOAc (116 mg,
190
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
1.19 mmol, 1.5 eq) and t-Bu XPhos (34 mg, 79.0 umol, 0.1 eq) at 25 C under N2.
The mixture
was heated to 80 C and stirred for 12 hrs. LCMS showed the reaction was
completed and desired
MS observed. The reaction mixture was filtered and concentrated under reduced
pressure to give
a residue. The residue was purified by column chromatography (SiO2, Petroleum
ether/Ethyl
acetate=10/1 to 0/1) to give 1-[trans-4-cyanotetrahydro-2H-pyran-3-y1]-3-[(2-
hydroxy-3,8-
dimethy1-1,2-benzoxaborinin-6-yl)amino]pyrazole-4-carboxamide (42 mg, 13.0%
yield) as a
white solid. 1H NMIR (DMSO-do, 400 MHz) 6 8.99 (s, 1H), 8.67 (s, 1H), 8.28 (s,
1H), 7.68 (br s,
1H), 7.55 (s, 1H), 7.47 (s, 1H), 7.21 (s, 1H), 7.14 (br s, 1H), 4.57-4.53 (m,
1H), 4.06-4.03 (m, 1H),
3.94-3.92 (m, 2H), 3.73-3.67 (m, 1H), 3.52 (t, J = 10.2 Hz, 1H), 2.34 (s, 3H),
2.19-2.16 (m, 1H),
2.03 (s, 3H), 2.01-1.98 (m, 1H). MS (ESI): mass calculated for C2oH22BN504,
407.18, m/z found
406.2 [M-H].HPLC: 94.85% (220 nm), 99.02% (254 nm).
[0308]
33. Preparation of 1-(trans-4-cyanotetrahydro-2H-pyran-3-y1)-34(4-ethyl-2-
hydroxy-1,2-
benzoxaborinin-6-Aaminokyrazole-4-carboxamide
6_1\ihrH2
0 0 0 0
NH2
0
OH
Br
AICI,,DCM Br
WI 0
LDA, PMDTA, THF Br
0õOH 0
PcI2dba3, tButyl-XPhos
65 C, 12 h 0 C,1 h
KOAc, iPrOH, 80 C, 12 h
0õOH
0
NH2
[0309]
33.1 Preparation of 1-(5-bromo-2-hydroxy-phenyl)propan-1-one
0
cI
OH
Br 011
0
AlC13,DCM
Br
0
65 C, 12h
To a solution of propanoyl chloride (4.95 g, 53.4 mmol, 4.95 mL, 2 eq) in DCM
(50 mL) was
191
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
added AlC13 (14.3 g, 107 mmol, 4 eq) at 0 C. After addition, the mixture was
stirred at 0 C for
30 min, and then 1-bromo-4-methoxy-benzene (5.00 g, 26.7 mmol, 1 eq) was added
at 0 C. The
resulting mixture was heated and stirred at 65 C for 12 h. TLC showed the
reaction was completed.
The reaction mixture was quenched by addition H20 (100 mL) at 0 C, and then
extracted with
DCM (50 mL x 3). The combined organic layers were washed with brine (50 mL),
dried over
Na2SO4, filtered and concentrated under reduced pressure to give a residue.
The residue was
purified by flash silica gel chromatography (ISCOS; 20 g SepaFlash Silica
Flash Column, Eluent
of 0-10% Ethyl acetate/Petroleum ether gradient @ 100 mL/min) to give 1-(5-
bromo-2-hydroxy-
phenyl)propan-1 -one (5.00 g, 81.6% yield) as a yellow solid. 1H NMR, (CDC13,
400 MHz) 6 =
12.26 (s, 1H), 7.88 (s, 1H), 7.54 (dd, J = 2.0, 8.9 Hz, 1H), 6.90 (d, J = 8.9
Hz, 1H), 3.03 (q, J =
7.2 Hz, 2H), 1.25 (t, J= 7.2 Hz, 3H).
[0310]
33.2 Preparation of 6-bromo-4-ethyl-2-hydroxy-1,2-benzoxaborinine
0 0
OH 0,B4OH
Br 0 LDA, PMDTA, THF Br
0 C,1 h
To a solution of LDA (2 M, 21.8 mL, 5 eq) in THF (30 mL) was dropwise added
N'42-
(dimethylamino)ethy1]-N,N,N-trimethyl-ethane-1,2-diamine (PMDTA, 6.05 g, 34.9
mmol, 7.29
mL, 4 eq) and 4,4,5,5-tetramethy1-2-[(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)methyl]- 1,3,2-
dioxaborolane (9.36 g, 34.9 mmol, 4 eq) at 0 C. After addition, the mixture
was stirred at 0 C for
30 min, and then 1-(5-bromo-2-hydroxy-phenyl)propan- 1-one (2 g, 8.73 mmol, 1
eq) in THF (10
mL) was added dropwise at 0 C. The resulting mixture was continue stirred at 0
C for 1 h. LCMS
showed the reaction was completed and desired MS observed. The reaction
mixture was quenched
by addition of NH4C1 (100 mL), adjust pH=7 with 1N HC1 and extracted with
Et0Ac (50 mL x 3).
The combined organic layers were washed with brine (100 mL), dried over with
Na2SO4, filtered
and concentrated under reduced pressure to give a residue The residue was
purified by flash silica
gel chromatography (ISCOk; 40 g SepaFlashe Silica Flash Column, Eluent of 0-
30% Ethyl
acetate/Petroleum ether gradient @ 100 mL/min) to give crude product. The
crude product was
triturated with Petroleum ether (10 mL) at 25 C for 10 min to give 6-bromo-4-
ethy1-2-hydroxy-
1 92
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
1,2-benzoxaborinine (0.8 g, 36.2% yield) as a white solid. 1H NMR (DMSO-d6,
400 MHz) 6 =
8.96 (s, 1H), 7.78 (d, J= 2.4 Hz, 1H), 7.54 (dd, J= 2.0, 8.9 Hz, 1H), 7.19 (d,
J= 8.4 Hz, 1H), 5.99
(s, 1H), 2.70 (q, J = 7.2 Hz, 2H), 1.19 (t, J= 7.3 Hz, 3H).
[0311]
33.3 Preparation of 1-(trans-4-eyanotetrahydropyran-3-y1)-3-[(4-ethy1-2-
hydroxy-1,2-
benzoxaborinin-6-yl)aminokyrazole-4-earboxamide
NH2
cjNç
0,B4OH 0
0 0,B4OH
N 1\1¨N
Br
Pd2dba3, tButyl-XPhos
KOAc, iPrOH, 80 C, 12 h
0
NH2
To a solution of 3-amino-1-(trans-4-cyanotetrahydropyran-3-yl)pyrazole-4-
carboxamide (279 mg,
1.19 mmol, 1.5 eq) in i-PrOH (5 mL) was added KOAc (155 mg, 1.58 mmol, 2 eq),
6-bromo-4-
ethy1-2-hydroxy-1,2-benzoxaborinine (200 mg, 791 umol, 1 eq), Pd2(dba)3 (36.0
mg, 39.5 umol,
0.05 eq) and t-Bu Xphos (33.1 mg, 79.0 umol, 0.1 eq) at 25 C. The resulting
mixture was stirred
at 80 C for 12 h. LCMS showed the reaction was completed and desired MS
observed. The
reaction mixture was filtered, and the filtrate was concentrated under reduced
pressure to give a
residue. The residue was purified by prep-HPLC (column: Waters Xbridge BEH C18
100*30mm*10um; mobile phase: [water (10mM NH4HCO3)-ACN];B%: 15%-45%,10min) to
give 1-(trans-4-cyanotetrahydropyran
-3 -y1)-3 -[(4-ethyl-2-hydroxy- 1,2-b enzoxab orini n-6-
yl)amino] pyrazole-4-carboxamide (100.2 mg, 15.5% yield) as a yellow solid. 1H
NMR (DMSO-
d, 400 MHz) 5 = 9.08 (s, 1H), 8.64 (s, 1H), 8.29 (s, 1H), 8.09 (s, 1H), 7.72
(s, 1H), 7.41 (d, J =
6.9 Hz, 1H), 7.19- 7.12 (m, 2H), 5.93 (s, 1H), 4.59 - 4.56 (m, 1H), 4.08 -
4.05 (m, 1H), 3.97 -3.94
(m, 1H), 3.72 - 3.62 (m, 2H), 3.41-3.42 (m, 1H), 2.81-2.76 (m, 2H), 2.20 -
2.17 (m, 1H), 2.01 -
1.99 (m, 1H), 1.27 (t, J= 7.2 Hz, 3H) MS (ES1): mass calculated for
C2oH22BN504, 407.18, m/z
found 406.2 [M-Hr. HPLC: 99.34% (220 nm), 99.51% (254 nm).
[0312]
34. Preparation of 1-(trans-2-eyanocyclohexyl)-34(2-hydroxy-4-isopropyl-1,2-
benzoxaborinin-
6-y1)antinokyrazole-4-carboxantide
193
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
N_ NH2
0,B4OH
0¨N\y-NH2
0B4OH
Br
Pd2dba3, tButyl-XPhos
KOAc, iPrOH, 12 h
0
NH2
To a solution of 3-amino-1-(trans-2-cyanocyclohexyl)pyrazole-4-carboxamide
(157 mg, 674 umol,
1.5 cq) in i-PrOH (5 mL) was added KOAc (88 mg, 899 umol, 2 eq), 6-bromo-2-
hydroxy-4-
isopropy1-1,2-benzoxaborinine (120 mg, 450 umol, 1 eq), Pd2(dba)3 (21 mg, 22.5
umol, 0.05 eq)
and t-Bu Xphos (19 mg, 45 umol, 0.1 eq) at 25 C under N2. The resulting
mixture was heated and
stirred at 80 C for 12 h. LCMS showed the reaction was completed and desired
MS observed.
The reaction mixture was filtered, and the filtrate was concentrated under
reduced pressure to give
a residue. The residue was purified by prep-HPLC (column: Waters Xbridge BEH
C18
100*30mm*10um; mobile phase: [water (10mM NH4HCO3)-ACN];B%: 30%-60%,10min) to
give 1-(trans-2-cyanocyclohexyl)-3-[(2- hydroxy-4-isopropy1-1,2-benzoxaborinin-
6-yl)amino]
pyrazole-4-carboxamide (17.3 mg, 9.18% yield) as a yellow solid. 1H NMR (DMSO-
d6, 400 MHz)
6 9.05 (s, 1H), 8.63 (s, 1H), 8.32 - 8.27 (m, 1H), 8.23 (s, 1H), 7.72 - 7.61
(m, 1H), 7.37 - 7.29 (m,
1H), 7.16 - 7.09 (m, 1H), 5.96 (s, 1H), 4.47 - 4.28 (m, 1H), 3.29 - 3.17 (m,
2H), 2.26 - 2.17 (m,
1H), 2.07 - 1.97 (m, 1H), 1.97 - 1.61 (m, 5H), 1.55 - 1.38 (m, 1H), 1.27 (t,
J= 7.0 Hz, 6H). MS
(ESI): mass calculated for C22H26BN503, 419.21, m/z found 418.3 [M-H]. HPLC:
97.39% (220
nm), 99.89% (254 nm).
[0313]
35. Preparation of 1-(trans-2-eyanoeyelopenty1)-3-[(2-hydroxy-4-isopropyl-1,2-
benzoxaborinin- 6-yl)aminolpyrazole-4-earboxamide
N .1r2
0õOH
NH2 ..µCN
Brf N¨N BOH
Pd2dba3, tButyl-XPh os
KOAc, iPrOH, 80 C, 12 h
CINH2H
To a solution of 3-amino-1-(trans-2-cyanocyclopentyl)pyrazole-4-carboxamide
(148 mg, 674
umol, 1.5 eq) in i-PrOH (3 mL) was added KOAc (88 mg, 899 umol, 2 eq), 6-bromo-
2-hydroxy-
1 94
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
4-isopropyl-1,2-benzoxaborinine (120 mg, 450 umol, 1 eq), Pd2(dba)3 (21 mg,
22.5 umol, 0.05 eq)
and t-Bu Xphos (19 mg, 45 umol, 0.1 eq) at 25 C under N2. The resulting
mixture was heated and
stirred at 80 C for 12 h. LCMS showed the reaction was completed and desired
MS observed.
The reaction mixture was filtered, and the filtrate was concentrated under
reduced pressure to give
a residue. The residue was purified by prep-HPLC (column: Waters Xbridge BEH
C18
100*30mm*10um; mobile phase: [water(1 OmM NH4TIC03)-ACN];B%: 30%-60%,10min) to
give
1-(trans-2-cyanocyclopentyl)
-3-[(2-hydroxy-4-isopropy1-1,2-benzoxaborinin-6-
yl)amino]pyrazole-4-carboxamide (30.2 mg, 16.5% yield) as a white solid. 1H
NMR (DMSO-do,
400 MHz) 6 9.09 (s, 1H), 9.63 (s, 1H), 8.28 (s, 1H), 8.28 - 8.27 (m, 1H), 7.63
(s, 1H), 7.33 - 7.29
(m, 1H), 7.12 (d, J= 8.8 Hz, 2H), 5.96 (s, 1H), 4.97 - 4.91 (m, 1H), 3.41 -
3.32 (m, 1H), 3.29 -
3.26 (m, 1H), 2.23 - 2.14 (m, 2H), 2.16 -2.14 (m, 1H), 1.93 ¨ 1.92 (m, 1H)
1.90 - 1.88 (m, 2H),
1.24 (t, J= 6.6 Hz, 6H) MS (ESI): mass calculated for C211-124BN503, 405.20,
m/z found 404.2 [M-
H]. HPLC: 92.21% (220 nm), 99.38% (254 nm).
[0314]
36. Preparation of 1-Itrans-4-cyanotetrahydro-2H-pyran-3-y11-3-1(1-hydroxy-3,3-
dintethyl -
2,1-henzoxahorol-6-y0aminokyrazole-4-earhoxamide
0 Br Br
>%-C1-1
MeMgBr, THE 0 TBSOTf, 2,6-dimethylpyridine, DCM 0 Br
04
0 _____________________________________________________ OTBS
C-26 C, 16 h OH 10 C-25 C, 2 h Ir(COD)2(0Me)2, 2-
methyltetrahydrofuran
0
c_0...)..N ,..,,,i),N3H,42,7,8-tetramethy1-1,10-phenanthroline,
C-90 C, 30 h
>%-Ci Na104, NH40Ako,
THE, H20 , HO' Br =, N-
O NH2
,B Br
0 40
N
OTBS 25 C, 16 h OTBS Cu(0A02, TEA, DMA
02, 15 Psi, 20 C-40 C, 16 h
NH2
0
/ I
op Br
7-/,..sirN op 13,0
N-N
Pd(PPh,),CI, KOAc, DMA, dioxane, N-N
OTBS
,-,--N 20 C-80 C, 4 h
0 NH,
. E N1
pH
HCI, THF , h- 40 13,0
N-N
0 C-20 C, 1 h
195
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
[0315]
36.1 Preparation of 2-(2-bromophenyl)propan-2-ol
lei Br IN Br
MeMgBr, THF
C-25 C, 16 h OH
MeMgBr (3 M, 232.5 mL, 3 eq) was added drop-wise tothe solution of methyl 2-
bromobenzoate
(50.0 g, 232 mmol, 32.68 mL, 1 eq) in THF (700 mL) at 10 C, and the resulting
mixture was stirred
at 25 C for 16 h. TLC showed the reaction was completed. The reaction mixture
was quenched
with sat. aq. NH4C1 (200 mL x 2) and extracted with Et0Ac (100 mL x 3). The
combined organics
were dried over Na2SO4, filtered and concentrated in vacuo to give a residue.
The residue was
purified by a silica gel column chromatography (Petroleum ether/Ethyl acetate
= 1:0-10:1) to give
2-(2-bromophenyl)propan-2-ol (49.5 g, 98.9% yield) as colorless oil. 111 NMIt
(CDC13-d6, 400
MHz) ö 7,.66 (d, J= 8.0 Hz, 1H), 7.58 (d, J= 8.0 Hz, 1H), 7.29 (d, J= 6.4 Hz,
1H), 7.11 (d, J=
6.0 Hz, 1H), 1.75 (s, 6H).
[0316]
36.2 Preparation of [1-(2-bromopheny1)-1-methyl-ethoxyl-tert-butyl-dimethyl-
silane
Br 40 Br
110 TBSOTf, 2,6-dimethylpyridine, DCM
OTBS
OH 10 C-25 C, 2 h
To a solution of 2-(2-bromophenyl)propan-2-ol (30.0 g, 139 mmol, 1 eq) and 2,6-
dimethylpyridine
(279 mmol, 32.49 mL, 2 eq) in DCM (300 mL) was added [tert-
butyl(dimethyl)silyl]
trifluoromethanesulfonate (209 mmol, 48.1 mL, 1.5 eq) drop-wise at 10 C. The
mixture was
allowed to warm to 25 C stirred at 25 C for 2 h. TLC showed the reaction was
completed.
The mixture was poured into ice-water (w/w = 1/1) (500 mL) and stirred for 10
min. The aqueous
phase was extracted with DCM (500 mL x 3). The combined organic phase was
washed with brine
(500 mL x 2), dried with anhydrous Na2S 04, filtered and concentrated in
vacuum to give a residue.
The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl
acetate=10/1
to 5/1) to give [1-(2-bromopheny1)-1-methyl-ethoxy] -tert-butyl-dimethyl-
silane (39.0 g, 84.9%
yield) as a yellow oil. 'H NNIR (CDC13-d6, 400 MHz) 6 7.91 (d, .1 = 8.0 Hz,
1H), 7.57 (d, .1 = 8.0
Hz, 1H), 7.28 (t, J= 6. g Hz, 114), 7.07 (t, J= 2.0 H7, 1H), 1.80 (s, 611),
0.99 (s, 914), 0.18 (s, 6H)
196
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
[0317]
36.3 Preparation of [1[2-bromo-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-
Aphenyll -1-
methyl-ethoxyPtert-butyl-dimethyl-silane and [142-bromo-5-(4,4,5,5-tetramethyl-
1,3,2-
dioxaborolan-2-yOphenyll -1-methyl-ethoxyl-tert-butyl-dimethyl-silane
Br 9
Br
>%0.BH
0 B Br 0, so
OTBS
OTBS _____________________________________ >r
Ir(COD)2(0Me)2, 2-MeTHF OTBS
3,4,7,8-tetramethy1-1,10-phenanthroline,
20 C-90 C, 30 h
To a mixture of [1-(2-bromopheny1)-1-methyl-ethoxy]-tert-butyl-dimethyl-silane
(8.0 g, 24.3
mmol, 1 eq), Ir(COD)2(0Me)2 (644 mg, 971 umol, 0.04 eq) and 3,4,7,8-
tetramethy1-1,10-
phenanthroline (574 mg, 2.43 mmol, 0.1 eq) in 2-methyltetrahydrofuran (80 mL)
was added
4,4,5,5-tetramethy1-1,3,2-dioxaborolane (194 mmol, 28.2 mL, 8 eq) drop-wise
under N2. The
mixture was heated to 90 C and stirred for 30 h. TLC showed the reaction was
completed. 3
parallel reactions were combined for work up The mixture was poured into ice-
water (w/w = 1/1)
(250 mL) and stirred for 10 min. The aqueous phase was extracted with ethyl
acetate (200 mL x
3). The combined organic phase was washed with brine (150 mL x 2), dried with
anhydrous
Na2SO4, filtered and concentrated in vacuum to give a residue. The residue was
purified by column
chromatography (SiO2, Petroleum ether/Ethyl acetate=5/1 to 3/1) to give [1-[2-
bromo-4-(4,4,5,5-
tetram ethyl-1,3 ,2-di oxaborolan-2-yl)pheny11-1- methyl -ethoxy]-tert-butyl-
dim ethyl-silane and [1 -
[2-brom o-5 -(4,4,5,5 -tetram ethyl -1,3,2- di oxab orol an-2-yl)phenyl] -1-m
ethyl-ethoxy] -tert-butyl -
dimethyl-sil ane (36 g, mixture) as a yellow solid. III NMR (CDC13-d6. 400
MHz) 6 7.99 (s, 1H),
7.92 (d, J= 7.6 Hz, 1H), 7.73 (d, J= 7.6 Hz, 1H), 1.78 (s, 6H), 1.34 (s, 12H),
0.97 (s, 9H), 0.16 (s,
6H).
[0318]
36.4 Preparation of (3-bromo-4-(2-((tert-butyldimethylsity0oxy)propan-2-
yl)phenyOboronic
acid and (4-bromo-3-(2-((tert-bntyldimethylsilyl)oxy)propan-2-AphenyOboronic
acid
rigu Br
O. IMP Na14, NH40Ac,
Br
OTBS 0F, ,H2 16 0 OH
HO- 410 Br
0 Ei Br
TH
B C 4 HO,B
11Ir OTBS
OTBS
OTBS (1) 25 h OH
To a solution of [1- [2-b rom o-4-(4,4, 5, 5-tetram ethyl -1,3,2-di oxaborol
an -2-y1 )ph enyl ] -1-m ethyl -
197
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
ethoxy]-tert-butyl-dimethyl-silane (24.0 g, 52.7 mmol, 1 eq) in THF (250 mL)
and H20 (100 mL)
was added NaI04 (33.8 g, 158 mmol, 3 eq) and NH40Ac (12.2 g, 158 mmol, 3 eq)
at 25 C. The
mixture was stirred at 25 C for 16 h. TLC showed the reaction was completed.
The mixture was
poured into ice-water (w/w = 1/1) (300 mL) and stirred for 10 min. The aqueous
phase was
extracted with ethyl acetate (200 mL x 3). The combined organic phase was
washed with brine
(200 mL x 2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum
to give a residue.
The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl
acetate=5/1 to
3/1) to give crude product. Then the crude product was triturated with
Petroleum ether (100 mL)
at 20 C for 10 min to give [3-bromo-441-[tert-b utyl(dimethyl) silyl]
oxy-l-m ethyl-
ethyl]phenyl]boronic acid (Compound 5, 5.0 g, 25.4% yield) as a white solid.
And (4-bromo-3-(2-
((tert-butyldimethylsilyl)oxy)propan-2-yl)phenyl)boronic acid (Compound 5A, 12
g, crude) as
brown oil. IH NMR (DMSO-do. 400 MHz) 6 8.17 (s, 2H), 7.94 (s, 1H), 7.74-7.67
(m, 2H), 1.69 (s,
6H), 0.90 (s, 9H), 0.09 (s, 6H). 1H N1VIR (DMSO-d6, 400 MHz) 6 8.19 (s, 1H),
8.07 (s, 2H), 7.57-
7.51 (m, 2H), 1.73 (s, 6H), 0.92 (s, 9H), 0.10 (s, 6H).
[0319]
36.5 Preparation of 3-P-bromo-441-Itert-bn01(dimethyl)silylloxy-1-methyl-
ethyllanilino] -1-
(trans 4-eyanotetrahydro-2H-pyran-3-y1)pyrazole-4-earboxamide
eo--\
ONH2
O
HOB Br N¨
NH2
N Br
OTBS
OTBS Cu(OAc)2, TEA, DMA JN
02, 15 Psi, 20 C-40 C, 16 h
To a mixture of 3 -ami no- 1-(trans-4-cy anotetrahydropyran-3 -y 1)pyrazol e-4-
carb oxami de (1.0 g,
4.25 mmol, 1 eq) and
[3 -b rom o-4-[1-[tert-butyl (dim ethyl)silyl] oxy-l-m ethyl -
ethyl]phenyl]boronic acid (1.90 g, 5.10 mmol, 1.2 eq) in DMA (20 mL) was added
4A molecular
sieve (7 g), TEA (2.96 mL, 21.2 mmol, 5 eq) and Cu(0Ac)2 (1.93 g, 10.6 mmol,
2.5 eq) in one
portion at 25 C under 02. The mixture was stirred at 40 C for 16 h. LCMS
showed the reaction
was completed and desired MS observed. 4 parallel reactions were combined for
work up. The
reaction mixture was filtered. The filtrate was added-H-20 (200 mL) at 20 C
and extracted with
ethyl acetate (80 mL x 4). The combined organic layers were washed with brine
(60 mL x 3), dried
over Na2SO4, filtered and concentrated under reduced pressure to give a
residue. The residue was
198
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=1/1 to
0/1) to give 3-[3-
bromo-4- [ 1 -[tert-butyl (di m ethyl)sily1 ] oxy-l-m ethyl -ethyl] anilino] -
1 -(trans-4-cy anotetrahy dro-
2H-pyran-3 -yl)pyrazole-4-carb oxami de (5.00 g, 52.2% yield) as a yellow
solid. 11-1NMR (DMSO-
d6. 400 MHz) 6 9.20 (s, 1H), 8.31 (s, 1H), 7.84 (d, J= 2.0 Hz, 1H), 7.74 (br
s, 1H), 7.61 (d, J= 8.8
Hz, 1H), 7..47-7.44 (m, 1H), 7.22 (br s, 1H), 4.61-4.57 (m, 1H), 4.06-4.04 (m,
1H), 3.93-3.90 (m,
1H), 3.65-3.62 (m, 1H), 3.61-3.45 (m, 1H), 2.18-2.14 (m, 1H), 2.04-1.99 (m,
2H), 1.71 (s, 6H),
0.92 (s, 9H), 0.10 (s, 6H).
[0320]
36.6 Preparation of 3-14-11-Itert-butyi(dimethyl)silylloxy-1-methyl-ethyll-3-
(5,5-dimethy1-
1,3,2-dioxaborinan-2-Aanilinol-1-(trans-4-eyanotetrahydro-2H-pyran-3-Apyrazole-
4-
carboxamide
07;2 07;2
N Br N cYJ
op 13,0
IN OTBS ____________________
N-N
Pd(PPh3)2Cl2, KOAc, DMA, dioxane,
OTBS
20 C-80 C, 4 h
To a mixture of 343-bromo-441-[tert-butyl(dimethypsilydoxy-1-methyl-
ethylianilino] -1-(4-
cyanotetrahydropyran-3-yl)pyrazole-4-carboxamide (500 mg, 889 umol, 1 eq) in
DMA (1 mL) and
dioxane (10 mL) was added Pd(PPh3)2C12 (62.4 mg, 88.9 umol, 0.1 eq), KOAc (262
mg, 2.67
mmol, 3 eq) and 245, 5 -dim ethyl-1,3 ,2- di oxab orinan-2-y1) -5,5-dim ethy1-
1,3,2-di oxab orinane
(1.00 g, 4.44 mmol, 5 eq) in one portion at 20 C under N2. The mixture was
stirred at 80 C for 4
h. 5 parallel reactions were combined for work up. The mixture was filtered
and the filtrate was
concentrated in vacuum to give a residue. The residue was purified by column
chromatography
(SiO2, Petroleum ether/Ethyl acetate=1/1 to 0/1) to give 3 -[4- [1-[tert-
butyl(dimethyl)silyl]oxy-1-
methyl-ethy1]-3 -(5,5 -dim ethyl-1,3 ,2-di oxab orinan-2-yl)anili no] -1 -(4-
cy an otetrahy dropy ran-3 -
yl)pyrazole-4-carb oxamide (2.5 g, crude) as brown oil.
[0321]
36.7 Preparation of 1-[trans-4-eyanotetrahydro-2H-pyran-3-y1]-3-[(1-hydroxy-
3,3-dimethyl -
2,1-benzoxaborol-6-Aaminokyrazole-4-earboxamide.
199
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
NH2 NH,
N
OH 14 HCI, THF (37Y ")
OTBS VC-20 C, 1 h
To a mixture of 3-[4-[1-[tert-butyl(dimethyl)silyl]oxy-1-methyl-ethy1]-3-(5,5-
dimethyl-1,3,2 -
di oxab ori nan-2-yl)anilino]-1 -(trans-4-cy anotetrahy dro-2H-pyran-3 -
yl)pyrazol e-4-carb oxami de
(2.0 g, 3.36 mmol, 1 eq) in THF (20 mL) was added 1-IC1 (6 N, 2.80 mL, 5 eq)
drop-wise at 0 C
under N2. The mixture was stirred at 20 C for 1 h. The mixture was poured into
ice-water (w/w
= 1/1) (10 mL) and stirred for 10 min. The aqueous phase was extracted with
ethyl acetate (10 mL
x 4). The combined organic phase was washed with brine (10 mL x 2), dried with
anhydrous
Na2SO4, filtered and concentrated in vacuum to give a residue. The residue was
purified by prep-
HPLC (column: Phenomenex luna c18 250mm*100mm*10um; mobile phase:
[water(0.05%HC1)-
ACN];B%: 15%-45%,25min) to give 1-[trans-4-cyanotetrahydro-2H-pyran-3-y1]-3 -
[(1-hydroxy-
3,3-dimethy1-2,1-benzoxaborol-6-yl)amino]pyrazole-4-carboxamide (580 mg),
which was
separated by SFC (column: DAICEL CHIRALPAK IC(250mm*30mm,10um);mobile phase:
[Neu-IPA] ;B%: 35%-35%,10min) to give 1-[trans-4-cyanotetrahydro-2H-pyran-3-
y1]-3 -[(1-
hydroxy-3,3-dimethy1-2,1-benzoxaborol-6-yl)amino]pyrazole-4-carboxamide
(stereoisomer one)
(215.2 mg, 16.2% yield, 98.1% purity, 100% ee, first peak, Rt = 2.860 min) as
a white solid. 1H
NMR (DMSO-do, 400 MHz) 6 9.20 (s, 1H), 8.94 (s, 1H), 8.30 (s, 1H), 7.73-7.68
(m, 2H), 7.64 (s,
1H), 7.28 (d, J= 8.0 Hz, 1H), 7.19 (br s, 1H), 4.59-4.55 (m, 1H), 4.06-4.02
(m, 1H), 3.95-3.91 (m,
1H), 3.73-3.67 (m, 2H), 3.49-3.48 (m, 1H), 2.19-2.14 (m, 1H), 2.02-1.98 (m,
1H), 1.43 (s, 6H).
MS (ESI): mass calculated for C19H22BN504 395.18, m/z found 396.2 [M+Hr HPLC:
98.12%
(220 nm), 98.23% (254 nm).and 1-[trans-4-cyanotetrahydro-2H-pyran-3-y1]-3-[(1-
hydroxy-3,3¨
dimethy1-2,1-benzoxa borol-6-yl)amino]pyrazole-4-carboxamide (stereoisomer
two) (215.4 mg,
16.2% yield, 100% purity, 100% ee, second peak, Rt = 3.633 min) as a white
solid. 1H NIVIR
(DMSO-d6, 400 MHz) 6 9.20 (s, 1H), 8.94 (s, 1H), 8.30 (s, 1H), 7.71-7.68 (m,
2H), 7.64 (s, 1H),
7.30 (d, J= 8.4 Hz, 1H), 7.18 (br s, 1H), 4.57-4.55 (m, 1H), 4.06-4.02 (m,
1H), 3.95-3.91 (m, 1H),
3.73-3.67 (m, 2H), 3.49-3.45 (m, 1H), 2.18-2.14 (m, 1H), 2.01-1.98 (m, 1H),
1.43 (s, 6H). MS
(ESI): mass calculated for CI9H22BN504395.18, m/z found 396.2 [M+Hr HPLC: 100%
(220 nm),
100% (254 nm).
200
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
[0322]
37. Preparation of 1-(trans-4-cyanotetrahydro-2H-pyran-3-y1)-3-[(1-hydroxy-3,3-
dimethyl-2,1-
benzoxaborol-6-Aaminolpyrazole-4-carboxamide
Br p An Br iiii Br ep 0,Boc20, NCO,, Me0H
MeMgBr HCl/Et0Ac, Et0Ac
H a2 ai Br
0 ..- , ________ IMPI OH ' OH
2 20 N B RN oc
20 C, 16 h 0 C-20 C, 2.5 h BocHN
20 C, 2 h H2N ill"
0 0
2,6-dimethylpyridine, Br Br
TBSOTf, DCM , la
t-BuONO, 32Pin2, MeCN 0, 0 0-res
Na104, NH40Ac, THE, H20 ati Br
OTBS _____________________________________ V H0,13 MP OTBS
10"C-40"C, 10 h H2N 111&111111P 20 C-80 C, 16 h ..---0 25 C, 16 h
41
PI-N
N 4)L
(--0), cr-0)_
NH2
Int A oj, B2neop2, Pc10.Ph;r12C12,
5)
NH2 ____________________________________________________________
HCI, THF
N/11,1__N la Br KOAc, dioxane .... /1--/-1\l-N
din B-0
Cu(OAc)2 TEA, 4A MS, DMA, 02 N 'IF OTBS 20 C-120 C, 20 min N\ 1
N OTBS 0 C-20 C, 1 h
-...
25 C-40 C, 16 h 1-1 H
0 0
NI-I2 NH2
// --i'l-N r P0
N , 01111 so
H
aNFi2
[0323]
37.1 Preparation of methyl 2-bromo-5-(tert-butoxycarbonylamino)benzoate
0 Br 0 Br
Boc20, Na2003, Me0H
0...õ, ____________________ 0,.....
H2N BocHN
20 C, 16 h
0 ci
To a mixture of methyl 5-amino-2-bromo-benzoate (10.0 g, 43.4 mmol, 1 eq) in
Me0H (90 mL)
was added Boc20 (20.8 g, 95.6 mmol, 2.2 eq) and Na2CO3 (13.8 g, 130 mmol, 3
eq) at 20 C. The
mixture was stirred at 20 C for 16 h. TLC showed the reaction was completed.
The reaction was
removed methanol under reduced pressure to give a residue. The residue was
added H20 (150 L)
and extracted with ethyl acetate (50 mL x 3). The combined organic layers were
washed with
brine (40 mL x 3), dried over Na2SO4, filtered and concentrated under reduced
pressure to give a
residue. The residue was purified by column chromatography (SiO2, Petroleum
ether/Ethyl
acetate=10/1 to 5/1) to give methyl 2-bromo-5- (tert-
butoxycarbonylamino)benzoate (11.0 g, 76.6%
yield) as a white solid. IH NMIR (CDC13-d6, 400 MHz) 157.84 (d, J = 2.8 Hz,
1H), 7.55 (d, J= 8.8
Hz, 1H), 7.40 (dd, J= 8.8 Hz, 2.8 Hz, 1H), 6.60 (s, 1H), 3.92 (s, 3H), 1.52
(s, 911).
201
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
[0324]
37.2 Preparation of tert-butyl N44-bromo-3-(1-hydroxy-1-methyl-
ethyl)phenylicarbamate
Br Br
MeMgBr
0 BocHN
BocHN OH
o 0 C-20 C, 2.5 h
To a solution of MeMgBr (3 M, 72.6 mL, 6 eq) was added methyl 2-bromo-5- (tert-
butoxycarbonylamino)benzoate (12.0 g, 36.3 mmol, 1 eq) dropwise at 0 C. was
allowed to warm
to 20 C and stirred at 20 C for 2 h. TLC showed the reaction was completed.
The reaction mixture
was poured into sat aq.NH4C1 (300 mL) and extracted with ethyl acetate (150 mL
x 3). The
combined organic layers were washed with brine (100 mL x 2), dried over
Na2SO4, filtered and
concentrated under reduced pressure to give tert-butyl N-[4-bromo-3-(1-hydroxy-
1-methyl-
ethyl)phenyl]carbamate (20.0 g, 60.5 mmol, 83.3% yield) as a white solid. 1-1-
1 NMR (CDC13-d6,
400 MHz) 6 7.61 (d, J= 2.8 Hz, 1H), 7.48 (d, J= 8.4 Hz, 1H), 7.25 (br s, 1H),
6.48 (br s, 1H),
2.67 (s, 1H), 1.74 (s, 6H), 1.52 (s, 9H).
[0325]
37.3 Preparation of 2-(5-amino-2-bromo-phenyl)propan-2-ol
Br Br
HCl/Et0Ac, Et0Ac
OH _____________________________________________________________ OH
BocHN 20 C, 2 h H2N
To a mixture of tert-butyl N-[4-bromo-3-(1-hydroxy-1-methyl-
ethyl)phenyl]carbamate (20.0 g,
60.5 mmol, 1 eq) in Et0Ac (100 mL) was added HC1/Et0Ac (4 M, 151 mL, 10 eq) in
one portion
at 20 C under N2, the mixture was stirred at 20 C for 2 h. TLC showed the
reaction was completed.
The reaction mixture was added water (200 mL) at 0 C and then adjusted to pH =
4 with solid
Na2CO3. Then the mixture was extracted with ethyl acetate (150 mL x 3). The
combined organic
layers were washed with brine (40 mL x 2), dried over Na2SO4, filtered and
concentrated under
reduced pressure to give a residue to give 2-(5-amino-2-bromo-phenyl)propan-2-
ol (13.0 g, 93.2%
yield) as an off-white solid.
[0326]
37.4 Preparation of 4-bromo-3-filtert-butyl(dimethyl)silylloxy-1-methyl-
ethyllaniline
202
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
Br 2.6-dimethylpyridine, Br
TBSOTf, DCM
OH _________________________________________________________ OTBS
H2N 10 C-40 C, 16 h H2N
To a solution of 2-(5-amino-2-bromo-phenyl)propan-2-ol (13.0 g, 56.5 mmol, 1
eq) and 2,6-
dimethylpyridine (19.7 mL, 169 mmol, 3 eq) in DCM (130 mL) was added [tert-
butyl(dimethypsilyl] trifluoromethanesulfonate (25.9 mL, 113 mmol, 2 eq) drop-
wise at 10 C.
The mixture was stirred at 40 C for 16 h. The reaction mixture was quenched by
addition H70
(30 mL) and extracted with dichloromethane (150 mL x 2). The combined organic
phase was
washed with brine (150 mL), dried with anhydrous Na2SO4, filtered and
concentrated in vacuum
to give a residue. The residue was purified by column chromatography (SiO2,
Petroleum
ether/Ethyl acetate=10/1 to 5/1) to give 4-bromo-3-[1-[tert-
butyl(dimethyl)silyl] oxy-l-methyl-
ethyl]aniline (10.0 g, 51.4% yield) as yellow oil. 1H NMR (CDC13-do, 400 MHz)
6 7.30 (s, 1H),
7.29 (d, J = 4.4 Hz, 1H), 6.41 (dd, J = 8.4 Hz, 2.8 Hz, 1H), 3.65 (br s, 1H),
1.75 (s, 6H), 0.98 (s,
9H), 0.17 (s, 6H).
[0327]
37.5 Preparation of 11-P-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yOphenyll-1-
methyl-ethoxyl-tert-butyl-dintethyl-silane
Br
t-BuONO, B2Pin2, MeCN Br
_ OTBS
OTBS
H2N 20 C-80 C, 16 h
To a mixture of 4-bromo-3-[1-[tert-butyl(dimethyl)silyl]oxy-l-methyl-
ethyl]aniline (10.0 g, 29.0
mmol, 1 eq) in MeCN (100 mL) was added t-BuONO (8.98 g, 87.1 mmol, 3 eq) and
4,4,5,5-
tetramethy1-2-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-1,3,2-
dioxaborolane (22.1 g, 87.1
mmol, 3 eq) at 20 C. The mixture was heated and stirred at 80 C for 16 h. LCMS
showed the
reaction was completed and desired MS observed. The mixture was concentrated
in vacuum to
give a residue. The residue was purified by column chromatography (SiO2,
Petroleum ether/Ethyl
acetate=10/1 to 5/1) to give [1- [2-bromo-5 -(4,4,5,5-tetramethy1-1,3 ,2-di
oxab orol an-2-yl)pheny1]-
1-methyl-ethoxy]-tert-butyl-dimethyl -silane (6.00 g, 45.3% yield) as yellow
oi1.1H NMR (CDC13-
d6. 400 MHz) 6 8.41 (s, 1H), 7.56 (d, J= 7.6 Hz, 1H), 7.45 (d, J= 7.6 Hz, 1H),
1.79 (s, 6H), 1.33
(s, 12H), 1.02 (s, 9H), 0.18 (s, 6H).
203
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
[0328]
37.6 Preparation of [4-bromo-341-ftert-butyl(dimethyl)silytioxy-1-methyl-
ethyllphenyil
boronic acid
Br
0,6 OTBS Na104, NH40Ac, THE, H20 Br
= HO,B
OTBS
25 C, 16 h
OH
To a solution of [1- [2-brom o-5-(4,4, 5, 5-tetramethy1-1,3 ,2-dioxab orolan-2-
yl)phenyl] -1-m ethyl-
ethoxyHert-butyl-dimethyl-silane (5.00 g, 10.9 mmol, 1 eq) in TI-1F (50 mL)
and H20 (20 mL)
was added NaI04 (7.05 g, 32.9 mmol, 3 eq) and NH40Ac (2.54 g, 32.9 mmol, 3 eq)
at 25 C. The
mixture was stirred at 25 C for 16 h. LCMS showed the reaction was completed
and desired MS
observed. The mixture was poured into ice-water (w/w = 1/1) (40 mL) and
stirred for 10 min. The
aqueous phase was extracted with ethyl acetate (50 mL x 3). The combined
organic phase was
washed with brine (40 mL x 2), dried with anhydrous Na2SO4, filtered and
concentrated in vacuum
to give a residue. The residue was separated by column chromatography (SiO2,
Petroleum
ether/Ethyl acetate=5/1 to 3/1) to give [4-bromo-341-[tert-
butyl(dimethyl)silyl]oxy-1-methyl-
ethyl]phenyl]boronic acid (4.0 g, 97.6% yield) as a white solid. 1H NMR (DMSO-
do, 400 MHz) 6
8.19 (s, 1H), 8.06 (s, 2H), 7.57-7.51 (m, 2H), 1.73 (s, 6H), 0.92 (s, 9H),
0.10(s, 6H).
[0329]
37.7 Preparation of 344-bromo-341-ftert-buOl(dimethyOsilylloxy-1-methyl-
ethyllanilinol -1-
(trans-4-cyanotetrahydro-2H-pyran-3-yl)pyrazole-4-carboxamide
(-5
40 Br Int A 0 NH2 /4(--/N¨N Br
HO.B OTBS
OH Cu(OAc)2, TEA, DMA, 02 OTBS
25 C-40 C, 16 h
NE1N
H2
To a mixture of 3 -am i n o- 1-(tran s-4-cy an otetrahydropyran-3 -y 1)pyrazol
e-4-carb ox am i de (600 mg,
2.55 mmol, 1 eq) and [4-bromo-3- [1 -[tert-butyl(di methypsily1 ]oxy-1-methyl-
ethyl]phenyl]
boronic acid (951 mg, 2.55 mmol, 1 eq) in DMA (15 mL) was added 4A molecular
sieve (1.3 g),
TEA (1.29 g, 12.7 mmol, 1.78 mL, 5 eq) and Cu(OAc)2 (1.16 g, 6.38 mmol, 2.5
eq) in one portion
204
CA 03201608 2023- 6- 7
WO 2022/133420 PCT/US2021/072885
at 25 C under 02. The mixture was heated and stirred at 40 C for 16 h. LCMS
showed the reaction
was completed and desired MS observed. 2 parallel reactions were combined for
work up. The
reaction mixture was filtered. The filtrate was added H20 (70 mL) at 20 C and
extracted with
ethyl acetate (30 mL x 3). The combined organic layers were washed with brine
(30 mL x 2), dried
over Na2SO4, filtered and concentrated under reduced pressure to give a
residue. The residue was
purified by column chromatography (Si02, Petroleum ether/Ethyl acetate=3/1 to
1/1) to give 3-[4-
bromo-3-[1-[tert-butyl(dimethyl)silyl]oxy-1-methyl-ethyl]anilino]-1-(4-
cyanotetrahydro -2H-
pyran-3-yl)pyrazole-4-carboxamide (1.60 g, 55.7% yield) as a yellow solid. 111
NMR (DMSO-d6,
400 MHz) 6 9.38 (s, 1H), 8.30 (s, 1H), 7.75 (br s, 1H), 7.67-7.61 (m, 2H),
7.46 (d, J= 8.4 Hz, 1H),
7.27 (br s, 1H), 4.61-4.55 (m, 1H), 4.05-4.03 (m, 1H), 4.02-4.01 (m, 1H), 3.70-
3.63 (m, 2H), 3.45-
3.42 (m, 1H), 2.18-2.13 (m, 1H), 2.00-1.95 (m, 1H), 1.74 (s, 1H), 0.95 (s,
1H), 0.13 (s, 6H).
[0330]
37.8 Preparation of 34341-Itert-btityl(dimethyl)silylloxy-1-methyl-ethyll-4-
(5,5-dimethyl-
1,3,2-dioxaborinan-2-Aanilinok1-(trans-4-cyanotetrahydro-2H-pyran-3-Apyrazole-
4-
earboxamide
0
P (0)
B2neop2, Pd(PPh3)2C12, 0
Br KOAc, dioxane
N// ''-N-N ii"------N-N
gam 6---c<
__________________________________________________ ) N
\ 1 N el OTBS 20 C-120 C, 20 min
yk.,N "PI OTBS
H H
0 0
NH2 NH2
To a mixture of 3-[4-bromo-3-[ 1 - [tert-butyl(dimethyl)silyl]oxy-l-methyl-
ethyl]anilino] -1-(trans-
4-cyanotetrahydropyran-3-yl)pyrazol e-4-carboxami de (100 mg, 177 umol, 1 eq)
in di oxane (4 mL)
was added KOAc (43.6 mg, 444 umol, 2.5 eq), Pd(PPh3)2C12 (12.4 mg, 17.7 umol,
0.1 eq) and 2-
(5,5-dimethy1-1,3,2-dioxaborinan-2-y1)-5,5-dimethy1-1,3,2- dioxaborinane (481
mg, 2.13 mmol,
12 eq) in one portion at 20 C under N2. The mixture was heated and stirred at
120 C for 20 min.
LCMS showed the reaction was completed and desired MS observed. 13 parallel
reactions were
combined for work up. The mixture was filtered and the filtrate was
concentrated in vacuum to
give a residue. The residue was purified by column chromatography (Si02,
Petroleum ether/Ethyl
acetate=3/1 to 1/1) to give 34341-[tert-butyl(dimethypsilyl]oxy-1-methyl-
ethyl]-4-(5,5-
di m ethyl -1,3,2-di oxabori nan -2-yl)ani Ii no] -1-(tran s-4-cyan
otetrahydropyran -3 -yl )pyrazol e-4-
carboxamide (2.3 g, crude) as brown oil.
205
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
[0331]
37.9 Preparation of 1-(trans-4-eyanotetrahydro-2H-pyran-3-y1)-3-[(1-hydroxy-
3,3-dimethyl-
2,1- benzoxaborol-6-yl)aminolpyrazole-4-earboxanzide
o
o
OH
---i\j_NI gibi L---::: HCI, THF i
0 )
.>
_____________________________________________________ // N_N
N N õ.1..L, 0
OTBS 0 C-20 C, 1 h
N 114-11111
H H
0 0
NH2 NH2
To a mixture of 34441-[tert-butyl(dimethypsilylloxy-1-methyl-ethyl]-3-(5,5-
dimethyl -1,3,2-
di oxab ori nan-2-yl)anilino]-1-(trans-4-cy anotetrahy dro-2H-pyran-3 -
yl)pyrazole-4-carb oxami de
(2.0 g, 3.36 mmol, 1 eq) in THF (20 mL) was added HC1 (4 N, 4.20 mL, 5 eq)
drop-wise at 0 C
under Nz. The reaction was allowed to warm to 20 C and stirred at 20 C for 1
h. The mixture was
poured into ice-water (w/w = 1/1) (40 mL) and stirred for 10 min. The aqueous
phase was extracted
with ethyl acetate (20 mL x 4). The combined organic phase was washed with
brine (20 mL),
dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give a
residue. The residue
was purified by prep-HPLC (column: Phenomenex luna C18 250*50mm*10 um;mobile
phase:
[water (HC1)-ACN];B%: 20%-50%,10min) to give 1-(4-cyanotetrahydropyran-3-y1)-3-
[(1-
hydroxy-3 ,3 -di m ethy1-2,1-benzoxaborol -6-yl)ami no] pyrazol e-4-carboxami
de (182.7 mg, 13.7%
yield) as a white solid. 1-1-1 NAIR (DMSO-d6, 400 MHz) 6 9.34 (s, 1H), 8.74
(s, 1H), 8.31 (s, 1H),
7.74 (br s, 1H), 7.55-7.52 (m, 1H), 7.48-7.46 (m, 2H), 7.21 (br s, 1H), 4.61-
4.56 (m, 1H), 4.08-
4.03 (m, 1H), 3.91-3.90 (m, 1H), 3.68-3.63 (m, 2H), 3.48-3.47 (m, 1H), 2.20-
2.15 (m, 1H), 2.01-
1.97 (m, 1H), 1.44 (s, 6H). MS (EST): mass calculated for C19H22BN504 395.18,
m/z found 396.2
[M-41]+. HPLC: 96.62% (220 nm), 92.95% (254 nm).
[0332]
38. Preparation of 1-1trans-4-cyanotetrahydro-211-pyran-3-y1]-3-[(7-fluoro-1-
hydroxy -311-2,1-
benzoxaborol-5-yl)amino]pyrazole-4-carboxamide
206
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
F
F F F
0 Br HNO3, H2804
, 0 Br
SOCl2, Me0H , 0 Br
Fe, NR4C1 , 0
Br
0
OH OH 68 C, 12 h o--.. Et0H,
I-120 H2N -,
0 C, 2 h 02N 02N 0
0 0 0 80 C, 4 h
N.,,
07.....7...NH2
F F 1-1
H
21Jj'i- 0 N
40
B2(Pin)2 0 Br Na104, NH40Ac Br
o 1
'
F
t-BuONO, MeCN PinB 0 H20/THF HO,B (:)
isi-N
40/ O. Cu(OAc)2, TEA
Br--, --,.
0-20 C, 126 0 OH DMA, 40 C, 4 h
80 C, 12 h 0 7'--
'N 0 (:).
NH2 NH2 NH2
N-N 10
., 07....T., 07/y
H H 77y H
N N N
LiBH,,, THF / 1 1 F TBSOTf F
________________________________________ ..- 02neoP2 0
_________________________________________________________________ a- I
N-N N -NI Oil
0-25 C, 4 h .., Br
2,6-lutidine, DCM = Br Pd(PPh3)2Cl2, KOAc
= I. F B-OH
00""eEN OH 0-25 C, 4 h 00-===-=-'-N OTBS
dioxane, 120 C, 4 h 00---',=3N 0
[0333]
38.1 Preparation of 2-bromo-3-fluoro-5-nitro-benzoic acid
F F
0 Br 0 Br
HNO3, H2SO4
OH 0 C, 2 h
02N OH
0 0
To a mixture of 2-bromo-3-fluoro-benzoic acid (100 g, 456 mmol, 4.07 mL, 1 eq)
in H2SO4 (300
mL) was added Fuming Nitric Acid (50.4 g, 800 mmol, 1.75 eq) dropwise at 0 C.
The mixture
was stirred at 0 C for 2 h. TLC showed the reaction was completed. The
reaction mixture was
poured into ice water (1500 mL) and some white solid formed. The result
mixture was filtered.
The filter cake was washed with water (300 mL x 10) and dried in vacuum to
give 2-bromo-3-
fluoro-5-nitro-benzoic acid (35.0 g, 14.5% yield) as an off-white solid. 11-
1NMR (CDC13, 400 MHz)
6 8.69 (dd, J = 2.4 Hz, 1.2 Hz, 1H), 8.19 (dd, J = 7.6 Hz, 2.8 Hz, 1H).
[0334]
38.2 Preparation of methyl 2-bromo-3-fluoro-5-nitro-benzoate
F F
0 Br 0 Br
SOCl2, Me0H
__________________________________________________ ,..
OH 68 C, 12 h
02N 02N
0 0
To a mixture of 2-bromo-3-fluoro-5-nitro-benzoic acid (15.0 g, 57 mmol, 1 eq)
in Me0H (100 mL)
207
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
was added SOC12 (7.5 g, 64 mmol, 1.1 eq) dropwise at 0 C. The mixture was
heated and stirred
at 68 C for 12 h. TLC showed the reaction was completed. The mixture was
concentrated in
vacuum to remove Me0H. The residue was poured into ice water (150 mL) and some
white solid
formed. The solid was filtered and the filter cake was washed with water (100
mL x 3) and dried
in vacuum to give methyl 2-bromo-3-fluoro-5-nitro-benzoate (27.6 g, 87.3%
yield) as an off-white
solid. 1H NIVIR (CDC13, 400 MHz) 6 8.69 (dd, ,T= 2.4 Hz, 1.2 Hz, 1H), 8.19
(dd, ,/= 7.6 Hz, 2.4
Hz, 1H), 4.02 (s, 3H).
[0335]
38.3 Preparation of methyl 5-amino-2-bromo-37fluoro-benzoate
Br
Fe, NH4CI
Br
02N
Et0H, H20 H2N is
0
0 80 C, 4 h
To a mixture of methyl 2-bromo-3-fluoro-5-nitro-benzoate (25.0 g, 90 mmol, 1
eq) in H20 (150
mL) and Et0H (150 mL) was added Fe powder (25.2 g, 450 mmol, 5 eq) and NH4C1
(29.0 g, 542
mmol, 6 eq) in portions at 20 C. The mixture was heated and stirred at 80 C
for 4 h. TLC showed
the reaction was completed. The reaction mixture was filter and the filtrate
was concentrated under
reduced pressure to give a residue. The residue was diluted with 1-120 (50 mL)
and extracted with
Et0Ac (100 mL x 2). The combined organic layers were washed with brine (100 mL
x 2), dried
over Na2SO4, filtered and concentrated under reduced pressure to give methyl 5-
amino-2-bromo-
3-fluoro-benzoate (18.6 g, 83.3% yield) as a yellow solid. 11-1N1VIR (CDC13,
400 MHz) 6 6.88 (dd,
J= 2.8 Hz, 1.2 Hz, 1H), 6.56 (dd, J= 10.0 Hz, 2.8 Hz, 1H), 3.96 (br s, 2H),
3.91 (s, 3H).
[0336]
38.4 Preparation of methyl 2-bromo-3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)
benzoate
Br B2(Pin)2
An Br
H2N t-BuONO, MeCN PinB
0 80 C, 12 h
To a mixture of methyl 5-amino-2-bromo-3-fluoro-benzoate (9.0 g, 36 mmol, 1
eq) in MeCN (250
mL) was added t-BuONO (9.4 g, 91 mmol, 2.5 eq) and 4,4,5,5-tetramethy1-2-
(4,4,5,5-tetramethyl-
208
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
1,3,2-dioxaborolan-2-y1)-1,3,2-dioxaborolane (16.6 g, 66 mmol, 1.8 eq) in
portions at 20 C. The
mixture was heated and stirred at 80 C for 12 h. The resulting mixture was
concentrated in vacuum
to give a residue. The residue was purified by column chromatography (SiO2,
Petroleum
ether/Ethyl acetate=20/1 to 10/1) to give methyl 2-bromo-3-fluoro-5-(4,4,5,5-
tetramethy1-1,3,2-
dioxaborolan-2-yl)benzoate (9 g, 51.8% yield, 75% purity) as a yellow solid.
1H NMR (CDC13,
400 MHz) 6 7.95 (s, 1H), 7.62 (d, J= 8.4 Hz, 1H), 3.93 (s, 3H), 1.31 (s, 12H).
[0337]
38.5 Preparation of (4-bromo-3-fluoru-5-rnethoxycarbonyl-phenyl)boronic acid
Br Na104, NH40Ac
Br
P inB
0 H20/THF HO,B 4..
0-20 C, 12 h OH 0
To a mixture of methyl 2-brom o-3-fluoro-5-(4,4,5,5-tetram ethyl -
1,3,2-di oxaborol an -2-
yl)benzoate (9.0 g, 18.8 mmol, 75% purity, 1 eq) in H20 (250 mL) and THF (150
mL) was added
NaI04 (40.2 g, 188 mmol, 10 eq) and NH40Ac (14.5 g, 188 mmol, 10 eq) in
portions at 0 C. The
mixture was stirred at 20 C for 12 h. TLC showed the reaction was completed.
The reaction
mixture was filtered. The filtrate was adjusted to pH=12 by Sat.aq.Na2CO3 and
extracted with
Et0Ac (100 mL x 3). The combined organic layer was discarded. The aqueous
phase was adjusted
to pH=4 by HC1 (3N). White solid was precipitated out and filtered. The filter
cake was dried in
vacuum to give crude product. The crude product was triturated with petroleum
ether: Et0Ac
(10:1, 150 mL) at 20 C for 10 min and filtered again to give (4-bromo-3-fluoro-
5-
methoxycarbonyl-phenyl)boronic acid (4.1 g, 78.7% yield) as a white solid.
[0338]
38.6 Preparation of methyl 2-bromo-5-1/4-carbamoyl-1-(trans-4-cyanotetrahydro-
2H-pyran-3-
yl) pyrazol-3-yllamino1-3-fluoro-benzoate
NH H
2
Br
H,N
--C---
F
HO el
Cu(0Ac)2, TEA N-N Br
OH 0 DMA, 40 C, 4 h
0
A mixture of 3-amino-1-(trans-4-cyanotetrahydro-2H-pyran-3-yl)pyrazole-4-
carboxamide (1.0 g,
209
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
4.3 mmol, 1.2 eq) and (4-bromo-3-fluoro-5-methoxycarbonyl-phenyl)boronic acid
(1.0 g, 3.6
mmol, 1 eq) in DMA (15 mL) was added TEA (2.5 mL, 5 eq), Cu(OAc)2 (131 mg, 722
umol, 0.2
eq) and 4A molecular sieve (500 mg) at 25 C. The resulting mixture was heated
and stirred at
40 C for 4 h under air atmosphere. LCMS showed the reaction was completed and
desired MS
observed. 4 parallel reactions were combined for work up. The reaction mixture
was quenched
with sat. aq. NH4C1 (30 mL) and extracted with Et0Ac (30 mL). The organic
phase was washed
with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced
pressure to give a
residue. The residue was purified by column chromatography (SiO2, Petroleum
ether/Ethyl
acetate=10/1 to 0/1) to give methyl 2-bromo-5-[[4-carbamoy1-1- (trans-4-
cyanotetrahydro-2H-
pyran-3-yl)pyrazol-3-yl]amino]-3-fluoro-benzoate (3.5 g, 51.9% yield) as a
yellow solid. 1H NMR
(DMSO-d6, 400 MHz) 6 9.53 (s, 1H), 8.34 (s, 1H), 7.92 (dd, J =11 .2 Hz, 2.4
Hz, 1H), 7.81 (br s,
1H), 7.75 (s, 1H), 7.30 (br s, 1H), 4.65-4.61 (m, 1H), 4.08-4.03 (m, 1H), 3.92-
3.89 (m, 1H), 3.88
(s, 3H), 3.69-3.63 (m, 2H), 3.50-3.46 (m, 1H), 2.18-2.15 (m, 1H), 2.01-1.98
(m, 1H).
[0339]
38.7 Preparation of 3-14-bromo-3-fluoro-5-
(hydroxymethyl)anilino1-1-(trans-4-
eyanotetrahydro-21-1-pyran-3-yOpyrazole-4-carhoxamide
NH 2 7_7N H:
z N F
LiBH4, THF 0
N-N
1111" Br 0-25 C N-N, 4 h 4" Br
09----=-=N e OH
To a mixture of methyl 2-bromo-5-[[4-carbamoy1-1-(trans-4-cyanotetrahydro-2T-1-
pyran-3-
y1)pyrazol-3-yl] amino]-3-fluoro-benzoate (4.00 g, 8.58 mmol, 1 eq) in THF (50
mL) was added
LiBH4 (1.12 g, 51.4 mmol, 6 eq) at 0 C. The resulting mixture was stirred at
25 C for 4 h under
N2 atmosphere. LCMS showed the reaction was completed and desired MS observed.
The
reaction mixture was quenched by sat. aq. NH4C1 (50 mL) at 0 C, and then
extracted with Et0Ac
(30 mL x 4). The combined organic layers were washed with brine (50 mL), dried
over Na2SO4,
filtered and concentrated under reduced pressure to give 3-[4-bromo-3-fluoro-5-
(hydroxymethyl)anilino]-1-(4-cyanotetrahydro-2H-pyran-3-yl)pyrazole-4-
carboxamide (3.5 g, 80%
purity) as a white solid. 1H NMR (DMSO-d6, 400 MHz) 6 9.46 (s, 1H), 8.33 (s,
1H), 7.80 (br s,
1H), 7.70 (dd, J=11.2 Hz, 2.4 Hz, 1H), 7.29 (br s, 1H), 7.28 (s, 1H), 5.53 (s,
1H), 4.64-4.60 (m,
210
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
1H), 4.50 (s, 2H), 4.07-4.02 (m, 1H), 3.94-3.89 (m, 1H), 3.70-3.65 (m, 2H),
3.50-3.46 (m, 1H),
2.17-2.14 (m, 1H), 2.01-1.98 (m, 1H).
[0340]
38.8 Preparation of 3-14-bromo-3-Wert-butyl(dimethyl)silylloxymethyll-5-ilaoro-
anilino] -144-
eyanotetrahydro-211-pyran-3-yOpyrazole-4-earboxantide
10,6 F da.6. F
TBSOTf
N-N N-N
Br Br
DCM
OH 0-25 C, 4 h OTBS
To a mixture of 3-[4-bromo-3-fluoro-5-(hydroxymethyl)anilino]-1-(trans-4-
cyanotetrahydro-2H-
pyran -3-yl)pyrazole-4-carboxamide (500 mg, 912 umol, 80% purity, 1 eq) in DCM
(15 mL) was
added 2,6-lutidine (196 mg, 1.8 mmol, 2 eq) and TBSOTf (362 mg, 1.4 mmol, 1.5
eq) at 0 C. The
resulting mixture was stirred at 25 C for 4 h under N2 atmosphere. TLC showed
the reaction was
completed. 7 parallel reactions were combined for work up. The reaction
mixture was
concentrated under reduced pressure to give a residue. The residue was
purified by column
chromatography (SiO2, Petroleum ether/Ethyl acetate=5/1 to 1/2) to give 344-
bromo-3-[[tert-
butyl(dimethyl)silyl]oxymethy1]-5¨fluoro -anilino]-1-(trans-4-
cyanotetrahydro-2H-pyran-3-
yl)pyrazole-4-carboxamide (2.4 g, 67.9% yield) as a yellow solid. 1H NMR (DMSO-
d6, 400 MHz)
6 9.52 (s, 1H), 8.34 (s, 1H), 7.79 (br s, 1H), 7.67 (dd, J=11.2 Hz, 2.4 Hz,
1H), 7.27 (br s, 1H),
7.26 (s, 1H), 4.69 (s, 2H), 4.60-4.54 (m, 1H), 4.06-4.02 (m, 1H), 3.94-3.89
(m, 1H), 3.70-3.65 (m,
2H), 3.52-3.47 (m, 1H), 2.15-2.12 (m, 1H), 2.01-1.98 (m, 1H), 0.93 (s, 9H),
0.13 (s, 6H).
[0341]
38.9 Preparation of Htrans-4-cyanotetrahydro-2H-pyran-3-y11-3-[(7-fluoro-1-
hydroxy -3H-
2,1-benzoxaborol-5-y0aminolpyrazole-4-carboxamide
0NH2 / 07.õ. jrNH2
F 146,.
B2neoP2 F
NN
N-N SP-
Br B-OH
Pd(PPh3)2012, KOAc
OTBS dioxane, 120 C, 4 h d
A mixture of 344-bromo-3-fftert-butyl(dimethyl)silyl]oxymethyl]-5-fluoro-
ani1ino]-1- (trans-4-
211
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
cyanotetrahydro-2H-pyran-3-yl)pyrazole-4-carboxamide (500 mg, 904 umol, 1 eq)
and 4,4,5,5-
tetramethy1-2-(4,4,5,5-tetramethy1-1,3 ,2-di oxab orol an-2-y1)-1,3 ,2-di oxab
orol ane (1.15 g, 4.52
mmol, 5 eq) in dioxane (20 mL) was added KOAc (178 mg, 1.8 mmol, 2 eq) ,
Pd(PPh3)2C12 (64
mg, 91 umol) at 25 C. The resulting mixture was stirred at 120 C for 4 h under
N2 atmosphere.
LCMS showed the reaction was completed and desired MS observed. 3 parallel
reactions were
combined for work up. The reaction mixture was filtered and the filtrate was
concentrated under
reduced pressure to give 1-[trans-4-cyanotetrahydro-2H-pyran-3 -y1]-3 -[(7-
fluoro-1-hydroxy-3H-
2,1-benzoxa borol- 5-yl)amino]pyrazole-4-carboxamide. The residue was purified
by prep-HPLC
(column: Phenomenex luna C18 250*50mm*10um; mobile phase: [water (HCl)-
ACN],B%: 15%-
40%,10min) and SFC separation (column: DAICEL CHIRALPAK IC(250mm*30mm,10um);
mobile phase: [Neu-ET014];13%: 50%-50%,9min) to give 1-[trans-4-
cyanotetrahydro-2H-pyran-
3-y1]-3-[(7-fluoro-1-hydroxy-3H-2, 1-benzoxa borol-
S -yl)amino]pyrazole-4-carboxami de
(stereoisomer one) (175 mg, 16.7% yield. 99.5% purity, 99.8 ee% first peak,
Rt=1.239 min) as a
white solid. 1H NMR (DMSO-d6, 400 MHz) 6 9.54 (s, 1H), 8.98 (s, 1H), 8.33 (s,
1H), 7.79 (br s,
1H), 7.35 (d, J= 10.8 Hz 1H), 7.27 (br s, 1H), 7.25 (s, 2H), 4.94 (s, 2H),
4.63-4.59 (m, 1H), 4.06-
4.02 (m, 1H), 3.93-3.89 (m, 1H), 3.70-3.64 (m, 2H), 3.52-3.47 (m, 1H), 2.17-
2.12 (m, 1H), 2.03-
1.97 (m, 114). MS (ESI): mass calculated for C174117BTN50.4, 385.14, m/z found
386.2 [M+H].
HPLC: 99.57% (220 nm), 100% (254 nm). and 1-[trans-4- cyanotetrahydropyran-3-
y1]-3-[(7-
fluoro-1-hydroxy-3H-2,1-benzoxaborol-5-yl)amino]pyrazole-4-carboxamide
(stereoisomer two)
(175 mg, 16.7% yield, 96.3% purity, 98.9 ee% second peak, Rt=1.468 min) as a
white solid. 1H
NMR (DMSO-d6, 400 MHz) 6 9.53 (s, 1H), 8.98 (s, 1H), 8.33 (s, 1H), 7.79 (br s,
1H), 7.35 (d, J
= 10.8 Hz 1H), 7.27 (br s, 1H), 7.25 (s, 2H), 4.94 (s, 2H), 4.63-4.59 (m, 1H),
4.06-4.02 (m, 1H),
3.93-3.89 (m, 1H), 3.70-3.64 (m, 2H), 3.52-3.47 (m, 1H), 2.17-2.12 (m, 1H),
2.03-1.97 (m, 1H).
MS (ESI): mass calculated for C17H17BFN504, 385.14, m/z found 386.2 [M+H]t
HPLC: 96.39%
(220 nm), 98.23% (254 nm).
[0342]
39. Preparation of 1-(trans-4-cyanotetrahydro-2H-pyran-3-y1)-3-1(3,4-diethyl-2-
hydroxy-1,2-
benzoxaborinin-6-y0aminokyrazole-4-earboxamid
212
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
6 --rOH 0õOH
B
A1C13, DCM Br 0 WA, PMDTA, THF Br
r
65 C, 125 0 C, 1.5 h
j,/
N NH2
,
NH2
0 0,B
Pd2dba3, tButyl-XPhos
KOAc, iPrOH, 80 C, 12 h
HN
NH2
[0343]
39.1 Preparation of 1-(5-bromo-2-hydroxy-phenyl)propan-1-one
ci)/ OH
A13, DCM Br
0
Br lC
65 C, 12h
To a solution of propanoyl chloride (5.00 g, 53.5 mmol, 5 mL, 2 eq) in DCM (50
mL) was added
A1C13 (14.3 g, 107 mmol, 4 eq) at 0 C. After addition, the mixture was stirred
at 0 C for 30 min,
and then 1-bromo-4-methoxy-benzene (5.00 g, 26.7 mmol, 3.4 mL, 1 eq) was added
dropwi se at
0 C. The resulting mixture was heated and stirred at 65 C for 12 h. LCMS
showed the reaction
was completed and desired MS observed. The reaction mixture was quenched by
addition H20
(100 mL) at 0 C and then extracted with DCM (50 mL x 3). The combined organic
layers were
washed with brine (50 mL), dried over with Na2SO4, filtered and concentrated
under reduced
pressure to give a residue. The residue was purified by flash silica gel
chromatography (ISCOO;
20 g SepaFlash Silica Flash Column, Eluent of 0-10% Ethyl acetate/Petroleum
ether gradient @
100 mL/min) to give 1-(5-bromo-2- hydroxy-phenyl)propan-1 -one (5.00 g, 21.8
mmol, 81.6%
yield) as a yellow solid. 1H NIVIR (CDC13, 400 MHz) 6 12.26 (s, 1H), 7.87 (d,
J 2.5 Hz, 1H),
7.54 (dd, J = 2.4, 8.8 Hz, 1H), 6.94 - 6.84 (m, 1H), 3.09 -2.97 (m, 2H), 1.25
(t, J= 7.2 Hz, 3H).
[0344]
39.2 Preparation of 6-bromo-3,4-diethy1-2-hydroxy-1,2-benzoxaborinine
213
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
B-
o 0
OH 0,B4OH
Br 0 LDA, PMDTA, THF Br
To a solution of LDA (2 M, 6.6 mL, 3 eq) in THE (10 mL) was added dropwise
N'42-
(dimethylamino)ethyli-N,N,N'-trimethyl-ethane-1,2-diamine (1.51 g, 8.73 mmol,
1.8 mL, 2 eq)
and 4,4,5,5-tetramethy1-2- [1 -(4,4,5,5-tetram ethy1-1,3,2-di
oxaborol an-2-yl)propyl ] -1,3,2 -
dioxaborolane (2.60 g, 8.73 mmol, 2 eq) at 0 C. After addition, the mixture
was stirred at 0 C for
30 min and then 1-(5-bromo-2-hydroxy-phenyl)propan- 1 -one (1.00 g, 4.4 mmol,
1 eq) in TFIF (5
mL) was added dropwise at 0 C. The resulting mixture was continue stirred at 0
C for 1 h. LCMS
showed the reaction was completed and desired MS observed. The reaction
mixture was quenched
by addition NH4C1 (50 mL), adjust pH=7 with 1N HC1, and then extracted with
Et0Ac (20 mL x
3). The combined organic layers were washed with brine (50 mL), dried over
with Na2SO4, filtered
and concentrated under reduced pressure to give a residue. The residue was
purified by flash silica
gel chromatography (ISCO , 20 g SepaFlashe Silica Flash Column, Eluent of 0-
30% Ethyl
acetate/Petroleum ether gradient g 100 mL/min) to give 6-bromo-3,4-diethyl-2-
hydroxy -1,2-
benzoxaborinine (1.50 g, crude) as a white solid. 1H NMR (CDC13, 400 MHz) 6
7.71 (d, J= 2.4
Hz, 1H), 7.42 - 7.38 (m, 1H), 7.11 - 7.08 (m, 1H), 1.66 - 1.53 (m, 4H), 0.93
(t, .J= 7.3 Hz, 6H).
[0345]
39.3 Preparation of 1-(trans-4-cyanotetrahydro-2H-pyran-3-A-3-[(3,4-diethyl-2-
hydroxy-1,2-
benzoxaborinin-6-y0aminokyrazole-4-earboxamide
d
NH,
(0,
0, BõOH 0 air NH2
Rr Pd2dba3, tButyl-XPhos
N
KOAc, iPrOH, 80 C, 12 h
0
NH2
To a solution of 3-amino-1-(trans4-cyanotetrahydro-2H-pyran-3-yl)pyrazole-4-
carboxamide (251
mg, 1.07 mmol, 1.5 eq) in i-PrOH (5 mL) was added KOAc (140 mg, 1.42 mmol, 2
eq), 6-bromo-
3,4-diethy1-2-hydroxy-1,2-benzoxaborinine (200 mg, 712 umol, 1 eq), Pd2(dba)3
(65 mg, 71.2
umol, 0.1 eq) and t-BuXPhos (60 mg, 142.4 umol, 0.2 eq) at 25 C. The resulting
mixture was
214
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
heated and stirred at 80 C for 12 h. LCMS showed the reaction was completed
and desired MS
observed. The reaction mixture was filtered and the filtrate was concentrated
under reduced
pressure to give a residue. The residue was purified by prep-HPLC (column:
Waters Xbridge BEH
C18 100*30mm*10um; mobile phase: [water (10mM NH4HCO3)-ACN] ;WA: 30%-
60%,10min)
to give 1-(trans-4-cyanotetrahydro-2H-pyran-3 -y1)-3 -[(3,
4-diethy1-2-hydroxy-1,2-
benzoxaborinin-6-y1) amino]pyrazole-4-carboxamide (43.5 mg, 14.0% yield) as a
yellow solid.
1H NMR (DMSO-d , 400 MHz) 6 9.09 (s, 1H), 8.57 (s, 1H), 8.31 (s, 1H), 8.16 (d,
J= 2.4 Hz, 1H),
7.74(s, 1H), 7.29 - 7.21 (m, 1H), 7.18 (s, 1H), 7.11 - 7.05 (m, 1H), 4.66 -
4.46 (m, 1H),4.13 -4.03
(m, 1H), 4.01 - 3.88 (m, 1H), 3.75 - 3.65 (m, 1H), 3.64 - 3.49 (m, 1H), 3.46 -
3.36 (m, 1H), 2.86 -
2.73 (m, 2H), 2.46 - 2.37 (m, 2H), 2.27 - 2.14 (m, 1H), 2.08 - 1.92 (m, 1H),
1.23 (t, J = 7.5 Hz,
3H), 1.08 - 0.97 (m, 3H) MS (ESI): mass calculated for C22H26BN504, 435.21,
m/z found 434.3
[M-H]-. HPLC: 96.06% (220 nm), 98.04% (254 nm).
[0346]
40. Preparation of 1-(trans-2-cyanocylopenty0-3-[(3,4-diethyl-2-hydroxy-1,2-
benzoxaborinin-6-
Aaminolpyrazole-4-carboxamide
0..INC;72
0,,OH NH2
0
0,õ OH N¨N
Br
Pd2dba3, tButyl-XPhos
KOAc, iPrOH, 80 C, 24 h
0 NH2
To a solution of 3-amino-1-(trans-2-cyanocyclopentyl)pyrazole-4-carboxamide
(316 mg, 1.44
mmol, 1.5 eq) in i-PrOH (5 mL) was added KOAc (189 mg, 1.92 mmol, 2 eq) at 25
C, 6-bromo-
3,4-diethy1-2-hydroxy-1,2-benzoxaborinine (270 mg, 961 umol, 1 eq), Pd2(dba)3
(88 mg, 96.1
umol, 0.1 eq) and t-Bu XPhos (82 mg, 192.2 umol, 0.2 eq) was added at 25 C.
The resulting
mixture was stirred at 80 C for 24 h. LCMS showed the reaction was completed
and desired MS
observed. The reaction mixture was filtered and the filtrate was concentrated
under reduced
pressure to give a residue. The residue was purified by prep-HPLC column:
column: column:
Waters Xbridge BEH C18 100*30mm*10um; mobile phase: [water (10mM NH4HCO3)-
ACN];B%. 32%-62%,10min to give 1-(trans-2-cyanocycl openty1)-3 - [(3,4-di
ethy1-2-hydroxy-1,2-
benzoxab ori ni n-6-yl)ami no] pyrazole-4-carboxamide (63.4 mg, 15.7% yield)
as a yellow solid.
215
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
1H NMR (DMSO-d6, 400 MHz) 6 9.07 (s, 1H), 8.54 (s, 1H), 8.28 (s, 1H), 8.19 -
8.09 (m, 1H),
7.63 (s, 1H), 7.27- 7.19 (m, 1H), 7.12 (s, 1H), 7.10 - 7.04 (m, 1H), 4.96-
4.89 (m, 1H), 3.40 -3.37
(m, 1H), 2.83 -2.72 (m, 2H), 2.46 - 2.36 (m, 2H), 2.31 -2.17 (m, 2H), 2.17 -
2.09 (m, 1H), 2.02 -
1.82 (m, 3H), 1.19 (t, J= 7.5 Hz, 3H), 1.03 (t, J= 7.5 Hz, 3H) MS (ESI): mass
calculated for
C22H26BN503, 419.21, m/z found 418.2 [M-H]. HPLC: 95.76% (220 nm), 98.83 (254
nm).
[0347]
41. Preparation of 1-(trans-4-cyanotetrahydro-2H-pyran-3-y0-341-hydroxy-1,3-
ilihydrobenzokff1,2Joxaborol-5-yl)arninu)-1H-pyrazole-4-earboxamide
0
HO,BõOH
Mel, K2CO3
1
i-PrMgCI, B(OMe)3 HN
HO2C DMF, 25 C, 16 h
Me02C 141
THF, 15-25-0 C, 1.5 h Cu(
0111 2 N
0A02, TEA DCM,
Me02C 25 C,
16 h
Br Br Br
0
0 H2W-kx....-\ 0
H2NN
0
,
HN N
HN N B2Pin2
NC
40 Pd(dppf)C12, KOAc
C
Me0
dioxane, 85 C, 12 h 2 111111111
Me02C
0 0
Br
0
0
NaBH4
HN
THF, Me0H, 0 C, 1 h
OH
[0348]
41.1 Preparation of methyl 2-hromo-5-iodo-henzoate
DmMFe 12, K0C2C013
HO2C 25 C. 6 hMe02C
Br Br
To a solution of 2-bromo-5-iodo-benzoic acid (10.0 g, 30.6 mmol, 1 eq) and
K2CO3 (6.34 g, 45.9
mmol, 1.5 eq) in DMF (100 mL) was added Mel (5.64 g, 39.8 mmol, 1.3 eq) at 25
C. The reaction
mixture was stirred at 25 C for 16 h. TLC showed the reaction was completed.
The reaction
216
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
mixture was quenched by addition water (200 mL) at 0 C, then extracted with
Et0Ac (50 mL x
3). The combined organic layers were washed with brine (100 mL x 3), dried
over Na2SO4, filtered
and concentrated under reduced pressure to give methyl 2-bromo-5-iodo-benzoate
(10.0 g, 95.9%
yield) as brown oil. 1H N_MR (CDC13, 400 MI-Iz) 6 8.11 (s, 1H), 7.63 (dd, J=
8.4 Hz, 2.4 Hz, 1H),
7.39 (d, .1= 8.4 Hz, 1H), 3.94 (s, 3H).
[0349]
41.2 Preparation of (4-bromo-3-methoxycarbonyl-phenyl)boronic acid
HO,BõOH
T Hi -FP r iM5g C2I5, Bo( 00: l e ) 35 h
Me02C
Me02C
Br Br
To a solution of 2-[2-(dimethylamino)ethoxy]-N,N-dimethyl-ethanamine (2.82 g,
17.6 mmol, 1.2
eq) in THF (80 mL) was added i-PrMgC1 (2 M, 8.8 mL, 1.2 eq) at 15 C. The
mixture was stirred
at 15 C. for 20 min. Then methyl 2-bromo-5-iodo-benzoate (5.00 g, 14.7 mmol, 1
eq) was added
dropwise to the reaction mixture. The resulting mixture was stirred at 25 C
for 10 min. Then the
reaction was cooled to 0 C and trimethyl borate (3.05 g, 29.3 mmol, 3.3 mL, 2
eq) was added
dropwise at 0 C. The reaction mixture was continue stirred at 0 C for 1 h. TLC
showed the
reaction was completed. The reaction mixture was quenched by addition of sat.
aq. NH4C1 (100
mL) at 0 C, then extracted with Et0Ac (40 mL x 3). The combined organic layers
were washed
with brine (90 mL x 3), dried over Na2SO4, filtered and concentrated under
reduced pressure to
give a residue. The residue was purified by flash silica gel chromatography
(ISC08; 80 g
SepaFlash Silica Flash Column, Eluent of 0-25% Ethyl acetate/Petroleum ether
gradient @ 75
mL/min) to give (4-bromo-3-methoxycarbonyl-phenyl)boronic acid (1.70 g, 44.8%
yield) as
yellow oil. 1H NMR (CDC13, 400 MHz) 6 8.14 (s, 1H), 7.83 (ddõI = 8.0 Hz, 1.6
Hz, 1H), 7.73 (d,
J= 8.0 Hz, 1H), 3.86 (s, 3H).
[0350]
41.3 Preparation of methyl 2-bromo-5[14-carbamoyl-1[trans-4-cyanotetrahydro-2H-
pyran -3-
yllpyrazol-3-yljaminolbenzoate
217
CA 03201608 2023- 6- 7
WO 2022/133420
PCT/US2021/072885
0
HO..B4OH H2N-Ar
H2N)Lr-A
)
H2N NC 40
HN N
Cu(OAc)2, TEA, DCM;
NC
Me02C
25 C, 16 h
Br
Me02C
Br
A mixture of (4-bromo-3-methoxycarbonyl-phenyl)boronic acid (1.00 g, 3.86
mmol, 1 eq), 3-
amino-1-[trans-4-cyanotetrahydro-2II-pyran-3-yl]pyrazole-4-carboxamide (908
mg, 3.86 mmol, 1
eq), TEA (1.95 g, 19.3 mmol, 2.7 mL, 5 eq), Cu(0Ac)2 (1.75 g, 9.65 mmol, 2.5
eq) and 4A
molecular sieve (2 g) in DCM (14 mL) was degassed and purged with 02 for 3
times. Then the
mixture was stirred at 25 C for 16 h under 02 atmosphere. LCMS showed the
reaction was
completed and desired MS observed. The reaction mixture was filtered and
filtrate was
concentrated under reduced pressure to give a residue. The residue was
purified by flash silica gel
chromatography (ISCOTO; 40 g SepaFlash Silica Flash Column, Eluent of 0-100%
Ethyl
acetate/Petroleum ether gradient @ 75 mL/min) to give methyl 2-bromo-5-[[4-
carbamoy1-1-[trans-
4-cyanotetrahydro-2H-pyran-3-yl]pyrazol-3-yl]amino]benzoate (0.50 g, 28.9%
yield) as a white
solid. 1H NMR (DMSO-d6, 400 MHz) 6 9.35 (s, 1H), 8.32 (s, 1H), 7.99 (d, J =
2.8 Hz, 1H), 7.77
(br s, 1H), 7.70 (dd, .1 = 2.8, 8.8 Hz, 1H), 7.57 (d, .1 = 8.8 Hz, 1H), 7.25
(hr s, 1H), 4.60 (dt, .1 =
4.4, 10.0 Hz, 1H), 4.10-4.03 (m, 1H), 3.94-3.90 (m, 1H), 3.86 (s, 3H), 3.72-
3.60 (m, 2H), 3.50-
3.41 (m, 1H), 2.18-2.10 (m, 1H), 2.05-1.92 (m, 1H).
[0351]
41.4 Preparation of methyl 5-114-earbamoy1-1-[trans-4-cyanotetrahydro-2H-pyran-
3-yll
pyrazol-3-yllamino]-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate
H,N)IX----\ C'N
HN N
N B2P1n2
HN NC's'
Pd(dppf)C12, KOAc
dioxane; 85 C, 12 h Me02C
Me02C
Br
A mixture of methyl 2-bromo-5-[[4-carbamoy1-1-[trans-4-cyanotetrahydro-2H-
pyran-3-yl]
pyrazol-3-yl]amino]benzoate (250 mg, 557 umol, 1 eq), B2Pin2 (283 mg, 1.12
mmol, 2 eq), KOAc
218
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
(164 mg, 1.67 mmol, 3 eq), Pd(dppf)C12 (20 mg, 27.9 umol, 0.05 eq) in dioxane
(6 mL) was
degassed and purged with N2 for 3 times. Then the mixture was heated and
stirred at 85 C for 12
h under N2 atmosphere. LCMS showed the reaction was completed and desired MS
observed. 2
parallel reactions were combined for work up. The reaction mixture was cooled
to 25 C and
filtered. The filtrate was concentrated under reduced pressure to give a
residue. The residue was
purified by flash silica gel chromatography (ISCOS; 40 g SepaFlash Silica
Flash Column, Eluent
of 0-100% Ethyl acetate/Petroleum ether gradient @ 75 mL/min) to give methyl -
5-[[4-
carb am oy1-1-[tran s-4-cy anotetrahy dro-2H-py ran-3 -yl] py razol -3 -yl]
amino]-2- (4,4,5,5-
tetramethy1-1,3,2-dioxaborolan-2-yl)benzoate (0.50 g, 90.5% yield) as a white
solid. NMR
(DMSO-d6, 400 MHz) 6 9.38 (s, 1H), 8.33 (s, 1H), 7.95 (d, J = 2.4 Hz, 1H),
7.80-7.71 (m, 2H),
7.40 (d, J' 8.0 Hz, 1H), 7.25 (br s, 1H), 4.60 (dt, J' 4.4, 10.0 Hz, 1H), 4.10-
4.04 (m, 1H), 3.95-
3.90 (m, 1H), 3.83 (s, 3H), 3.70-3.58 (m, 2H), 3.51-3.41 (m, 1H), 2.19-2.15
(m, 1H), 2.06-1.97
(m, 1H), 1.30 (s, 12H).
[0352]
41.5 Preparation of 1-(trans-4-cyanotetrahydro-2H-pyran-3-yl)-34(1-hydroxy-1,3-
dihydrobenzo[c][1,21oxaborol-5-y9amino)-111-pyrazole-4-earhoxamide
0
0 H2N--4x¨N
HN H2N (3\
)1r¨
NC' NaBH4 HNNd
N
THF, Me0H; 0 C, 1 h
Me02C
B.
0- 0
0¨B,
OH
To a solution of methyl 5-[[4-carbamoy1-1-(trans-4-cyanotetrahydro-2H-pyran-3-
yl)pyrazol-3-
yl] amino] -2-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)benzoate (0.85 g,
1.31 mmol, 1 eq) in
Me0H (1 mL) and THE (10 mL) was added NaBH4 (248 mg, 6.56 mmol, 5 eq) at 0 C.
The
mixture was stirred at 0 C for 1 h. LCMS showed the reaction was completed and
desired MS
observed. The reaction mixture was quenched with water (10 mL) at 0 C, then
the resulting
mixture was adjusted pH to 5 with HC1 (2 M) and stirred for 30 min at 0 C. The
solution was
diluted with Et0Ac (5 mL) and extracted with Et0Ac (10 mL x 3). The combined
organic layers
were washed with brine (15 mL x 2), dried over Na2SO4, filtered and
concentrated under reduced
219
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
pressure to give a residue. The residue was purified by prep-HPLC (column:
Phenomenex Luna
80*30mm*3um; mobile phase: [water(HC1)-ACN];B%: 5%-35%,8min) to give 1-(trans-
4-
cyanotetrahy dro-2H-pyran-3 -y1)-3 -((l-hy droxy-1,3 - dihy drobenzo [c] [1,2]
oxaborol-5-yl)ami no)-
1H-pyrazole-4-carboxamide (0.5 g, purity 95.1%) as a white solid, which was
further separated by
SFC (condition: column: DAICEL CHIRALPAK IC(250mm*30mm,10um);mobile phase:
[Neu-
IPA];B%: 60%-60%,12min) to give 1-(tran s-4-cyanotetrahydro-2H-pyran-3-y1)-3 -
((1-hydroxy-
1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)amino)-1H-pyrazole-4-carboxamide
(stereoisomer one)
(221 mg, 45.8% yield, 100% cc, first peak, Rt = 2.436 min) as a white solid.
1H NMR (DMSO-d6,
400 MHz) 6 9.41 (s, 1H), 8.89 (br s, 1H), 8.32 (s, 1H), 7.75 (br s, 1H), 7.62-
7.56 (m, 2H), 7.38 (d,
J = 8.0 Hz, 1H), 7.21 (br s, 1H), 4.94 (s, 2H), 4.58 (dt, J = 4.4, 10.0 Hz,
1H), 4.04 (dd, J = 4.0,
11.2 Hz, 1H), 3.95-3.85 (m, 1H), 3.75-3.63 (m, 2H), 3.50 (t, 1= 10.8 Hz, 1H),
2.16 (d, J= 10.8
Hz, 1H), 2.05-1.92 (m, 1H). MS (ESI): mass calculated for C17E118BN504367.15,
m/z found 368.2
[M+H]+. HPLC: 99.61% (220 nm), 100% (254 nm). and 1-(trans-4-cyanotetrahydro-
2H-pyran-3-
y1)-3 -((l-hydroxy-1,3 -dihydrobenzo[c] [1,2] oxaborol-5 -yl)amino)-1H-
pyrazole-4-carboxamide
(stereoisomer two) (204 mg, 42.3% yield, 100% cc, second peak, Rt = 3.141 min)
as a white solid.
1H NMR (DMSO-d6, 400 MHz) 6 9.41 (s, 1H), 8.88 (br s, 1H), 8.32 (s, 1H), 7.75
(br s, 1H), 7.62-
7.56 (m, 214), 7.38 (d, J= 8.0 Hz, 111), 7.21 (br s, 1H), 4.94 (s, 2H), 4.58
(dt, 1=4.4, 10.0 Hz,
1H), 4.04 (dd, 1= 4.0, 11.2 Hz, 1H), 3.95-3.85 (m, 1H), 3.75-3.63 (m, 2H),
3.50 (t, J= 10.8 Hz,
1H), 2.16 (d, 1= 10.8 Hz, 1H), 2.05-1.92 (m, 1H). MS (ESI): mass calculated
for C171-118BN504
367.15; m/z found 368.1 [M+H]. HPLC: 100% (220 nm), 100% (254 nm).
[0353]
42. Preparation of 1-ftrans-4-eyanotetrahydro-2H-pyran-3-y11-3-1(1-hydroxy-3,4-
dihydro- 2,1-
benzoxaborinin-7-yl)aminokyrazole-4-carboxamide
220
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
0
Q-41,1112
0 Br HBPin
_____________________________ ..->1---1 9B Br Na102,
NH4OAC (H0)213 aisti Br NH2
_______________________________________________________________________________
_____ i...
CO2Me 0
Ir(OMe)2(COD)2, dtbhPY - 40 THF, H20 Mr CO2Me
Cu(0A02, TEA, DMSO
Me
2-Me-THF, 9000, 12 h CO2 25 C, 2 h
40 C, 12 h
0QõN
NaBH4
N-N 0 CO2Me B2ne0P2 NN Op CO2Me _________ ...- N-N 40
yl, .., yi,
Pd(PPh3)2C12, KOAc v.:0 THE, Me0H
B4O
N Br N N
H dioxane, 120 C, 1 h H 0-25 C,
1 h H 01-1
0 0 0 0
NH2 NH2 NI-12
[0354]
42.1 Preparation of methyl 2-12-bromo-4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-y0
phenyllacetate
0 Br HBPin
.>"-----B Br
CO2Me 0 101
CO2Me
Ir(OMe)2(COD)2, dtbbpY
2-Me-THF, 90 C, 12 h
To a solution of methyl 2-(2-bromophenyl)acetate (2.00 g, 8.73 mmol, 1 eq) in
2-MeTtlf (20 mL)
was added 4-tert-butyl-2-(4-tert-butyl-2-pyridyl)pyridine (234 mg, 873 umol,
0.1 eq),
Ir(COD)2(0Me)2 (289 mg, 436 umol, 0.05 eq) and 4,4,5,5-tetramethy1-1,3,2-
dioxaborolane (4.50
g, 34.9 mmol, 5.1 mL, 4 eq) under N2. The mixture was heated and stirred at 90
C for 12 h under
N2. TLC showed the reaction was completed. 6 parallel reactions were combined
for work up.
The reaction mixture was concentrated under reduced pressure to give a
residue. The residue was
purified by flash silica gel chromatography (ISCOO; 12 g SepaFlash Silica
Flash Column, Eluent
of 0-20% Ethyl acetate/Petroleum ether gradient @ 50 mL/min) to give methyl 2-
[2-bromo-4-
(4,4,5,5 -tetramethy1-1,3,2-dioxaborolan-2-yl)phenyl]acetate (totally 10 g,
crude) as brown oil. 1H
NMR (CDC13, 400 MHz) 6 8.01 (s, 0.5H), 7.71 - 7.69 (m, 1H), 7.60 - 7.55 (m,
1H), 7.29 (d, .1=
7.5 Hz, 0.5H), 3.82 (s, 2H), 3.71 (s, 3H), 1.34 (s, 12H).
[0355]
42.2 Preparation of p-bromo-4-(2-methoxy-2-oxo-ethyl)phenyllboronic acid
221
CA 03201606 2023- 6-7
WO 2022/133420
PCT/US2021/072885
Na104, NH40Ac (H0)2B so Br
...."-C13 Br
0
THE. H20 CO2Me
CO2Me
25 C, 2 h
To a solution of methyl 242-bromo-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-
yl)phenyl]
acetate (10.0 g, 28.2 mmol, 1 eq) and methyl 2-[2-bromo-5-(4,4,5,5-tetramethy1-
1,3,2-
dioxaborolan-2-yl)phenyl]acetate (10.0 g, 28.2 mmol, 1 eq) in TI-IF (60 mL)
and H20 (30 mL) was
added NaI04 (24.1 g, 113 mmol, 6.2 mL, 4 eq) and NH40Ac (8.7 g, 113 mmol, 4
eq). The mixture
was stirred at 25 C for 2 h. LCMS showed the reaction was completed and
desired MS observed.
The reaction mixture was quenched by addition H20 (200 M1), and adjust pH=6
with 2N HC1.
Then the mixture was extracted with Et0Ac (100 mL x 3). The combined organic
layers were
washed with brine (100 mL x 1), dried over with Na2SO4, filtered and
concentrated under reduced
pressure to give a residue. The residue was purified by prep-HPLC (column:
Waters Xbridge BEH
C18 100*30mm*10um; mobile phase: [water (10mM NH4HCO3)-ACN];B%: 20%-50%,10min)
to give [3-bromo-4-(2-methoxy-2- oxo-ethyl)phenyl]boronic acid (5.00 g, 21.6%
yield) as a white
solid. 1H NM:1Z (DMSO-d6, 400 MHz) ö 8.23 (s, 2H), 7.97 (s, 1H), 7.71 (d, J=
7.5 Hz, 1H), 7.37
(d, J = 7.5 Hz, 1H), 3.82 (s, 2H), 3.62 (s, 3H).
[0356]
42.3 Preparation of methyl 242-bromo-4-[[4-earbamoyl-1-(trans-4-
cyanotetrahydro-2H-
pyran-3-y1) pyrazol-3-yllamino]phenyllacetate
0
N- NH2 0
(H0)2B 40 Br NH2
4111 CO2Me
CO2Me
Cu(0A02, TEA, DMS0 Br
40 C, 12 h
0
NH2
To a solution of [3-bromo-4-(2-methoxy-2-oxo-ethyl)phenyl]boronic acid (500
mg, 1.83 mmol, 1
eq) in DMSO (20 mL) was added Cu(0Ac)2 (832 mg, 4.58 mmol, 2.5 eq), 3-amino-1-
(trans-4-
cyanotetrahydro-2H-pyran-3-yl)pyrazole-4-carboxamide (517 mg, 2.2 mmol, 1.2
eq) and TEA
(927 mg, 9.16 mmol, 1.28 mL, 5 eq) at 25 C. The resulting mixture was heated
and stirred at 40 C
for 12 h under 02 atmosphere. LCMS showed the reaction was completed and
desired MS
observed. 3 parallel reactions were combined for work up. The reaction mixture
was filtered. The
222
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
filtrate was diluted with H20 (30 mL) and extracted with Et0Ac (10 mL x 3).
The combined
organic layers were washed with brine (15 mL), dried over Na2SO4, filtered and
concentrated under
reduced pressure to give a residue. The residue was purified by flash silica
gel chromatography
(ISCOg; 20 g SepaFlash Silica Flash Column, Eluent of 0-50% Ethyl
acetate/Petroleum ether
gradient @ 50 mL/min) to give methyl 2-[2-bromo-4-[[4- carbamoy1-1-(trans-4-
cyanotetrahydro-
2H-pyran-3-yl)pyrazol-3-yl]amino]phenyflacetate (1.50 g, 59.0% yield) as a
yellow solid.
[0357]
42.4 Preparation of methyl 2444[4-eurbamuyl-1-(trans-4-eyanotetrahydro-2H-
pyran-3-
Apyrazol -3-yllaminol-2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)phenylfacetate
oQ ,,N -N
B2neoP2
NN 0 CO2Me _________________________________________ l N-N 410 CO2Me
N
Br ==,,....11....
Pd(PPh3)2Cl2, KOAc
N B0"
H 0.
H dioxane, 120 C, 1 h
0 0
NH2 NH2
A mixture of 2-(5,5-dimethy1-1,3,2-dioxaborinan-2-y1)-5,5-dimethy1-1,3,2-
dioxaborinane (611
mg, 2.70 mmol, 2.5 eq), methyl 2-[2-bromo-4-[[4-carbamoy1-1-(trans-4-
cyanotetrahydro-2H-
pyran -3-yl)pyrazol-3-yl]amino]phenyl]acetate (500 mg, 1.08 mmol, 1 eq), KOAc
(265 mg, 2.70
mmol, 2.5 eq) and Pd(PPh3)2C12 (76 mg, 108 umol, 0.1 eq) in dioxane (10 mL)
was degassed and
purged with N2 for 3 times. Then the mixture was heated and stirred at 120 C
for 1 h under N2
atmosphere. LCMS showed the reaction was completed and desired MS observed. 4
parallel
reactions were combined for work up. The reaction mixture was filtered and the
filtrate was
concentrated under reduced pressure to give a residue. The residue was
triturated with MTBE (10
mL) at 25 C for 10 min to give methyl 2-[4-[[4-carbamoy1-1-(trans-4-cy
anotetrahydro-2H-pyran-
3-y1) pyrazol-3-yflamino]-2- (5,5-dimethy1-1,3,2-dioxaborinan-2-
yl)phenyflacetate (1.30 g) as a
brown solid.
[0358]
42.5 Preparation of 1-Itrans-4-cyanotetrahydro-211-pyran-3-y11-34(1-hydroxy-
3,4-dihydro- 2,1-
benzoxaborinin- 7-y0 amin ofryrazole-4-carboxamide
223
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
OcN 0
N¨N CO2Me NaBH4
N¨N
,0 THF, Me0H
N
0-25 C, 1 h
0
OH
NH2 0
N H2
To a solution of methyl 2-[4-[[4-carbamoy1-1-(trans-4-cyanotetrahydro-2H-pyran-
3-yl)pyrazol-3-
yl] amino]-2-(5,5-dimethy1-1,3,2-dioxaborinan-2-yl)phenydacetate (1.30 g, 2.62
mmol, 1 eq) in
THF (20 mL) and Me0H (4 mL) was added NaBH4 (496 mg, 13 mmol, 5 eq) at 0 C.
The resulting
mixture was stirred at 25 C for 1 h. LCMS showed the reaction was completed
and desired MS
observed. The mixture was adjusted pH=4 with 2N HC1 and stirred for 30 min.
LCMS showed
the reaction was completed and desired MS observed. The mixture was quenched
with H20 (100
mL) at 0 C and extracted with ethyl acetate (30 mL x 3). The combined organic
phase was washed
with brine (50 mL), dried with anhydrous Na2SO4, filtered and concentrated in
vacuum to give the
residue. The residue was purified by prep-HPLC (column: Waters Xbridge BEH C18
100*30mm*10um; mobile phase: [water(1 OmM NE-14HCO3)-ACN];B%: 20%-50%,10min)
to give
1- [trans-4-cy anotetrahy dro-2H-pyran-3 -yl] -3- [(1-hydroxy-3 ,4-di hy dro-
2,1 -b enzoxab orinin-7-
yl)amino]pyrazole-4-carboxamide (640 mg, yield 93.84%, purity 98%) as a white
solid, which
was further separated by SFC (column: DAICEL CHIRALPAK
IC(250mm*30mm,10um);mobile
phase: [Neu-IPA];B%: 40%-40%,8min) to give 1- [trans-4-cyanotetrahydro-2H-
pyran-3-y1]-3-
[(1-hydroxy-3,4-dihydro-2,1-b enzoxab orinin-7-yl)amino]pyrazole-4-carb
oxamide (stereoisomer
one) (260 mg, 25.9% yield, 100% ee, first peak, Rt = 2.120 min) as a white
solid. 1H NMR
(DMSO-d6, 400 MHz) 6 = 9.12 (s, 1H), 8.38 (s, 1H), 8.28 (s, 1H), 7.80 (dd, J=
2.4, 8.2 Hz, 1H),
7.70 (s, 1H), 7.54 (d, J= 2.4 Hz, 1H), 7.18 (s, 1H), 7.12 (d, J= 8.3 Hz, 1H),
4.55 (dt, J= 4.4, 10.1
Hz, 1H), 4.06 ¨4.02 (m, 3H), 3.93 ¨ 3.90 (m, 1H), 3.71 - 3.65 (m, 2H), 3.49 -
3.44 (m, 1H), 2.79
(t, .1 = 5.8 Hz, 2H), 2.18 - 2.14 (m, 1H), 2.03 - 1.93 (m, 1H) MS (ESI): mass
calculated for
C18H20BN504, 381.16, m/z found 382.2 [M+I-1] . HPLC: 99.16% (220 nm), 100%
(254 nm). and
1- [trans-4-cy anotetrahy dro-2H-pyran-3 -yl] -3- [(1-hydroxy-3 ,4-di hy dro-
2,1 -b enzoxab orinin-7-
yl)amino]pyrazole-4-carboxamide (stereoisomer two) (262 mg, 26.1% yield, 100%
cc, second
peak, Rt = 2.521 min) as a white solid. 1H NMR (DMSO-d6, 400 MHz) 6 = 9.12 (s,
1H), 8.38 (s,
1H), 8.28 (s, 1H), 7.80 (dd, J= 2.4, 8.2 Hz, 1H), 7.70 (s, 1H), 7.54 (d, J=
2.4 Hz, 1H), 7.18 (s,
1H), 7.12 (d, J= 8.3 Hz, 1H), 4.55 (dt, J= 4.4, 10.1 Hz, 1H), 4.06 ¨ 4.01 (m,
3H), 3.93 ¨ 3.90 (m,
1H), 3.71 -3.62 (m, 2H), 3.49 - 3.43 (m, 1H), 2.79 (t, J= 5.8 Hz, 2H), 2.18 -
2.14 (m, 1H), 2.03 -
224
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
1.99 (m, 1H) MS (ESI): mass calculated for C1sH2oBN504, 381.16, m/z found
382.2 [M+H]t
HPLC: 99.53% (220 nm), 99.84% (254 nm).
[0359]
43. Preparation of 3-1(4-chloro-2-hydroxy-1,2-benzoxaborinin-6-yl)amino] -
14trans-4-
cyanotetrahydro-21-1-pyran-3-yllpyrazole-4-carboxamide
Cr[N
0
OP OH
SEMCI, NaH 0
a 'SEM EE¨TMS 0
____________________________________________ Br 0 'SEM
n-BuLi, B(01Pr), HOB 14 0 SEM
N-----4(NH NH2 2
Br I THF, 0-20 C, 2 h Br .1LIIIIIIF I
Pd(PPh3)2Cl2 TMS OH TMS -40 C, 1 h \ Cu(OAc)2, Pyridine
TEA, 20 C, 1 h
DMA, 20-35 C, 161
0QN
K2CO3 BCI3 , DCM 0õOH
\
N¨N s,. 0, __ . p, B
1.1 'SEM Me0H, 20 C, 2 H 20 C, 1 h 0
H \ N 44.1111P
H \
\ N
H
[0360]
43.1 Preparation of 2-[(4-hromo-2-iodo-phenoxy)methoxy] ethyl-trimethybsilane
0 OH
SEMCI, NaH 0 o,SEM
Br I THE, 0-20 C, 2 h Br I
To a mixture of 4-bromo-2-iodo-phenol (20.0 g, 66.9 mmol, 1 eq) in THF (200
mL) was added
NaH (4.01 g, 100 mmol, 60% purity, 1.5 eq) portion-wise at 0 C under N2. The
mixture was stirred
at 0 C for 1 h. Then to this mixture was added drop-wise (2-(chloromethoxy)
ethyl)trimethylsilane
(73.6 mmol, 13.0 mL, 1.1 eq) at 0 C. The reaction was allowed to warm to 20 C
and stirred at
20 C for 1 h. TLC showed the reaction was completed. The reaction mixture was
poured into sat.
aq. NH4C1 (200 mL) and extracted with ethyl acetate (100 mL x 3). The combined
organic phase
was washed with brine (200 mL x 2), dried with anhydrous Na2SO4, filtered and
concentrated in
vacuum to give a residue. The residue was purified by flash silica gel
chromatography (ISCO ,
330g SepaFlashe Silica Flash Column, Eluent of 0-25% Ethyl acetate/Petroleum
ether gradient
@ 100 mL/min) to give 2-[(4-bromo-2-iodo-phenoxy)methoxy] ethyl-trimethyl-
silane (27.0 g,
94.0% yield) as yellow oil. 'El NMR (CDC13, 400 MHz) 6 7.89 (d, J = 2.4 Hz,
1H), 7.39 (dd, J =
8.8 Hz, 2.4 Hz, 1H), 6.97 (d, J= 8.8 Hz, 1H), 5.27 (s, 2H), 3.78 (t, J= 8.4
Hz, 2H), 0.95 (t, J= 8.0
Hz, 2H), 0.01 (s, 9H).
225
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
[0361]
43.2 Preparation of 2[5-bromo-2-(2-trimethylsilylethoxymethoxy)phenyllethynyl-
trimethyl-
silane
o SEM TMS A SEM
Br
Br I Pd(PPh3)2C12, Cul
TMS
TEA, 20 C, 1 h
To a mixture of 2-[(4-bromo-2-iodo-phenoxy)methoxy]ethyl-trimethyl-silane
(27.0 g, 62.9 mmol,
1 eq) and ethynyl(trimethyl)silane (189 mmol, 26.2 mL, 3 eq) in THF (300 mL)
was added a
solution of CuI (1.20 g, 6.29 mmol, 0.1 eq), Pd(PPh3)2C12 (2.21 g, 3.15 mmol,
0.05 eq) and TEA
(440 mmol, 61.3 mL, 7 eq) in THF (100 mL) drop-wise at 20 C under N2. The
mixture was stirred
at 20 C for 1 h. LCMS showed the reaction was completed and desired MS
observed. The reaction
mixture was quenched with sat. aq. NH4C1 (300 mL), and extracted with ethyl
acetate (100 mL x
3). The combined organic phase was washed with brine (150 mL x 2), dried with
anhydrous
Na2SO4, filtered and concentrated in vacuum to give a residue. The residue was
purified by flash
silica gel chromatography (ISCOO; 330 g SepaFlash Silica Flash Column, Eluent
of 0-10%
Ethyl acetate/Petroleum ether gradient @ 100 mL/min) to give 2-[5-bromo-2-(2-
trimethylsilylethoxymethoxy)phenyl]ethynyl- trimethyl-silane (23.5 g, 93.5%
yield) as brown oil.
1H NMR (CDC13, 400 MHz) 6 7.55 (d, J= 2.4 Hz, 1H), 7.34 (dd, J= 9.2 Hz, 2.8
Hz, 1H), 6.99 (d,
J= 8.8 Hz, 1H), 5.27 (s, 2H), 3.80 (t, J= 8.4 Hz, 2H), 0.96 (t, J= 8.4 Hz,
2H), 0.26 (s, 9H), 0.02
(s, 9H).
[0362]
43.3 Preparation of 14-(2-trimethylsilylethoxymethoxy)-3-(2-
trimethylsilylethynAphenyll
boronie acid
o,SEM 41) o,SEM
n-BuLi, B(0iPr)3
HO..
B
Br
THF, -40 C, 1 h
TMS TMS
To a solution of 2-[5-bromo-2-(2-trimethylsilylethoxymethoxy)phenyl]ethynyl-
trimethyl-silane
(10.0 g, 25.0 mmol, 1 eq) and triisopropyl borate (30.0 mmol, 6.91 mL, 1.2 eq)
in THF (100 mL)
was added n-BuLi (2.5 M, 22.0 mL, 2.2 eq) at -40 C under N2. The mixture was
stirred at -40 C
for 1 h. TLC showed the reaction was completed. The reaction mixture was
quenched by sat. aq.
NH4C1 (100 mL) at 0 C, and extracted with ethyl acetate (50 mL x 3). The
combined organic
226
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
layers were washed with brine (80 mL x 3), dried over Na2SO4, filtered and
concentrated under
reduced pressure to give a residue. The residue was purified by flash silica
gel chromatography
(ISCOO; 80 g SepaFlash Silica Flash Column, Eluent of 0-50% Ethyl
acetate/Petroleum ether
gradient @ 100 mL/min) to give [4-(2-trimethylsilylethoxymethoxy)-3-(2-
trimethylsilylethynyl)phenyl] boronic acid (7.00 g, 61.3% yield, 80% purity)
as a white solid. 1H
NMR (CDC13, 400 MHz) 6 8.28 (s, 1H), 8.12 (dd, J= 8.4 Hz, 1.2 Hz, 1H), 7.22
(d, J= 8.4 Hz,
1H), 5.39 (s, 2H), 3.86 (t, J= 8.4 Hz, 2H), 0.99 (t, J= 8.4 Hz, 2H), 0.32 (s,
9H), 0.03 (s, 9H).
[0363]
43.4 Preparation of 1-(trans-4-cyanotetrahydro-2H-pyran-3-
y1)- 3-1442-
trimethylsilylethoxymethoxy) -3-(2-trimethylsilylethynyl)anilinolpyrazole-4-
carboxamide
ON ON
0
N- NH2
o,SEM NH2
HO, v. N-N o,SEM
Cu(OAc)2, Pyridine
OH TMS DMA, 20-35 C, 16 h
0 TMS
NH2
To a mixture of [4-(2-trimethylsilylethoxymethoxy)-3-(2-
trimethylsilylethynyl)phenyl]boronic
acid (4.05 g, 10.0 mmol, 90% purity, 1 eq) and 3-amino-1-(trans-4-
cyanotetrahydro-2H-pyran-3-
yl) pyrazole-4-carboxamide (2.52 g, 10.7 mmol, 1.07 eq) in DMA (100 mL) was
added Cu(OAc)2
(4.54 g, 25.0 mmol, 2.5 eq) and Pyridine (50.0 mmol, 4.04 mL, 5 eq) at 20 C
under air. The mixture
was heated and stirred at 35 C for 16 h. LCMS showed the reaction was
completed and desired
MS observed. 4 parallel reactions were combined for work up. The reaction
mixture was filtered
and the filtrate was concentrated in vacuum to give a residue. H20 (100 mL)
was added to the
residue and then extracted with ethyl acetate (100 mL x 3). The combined
organic layers were
washed with brine (100 mL x 3), dried over Na2SO4, filtered and concentrated
under reduced
pressure to give a residue. The residue was purified by flash silica gel
chromatography (ISCOO;
120 g SepaFlash Silica Flash Column, Eluent of 0-50% Ethyl acetate/Petroleum
ether gradient
@ 100 mL/min) to give 1 -(tran s-4-cy anotetrahy dro-2H-
pyran-3 -y1)- 3- [4-(2-
trim ethylsilylethoxymethoxy)-3 -(2-trimethyl silyl ethynyl)anilino]pyrazol e-
4-carb oxamide (6 g,
54.1% yield) as a yellow solid.
1H NMR (CDC13, 400 MHz) 68.64 (s, 1H), 7.75 (s, 1H), 7.58 (d, J= 2.8 Hz, 1H),
7.48 (ddõI =
227
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
9.2 Hz, 2.8 Hz, 1H), 7.05 (d, J= 9.2 Hzõ 1H), 5.49 (br s, 2H), 5.25 (s, 2H),
4.23-4.18 (m, 1H),
4.16-4.10 (m, 1H) 4.06-4.01 (m, 2H), 3.83 (t, J= 8.4, Hz, 2H), 3.66-3.56 (m,
2H), 2.17-2.09 (m,
1H), 2.05-1.99 (m, 1H), 0.98 (t, J= 8.4, Hzõ 2H), 0.27 (s, 9H), 0.03 (s, 9H).
[0364]
43.5 Preparation of 1-(trans-4-cyanotetrahydro-2H-pyran-3-y0 -3[3-ethyny1-4-
(2-
trimethylsilylethoxymethoxy)anifinolpyrazole-4-carboxamide
K2CO3
N-N 410) o,SEM N-N Si o,SEM
Me0H, 20 C, 2 H
N
0 TMS 0
NH2 NH2
To a mixture of 1-(trans-4-cyanotetrahydro-2H-pyran-3-y1)-3-[4-(2-
trimethylsilylethoxymethoxy)
-3-(2-trimethylsilylethynyl)anilino]pyrazole-4-carboxamide (2.8 g, 5.06 mmol,
1 eq) in Me0H
(100 mL) was added K2CO3 (489 mg, 3.54 mmol, 0.7 eq) at 20 C. The mixture was
stirred at 20 C
for 2 h. LCMS showed the reaction was completed and desired MS observed. 2
parallel reactions
were combined for work up. The reaction mixture was quenched with H20 (60 mL),
adjusted pH
to 7 with 2 N HC1 at 0 C and extracted with ethyl acetate (30 mL x 3). The
combined organic
layers were washed with brine (35 mL x 3), dried over Na2SO4, filtered and
concentrated under
reduced pressure to give 1-(trans-4-cyanotetrahy dro-2H-pyran-3 -y1) -3- [3 -
ethynyl -4-(2-
trimethylsilylethoxymethoxy)anilino]pyrazole-4-carboxamide (4.30 g 88.2%
yield) as a yellow
solid. H NMR (DMSO-d6, 400 MHz) 6 9.02 (s, 1H), 8.28 (s, 1H), 7.73-7.66 (m,
1H), 7.56-7.52 (m,
2H), 7.18 (hr s, 1H), 7.08 (d, J= 8.8, Hz, 1H), 5.21 (s, 2H), 4.56 (td, J=
10.4, Hz, 1H), 4.20 (s,
1H), 4.05-4.02 (m, 1H), 3.92-3.89 (m, 1H), 3.74 (t, J= 8.4, Hz, 2H), 3.67-3.59
(m, 2H), 3.48-3.43
(m, 1H), 2.17-2.13 (m, 1H), 2.03-1.96 (m, 1H), 0.89 (t,,/ = 8.0, Hzõ 2H),
0.02(s, 9H).
[0365]
43.6 Preparation of chiral 3-[(4-ehloro-2-hydroxy-1,2-benzoxaborinin-6-Aaminol
-14trans-4-
cyanotetrahydr-2H-opyran-3-yllpyrazole-4-carboxamide
228
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
BCI3,DCM 0õOH
N-N i
o,SEM N-NiL B
0-20 C, 1 h
YLN
0 0 CI
NH2 NH2
To a solution of BC13 (1 M, 10.38 mL, 10 eq) was added 1-(trans-4-
cyanotetrahydro-211-pyran-3-
y1) -3 -[3 -ethynyl-4-(2-trimethylsilylethoxymethoxy)anilino]pyrazole-
4-carboxamide (500 mg,
1.04 mmol, 1 eq) at 0 C. The reaction was allowed to warm to 20 C and stirred
at 20 C for 1 h.
LCMS showed the reaction was completed and desired MS observed. 5 parallel
reactions were
combined for work up. The reaction mixture was quenched by H20 (150 mL) and
extracted with
ethyl acetate (50 mL x 3). The combined organic layers were washed with brine
(30 mL x 3), dried
over Na2SO4, filtered and concentrated under reduced pressure to give a
residue. The residue was
purified by prep-HPLC (column: Phenomenex luna C18 250*50mm*10 um;mobile
phase:
[water(TFA)-ACN];B%: 25%-55%, 10mi n) to give 3 -[(4-chl oro-2-hy droxy-1,2-b
enzox ab orini n-6-
yl)amino]-1-(trans-4- cyanotetrahydro-2H-pyran-3-yl)pyrazole-4-carboxamide
(550 mg, 25.6%
yield, 99.4% purity) as an off white solid, which was further separated by SFC
(column: DAICEL
CHIRALPAK AD(250mm*30mm,10um); mobile phase: [Neu-ETOH];B%: 44%-44%,7min) to
give 3-[(4-chloro-2-hydroxy-1,2-benzoxaborinin-6-yl)amino]-1-[trans-
4-cyanotetrahydro-2H-
pyran-3-yl]pyrazole-4-carboxamide (stereoisomer one) (221 mg, 10.1% yield,
98.1% purity, 100%
ee ,first peak, Rt = 1.301 min) as an off white solid. 11-1 N1VIR (DMSO-d6,
400 MHz) 6 9.17 (br s,
1H), 9.16 (s, 1H), 8.31 (br s, 1H), 8.29 (d, J= 2.8 Hz, 1H), 7.71 (br s, 1H),
7.55 (dd, J = 8.4 Hz,
2.8 Hz, 1H), 7.29-7.09 (m, 2H), 6.30 (s, 1H), 4.60 (td, J= 10.4 Hz, 1H), 4.07
(dd, J= 11.2 Hz, 4.0
Hz, 1H), 3.93 (d, J= 9.2 Hz, 1H), 3.70 (t, J= 10.0 Hz, 1H), 3.62 (td, J = 11.2
Hz, 1H), 3.44-3.39
(m, 1H), 2.21-2.17 (m, 1H), 2.04-1.94 (m, 1H). MS (ESI): mass calculated for
C481-147BC1N504
413.11, m/z found 414.1 [M-FH]'. HPLC: 98.14% (220 nm), 99.03% (254 nm) and 3-
[(4-chloro-
2-hydroxy- 1,2-b enz oxab orini n-6-yl)amino] -1- [tran s-4-cyanotetrahy dro-
2H-pyran-3 -yl] py razol e-
4-carb oxamide (stereoisomer two) (220 mg, 10.1% yield, 99.0% purity, 100% ee,
second peak, Rt
= 1.440 min) as an off-white solid. 1H NMR (DMSO-d6, 400 MHz) 6 9.17 (br s,
1H), 9.16 (s, 1H),
8.31 (br s, 1H), 8.29 (d, = 2.8 Hz, 1H), 7.74 (br s, 1H), 7.56 (dd, .1= 9.2
Hz, 2.8 Hz, 1H), 7.27-
7.09 (m, 2H), 6.30 (s, 1H), 4.60 (td, .1= 10.0 Hz, 1H), 4.07 (dd, .1= 11.2 Hz,
4.4 Hz, 1H), 3.94 (d,
= 11.2 Hz, 1H), 3.71 (t, J= 10.4 Hz, 1H), 3.61 (td, J= 14.8 Hz, 1H), 3.43-3.40
(m, 1H), 2.23-
2.16 (m, 1H), 2.03-1.95 (m, 1H). MS (ESI): mass calculated for C481-147BC1N504
413.11; m/z found
229
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
414.1 [M-41] . HPLC: 99.00% (220 nm), 99.47% (254 nm).
[0366]
44. Preparation of 1-[trans-4-eyanotetrahydro-2H-pyran-3-y11-3-[(8-fluoro-2-
hydroxy-1,2 -
benzoxaborinin-6-yl)aminolpyrazole-4-earboxamide
00 OH NBS 40 OH PinB"--ThPin OH Ir(PPY)3
1110
B
MeCN, NH40Ac LDA, PMDTA, THF
,0 WON, 25 C, 16h
Br Br Br
20 C, 2 h 0-25 C, 1 h
0
cc>Ni.N_NrH,N,Hz 0 õ õ N F
0 A N-N 0 BõOH
Pd2(dba)2, tBuXPhos, KOAc,
iPrOH, 20-80 C, 12 h
0
NH2
[0367]
44.1 Preparation of 5-bromo-3-fluoro-2-hydroxy-benzaldehyde
OH NBS I. OH
0 MeCN, NH40Ac
Br
20 C, 2 h
To a mixture of 3-fluoro-2-hydroxy-benzaldehyde (5.00 g, 35.7 mmol, 1 eq) in
CH3CN (80 mL)
was added NH40Ac (275 mg, 3.57 mmol, 0.1 eq) and NBS (6.99 g, 39.3 mmol, 1.1
eq) at 20 C
under N2. The mixture was stirred at 20 C for 2 h. TLC showed the reaction was
completed. The
reaction mixture was concentrated in vacuum to give a residue. The residue was
purified by flash
silica gel chromatography (ISC0a); 80g SepaFlashe Silica Flash Column, Eluent
of 0-10% Ethyl
acetate/Petroleum ether gradient @ 75 mL/min) to give 5-bromo-3-fluoro-2-
hydroxy-
benzaldehyde (7.05 g, 95.9% yield) as a yellow solid. 1H NMR (CDC13, 400 MHz)
6 10.89 (s, 1H),
9.88 (s, 1H), 7.54-7.52 (m, 1H), 7.52-7.48 (m, 1H).
[0368]
44.2 Preparation of 4-bromo-2-fluoro-64(E)-2-(4,4,5,5-tetramethy1-1,3,2-
dioxaborolan-2-y1)
vinyllphenol
230
CA 03201608 2023-6-7
WO 2022/133420
PCT/US2021/072885
OH __________________________________________________ 40 OH
o LDA, PMDTA,
THF 0
Br 0-25 C, 1 h Si 131.<
To a mixture of LDA (2 M, 28.5 mL, 2.5 eq) in THF (50 mL) was added N'42-
(dimethylamino)ethy1]-N,N,N'-trimethyl-ethane-1,2-diamine (7.91 g, 45.7 mmol,
9.53 mL, 2 eq)
and a solution of 4,4,5,5-tetramethy1-2-[(4,4,5,5-tetramethy1-1,3,2-
dioxaborolan -2-yl)methyl[-
1,3,2-di oxaborolane (12.2 g, 45.7 mmol, 2 eq) in TFW (60 mL) at 0 C under N2.
The mixture was
stirred at 0 C for 20 min. Then dropwise added a solution of 5-bromo-3-fluoro-
2-hydroxy-
benzaldehyde (5 g, 22.8 mmol, 1 eq) in THF (40 mL) at 25 C. The mixture was
continue stirred
at 25 C for 40 min. LCMS showed the reaction was completed and desired MS
observed. The
reaction was quenched by sat aq. NH4C1 (100 mL) and extracted with Et0Ac (80
mL x 3). The
combined organic phase was washed with brine (100 mL x 3), dried over Na2SO4,
filtered and
concentrated under reduced pressure to give a residue. The residue was
purified by flash silica gel
chromatography (ISCOR; 80 g SepaFlash Silica Flash Column, Eluent of 0-10%
Ethyl
acetate/Petroleum ether gradient @ 75mL/min) to give 4-bromo-2-fluoro-6-[(E)-2-
(4,4,5,5-
tetramethy1-1,3,2-dioxaborolan-2-y1) vinyl]phenol (8 g, 63.3% yield, 62%
purity) as yellow oil.
1_14 NMR (DMSO-d6, 400 MHz) 6 7.58 (d, J= 18.8 Hz, 1H), 7.42 (s, 1H), 7.17
(dd, J' 9.6 Hz, 2.4
Hz, 1H), 6.22 (d, ,/ = 18.4 Hz, 1H), 5.58 (br s, 11-1) 1.32 (s, 12H).
[0369]
44.3 Preparation of 6-bromo-8- fluoro-2-hydroxy-1,2-benzoxaborinine
is OH Ir(PPY)3 ask. 0õOH
B
o MeCN, 25 C, 16 h
11.11
Br Br
0
To a mixture of (E)-4-b rom o-2-fluoro-6-(2-(4,4, 5,5-tetram ethy1-1
,3 ,2-di oxab orol an -2-
yl)vinyl)phenol (2.70 g, 4.88 mmol, 62% purity, 1 eq) in MeCN (30 mL) was
added tris[2-(2-
pyridyl)phenylliridium (79.8 mg, 122 umol, 0.025 eq) in one portion at 25 C
under N2. The
reaction was stirred and irradiated using 34W blue LED lamps for 16 h. TLC
showed the reaction
was completed. 3 parallel reactions were combined for work up. The reaction
was concentrated
under reduced pressure to give a residue. The residue was purified by flash
silica gel
231
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
chromatography (ISCOg; 40 g SepaFlash Silica Flash Column, Eluent of 0-20%
Ethyl
acetate/Petroleum ether gradient @ 75 mL/min) to give 6-bromo-8- fluoro-2-
hydroxy-1,2-
benzoxaborinine (4.00 g, 90.0% yield) as a yellow solid. 1H NMR (DMSO-do, 400
MHz) 6 9.42
(s, 1H), 7.79 (d, J= 12.0 Hz, 1H), 7.67-7.63 (m, 2H), 6.27 (d, J= 12.0 Hz,
1H).
[0370]
44.4 Preparation of 1-[trans-4-cyanotetrahydro-2H-pyran-3-y11-3-[(8-fluoro-2-
hydroxy-1,2 -
benzoxaborinin-6-yl)aminokyrazole-4-earboxamitle
?/ 0
Cr\IN\1:4;12 ¨N
0,B4OH NH2
jj
0 OH
0 A
Br Pd2(dba)3, tBuXPhos, KOAc,
iPrOH, 20-80 C, 12 h 0
NH2
To a mixture of 3 -am i n o-1 -(trans-4-cy an otetrahy dro-2H-pyran-3 -yl
)pyrazol e-4-carb ox am i de (500
mg, 2.13 mmol, 1 eq) and 6-bromo-8-fluoro-2-hydroxy-1,2-benzoxaborinine (516
mg, 2.13 mmol,
1 eq) in i-PrOH (12 mL) was added t-BuXphos (162 mg, 383 umol, 0.18 eq), KOAc
(417 mg,
4.25 mmol, 2 eq) and Pd2(dba)3 (175 mg, 191 umol, 0.09 eq) in one portion at
20 C under N2. The
mixture was heated and stirred at 80 C for 12 h. LCMS showed the reaction was
completed and
desired MS observed. 2 parallel reactions were combined for work up. The
mixtrue was filtered
and the filtrate concentrated in vacuum to give a residue. The residue was
dissolved in H20 (20
mL), adjusted pH to 7 with 2H HC1 at 0 C, and then extracted with Et0Ac (10 mL
x 3). The
combined organic layers were washed with brine (10 mL x 3), dried over Na2SO4,
filtered and
concentrated under reduced pressure to give a residue. The residue was
triturated with DCM (20
mL) at 25 C to give 1-(trans-4-cyanotetrahydro-2H-pyran-3-y1)-3-[(8-fluoro-2-
hydroxy-1,2-
benzoxaborinin -6-yl)amino]pyrazole-4-carboxamide (600 mg, 33.8% yield, 95.1%
purity) as a
yellow solid, which was further separated by SFC (column: DAICEL CHIRALPAK
IC (250mm*3 0mm,10um);mobil e phase: [Neu-ETOH] ;B%: 35%-35%,10min) to give 1 -
[trans-4-
cyanote trahy dro-2H-py ran-3 -y1]-3 - [(8-fluoro-2-hydroxy- 1,2-
benzoxaborinin-6-
yl)amino]pyrazole-4-carboxamide (stereoisomer one) (200 mg, 11.5% yield, 97.1%
purity, 100%
ee , first peak, Rt = 1.822 min) as a yellow solid. 1FINMR (DMSO-d6, 400 MHz)
6 9.18 (s, 1H),
9.12 (s, 1H), 8.30 (s, 1H), 7.81 (d, J= 11.6 Hz, 1H), 7.76-7.65 (m, 2H), 7.41
(s, 1H), 7.20 (br s,
1H), 6.18 (d, J= 12.0 Hz, 1H), 4.57 (td, J= 10.0 Hz, 1H), 4.03 (dd, J= 11.2
Hz, 4.0 Hz, 1H), 3.91
232
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
(br d, J= 10.4 Hz, 1H) 3.75-3.66 (m, 2H), 3.51 (t, J= 11.6 Hz, 1H), 2.20-2.12
(m, 1H), 2.04-1.95
(m, 1H). MS (ESI): mass calculated for C18H17BFN504 397.14, m/z found 398.2 [M-
l-H]t HPLC:
97.13% (220 nm), 98.26% (254 nm) and 1-[trans-4-cyanotetrahydro-2H-pyran-3-y1]-
3-[(8-fluoro-
2-hydroxy-1,2-benzoxaborinin-6-yl)amino]pyrazole-4-carboxamide (stereoisomer
two) (181.7
mg, 10.5% yield, 98.0% purity, 100% ee, second peak, Rt = 2.151 min) as a
yellow solid. N1VIR
(DMSO-d6, 400 MHz) 6 9.21 (s, 1H), 9.12 (s, 1H), 8.30 (s, 1H), 7.81 (d, J=
11.2 Hz, 1H), 7.77-
7.65 (m, 2H), 7.41 (s, 1H), 7.20 (br s, 1H), 6.18 (d, J= 12.0 Hz, 1H), 4.57
(td, J= 10.4 Hz, 1H),
4.03 (dd, J= 10.8 Hz, 3.6 Hz, 1H),3.96-3.83 (m, 1H) 3.75-3.66 (m, 2H), 3.51
(t, J= 12.4 Hz, 1H),
2.20-2.15 (m, 1H), 2.04-1.95 (m, 1H). MS (ESI): mass calculated for
C181117BFN504 397.14, m/z
found 398.2 [M+H]t. HPLC: 98.00% (220 nm), 99.19% (254 nm).
[0371]
45. Preparation of Htrans-2-cyanocyclopenty1]-34(8-flaoro-2-hydroxy-3-methyl-
1,2-
benzoxaborinin-6-Aaminokyrazole-4-carboxamide
0 A NH2
00 0.õ.õ,B_OH NH2
N--Ti
0...B4OH
Pd2dba3, tBuXPhos, KOAc. iPrOH
Br
80 C, 12 h 0 NH2
To a mixture of 6-bromo-8-fluoro-2-hydroxy-3-methyl-1,2-benzoxaborinine (500
mg, 1.95 mmol,
1 eq) and 3-amino-1-(trans-2-cyanocyclopentyl)pyrazole-4-carboxamide (513 mg,
2.34 mmol, 1.2
eq) in i-PrOH (10 mL) was added t-Bu Xphos (165 mg, 390 umol, 0.2 eq), KOAc
(478 mg, 4.88
mmol, 2.5 eq) and Pd2(dba)3 (178 mg, 195 umol, 0.1 eq) in one portion at 20 C
under N2. The
mixture was heated to 80 C and stirred at 80 C for 12 h. LCMS showed the
reaction was
completed and desired MS observed. The reaction mixture was filtered and
concentrated under
reduced pressure to give a residue. The residue was purified by prep-HPLC
(column: Ph en om en ex
luna C18 (250*70mm,15 um);mobile phase: [water(HC1)-ACN];B%: 25%-55%,20min) to
give
desired compound (1.00 g, yield 52%, purity 95.3%) as a white solid, which was
further separated
by SFC (condition: column: DAICEL CHIRALPAK IC(250mm*30mm,10um);mobile phase:
[Neu-IPA] B%: 40%-40%,10min) to give 1-[trans-2-cyanocyclopenty1]-3-[(8-fluoro-
2-hydroxy-
3-methyl-1,2-benzoxaborinin-6-yl)amino] pyrazole-4-carboxamide (stereoisomer
one) (223 mg,
14.5% yield, 100% ee, first peak, Rt = 2.034 min) as a white solid. 1H NMR
(DMSO-d6, 400 MHz)
233
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
6 9.12 (s, 1H), 9.09 (s, 1H), 8.29 (s, 1H), 7.62 (dd, J= 2.4, 13.2 Hz, 2H),
7.45 (s, 1H), 7.35 (d, J=
1.2 Hz, 1H), 7.15 (br s, 1H), 4.88 (q, J= 8.0 Hz, 1H), 3.42-3.41 (m, 1H), 2.34-
2.33 (m, 1H), 2.23-
2.19 (m, 1H), 2.12-2.05 (m, 1H), 1.95 (d, J=0.8 Hz, 3H), 1.97-1.89 (m, 3H). MS
(ESI): mass
calculated for Ci9H19BFN503, 395.20, m/z found 396.2 [M+H]. HPLC: 98.72% (220
nm), 99.54
(254 nm). and 14-trans-2-cyanocyclopentyl]-3- [(8-fluoro-2-hydroxy-3-methy1-
1,2-
benzoxaborinin-6-yl)amino]pyr azole-4-carboxami de (stereoisomer two) (210 mg,
13.6% yield,
99.7% ee, second peak, Rt = 2.291 min) as a white solid. 1H NMR (DMSO-do, 400
MHz) 6 9.12
(s, 1H), 9.09 (s, 1H), 8.29 (s, 1H), 7.62 (dd, J= 2.4, 13.2 Hz, 2H), 7.46 (s,
1H), 7.35 (d, J= 1.2
Hz, 1H), 7.16 (br s, 1H), 4.88 (q, J= 8.0 Hz, 1H), 3.42-3.40 (m, 1H), 2.34-
2.33 (m, 1H), 2.27-2.19
(m, 1H), 2.12-2.01 (m, 1H), 1.95 (d, J=0.8 Hz, 3H), 1.95-1.89 (m, 3H). MS
(ESI): mass calculated
for C19H19BFN503, 395.20, m/z found 396.2 [M-FfI]. HPLC: 96.61% (220 nm),
99.33% (254 nm).
[0372]
46. Preparation of 1-(trans-4-cyanotetrahydro-2H-pyran-3-y1)-342-hydroxy-7-
methyl-2H-
benzole 1[1,2Joxaborinin-6-Aamino)-1H-pyrazole-4-earboxamide
Br (HCHO)n, MgC12, TEA OH Pine''BPin B1 OH
IrIPPY)3
LD
HO 414111P 70 C, 7h Br WI , is A,
PMDTA THF, Br MeCN, 25 C, 1617 Br el I
0-25 C, 1
NI-12 Og
0 A OBOH
N¨N
Pc12(dba)3, tBuXPhos, KOAc, iPrOH
80 C, 12h
0 NH2
[0373]
46.1 Preparation of 5-bromo-2-hydroxy-4-methylbenzaldehyde
001 Br (HCHO)n, MgC12, TEA
401 OH
HO 70 C, 7h Br
1 2
A mixture of 4-bromo-3-methyl-phenol (10 g, 53.4 mmol, 1 eq), HCHO (8.0 g, 267
mmol, 5 eq),
TEA (10.8 g, 106 mmol, 2 eq) and MgCl2 (7.6 g, 80.2 mmol, 1.5 eq) in MeCN (100
mL) was
degassed and purged with N2 for 3 times. The mixture was stirred at 70 C for 7
hrs under N2
atmosphere. TLC showed the reaction was completed. The reaction mixture was
quenched with
H20 (100 mL) and extracted with Et0Ac (50 mLx3). The combined organic layers
were washed
234
CA 03201606 2023- 6-7
WO 2022/133420
PCT/US2021/072885
with brine (50 mL), dried over anhydrous Na2SO4, filtered and concentrated
under reduced
pressure to give a residue. The residue was purified by silica gel column
chromatography
(Petroleum ether: Et0Ac = 100:1 to 10:1) to give 5-bromo-2-hydroxy-4-methyl-
benzaldehyde (10
g, 86.9% yield) as a yellow solid. 1H NMR (400 MHz, CHLOROFORM_-d) 6 = 10.87
(s, 1H), 9.80
(s, 1H), 7.69 (s, 1H), 6.91 (s, 1H), 2.43 (s, 3H).
[0374]
46.2 Preparation of 4-bromo-5-methy1-2-(2-(4,4,5,5-tetramethy1-1,3,2-
dioxaborolan-2-
Avinyi)phenol
001 OH PinBBPin OH
__________________________________________________ 30.
,0
Br LDA, PMDTA, THE, Br BPin
0-25 C, 1 h
To a mixture of LDA (2 M, 45 mL, 2.5 eq) in THF (100 mL) was added N'42-
(dimethylamino)ethyli-N,N,N'-trimethylethane-1,2-diamine (12.5 g, 72.5 mmol, 2
eq) and a
solution of 4õ4,5,5-tetram ethyl -2-[(4,4,5,5-tetram ethyl -1,3,2-di ox ab
orol an-2-yl)methyl ] -1,3,2-
dioxaborolane (19.4 g, 72.5 mmol, 2 eq) in THF (100 mL) at 0 C under N2. The
mixture was
stirred at 0 C for 20 min. Then dropwise added a solution of 5-bromo-2-hydroxy-
4-methyl-
benzaldehyde (7.8 g, 36.2 mmol, 1 eq) in THF (100 mL) at 25 C, the mixture was
stirred at 25 C
for 40 min. TLC showed the reaction was completed. The reaction mixture was
diluted with
aq.NH4C1 (200 mL) and extracted with Et0Ac (200 mL x 3). The combined organic
layers were
washed with brine (500 mL), dried over anhydrous Na2SO4, filtered and
concentrated under
reduced pressure to give a residue. The residue was purified by silica gel
column chromatography
(Petroleum ether: Et0Ac = 100:1 to 10:1) to give 4-bromo-5-methy1-2-[(E)-2-
(4,4,5,5-
tetramethy1-1,3,2-dioxaborolan-2-yl)vinyl]phenol (5.5 g, 44.7% yield) as a
yellow solid. 1H NMR
(400 MHz, CHLOROFORM-d) 6 = 7.59 (s, 1H), 7.55 (d, J = 18.4 Hz, 1H), 6.70 (s,
1H), 6.11 (d,
= 18.4 Hz, 1H), 2.31 (s, 3H), 1.31 (s, 121-1).
[0375]
46.3 Preparation of 6-bromo-2-hyclro_vy-7-methy1-1,2-benzo_vaborinine
235
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
OH Ir(PPY)3 0,B4OH
MeCN, 25 C, 16 h 140
Br BPin Br
To a mixture of 4-bromo-5-methy1-2-[(E)-2-(4,4,5,5-tetramethy1-1,3,2-
dioxaborolan-2-
yl)vinyl]phenol (5.4 g, 15.9 mmol, 1 eq) in MeCN (20 mL) was added tris[2-(2-
pyridyl)phenyl]iridium (260 mg, 0.398 mmol, 0.025 eq) in one portion at 25 C
under Nz. The
reaction was stirred and irradiated using 34W blue LED lamps for 16 h. TLC
showed the reaction
was completed. The reaction mixture was filtered and the filter cake was
washed with 5 mL of
MeCN. The filter cake was dried in vacuum to give 6-bromo-2-hydroxy-7-methy1-
1,2-
benzoxaborinine (3.3 g, 86.7% yield) as a yellow solid.
[0376]
46.4 Preparation of chiral 1-(trans-4-cyanotetrahydro-21-1-pyran-3-y0-342-
hydroxy-7-methyl-
2H-benzo[e][1,2]oxaborinin-6-yl)amino)-1H-pyrazole-4-earboxamide
0130H z
\o_rN
40 .-
0
0õOH
Br Pc12(dba), tBuXPhos, KOAc, iPrOH,
80 C, 12h
0
NH,
A mixture of 6-bromo-2-hydroxy-7-methyl-1,2-benzoxaborinine (3.3 g, 13.8 mmol,
1 eq) , 3-
amino-1-[trans-4-cyanotetrahydro-2H-pyran-3-yl]pyrazole-4-carboxamide (3.2 g,
13.8 mmol, 1
eq), KOAc (2.7 g, 27.6 mmol, 2 eq), t-Bu Xphos(1.2 g, 2.76 mmol, 0.2 eq) and
Pcl2(dba)3 (1.3 g,
1.38 mmol, 0.1 eq) in i-PrOH (50 mL) was degassed and purged with N2 for 3
times, and then
the mixture was stirred at 80 C for 12 h under N2 atmosphere. LCMS showed the
reaction was
completed and desired MS observed. The reaction mixture was quenched with H20
(100 mL)
and extracted with Et0Ac (50 mL x 3). The combined organic layers were washed
with brine
(50 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced
pressure. The
residue was purified by prep-HPLC (column: Phenomenex luna C18 (250*70mm,15
urn); mobile
phase: [water (HC1)-ACN];B%: 15%-45%,20min) to give 1-(trans-4-cyanotetrahydro-
2H-pyran-
3-y1)-3-42-hydroxy-7-methy1-2H-benzo[e][1,2]oxaborinin-6-yl)amino)-1H-pyrazole-
4-
carboxamide (600 mg, 98%purity) as a white solid. The product was further
separated by
SFC(column: REGIS(S,S)WITELK-01(250mm*25mm,10um); mobile phase: [Neu-ETOH];B%:
55%-55%,6min) to give 1-(trans-4-cyanotetrahydro-2H-pyran-3-y1)-34(2-hydroxy-7-
metby1-2H-
benzo[e][1,2]oxaborinin-6-yl)amino)-1H-pyrazole-4-carboxamide (stereoisomer
one) (236 mg,
236
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
47.2% yield, 99.1% purity, 99.7% ee , first peak, Rt = 1.513 min) as a white
solid 'H NIVIR (400
MHz, DMSO-d6)6 = 9.22 (s, 1H), 8.73 (s, 1H), 8.28 (d, J= 17.6 Hz, 2H), 7.84
(d, J= 11.4 Hz,
1H), 7.79-7.66 (m, 1H), 7.16 (br d, I= 1.2 Hz, 1H), 7.07 (s, 1H), 6.05 (d, .1=
11.4 Hz, 1H), 4.57
(dt, J= 4.4, 10.2 Hz, 1H), 4.05 (dd, J= 4.4, 11.2 Hz, 1H), 3.96-3.88 (m, 1H),
3.77-3.67 (m, 2H),
3.57-3.47 (m, 1H), 2.31 (s, 3H), 2.22-2.11 (m, 1H), 2.06-1.93 (m, 1H), MS
(ESI): mass
calculated for C19H20BN504, 393.16, m/z found 394.2[M+1-1]+. HPLC: 99.19% (220
nm),
99.51 (254 nm), and 1-(trans-4-cyanotetrahydro-2H-pyran-3-y1)-34(2-hydroxy-7-
methy1-2H-
benzo[e][1,2]oxaborinin-6-yl)amino)-1H-pyrazole-4-carboxamide (stereoisomer
two) (241.5 mg,
614 umol, 48.3% yield, 98.0% purity, 98.7% ee , second peak, Rt = 1.683 min)
as a white solid.
lEINIVIR (400 MHz, DMSO-d6) 6 = 9.22 (s, 1H), 8.74 (s, 1H), 8.31 (s, 1H), 8.26
(s, 1H), 7.85
(d, J= 12.0 Hz, 1H), 7.80-7.62 (m, 1H), 7.27 - 7.10 (m, 1H), 7.07 (s, 1H),
6.05 (d, J= 11.8 Hz,
1H), 4.58 (dt, J= 4.4, 10.2 Hz, 1H), 4.05 (dd, J= 4.4, 11.2 Hz, 1H), 3.98 -
3.88 (m, 1H), 3.79 -
3.67 (m, 2H), 3.57- 3.48 (m, 1H), 2.31 (s, 3H), 2.22 - 2.13 (m, 1H), 2.06-
1.94 (m, 1H), MS
(ESI): mass calculated for C19H20BN504, 393.16, m/z found 394.1[M+1-1]+, HPLC:
98.09%
(220 nm), 98.82 (254 nm).
[0377]
47. Preparation of 1-(trans-4-cyanotetrahydro-2H-pyran-3-yl)-342-hydroxy-4,8-
dimethyl-2H-
benzofeff1,21oxaborinin-6-y0amino)-1H-pyrazole-4-carboxamide
OH NBS OHPinBBPin atik.
013õOH
RI 0 DMF,25 C, 10 hs Br 0
LDA PMDTA, THE Br
0-20 0, 1 h
Nj NH2
NO¨/¨N1 H2 OQN
0 N¨N 0, OH
Pd2dba3, tBuXPhos, KOAc, iPrOH
80 C, 50 hs 0 ,õ
==
[0378]
47.1 Preparation of 1-(5-bromo-2-hydroxy-3-methylphenyl)ethan-1-one
40 OH OH
NBS
0 DMF Br
NBS (10.5 g, 59.4 mmol, 1.05eq was added to the solution of 1-(2-hydroxy-3-
methyl-
237
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
phenyl)ethanone (8.5 g, 56.6 mmol, 1 eq) in DMF (20 mL) at 25 C. The result
mixture was stirred
at 25 C for 10 h. TLC showed the reaction was completed. Brine (250 mL) was
added to the
solution, and then the mixture was extracted with Et0Ac (150 mL x 2). The
combined organic
layers were dried over Na2SO4 and concentrated to give yellow solid, which was
purified by silica
gel chromatography (Petroleum ether/Ethyl acetate=100:1 to 10:1) to give 1-(5-
bromo-2-hydroxy-
3-methyl-phenyl)ethanone (8 g, 61.7% yield) as light-yellow solid.
[0379]
47.2 Preparation of 6-bromo-4,8-dimethyl-2H-benzo[4[1,21oxaborinin-2-ol
OH PinBBPin
0,BOH
Br 0 LDA, PMDTA, THE Br
To a solution of T,DA (2 M, 10.9 mL, 2.5 eq) in THF (20 mI,) was added N'42-
(dimethylamino)ethy1]-N,N,N'Arimethylethane-1,2-diamine (PMDTA, 3.03 g, 17.5
mmol, 3.65
mL, 2 eq) and a solution of 4,4,5,5-tetramethy1-2-[(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-
yOmethyl]-1,3,2-dioxaborolane (B1, 4.68 g, 17.5 mmol, 2 eq) in THF (4 mL) at 0
C under N2.
The mixture was stirred at 0 C for 20 min. Then to this was added dropwise a
solution of 1-(5-
bromo-2-hydroxy-3-methyl-phenyl)ethanone (2 g, 8.73 mmol, 1 eq) in THF (2 mL)
at 25 C. The
mixture was stirred at 25 C for 40 min. LCMS showed the reaction was completed
and desired
MS observed. The mixture was quenched by sat. aq. NH4C1 (50 mL) and adjusted
pH=5-6 with
HC1 (2N) at 0 C. The suspension was extracted with Et0Ac (30 mL x 2). The
combined organic
layers were washed by brine (50 mL x 2), dried over Na2SO4, filtered and
concentrated under
reduced pressure to get the residue. The residue was purified by flash silica
gel chromatography
(ISCOC; 80 g SepaFlash Silica Flash Column, Eluent of 5-7% Ethyl
acetate/Petroleum ether
gradient @ 100 mL/min) to give 6-bromo-2-hydroxy-4,8-dimethy1-1,2-
benzoxaborinine (0.5 g,
22.6% yield) as a white solid. -1-1-1N1VfR (400 MHz, DMSO-d6) 6 8.92 (s, 1H),
7.57 (s, 1H), 7.48 (s,
1H), 5.97 (s, 1H), 2.48 - 2.28 (s, 6H).
[0380]
47.3 Preparation of chiral 1-(trans-4-cyanotetrahydro-2H-pyran-3-y0-342-
hydroxy-4,8-
dimethyl-2H-benzok][1,21oxaborinin-6-yl)amino)-1H-pyrazole-4-carboxamide
238
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
0,B4OH 0 NH2
0 N_N 0,B4OH
Br
Pd2dba3, tBuXPhos, KOAc, iPrOH
80 C, 50 hs
0
NI-12
To a mixture of 6-bromo-4,8-dimethy1-2H-benzo[e][1,2]oxaborinin-2-ol (2.0 g,
7.9 mmol, 1.0 eq)
and 3-amino-1-(trans-4-cyanotetrahydropyran-3-yl)pyrazole-4-carboxamide (1.86
g, 7.9 mmol,
1.0 eq) in i-PrOH (30 mL) was added Pd2(dba)3 (362 mg, 395 umol, 0.05 eq), t-
Bu Xphos (335
mg, 790 umol, 0.1 eq) and KOAc (1.55 g, 15.8 mmol, 2.0 eq) in one portion at
25 C under N2.
The mixture was heated to 80 C and stirred at 80 C for 50 h. LCMS showed the
reaction was
completed and desired MS observed. The mixture was quenched with H20 (2 mL) at
25 C, filtered
and concentrated under reduced pressure to get the residue. The residue was
purified by as purified
by silica gel column chromatography (Petroleum ether/Ethyl acetate=1:1) to
afford the desired as
a yellow solid, which was further separated by SFC (REGIS(S,S)WHELK-
01(250mm*25mm,10um); mobile phase: [Neu-IPA];B%: 50%-50%,7min) to give two
isomers:
1- [trans-4-cy anotetrahydro-2H-pyran-3 -yl] -3- [(2-hydroxy-4,8 -dimethy1-1,2-
b enzoxab orinin-6-
yl)amino]pyrazole-4-carboxamide (stereoisomer one) (257.9 mg, 27.1% yield, ee
100%, first peak,
Rt = 1.487 min) as a white solid 'FI NMR (400 MHz, DMSO-d6) 6 9.06 (s, 1H),
8.66 (s, 1H), 8.35
(s, 1H), 7.96 (s, 1H), 7.76 (br s, 1H), 7.35 (s, 1H), 7.23 (br s, 1H), 5.98
(s, 1H), 4.70-4.55 (m, 1H),
4.15-4.10 (m, 1H), 4.05-3.95 (m, 1H), 3.85-3.65 (m, 2H), 3.55-3.45 (m, 1H),
2.47 (s, 3H), 2.40 (s,
3H), 2.30-2.20 (m, 1H), 2.10 - 1.93 (m, 1H) MS (ESI): mass calculated for
C2oH22BN504, 407.18,
m/z found 408.2[M+H]+. HPLC: 95.68% (220 nm), 99.77% (254 nm) and 1-[trans-4-
cyanotetrahydro2H-pyran-3 -y1]-3 - [(2-hydroxy-4, 8-di methyl -1,2-b enzoxab
orini n-6-
yl)amino]pyrazole-4-carboxamide (stereoisomer two) (280 mg, 29.4% yield, 99.5%
ee, second
peak, Rt = 1.650 mm) as a white solid 41 NMR (400 MHz, DMSO-do) 6 9.00 (s,
1H), 8.59 (s, 1H),
8.29 (s, 1H), 7.90 (s, 1H), 7.71 (br s, 1H), 7.29 (s, 1H), 7.17 (br s, 1H),
5.93 (s, 1H), 4.65-4.50 (m,
1H), 4.10-4.05 (m, 1H), 4.00-3.90 (m, 1H), 3.80-3.60 (m, 2H), 3.50-3.40 (m,
1H), 2.41 (s, 3H),
2.35 (s, 3H), 2.25-2.15 (m, 1H), 2.05- 1.90 (m, 1H). MS (EST): mass calculated
for C2oH22BN504,
407.18, m/z found 408.2[M+H]t HPLC: 97.77% (220 nm), 97.57% (254 nm).
[0381]
48. Preparation of 1-(trans-4-cyanotetrahydro-2H-pyran-3-y!) -3-((2-hydroxy-3-
isopropyl-2H-
benzok] [1, 2] oxaborinin-6-y1) amino) -IH-pyrazole-4- carboxamide
239
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
at OH
B2Pin2
0, -0 Br 11111IP
1761-61-1 0, OH
B B
Cul, t-BuONa, PhMe 01 01 LDA, PMDTA, THF Br
100 C, 15 hrs, N2 0 C, 3.5 hrs,
N2
0
\
/./--/¨;NFri2 0Q",CN
O NH2
0,6,0H
int.A 0 N¨N
Pd2dba3, tBuXPhos, KOAc, iPrOH
85 C, 16 hrs, N2 0
NH2
[0382]
48.1 Preparation of 2, 2'-(2-methylpropane-1, 1-diy1) bis (4, 4, 5, 5-
tetramethy1-1, 3, 2-
dioxaborolane)
B2P i n2
0- -0
_________________________________________________ )0- B B
Cul, t-BuONa, PhMe 0 0
100 C, 15 hrs, N2
A mixture of 2-methylpropanal (0.5 g, 6.93 mmol, 632 uL, 1 eq), 4,4,5,5-
tetramethy1-2-(4,4,5,5-
tetramethy1-1,3,2-dioxaborolan-2-y1)-1,3,2-dioxaborolane (B2Pin2, 3.87 g, 15.2
mmol, 2.2 eq),
CuI (132 mg, 693 umol, 0.1 eq) and t-BuONa (866 mg, 9.01 mmol, 1.3 eq) in
toluene (30 mL) was
degassed and purged with N2 for 3 times, and then the mixture was stirred at
100 C for 15 hours
under N2 atmosphere. 10 parallel reactions were combined for work up. TLC
(Petroleum ether:
Ethyl acetate = 10: 1) indicated 2-methylpropanal was consumed completely and
one new spot
formed. The reaction was cooled to room temperature and filtered. The filtrate
was concentrated
under reduced pressure to give a residue. The residue was purified by flash
silica gel
chromatography (ISCO , 220 g SepaFlash Silica Flash Column, Eluent of 0-15%
Ethyl
acetate/Petroleum ether gradient @ 150 mL/min) to give 2, 2'-(2-methylpropane-
1, 1-diy1) bis(4,
4, 5, 5-tetramethy1-1, 3, 2-dioxaborolane) (6 g, 34.8% yield) as colorless
oil. IH NMR (CDC13, 400
MHz) 6 2.11-1.98 (m, 1H), 1.23 (d, J= 3.6 Hz, 24H), 0.96 (d, J = 6.8 Hz, 6H),
0.61 (br d, J = 10.1
Hz, 1H).
[0383]
48.2 Preparation of 6-bromo-3-isopropy1-2H-benzok][1,21oxaborinin-2-ol
240
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
OH
BrB
0¨ 0
LDA, PMDTA, THF Br
0 C, 3.5 hrs, N2
To a solution of LDA (2 M, 6.5 mL, 2 eq) in THF (10 mL) was added N'42-
(dimethylamino)ethy1]-
N,N,N'-trimethyl-ethane-1,2-diamine (2.24 g, 12.9 mmol, 2.70 mL, 2 eq) and 2,
2'-(2-
methylpropane-1, 1-diy1) bis(4, 4, 5, 5-tetramethy1-1, 3, 2-dioxaborolane) (4
g, 12.9 mmol, 2 eq)
in portions at 0 C over a period of 10 minutes under N2. The mixture was
stirred at 0 C for 20
minutes. Then a solution of 5-bromo-2-hydroxy-benzaldehyde (1.3 g, 6.47 mmol,
1 eq) in THF
(5 mL) was added to the above mixture at 0 C, the resulting mixture was
stirred at 0 C for 3
hours. TLC (Petroleum ether: Ethyl acetate = 5: 1, Rf = 0.6) indicated new
spot formed. The
reaction mixture was quenched by addition of sat. aq. NH4C1 (30 mL) at 0 C,
and then extracted
with Et0Ac (30 mL x 3). The combined organic layers were washed with brine (30
mL x 3), dried
over Na2SO4, filtered and concentrated under reduced pressure to give a
residue. The residue was
purified by flash silica gel chromatography (ISCOS; 40 g SepaFlash Silica
Flash Column, Eluent
of 0-10% Ethyl acetate/Petroleum ether gradient @ 60 mL/min) to give 6-bromo-3-
isopropy1-2H-
benzo[e] [1, 2] oxaborinin-2-ol (1.2 g, crude) as yellow oil. 1H NIVIR (DMSO-
d6, 400 MHz) 5 9.07
(s, 1H), 7.70 (d, = 2.4 Hz, 1H), 7.47-7.42 (m, 2H), 7.13 (d, .1= 8.8 Hz, 1H),
2.80-2.55 (m, 1H),
1.15 (d, J= 1.6 Hz, 6H). MS (ESI): mass calculated for Ci1H12BBrO2 266.01; m/z
found 265.0
[M-H].
[0384]
48.3 Preparation of 1-(trans-4-cyanotetrahydro-2H-pyran-3-y1) -3-((2-hydroxy-
3-isopropyl-
2H-benzolel 11, 21 oxaborinin-6-y!) amino) -1H-pyrazole-4- carboxatnide
NH2
,
Q"'CN
0,B_OH 0 \--Thr N H2
int.A 0 N¨N
Br Pd2dba3, tBuXPhos, KOAc, iPrOH
BOH
85 C, 16 hrs, N2 0
NH2
A mixture of 3 -amino-1-(tran s-4-cy anotetrahydro-2H-pyran-3 -y1) -1H-
pyrazole- 4- carb oxami de
(0.9 g, 3.83 mmol, 1 eq), 6-bromo-3-isopropyl-2H-benzo[e] [1, 2] oxaborinin-2-
ol (1.12 g, 4.21
241
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
mmol, 1.1 eq), KOAc (563 mg, 5.74 mmol, 1.5 eq), Pd2(dba)3 (350 mg, 382 umol,
0.1 eq) and t-
BuXphos (324 mg, 765.17 umol, 0.2 eq) in i-PrOH (20 mL) was degassed and
purged with N2 for
3 times, and then the mixture was stirred at 85 C for 16 hours under N2
atmosphere. LCMS
showed the reaction was completed and desired MS observed. The reaction was
cooled to room
temperature and filtered. The filtrate was concentrated under reduced pressure
to give a residue.
The residue was purified by flash silica gel chromatography (ISCOO; 220 g
SepaFlashe Silica
Flash Column, Eluent of 0-15% Ethyl acetate/Petroleum ether gradient @ 150
mL/min) to give 1-
(trans-4-cyanotetrahy dro-2H-pyran-3 -y1) -3 -((2-hy droxy-3 sopropy1-2H-b
enzo [e] [1, 2]
oxaborinin-6-y1) amino) -1H-pyrazole-4-carboxamide (1.2 g, 33.8% yield, 91%
purity) as yellow
solid. MS (ESI): mass calculated for C21H24BN504 421.19; m/z found 420.2 [M-
H]. 1-(trans-4-
cyanotetrahy dro-2H-pyran-3 -y1)-3 -((2-hydroxy-3 sopropy1-2H-b enzo [e] [1,
2] oxaborinin-6-y1)
amino) -1H-pyrazole-4-carboxamide (1.2 g) was separated by SFC to give 1-
(trans-4-
cyanotetrahy dro-2H-pyran-3 -y1) -3-((2-hydroxy-3-isopropyl- 2H-benzo[e] [1,
2] oxaborinin-6-y1)
amino) -1H-pyrazole-4-carboxamide (stereoisomer one) (454.1 mg, 36.8% yield,
97.4% purity,
100% cc, first peak, Rt = 1.232 min) as a white solid.1HNMR (DMSO-d6, 400 MHz)
9.07 (s, 1H),
8.74 (s, 1H), 8.28 (s, 1H), 7.69 (br s, 1H), 7.57 (d, .1=2.8 Hz, 1H), 7.52
(dd, .1 = 2.8, 8.8 Hz, 1H),
7.44 (s, 114), 7.16 (br s, 1H), 7.09 (d, J= 8.8 Hz, 114), 4.55 (dt, J= 4.4,
10.4 Hz, 114), 4.04 (dd,
= 4.4, 11.3 Hz, 1H), 3.92 (br d, J= 10.4 Hz, 1H), 3.74-3.62 (m, 2H), 3.58-3.45
(m, 1H), 2.81-2.70
(m, 1H), 2.16 (br d, J= 9.6 Hz, 1H), 2.05-1.91 (m, 1H), 1.16 (d, J= 6.8 Hz,
6H). MS (ESI): mass
calculated for C21f124BN504 421.19; m/z found 420.1 [M-H]-. HPLC: 97.46% (220
nm), 98.44%
(254 nm). and 1-(trans-4-cyanotetrahydro-2H-pyran-3 -y1)-3 -((2-hydroxy-3
sopropy1-2H-
benzo[e][1,2]oxaborinin-6-yl)amino)-1H-pyrazole-4-carboxamide (stereoisomer
two) (446.8 mg,
36.3% yield, 97.4% purity, 100% ee, second peak, Rt = 1.422 min) as an off-
white solid. 1H NMR
(DMSO-d6, 400 MHz) 6 9.07 (s, 1H), 8.74 (s, 1H), 8.28 (s, 1H), 7.69 (br s,
1H), 7.57 (d, J = 2.8
Hz, 1H), 7.52 (dd, J= 2.8, 8.8 Hz, 1H), 7.44 (s, 1H), 7.17 (br s, 1H), 7.09
(d, J= 8.8 Hz, 1H), 4.55
(dt, J= 4.4, 10.4 Hz, 1H), 4.04 (dd, J = 4.4, 11.2 Hz, 1H), 3.96-3.87 (m, 1H),
3.75-3.64 (m, 2H),
3.56-3.44 (m, 1H), 2.75 (td, J = 6.8, 13.2 Hz, 1H), 2.16 (br d, J= 9.6 Hz,
1H), 2.05-1.92 (m, 1H),
2.05-1.92 (m, 1H), 1.16 (d, ./ = 6.8 Hz, 614). MS (ESI): mass calculated for
C211124BN504 421.19,
m/z found 420.2 [M-Hr.HPLC: 97.48% (220 nm), 98.92% (254 nm).
[0385]
49 Preparation of 1-(trans-2-cyanocyclohe)97)-3-1(2-hydroxy-3-isopropy1-1,2-
benzoxaborinin -
242
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
6-yl)aminolpyrazole-4-earboxamide
N QCN
BõOH H2N
N-N
Nd. 0,BõOH
Br
Pd2dba3, tBuXPhos, KOAc,
iPrOH, 85 C, 48 h C H
AN H2
A mixture of 3-amino-1-(trans-2-cyanocyclohexyl)pyrazole-4-carboxamide (210
mg, 899 umol,
1.2 eq), 6-bromo-2-hydroxy-3-isopropyl-1,2-benzoxaborinine (200 mg, 749 umol,
1 eq), KOAc
(110 mg, 1.12 mmol, 1.5 eq), Pd2(dba)3 (34 mg, 37 umol, 0.05 eq) and t-BuXphos
(32 mg, 75 umol,
0.1 eq) in i-PrOH (15 mL) was degassed and purged with N2 for 3 times, and
then the mixture was
stirred at 85 C for 48 h under N2 atmosphere. LCMS showed the reaction was
completed and
desired MS observed. The reaction mixture was cooled to room temperature and
quenched with
sat. aq. NH4C1 (0.2 mL). The resulting solution was filtered and washed with
Et0H (10 mL x 3).
The filtrate was concentrated under reduced pressure to give a residue. The
residue was purified
by prep-HPLC (column: Waters Xbridge BEH C18 100*30mm*10um; mobile phase:
[water
(10mM NH4HC 03)-ACN];B%: 20%-50%,10min) to give 1-(2-cyanocyclohexyl)-3-[(2-
hydroxy-
3-isopropy1-1,2-benzoxaborinin-6-yl)amino] pyrazoe -4-carboxamide (67.2 mg,
19.8% yield, 92.6%
purity) as a yellow solid. IFINMR (DMSO-d6, 400 MHz) 69.05 (s, 1H), 8.73 (s,
1H), 8.23 (s, 1H),
7.78-7.61 (m, 1H), 7.58-7.52 (m, 2H), 7.42 (s, 1H), 7.20-7.10 (m, 1H), 7.08
(d, J= 8.8 Hz, 1H),
4.36 (dt, J = 3.6, 11.2 Hz, 1H), 3.30-3.24 (m, 1H), 2.80-2.70 (m, 1H), 2.18
(d, J= 10.8 Hz, 1H),
2.05-1.95 (m, 1H), 1.93-1.67 (m, 4H), 1.58-1.27 (m, 2H), 1.16 (d, J= 6.8 Hz,
6H).
MS (ESI): mass calculated for C22H26BN503 419.21; m/z found 418.1 [M-H]-.
HPLC: 92.69%
(220 nm), 97.51% (254 nm).
[0386]
50. Preparation of 1-(trans-2-cyanocyclopenty1)-3-1(2-
hydroxy-3-isopropy1-1,2-
benzoxaborinin-6-yl)aminokyrazole-4-earboxamide
0
H2N-1--`. N-0 CN
0,BõOH m -1\1 :
11211 Nc 0,BõOH
N-N
Br
Pd2dba3, tBuXPhos, KOAc,
iPrOH, 85 C, 48 h H
0J`=NH2
A mixture of 3-amino-1-(trans-2-cyanocyclopentyl)pyrazole-4-carboxamide (197
mg, 899 umol,
243
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
1.2 eq), 6-bromo-2-hydroxy-3-isopropyl-1,2-benzoxaborinine (200 mg, 749 umol,
1 eq), KOAc
(110 mg, 1.12 mmol, 1.5 eq), Pd2(dba)3 (34 mg, 37 umol, 0.05 eq) and t-Bu
Xphos (32 mg, 74.9
umol, 0.1 eq) in i-PrOH (15 mL) was degassed and purged with N2 for 3 times,
and then the mixture
was stirred at 85 C for 48 h under N2 atmosphere. LCMS showed the reaction was
completed and
desired MS observed. The reaction mixture was cooled to room temperature and
added sat. aq.
NJ-14C1 (0.2 mL). The resulting solution was filtered and washed with Et0H (10
mL x 3), the
filtrate was concentrated under reduced pressure to give a residue. The
residue was purified by
prep-HPLC (column: Waters Xbridge BEH C18 100*30mm*10um; mobile phase: [water
(10mM
NH4HCO3)-ACN],13%; 20%-50%,10min) to give 1-(trans-2-cyanocyclopenty1)-3-[(2-
hydroxy-3 -
isopropy1-1,2-benzoxaborinin-6-yl)amino]pyrazole-4-carboxamide (56.6 mg, 18.1%
yield, 97.1%
purity) as a yellow solid. 1H NMit (DMSO-d6, 400 MHz) 69.03 (s, 1H), 8.73 (s,
1H), 8.27 (s, 1H),
7.73 (d, J = 2.4 Hz, 1H), 7.60 (br s, 1H), 7.48-7.39 (m, 2H), 7.12 (br s, 1H),
7.07 (d, J= 8.8 Hz,
1H), 4.90-4.83 (m, 1H), 3.47-3.37 (m, 1H), 2.81-2.70 (m, 1H), 2.33-2.20 (m,
2H), 2.13-2.04 (m,
1H), 2.00-1.85 (m, 3H), 1.15 (d, J= 6.8 Hz, 6H). MS (ESI): mass calculated for
C211-124BN503
405.2; m/z found 404.1 [M-H]-. TIPLC: 97.11% (220 nm), 98.79% (254 nm).
[0387]
51. Preparation of 1-firans-4-cyanotetrahydro-211-pyran-3-y11-34(2-hydroxy-1,2-
benzoxaborinin-6-yl)aminokyrazole-4-carboxamide
OH
arr&r. OH Ir(PPY)3 0õOH
LDA, PMDTA THF, Br B< MeCN, 2500,
IMF ,o
Br 0 C-25 C, 1 h 34 VV,15 h Br =
N,N r NH2
-N =
I-12N Nd
N
Int. A HN
NC'
tButyl-XPhos, Pd2dba3
KOAc, iPrOH
20 C-80 C, 18 h I 0
OH
[0388]
51.1 Preparation of 4-bromo-2-[(E)-2-(4,4,5,5-tetranzethyl-1,3,2-dioxaborolan-
2-y1)
vinyllphenol
244
CA 03201608 2023-6-7
WO 2022/133420
PCT/US2021/072885
OB >5c'
0 OH
OH
0
LDA, PMDTA THE Br
Br 0 C-25 C, 1 h 0
To a mixture of LDA (2 M, 27.3 mL, 2.2 eq) in THF (40 mL) was added N'42-
(dimethylamino)ethy1]-N,N,N'-trimethyl-ethane-1,2-diamine (8.62 g, 49.8 mmol,
10.4 mL, 2 eq)
and a solution of 4,4,5,5 -tetram ethyl -2- [(4,4,5,5 -tetram ethyl -1,3,2- di
ox ab orol an-2-y1) m ethyl ] -
1,3,2-di oxaborolane (13.3 g, 49.8 mmol, 2 eq) in THF (30 mL) at 0 C under N2.
The reaction was
stirred for 20 min. Then added a solution of 5-bromo-2-hydroxy-benzaldehyde
(5.00 g, 24.9 mmol,
1 eq) in THE (30 mL) at 0 C. The reaction was allowed to warm to 25 C and
stirred at 25 C for 1
h. LCMS showed the reaction was completed and desired MS observed. 2 parallel
reactions were
combined for work up. The mixture was quenched by sat. aq. NH4C1 (200 mL),
adjusted pH to 6
with 2 N HC1 and then extracted with Et0Ac (80 mL x 3). The combined organic
layers were
washed by brine (100 mL x 2), dried over Na2SO4, filtered and concentrated
under reduced
pressure to get a residue. The residue was purified by flash silica gel
chromatography (ISCO ,
220 g SepaFlash Silica Flash Column, Eluent of 0-15% Ethyl acetate/Petroleum
ether gradient
100 mL/min) to give 4-bromo-2-[(E)-2-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-
yl)vinyl]
phenol (12.0 g, 63.0% yield, 85% purity) as yellow oil. 1-FI NMR_ (CDC13, 400
MHz) 6 7.59-7.54
(m, 2H), 7.25 (dd, J= 8.8 Hz, 2.8 Hz, 1H), 6.70 (d, J= 8.8 Hz, 1H), 6.15 (d, J
= 18.8 Hz, 1H),
5.62 (br s, 1H), 1.32 (s, 12H).
[0389]
51.2 Preparation of 6-bromo-2-hydroxy-1,2-benzoxaborinine
OH
Ir(PPY)3 O.
0
Br MeCN, 25 C, 1.1 B
v
0 34 VV,15 h Br
To a mixture of 4-bromo-2-[(E)-2-(4,4,5,5-tetram ethyl -1,3,2-di ox ab orol an
-2-yl)vi n ]phenolyl (3 g,
7.85 mmol, 85% purity, 1 eq) in MeCN (30 mL) was added tris[2-(2-
pyridyl)phenyl]iridium
(Ir(PPY)3,51.4 mg, 78.5 umol, 0.01 eq) in one portion at 25 C under N2. The
reaction was stirred
and irradiated using 34W blue LED lamps for 15 h. LCMS showed the reaction was
completed
and desired MS observed. The mixture was concentrated under reduced pressure
to give the
245
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
residue. The residue was purified by flash silica gel chromatography (ISCO ;
60 g SepaFlashe
Silica Flash Column, Eluent of 0-15% Ethyl acetate/Petroleum ether gradient @
100 mL/min) to
give 6-bromo-2-hydroxy-1,2-benzoxaborinine (2.50 g, 70.8% yield) as a yellow
solid. 1-1-1 NMR
(DMSO-d6, 400 MHz) 6 9.14 (s, 1H), 7.79-7.75 (m, 2H), 7.53 (dd, J= 8.48 Hz,
2.4 Hz, 1H), 7.19
(d, ./ = 8.8 Hz, 1H), 6.18 (d, .1 = 11.6 Hz, 1H).
[0390]
51.3 Preparation of chiral 1-Itrans-4-cyanotetrahydro-2H-pyran-3-y11-3-f(2-
hydroxy-1,2-
benzoxaborinin-6-yl)aminokyrazole-4-carboxatnitle
NH2
H2N _.c)0
0
N
H2N NC
HN =
is O., _OH Int. A NC
B
tButyl-XPhos, Pd2dba3 41
Br KOAc, iPrOH
20 C-80 C, 18 h I BA)
OH
To a mixture of 3-amino-1-(trans-4-cyanotetrahydro-2H-pyran-3-yl)pyrazole-4-
carboxamide (500
mg, 2.13 mmol, 1 eq) and 6-bromo-2-hydroxy-1,2-benzoxaborinine (526 mg, 2.34
mmol, 1.1 eq)
in i-PrOH (10 mL) was added t-BuXPhos (162 mg, 383 umol, 0.18 eq), KOAc (417
mg, 4.25
mmol, 2 eq) and Pd2(dba)3 (175 mg, 191 umol, 0.09 eq) in one portion at 20 C
under N2. The
mixture was heated and stirred at 80 C for 18 h. LCMS showed the reaction was
completed and
desired MS observed. 4 parallel reactions were combined for work up. The
mixture was filtered
and filtrate was concentrated in vacuum to give a residue. The residue was
dissolved with H20
(60 mL) and adjusted pH to 6 with 2 N HC1 at 0 C, and then extracted with
Et0Ac (30 mL x 3).
The combined organic layers were washed with brine (40 mL x 3), dried over
Na2SO4, filtered and
concentrated under reduced pressure to give a residue. The residue was
purified by prep-HPLC
(column: Welch Xtimate C18 250*70mm#10um; mobile phase: [water(NH4HCO3)-
ACN];B%:
20%-50%,20min) to give 1-(trans-4-cyanotetrahydro-2H-pyran-3-y1) -3-[(2-
hydroxy-1,2-
benzoxaborinin-6-yl)amino]pyrazole-4-carboxamide (1.50 g, 37.2% yield) as an
off-white solid.
The product was further separated by SFC (column: DAICEL CHIRALPAK
IC(250mm*30mm,10um);mobile phase: [Neu-IPA];B%: 50%-50%,10min) to give 1-
[trans-4-
cyanotetrahy dro-2H-py ran-3 -y1]-3 - [(2-hy droxy-1,2-b enzoxab orinin-6-
yl)amino] pyrazol e-4-
246
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
carboxamide (stereoisomer one) (435.1 mg, 13.4% yield, 99.4% purity, 100% ee,
first peak, Rt =
2.239 min) as an off-white solid.1H NIVIR (DMSO-d6, 400 MHz) 6 9.09 (s, 1H),
8.80 (s, 1H), 8.28
(s, 1H), 7.81 (d, J = 11.6 Hz, 1H), 7.75-7.63 (m, 2H), 7.54 (dd, J = 8.8 Hz,
2.8 Hz, 1H), 7.23-7.12
(m, 2H), 6.11 (d, J= 11.6 Hz, 1H), 4.55 (td, J = 10.0 Hz, 1H), 4.03 (dd, J =
11.2 Hz, 4.4 Hz, 1H),
3.95-3.90 (m, 1H) 3.75-3.66 (m, 2H), 3.54-3.48 (m, 1H), 2.20-2.12 (m, 1H),
2.04-1.95 (m, 1H).
MS (EST): mass calculated for C18H18BN504 379.15; m/z found 380.1 [M+H] .
HPLC: 99.40%
(220 nm), 99.73% (254 nm). and 1-[trans-4-cyanotetrahydropyran-3-yl] -3-[(2-
hydroxy-1,2-
benzoxaborinin-6-yl)amino] pyrazole-4-carboxamide (stereoisomer two) (469.7
mg, 14.3% yield,
98.5% purity, 100% ee, second peak, Rt = 2.722 min) as a yellow solid. IH NAIR
(DMSO-d6, 400
MHz) 6 9.09 (s, 1H), 8.80 (s, 1H), 8.29 (s, 1H), 7.81 (d, J= 12.0 Hz, 1H),
7.75-7.63 (m, 2H), 7.54
(dd, J = 8.8 Hz, 2.8 Hz, 1H), 7.25-7.00 (m, 2H), 6.11 (d, J= 12.0 Hz, 1H),
4.55 (td, J= 14.4 Hz,
1H), 4.03 (dd, J= 11.2 Hz, 4.0 Hz 1H), 3.96-3.87 (m, 1H), 3.75-3.67 (m, 1H),
3.55-3.47 (m, 1H),
2.20-2.12 (m, 1H), 2.04-1.95 (m, 1H). MS (EST): mass calculated for
C18H18BN504 379.15; m/z
found 380.1 [M-41] . HPLC: 98.56% (220 nm), 98.75% (254 nm).
[0391]
52. Preparation of 347-chloro-1-hydroxy-1,3-dihydrobenzo[c][1,21oxaboro1-5-
yl)amino) -1-
(trans-4-cyanotetrahydro-2H-pyran-3-y1)-1H-pyrazole-4-carboxamide
0Q,,,c,,
CI ..\
CI ,di Br CI r
Br mi
HBPin Na10 ifo B
4, NH40Ac l
0-B IP NH I
IA
CO2M Ir(OMe),(COD), , dtbbpy _ T - - co 2m e
THF, H20; 25 C, 16 h Fl 'y ull'ILIP CO2Me Cu(OAc)2, TEA, DMA;
411111j-IP e 0
2-Me-THF, 90 C, 50 h OH 40 C,
169
0Qõ.CN ci
Br mBH4 Br
B2(PeoP)2
CO 2M OR,,.CN ci
Br TBSOTf
OQ,..CN a
yN-N 40 N-N 41110 N-N 40
THF, 40 C 12 h
y OH 2,6-lutidine YN
OTBS Pd(PP113)2C12, KOAc
N e N
H H DCM, 20 C, 39 dioxane; 120 C, 1 h
0
NH2 NH2 0 NH2
0Q."CN CI OH
1 R..CN CI OH
SIN 0 13' 0THBS THF,H4C01 C, 1 h 5-1N 0 140
H H
0 0
NH2 NH,
[0392]
52.1 Preparation of methyl 2-bromo-3-chloro-5-(4,4,5,5-tetramethy1-1,3,2-
dioxaborolan-2-y1)
247
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
benzoate
CI
CI io Br
HBPin
401 Br O.
CO2Me CO2Me
Ir(OMe)2(COD)2 , dtbbPY
0
2-Me-THF, 90 C, 50 h
A mixture of methyl 2-bromo-3-chloro-benzoate (5 g, 20.0 mmol, 1 eq), 4,4,5,5-
tetramethy1-1,3,2-
dioxaborolane (10.3 g, 80.2 mmol, 11.6 mL, 4 eq), 4-tert-butyl-2-(4-tert-butyl-
2-pyridyl)pyri dine
(dtbbpy, 538 mg, 2.00 mmol, 0.1 eq), (1Z,5Z)-cycloocta-1,5-diene;2,4-dimethyl-
BLAHbicyclo[1.1.0]butane (Ir(OMe)2(COD)2, 531 mg, 801 umol, 0.04 eq) in 2-
methyltetrahydrofuran (40 mL) was degassed and purged with N2 for 3 times, and
then the mixture
was stirred at 90 C for 50 h under N2 atmosphere. TLC showed the reaction was
completed. The
reaction mixture was cooled to room temperature and filtered. The filtrate was
concentrated under
reduced pressure to give a residue. The residue was purified by flash silica
gel chromatography
(ISCO , 330 g SepaFlash Silica Flash Column, Eluent of 0-7% Ethyl
acetate/Petroleum ether
gradient @ 150 mL/min) to give methyl 2-bromo-3-chloro-5-(4,4,5,5-tetramethy1-
1,3,2-
dioxaborolan-2-y1) benzoate (32 g, 85.0% yield) as a yellow solid. 1-1-1NMR
(CDC13, 400 MHz) 6
7.97 (s, 1H), 7.93 (s, 1H), 3.94 (s, 3H), 1.35 (s, 12H).
[0393]
52.2 Preparation of (4-bromo-3-chloro-5-methoxycarbonyl-phenyl)boronic acid
CI
CI
Br
Na104, NH40Ac Br
o
CO2Me
THF, H20; 25 C, 16 h HO,B CO2Me
01H
To a solution of methyl 2-bromo-3-chloro-5-(4,4,5,5-tetramethy1-1,3,2-
dioxaborolan-2-y1)
benzoate (11 g, 29.3 mmol, 1 eq) in THE (110 mL) and H20 (55 mL) was added
NaI04 (18.8 g,
87.9 mmol, 3 eq) and NH40Ac (6.77 g, 87.9 mmol, 3 eq). The mixture was stirred
at 25 C for 16
h. TLC showed the reaction was completed. The reaction mixture was filtered
and washed with
water (30 mL x 3). The filtrate was extracted with Et0Ac (50 mL x 3). The
combined organic
layers were washed with brine (150 mL x 2), dried over Na2SO4, filtered and
concentrated under
reduced pressure to give a residue. The residue was triturated with a mixture
of Petroleum ether
248
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
(80 mL) and Ethyl acetate (15 mL) at 25 C for 10 min to give (4-bromo-3-chloro-
5-
methoxycarbonyl-phenyl)boronic acid (7 g, 81.4% yield) as a white solid ill
NMR (DMSO-d6,
400 MHz) 6 8.53 (s, 2H), 8.08 (s, IH), 7.95 (s, I H), 3.88 (s, 3H).
[0394]
52.3 Preparation of methyl 2-bromo-5-1/4-carbamoy1-1-(trans-4-cyanotetrahydro-
2H-pyran-3-
y1) pyrazol-3-yllamino1-3-chloro-benzoate
CQ'"CN
N-N
" ' CI
CI Ni 12 ORC N
Br 0 Int A N¨N Br
NH2
HO,B CO2Me Cu(OAc)2, TEA, DMA; CO2Me
OH 40 C, 16 h 0 NH2
A mixture of 3-amino-1-(trans-4-cyanotetrahydropyran-3-yl)pyrazole-4-
carboxamide (1 g, 4.25
mmol, 1 eq), (4-bromo-3-chloro-5-methoxycarbonyl-phenyl)boronic acid (1.37 g,
4.68 mmol, 1.1
eq), TEA (2.15 g, 21.25 mmol, 3.0 mL, 5 eq), Cu(OAc)2 (1.93 g, 10.6 mmol, 2.5
eq) and 4A
molecular sieve (2.5 g, 4.25 mmol, 1 eq) in DMA (30 mL) was stirred at 40 C
for 16 h under air.
LCMS showed the reaction was completed and desired MS observed. 4 parallel
reactions were
combined for work up. The reaction mixture was filtered. The filtrate was
added H20 (300 mL)
at 20 C, and then extracted with Et0Ac (50 mL x 3). The combined organic
layers were washed
with brine (50 mL x 3), dried over Na2SO4, filtered and concentrated under
reduced pressure to
give a residue. The residue was purified by flash silica gel chromatography
(ISCOg; 80 g
SepaFlashg Silica Flash Column, Eluent of 0-100% Ethyl acetate/Petroleum ether
gradient @
100 mL/min) to give methyl 2-bromo-54[4-carbamoy1-1-(trans-4-cyanotetrahydro-
2H-pyran-3-
yl)pyrazol-3-yl]amino]-3-chloro-benzoate (5 g, 60.9% yield) as a yellow solid.
1-E1 NMR (DMSO-
d6, 400 MHz) 6 9.46 (s, 1H), 8.34 (s, 1H), 8.08 (s, 1H), 7.86 (s, 1H), 7.79
(br s, 1H), 7.28 (br s,
1H), 4.63 (dt, J= 4.4, 10.4 Hz, 1H), 4.10-4.05 (m, 1H), 3.95-3.90 (m, 1H),
3.87 (s, 3H), 3.67-3.55
(m, 2H), 3.50-3.40 (m, 1H), 2.20-2.10 (m, 1H), 2.05-1.95 (m, 1H).
[0395]
52.4 Preparation of 344-bromo-3-chloro-5-
(hydroxymethyl)anilino]-1-(trans-4-
cyanotetrahydro-2H-pyran-3-Apyrazole-4-carboxamide
249
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
Og'"CN OR"'CN
CI CI
Br LiBH4
CO2Me Br
N
N--N 410 N--N
THF, 40 C 12 h =OH
0 0
NH2 NH2
To a solution of methyl 2-bromo-5-[[4-carbamoy1-1-(4-cyanotetrahydropyran-3-
y1) pyrazol-3-
yl]amino]-3-chloro-benzoate (1.7 g, 3.52 mmol, 1 eq) in anhydrous THF (30 mL)
was added
LiBH4 (5.3 mL, 4 N, 6 eq) dropwi se at 0 C and then the mixture was heated to
40 C and stirred at
40 C for 12 h. TLC showed the reaction was completed. The reaction was cooled
to room
temperature and quenched with ice-water (50 mL) and adjust pH to 6 with HC1
(1N). The resulting
solution was extracted with Et0Ac (30 mL x 3). The combined organic layers
were washed with
brine (40 mL x 3), dried over Na2SO4, filtered and concentrated under reduced
pressure to give 3-
[4-brom o-3 -chl oro-5 -(hy droxy m ethy 1)anil i n o] -1 -(trans-4-cy
anotetrahy dro-2H-py ran-3 -
yl)pyrazole-4-carboxamide (1.4 g, crude) as a yellow solid.
[0396]
52.5 Preparation of 344-bromo-3-iftert-htttyl(dimethyl)silyiloxymethyll-5-
ehloro-anilinal -1-
(trans-4-cyanotetrahydro-2H-pyran-3-yl)pyrazole-4-carboxamitle
ORCN Q'"CN
CI CI
Br TBSOTf Br
N--N N--N
OH 2,6-lutidine OTBS
Fl DCM, 20 C, 3 h
O 0
NH2 NH2
To a solution of 3-[4-bromo-3-chloro-5-(hydroxymethyl)anilino]-1-(trans-4-
cyanotetrahydro-2H-
pyran -3-yl)pyrazole-4-carboxamide (2 g, 4.40 mmol, 1 eq) and 2,6-
dimethylpyridine (1.18 g, 11.0
mmol, 1.3 mL, 2.5 eq) in DCM (40 mL) was added TBSOTf (1.74 g, 6.60 mmol, 1.5
mL, 1.5 eq)
at 0 C. The mixture was stirred at 20 C for 3 h. The reaction mixture was
quenched by addition
of sat. aq. NH4C120 mL at 0 C, and then extracted with DCM (20 mL x 3). The
combined organic
layers were washed with brine (10 mL x 2), dried over Na2SO4, filtered and
concentrated under
reduced pressure to give a residue. The residue was purified by flash silica
gel chromatography
(ISCOe; 40 g SepaFlashe Silica Flash Column, Eluent of 0-100%
Ethylacetate/Petroleum ether
gradient @ 75 mL/min) to give 3 -[4-b rom o-3 - [[tert-butyl (di m ethypsi
lyl] oxymethyl] -5-chl oro-
anilino] -1 -(trans -4-cy anotetrahy dro-2H-pyran-3 -yl)pyrazole-4-carb
oxamide (1.6 g, 63.9% yield)
250
CA 03201608 2023- 6- 7
WO 2022/133420
PCT/US2021/072885
as a white solid. 1H NAIR (DMSO-d6, 400 MHz) 6 9.47 (s, 1H), 8.34 (s, 1H),
7.84 (d, J= 2.8 Hz,
1H), 7.79 (br s, 1H), 7.46 (d, J= 2.4 Hz, 1H), 7.29 (br s, 1H), 4.69 (s, 2H),
4.60 (dt, J = 4.4, 10.0
Hz, 1H), 4.10-4.04 (m, 1H), 3.96-3.89 (m, 1H), 3.70-3.62 (m, 1H), 3.58 (dt,
.1=4.0, 10.8 Hz, 1H),
3.50-3.42 (m, 1H), 2.20-2.10 (m, 1H), 2.05-1.92 (m, 2H), 0.93 (s, 9H), 0.13
(s, 6H).
[0397]
52.6 Preparation of 12- fftert-butyl(dimethyl)silylloxymethyll-4-114-carbamoyl-
1-(trans-4-
cyanotetrahydro-2H-pyran-3-yl) pyrazol-3-yllaminol-6-chloro-phenyllboronic
acid
.CN CI
Br 132(neoP)2 OgCN CI OH
N-N N'N 41 `OH
4N =OTBS Pd(PPh3)2Cl2, KOAc OTBS
dioxane; 120 C, 1 h H
0
NH2 NH2
A mixture of 2-(5,5-dimethy1-1,3,2-dioxaborinan-2-y1)-5,5-dimethy1-1,3,2-
dioxaborinane (595
mg, 2.64 mmol, 5 eq), 344-bromo-3-fftert-butyl(dimethypsilyl]oxymethyl] -5-
chloro-anilino]-1-
(trans-4-cyanotetrahydro-2H-pyran-3-yl)pyrazole-4-carboxamide (300 mg, 527
umol, 1 eq),
KOAc (155 mg, 1.58 mmol, 3 eq) and Pd(PPh3)2C12 (37 mg, 52 umol, 0.1 eq) in
dioxane (8 mL)
was degassed and purged with N2 for 3 times, and then the mixture was stirred
at 120 C for 1 h
under N2 atmosphere. TLC showed the reaction was completed. 5 parallel
reactions were combined
for work up. The reaction was cooled to room temperature and filtered. The
filtrate was
concentrated under reduced pressure to give a residue. The residue was
purified by prep-HPLC
(column: Waters Xbridge BEH C 18 250*50mm*10um; mobile phase: [water (10mM
NH4HCO3)-
ACN];B%. 45%-85%,10min) to give [2-fftert-butyl(dimethyl)silyl]oxymethyl]-4-
[[4-carbamoyl-
1-(tran s-4-cy an otetrahydro-2H-pyran -3 -yl )pyrazol -3 -yl ]amino]-6-chl
oro-phenyl ] b oroni c acid
(0.8 g, crude) as a yellow solid.
[0398]
52.7 Preparation of chiral 347-chloro-1-hydroxy-1,3-dihydrobenzok
1[1,21oxaborol-5-
yl)amino) -1-(trans-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide
oR"'CN CI OH OCN CI OH
HCI
00) B4OH N-N b g
OTBS THF, 40 C, 1 h 410
0 0
NH2 NH2
To
a solution of [2- [[ tert-butyl(dimethypsilyl] oxymethy1]-44 [4-carbam
oyl-1 -(trans-4-
251
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
cyanotetrahydro-2H-pyran-3-yl)pyrazol-3-yl]amino]-6-chloro-phenyl]boronic acid
(800 mg, 1.50
mmol, 1 eq) in THF (12 mL) was added HCl (800 uL, 6N, 3.20 eq) at 20 C. The
mixture was
heated and stirred at 40 C for 1 h. LCMS showed the reaction was completed and
desired MS
observed. The reaction mixture was concentrated under reduced pressure to give
a residue. The
residue was triturated with CH3CN (15 mL) at 20 C for 10 min to give 3-((7-
chloro-1-hydroxy-
1,3 -dihydrob enzo[c] [1,2] oxaborol -5-yl)amino)-1-(trans-4-cyanotetrahydro-
2H-pyran-3-y1)-1H-
pyrazole-4-carboxamide (500 mg). Further separated by SFC (column: DAICEL
CHIRALPAK
IC(250mm*30mm,10um);mobile phase: [Neu-MeOFI];B%: 50%-50%,10min) to give 3-((7-
chl oro-1-hy droxy-1,3 -dihy drob enzo [c] [1,2]oxab orol-5-yl)amino)-1 -
(trans-4-cy anotetrahy dro-
2H-pyran-3-y1)-1H-pyrazole-4-carboxamide (stereoisomer one) (210 mg, 34.2%
yield, 98.0%
purity, 94.6% ee , first peak, Rt = 1.417 min) as a white solid.
NMR (DMSO-d6, 400 MHz) 6
9.51 (s, 1H), 8.85 (s, 1H), 8.34 (s, 1H), 7.78 (br s, 1H), 7.52 (s, 1H), 7.47
(s, 1H), 7.27 (br s, 1H),
4.94 (s, 2H), 4.63-4.57 (m, 1H), 4.06 (dd, J = 4.4, 11.2 Hz, 1H), 3.92 (d, J=
10.8 Hz, 1H), 3.70-
3.60 (m, 2H), 3.49 (t, J = 10.4 Hz, 1H), 2.18-2.15 (m, 1H), 2.05-1.90 (m, 1H).
MS (ESI): mass
calculated for Ct7Ht7BC1N504401.11; m/z found 400.2 [M-H]-. HPLC: 98.08% (220
nm), 96.05%
(254 nm). and 3-((7-chloro-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-
yDamino)-1-(trans-4-
cyanotetrahydro-2H-pyran-3-y1)-1H-pyrazol e-4-carboxam i de (stereoi somer
two) (205 mg, 33.5%
yield, 98.4% purity, 99.6% ee, second peak, Rt = 1.597 min) as a white solid.
'H NMR (DMSO-
d6, 400 MHz) 6 9.51 (s, 1H), 8.85 (s, 1H), 8.34 (s, 1H), 7.78 (br s, 1H), 7.52
(s, 1H), 7.47 (s, 1H),
7.26 (br s, 1H), 4.94 (s, 2H), 4.63-4.57 (m, 1H), 4.06 (dd, .1 = 4.4, 11.2 Hz,
1H), 3.92 (d, = 10.8
Hz, 1H), 3.70-3.60 (m, 2H), 3.55-3.45 (m, 1H), 2.18-2.15 (m, 1H), 2.05-1.90
(m, 1H). MS (ESI):
mass calculated for C171-117BC1N504 401.11; m/z found 400.2 [M-H]. HPLC:
98.48% (220 nm),
98.61% (254 nm).
[0399]
53. Preparation of Htrans-4-cyanotetrahydro-2H-pyran-3-yll-34[2-hydroxy-8-
(trifluoromethoxy)-1,2-benzoxaborinin-6-yllaminolpyrazole-4-earboxamide
252
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
OCF3 OCF3 OCF3 OCF3
OCF3
.... OH MCECI, DIEA OMOE rI-B OMOE uLi HCI aim OH
NBS OH
ItIP DCM,0-20 C, 2 h
CHO
DMF, THF _____________________________ s ain
THF, 50 C, 16 hr 11141P cHo DMF, 25 C, 2 h
0...
Br .... CHO
MP'
rsj
,r\II;NrEl:
OCF3 OH OCF3
\O¨/¨N -- NH2 QN
OCF3
PinB-----BPin Ir(PPY)3 s 0 0,13-OH
/ 0 14
s
..,,,, ...I,
,
0 0,B4OH
,-'
LDA, PMDTA, THE Br ---- BPin MeCN, 25 C, 16 h Br
PclAba, tBuXPhos, KOAc, iPrOH N
H
80 C, 12 h 0
NH2
[0400]
53.1 Preparation of 1-(ethoxymethoxy)-2-(triflnoromethoxy)benzene
OCF3 OCF3
EOMCI, DIEA
0 OH ________________ OMOE
vs-
DCM,0-20 C, 2 h 0
To a mixture of 2-(trifluoromethoxy)phenol (15 g, 84.2 mmol, 1 eq) and DIEA
(252 mmol, 44 mL,
3 eq) in DCM (150 mL) was drop-wise added chloromethoxyethane (MOEC1, 168
mmol, 15.6 mL,
2 eq) at 0 C under N2 atmosphere. The reaction mixture was stirred at 20 C for
2 hours. TLC
(Petroleum ether/Ethyl acetate=5/1) showed the reaction was completed. The
reaction mixture
was quenched by addition H20 (20 mL) at 0 C, and then extracted with Et0Ac
(100 mL x 3). The
combined organic layers were dried over Na2SO4, filtered and concentrated
under reduced pressure
to give a residue. The residue was purified by column chromatography (SiO2,
Eluent of 0-100%
Ethyl acetate/Petroleum ether gradient) to give compound 1-(ethoxymethoxy)-2-
(trifluoromethoxy)benzene (19 g, 95.5% yield) as colorless oil. 1-1-1NMR (400
MHz, DMSO-d6) 6
7.42 - 7.26 (m, 3 H), 7.14 - 6.99 (m, 1 H), 5.32 (s, 2 H), 3.67 (q, J= 7.2 Hz,
2 H), 1.12 (t, J= 7.2
Hz, 3 H).
[0401]
53.2 Preparation of methyl 2-(ethoxymethoxy)-3-(trifluoromethoxy)benzaldehyde
253
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
OCF3 ocF3
OMOE ____________________________________ n-BuLi OMOE
DMF, THE
CHO
-65 C, 1 h
To a solution of 1-(ethoxymethoxy)-2-(trifluoromethoxy)benzene (19 g, 80.4
mmol, 1 eq) in THE
(180 mL) was drop-wise added n-BuLi (2.5 M, 37 mL, 1.15 eq) at -65 C under N2
atmosphere.
The reaction mixture was stirred at -65 C for 30 min, then DMF (9.3 mL, 120
mmol, 1.5 eq) was
drop-wise added to the reaction mixture and stirred for 1 h. TLC (petroleum
ether: ethyl acetate
= 10: 1 ) showed the reaction was completed and the starting material was
consumed. The reaction
mixture was warmed to the room temperature and poured into aq. NH4C1 (150 mL)
and stirred for
20 min under N2 atmosphere. The aqueous phase was extracted with ethyl acetate
(100 mL x 3).
The combined organic phases were washed with brine (100 mL x 2), dried with
anhydrous Na2SO4,
filtered and concentrated under reduce pressure to give a residue. The residue
was purified by
column chromatography (SiO2, Eluent of 0-100% Ethyl acetate/Petroleum ether
gradient) to give
compound 2-(ethoxymethoxy)-3-(trifluoromethoxy)benzaldehy de (15 g, 71.5%
yield) as yellow
oil. 1H NMR (400 MHz, DMSO-do) 6 10.25 (s, 1 H), 7.79 (d, J = 7.6 Hz, 2 H),
7.43 (t, J = 7.6 Hz,
1 H), 5.25 (s, 2 H), 3.78 (q, J= 7.2 Hz, 2 H), 1.13 (t, J = 7.2 Hz, 3 H).
[0402]
52.3 Preparation of 2-hydroxy-3-(trifittoromethoxy)benzaldehyde
OCF3 OCF3
HCI OH
OMOE _________________________________________________
THF,50 C, 16 h
CHO CHO
To a solution of 2-(ethoxymethoxy)-3-(trifluoromethoxy)benzaldehyde (15 g,
59.0 mmol, 1 eq) in
THE (78 mL) was added HC1 (4.9 mL, 12 N) in one portion at 25 C under N2
atmosphere. The
reaction mixture was heated and stirred at 50 C for 16 hours. LCMS showed the
starting material
was consumed completely and desired MS detected. The reaction mixture was
poured into water
(100 mL) and stirred for 20 min under N2 atmosphere. The aqueous phase was
extracted with ethyl
acetate (150 mL x 3). The combined organic phases were washed with brine (30
mL x 2), dried
with anhydrous Na2SO4, filtered and concentrated under reduce pressure to give
a residue. The
residue was purified by column chromatography (SiO2, Eluent of 0-100% Ethyl
acetate/Petroleum
ether gradient) to give compound 2-hydroxy-3-(trifluoromethoxy)benzaldehy de
(10 g, 82.2%
254
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
yield) as a white solid. 1-H NMR (400 MHz, DMSO-d6) (511.14 (s, 1 H), 10.24
(s, 1 H), 7.80 - 7.60
(m, 2 H), 7.08 (t, J=8.0 Hz, 1 H).
[0403]
53.4 Preparation of methyl 5-bromo-2-hydroxy-3-(trifittoromethoxy)benzaldehyde
OCF3 OCF3
OH NBs le OH
DMF, 25 C, 2 hr
CHO Br CHO
To a solution of 2-hydroxy-3-(trifluoromethoxy)benzaldehyde (3.96 g, 19.2
mmol, 1 eq) in DMF
(25 mL) was added NBS (3.66 g, 20.6 mmol, 1.07 eq) in one portion at 25 C
under N2 atmosphere.
The reaction mixture was stirred at 25 C for 2 hours. TLC (petroleum ether:
ethyl acetate = 10:1)
showed the reaction was completed. The reaction mixture was poured into water
(80 mL) and
stirred for 20 min and extracted with ethyl acetate (100 mL x 3). The combined
organic phases
were washed with brine (80 mL x 2), dried with anhydrous Na2SO4, filtered and
concentrated
under reduce pressure to give a residue. The residue was purified by column
chromatography
(S102, Eluent of 0-100% Ethyl acetate/Petroleum ether gradient) to give
compound 5-bromo-2-
hydroxy-3-(trifluoromethoxy)benzaldehyde (4.9 g, 17.1 mmol, 89.5% yield) as a
white solid.
1H NMR (400 MHz, DMSO-d6) 6 11.42 (s, 1 H), 10.19 (s, 1 H), 7.90 (dd, J=2.4,
1.2 Hz, 1 H),
7.83 (d, J=2.4 Hz, 1 H).
[0404]
53.5 Preparation of 4-bromo-2-[(E)-2-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-
yl)vinyll-6-
(trifluoromethoxy)phenol
OCF3
OCF3 Pi OH
is OH nBBPin
LDA, PMDTA, THF Br BPin
Br CHO
To a solution of LDA (2 M, 26.3 mL, 2.5 eq) in THF (20 mL) was added N'-[2-
(dimethylamino)ethy1]-N,N,N'-trimethyl-ethane-1,2-diamine (PMDTA, 7.30 g, 42.1
mmol, 8.8
mL, 2 eq) in one portion at 0 C under N2 atmosphere. Then 4,4,5,5-tetramethy1-
2-[(4,4,5,5-
tetram ethyl -1,3,2-di oxaborol an-2-y1 )m ethy1]-1,3,2- di oxaborol ane (14.1
g, 52.6 mmol, 2.5 eq) in
THF (10 mL) was added to the reaction mixture. The reaction mixture was
stirred at 0 C for 30
min. Then 5-bromo-2-hydroxy-3-(trifluoromethoxy)benzaldehyde (6 g, 21.1 mmol,
1 eq) in THF
(10 mL) was added to the reaction mixture at 0 C under N2. The reaction
mixture was stirred at
255
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
25 C for 40 min. LCMS showed the starting material was consumed completely
and desired MS
detected. The reaction mixture was poured into aq. NH4C1 (150 mL) and stirred
for 10 min. The
aqueous phase was extracted with ethyl acetate (100 mL x 3). The combined
organic phases were
dried with anhydrous Na2SO4, filtered and concentrated under reduce pressure
to give a residue.
The residue was purified by column chromatography (SiO2, Eluent of 5-95% Ethyl
acetate/Petrol eum ether gradient) to give compound 4-brom o-2-[(E)-2-(4,4,
5,5 -tetram ethyl -1,3 ,2-
di oxab orolan-2-yl)viny1]-6-(trifluoromethoxy)phenol (13.2 g, crude) as
yellow oil.
[0405]
53.6 Preparation of 6-bromo-2-hydroxy-8-(trifluoromethoxy)-1,2-benzoxaborinine
OCF3 OCF3
OH I r(P PY)3 0,13,0H
MeCN, 25 C, 16 h
Br BPin Br
To a solution of 4-brom o-2-[(E)-2-(4,4, 5,5-tetra m ethyl -1,3,2-di
oxaborol an -2-y1 )vi ny1]-6-
(trifluoromethoxy)phenol (1.72 g, 4.21 mmol, 1 eq) in MeCN (18 mL) was added
tris[2-(2-
pyridyl)phenyl]iridium (Ir(PPY)3, 69 mg, 105 umol, 0.025 eq) in one portion at
25 C under N2
atmosphere. The reaction mixture was stirred at 25 C and irradiated using 34W
blue LED lamps
for 16 h. TLC (petroleum ether: ethyl acetate=5:1) showed the reaction was
completed. After
filtration, compound 6-bromo-2-hydroxy-8-(trifluoromethoxy)-1,2-
benzoxaborinine (850 mg,
65.5% yield) was obtained as a yellow solid without further purification. ill
NMR (400 MHz,
DMSO-d6) 5 9.52 (br s, 1 H), 7.86 (d, J= 2.4 Hz, 1 H), 7.82 (d, J = 12.0 Hz, 1
H), 7.72 (d, J = 1.2
Hz, 1 H), 6.29 (d, J=11.6 Hz, 1 H).
[0406]
53.7 Preparation of 1-1trans-4-cyanotetrahydro-2H-pyran-3-y1J-3-112-hydroxy-8-
(trifluorotnethoxy)-1,2-benzoxaborinin-6-yliaminolpyrazole-4-carboxamide
i_NiNalNrH2
OCF3 OCF3
0 NH2
OH 0õOH
N-N g
Br Pd2dba3, tBuXPhos, KOAc, iPrOH
80 C, 12 h 0
NH2
To a mixture of 6-bromo-2-hydroxy-8-(trifluoromethoxy)-1,2-benzoxaborinine (2
g, 6.48 mmol,
1 eq) and 3-amino-1-[trans-4-cyanotetrahydropyran-3-yl]pyrazole-4-carboxamide
(1.52 g, 6.48
256
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
mmol, 1 eq) in i-PrOH (20 mL) was added KOAc (1.27 g, 13.0 mmol, 2 eq) in one
portion at 25 C
under N2. Then ditert-butyl-[2-(2,4,6-triisopropylphenyl)phenyl]phosphane (495
mg, 1.17 mmol,
0.18 eq) and Pd2(dba)3 (534 mg, 583 umol, 0.09 eq) was added to the reaction
mixture at 25 C
under N2. The system was degassed and purged with N2 for 3 times and stirred
at 25 C for 5 min,
then the reaction was heated to 80 C and stirred for 12 hours. LCMS showed the
reaction was
completed and desired MS observed. The reaction mixture was cooled to 25 C and
poured into
water (100 mL). The aqueous phase was extracted with ethyl acetate (80 mL x
3). The combined
organic phase was washed with brine (50 mL x 2), dried over anhydrous Na2SO4,
filtered and
concentrated under reduce pressure to give a residue. The residue was purified
by prep-HPLC
(HC1 condition: column: Phenomenex luna C18 (250*70mm,15 um);mobile phase:
[water (HC1)-
ACN];B%: 24%-54%,20min) to give desired compound 1-[trans-4-
cyanotetrahydropyran-3-y1]-3-
[[2-hydroxy-8-(trifluoromethoxy)-1,2-benzoxaborinin-6-yl]amino]pyrazole-4-
carboxamide (700
mg, yield 23.3%, purity 98.3%) as a white solid. 1H NM-R (400 MHz, DMSO-d6) 6
9.20 (s, 2 H),
8.31 (s, 1 H), 7.92 (d, J= 1.2 Hz, 1 H), 7.84 (d, J= 11.6 Hz, 1 H), 7.79 -
7.69 (m, 1 H), 7.62 (d, J
= 2.4 Hz, 1 H), 7.30 - 7.14 (m, 1 H), 6.21 (d, J= 11.6 Hz, 1 H), 4.59 (td, J=
10.0, 4.4 Hz, 1 H),
4.06 (dd, .1=11.2, 4.4 Hz, 1 H), 4.01-3.89 (m, 1 H), 3.72-3.57 (m, 2 H), 3.48-
3.43 (m, 1 H), 2.25-
2.10 (m, 1 H), 2.08-1.90 (m, 1 H). MS (ESI): mass calculated for
C19fl17BF3N505 463.13; m/z
found 464.0 [M-41]+. HPLC: 98.34% (220 nm), 99.48% (254 nm). 1-[trans-4-
cyanotetrahydro-
2H-pyran-3 -yl] -3- [[2-hydroxy-8-(trifluoromethoxy)-1,2-benzoxaborinin-6-
yl]amino]pyrazole-4-
carboxamide (1.08 g) was separated by SFC (condition: column: DAICEL CHIRALPAK
IC(250mm*30mm,10um);mobile phase: [Neu-IPA];B%: 33%-33%,6min) to give 1-[trans-
4-
cyanotetrahy dr-2H-opy ran-3 -yl] -3 -[ [2-hy droxy-8-(trifluorom ethoxy)-1,2-
b enz ox ab orini n-6-
yl]amino]pyrazole-4-carboxamide (stereoisomer one) (319 mg, 31.9% yield, 100%
ee , first peak,
Rt = 1.074 min) as a white solid. 1H NMR (400 MHz, DMSO-d6) 6 9.19 (d, J=2.0
Hz, 2 H), 8.31
(s, 1 H), 7.92 (d, J=1.2 Hz, 1 H) 7.84 (d, J=12.0 Hz, 1 H), 7.75 (br d, J=5.2
Hz, 1 H), 7.61 (d,
J=2.8 Hz, 1 H), 7.31 -7.12 (m, 1 H), 6.21 (d, J=11.6 Hz, 1 H), 4.58 (td,
J=10.0, 4.4 Hz, 1 H), 4.06
(dd, J=11.2, 4.4 Hz, 1 H), 3.99 - 3.88 (m, 1 H), 3.70 -3.60 (m, 3 H), 2.23 -
2.11 (m, 1 H), 2.07 -
1.89 (m, 1 H). MS (ESI): mass calculated for C19111713F3N505 463.13; m/z found
464.0 [M+H].
HPLC: 98.85% (220 nm), 99.58% (254 nm). and 1-[trans-4-cyanotetrahydr-2H-
opyran-3-y1]-3-
[[2-hydroxy-8-(trifluoromethoxy)-1,2-benzoxaborinin-6-yl]amino]pyrazole-4-
carboxamide
(stereoisomer two) (349 mg, 34.9% yield, 96.4% cc, second peak, Rt = 1.184
min) as a white solid.
257
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
NMR (400 MHz, DMSO-do) 6 9.30 - 9.21 (m, 2 H), 8.38 (s, 1 H), 7.99 (d, J=1.2
Hz, 1 H), 7.90
(d, J=12.0 Hz, 1 H), 7.81 (br s, 1 H), 7.68 (d, J=2.8 Hz, 1 H), 7.37 - 7.22
(m, 1 H), 6.28 (d, J=11.6
Hz, 1 H), 4.65 (td, J=10.0, 4.4 Hz, 1 H), 4.13 (dd, J=11.2, 4.4 Hz, 1 H), 4.05
-3.95 (m, 1 H), 3.77
- 3.64 (m, 2 H), 3.54 - 3.48 (m, 1 H), 2.09 - 2.08 (m, 1 H), 2.06 - 2.03 (m, 1
H). MS (ESI): mass
calculated for C19H17BF3N505 463.13; m/z found 464.0 [M+14] . HPLC: 99.21%
(220 nm), 99.68%
(254 nm).
[0407]
54. Preparation of 1-(trans-4-eyanotetrahydro-2H-pyran-3-y1)-3-05-fluoro-2-
hydroxy-2H-
benzole 1[1,21oxaborinin-6-yhamino)-1H-pyrazole-4-earboxamide
Br = ()me LDA, DMF Br OMe BBr3 Br OH
410 OH
THE, -65 C,0.5 h F CHO DCM, 10-2000, 1.5 h F CHO
LDA, PMDTA, Br HPin
THF, 0-25 C,1 h
//,
i_Nirsic_x;r1H2
0õH () NH2
BO 0, OH
Ir(PPY)3 int.A 0 N-N 010 B'
MeCN, 25cC, 16 h Br Pd2dba3, tBuXPhos KOAc,
iPrOH,100 00,2 h
NH2
[0408]
54.1 Preparation of 3-bromo-2-fluoro-6-methoxybenzaldehyde
Br OMe LDA, DMF Br 4* OMe
THF, -65 C,0.5 h
F CHO
To a solution of 1-bromo-2-fluoro-4-methoxy-benzene (4 g, 19.5 mmol, 1 eq) in
THF (40 mL)
was added LDA (11.7 mL, 2 M, 1.2 eq) at -65 C. The mixture was stirred -65 C
for 20 mins.
Then dropwise added DMF (1.71 g, 23.4 mmol, 1.80 mL, 1.2 eq) at -65 C, The
mixture was
stirred at -65 C for 10 mins. TLC showed the reaction was completed. The
reaction mixture was
quenched with aq. NTI4C1 (100 mL) and extracted with Et0Ac (30 mL x 3). The
combined organic
layers were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered
and concentrated
under reduced pressure to give a residue. The residue was purified by silica
gel column
chromatography (PE: Et0Ac = 10:1 to 5:1) to give 3-bromo-2-fluoro-6-methoxy-
benzaldehy de
(1.8 g, 39.5% yield) as a yellow solid. NIVIR (400 MHz, DMSO-d6) 6 10.24
(d, J=1.60 Hz, 1
H) 7.93 (dd, J=9.00, 8.00 Hz, 1 H) 7.07 (dd, J=9.20, 1.16 Hz, 1 H) 3.92 (s, 3
H).
[0409]
258
CA 03201606 2023- 6-7
WO 2022/133420 PCT/US2021/072885
54.2 Preparation of methyl 3-bromo-2-fluoro-6-hydroxybenzaldehyde
Br OMe BBr3 Br OH
DCM, -10-20 C,1.5 h
F CHO F CHO
To a solution of 3-bromo-2-fluoro-6-methoxy-benzaldehyde (1.8 g, 7.72 mmol, 1
eq) in DCM (20
mL) was added BBr3 (5.42 g, 21.6 mmol , 2.8 eq) at -10 C. The reaction was
allowed to warm to
20 C and stirred at 20 C for 1 5 h. TLC showed the reaction was completed. The
reaction mixture
was quenched with saturated NaHCO3 aqueous solution (50 mL) and extracted with
Et0Ac (20
mL x 3). The combined organic layers were washed with brine (25 mL), dried
over anhydrous
Na2SO4, filtered and concentrated under reduced pressure to give 3-bromo-2-
fluoro-6-hydroxy-
benzaldehyde (1.3 g, crude) as a yellow solid used directly for next step
without further purification.
1H NMR (400 MHz, DMSO-d6) 6 11.35 (s, 1 H) 10.22 (s, 1 H) 7.78 (dd, J=8.80,
8.00 Hz, 1 H)
6.82 (dd, J=9.00, 1.20 Hz, 1 H).
[0410]
54.3 Preparation of (E)-4-bromo-3-fluoro-2-(2-(4,4,5,5-tetramethy1-1,3,2-
dioxaborolan-2-
Avinyl)phenol
OH
Br = OH
PinB BPin
1"-- Br BPin
F CHO LDA, PMDTA,
THF, 0-25 C,1 h
A solution of LDA (7.4 mL, 2N, 2.5 eq) in TUE (13 mL) was added N'42-
(dimethylamino)ethy1]-
N,N,N-trimethyl-ethane-1,2-diamine (2.00 g, 11.8 mmol , 2 eq) and 4,4,5,5-
tetramethy1-2-
[(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)methyl]-1,3,2-dioxaborolane
(3.18 g, 11.8 mmol, 2
eq), and then the mixture was stirred at 0 C for 20 mins under N2 atmosphere.
Then dropwise
added 3-bromo-2-fluoro-6-hydroxy-benzaldehyde (1.3 g, 5.94 mmol, 1 eq) at 0 C.
The reaction
was allowed to warm to 25 C and stirred at 25 C for 40 ruins under N2
atmosphere. TLC showed
the reaction was completed. The reaction mixture was quenched with aq.NH4C1
(50 mL) and
extracted with Et0Ac (20 mL x 3). The combined organic layers were washed with
brine (50 mL),
dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure
to give a residue.
The residue was purified by silica gel column chromatography (PE:Et0Ac = 100:1
to 10:1) to give
4-bromo-3 uoro-2-[(E)-2-(4,4, 5, 5-tetram ethy1-1 ,3 ,2-di ox aborol an-2-y1
)vinyl ]ph en ol (1 .2 g, 58.9%
yield) as a yellow solid.
259
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
[0411]
54.4 Preparation of 6-bromo-5-fluoro-2H-benzofe][1,21oxaborinin-2-ol
OH 0,BOH
Ir(PPY)3
Br BPin Br
MeCN, 25 C, 16h
To a solution of 4-b rom o-3 -fluoro-2- [(E)-2-(4,4, 5,5 -tetram
ethyl-1,3 ,2-di oxab orol an-2 -
yl)vinyl]phenol (1.2 g, 3.50 mmol, 1 eq) in MeCN (15 mL) was added tris[2-(2-
pyridyl)phenyl]iridium (Ir(PPY)3, 57.2 mg, 87.4 umol, 0.025 eq). The reaction
mixture was stirred
at 25 C and irradiated using 34W blue LED lamps for 16 hrs. TLC showed the
reaction was
completed. The reaction mixture was concentrated under reduced pressure to
give 6-bromo-5-
fluoro-2-hydroxy-1,2-benzoxaborinine (1.8 g, crude) used for the next step
without further
purification.
[0412]
54.5 Preparation of 1-(trans-4-eyanotetrahydro-2H-pyran-3-y0-3-05-fluoro-2-
hydroxy-2H-
benzoleffl,2Joxaborinin-6-y0amino)-1H-pyrazole-4-carboxamide
././/
N NH2
N OR ¨N
B 0 H2
N 0BõOH
j
int.A ( 4110l¨N
Br
Pd2dba3, tBuXPhos, KOAc,
iPrOH,16 h
0
NH2
A mixture of 3-amino-1-(trans-4-cy anotetrahy dropy ran-3 -yl)p y razol e-4-
carb oxami de (100 mg,
425 umol, 1 eq), 6-bromo-5-fluoro-2-hydroxy-1,2-benzoxaborinine (155 mg, 637
umol, 1.5 eq),
Pd2(dba)3 (38.9 mg, 42.5 umol, 0.1 eq), t-Bu Xphos (36.0 mg, 85.0 umol, 0.2
eq) and K2CO3 (117
mg, 850 umol, 2 eq) in i-PrOH (5 mL) was degassed and purged with N2 for 3
times, and then the
mixture was stirred at 100 C for 2 hrs under N2 atmosphere. LCMS showed the
reaction was
completed. Then the reaction mixture was filtered and the filtrate was
concentrated under reduced
pressure to give a residue. The residue was quenched with H20 (10 mL) and
extracted with Et0Ac
(5 mL x 3). The combined organic layers were washed with brine (5 mL), dried
over anhydrous
Na2SO4, filtered and concentrated under reduced pressure to give a residue.
The residue was
purified by silica gel column chromatography (PE: Et0Ac = 5:1 to 3: 1 ) to
give 160 mg crude
compound. The crude compound was further purified by prep-FIPLC (HC1
condition, column:
260
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
Phenomenex luna C18 80*40mm*3 um;mobile phase: [water (HC1)-ACN];B%: 27%-
42%,7min)
to give 116 mg crude compound. The crude compound was further purified by prep-
HPLC (neutral
condition, column: Waters Xbridge BEH C18 100*30mm*10um; mobile phase: [water
(NH4HCO3)-ACN];B%: 20%-40%,10min)x3 to give 1 -(trans-4-cyanotetrahydro-2H-
pyran-3 -y1)-
3-[(5-fluoro-2-hydroxy-1,2-benzoxaborinin-6-yl)amino]pyrazole-4-carboxamide
(60.2 mg, 35.6%
yield) as a white solid. ITINMR (400 MHz, DMSO-d6) 6 9.38 (d, J=2.80 Hz, 1 H)
9.02-9.09 (m,
1 H) 8.28-8.39 (m, 2 H) 7.97 (d, J=12.00 Hz, 1 H) 7.77 (br s, 1 H) 7.22 (br s,
1 H) 7.06 (d, J=9.00
Hz, 1 H) 6.23 (d, J=12.00 Hz, 1 H) 4.58 (td, J=10.00, 4.38 Hz, 1 H) 4.03 (dd,
J=11.2, 4.38 Hz, 1
H) 3.91 (br d, J=10.4 Hz, 1 H) 3.64-3.77 (m, 2 H) 3.46-3.55 (m, 1 H) 2.15 (br
d, J=9.60 Hz, 1 H)
1.91-2.06 (m, 1 H). MS (ESI): mass calculated for C18H17BFN504397.14; m/z
found 396.1 [M-
H]. HPLC: 97.84% (220 nm), 98.55% (254 nm).
[0413]
55. Preparation of 1-ftrans -4-eyanotetrahydro-2H-pyran-3-ylj -3-[(8-
cyclopropy1-2-hydroxy-1,
2-benzoxaborinin-6-y1) aminolpyrazole-4-carboxamide
V
Br OH V
NBS, CH3CN LDA, PMDTA, THF
OH OH OH ____________ OH
OH
Pd(0A02, K3PO4, P(CY)3 -10 C, 75mi: 0 C, 3.5 hrs, N2
toluene/H20 CHO Br CHO Br -- BPin
100 C, 18 hrs
\O¨r14
_1\1:x17:H2
Int A 0
Pd2dba3, tBuXPhos, KOAc, iPrOH
0,B4OH
Ir(PPY)3 0õOH ___________________________ N¨N
MeCN, 25 C, 16 h 90 C,16 h, N2
Br
0
NH2
[0414]
55.1 Preparation of 3-cyclopropy1-2-hydroxy-benzaldehyde
10H
Br V
OH OH 41, OH
Pd(OAc)2, K3PO4, P(Cy)3
toluene/H20, CHO
100 C, 18 hrs
A mixture of cyclopropylboronic acid (1.71 g, 19.9 mmol, 2 eq), 3-bromo-2-
hydroxy-
benzaldehyde (2 g, 9.95 mmol, 1 eq), K3PO4 (7.39 g, 34.8 mmol, 3.5 eq),
Pd(OAc)2 (446 mg, 1.99
261
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
mmol, 0.2 eq) and tricyclohexylphosphane (1.12 g, 3.98 mmol, 1.29 mL, 0.4 eq)
in toluene (40
mL) and H20 (10 mL) at 25 C was degassed and purged with N2 for 3 times, and
then the mixture
was heated and stirred at 100 C for 18 hrs under N2 atmosphere. TLC showed the
reaction was
completed. The reaction mixture was concentrated under reduced pressure to
remove toluene, and
then adjusted pH to 6 with 2N HC1. The reaction was extracted with Et0Ac (50
mL x 3). The
combined organic layers were washed with brine 50 mL, dried over Na2SO4,
filtered and
concentrated under reduced pressure to give a residue. The residue was
purified by flash silica gel
chromatography (ISCO , 120 g SepaFlashe Silica Flash Column, Eluent of 0-10%
Ethyl
acetate/Petroleum ether gradient @ 50 mL/min) to give 2-hy droxy -3 -
(trifluoromethyl)
benzaldehyde (10.7 g, 65.1% yield) as yellow oil. 11-1 NMR (CDC13, 400 MHz) 6
11.40 (s, 1H),
9.89 (s, 1H), 7.38 (dd, J= 1.6, 7.6 Hz, 1H), 7.12 (dd, J= 0.8, 7.2 Hz, 1H),
6.95-6.92 (m, 1H), 2.24-
2.19 (m, 1H), 1.03-0.98 (m, 2H), 0.72-0.69 (m, 2H).
[0415]
55.2 Preparation of 5-bromo-3-eyelopropyl-2-hydroxy-benzaldehyde
NBS, CH3CN
OH ______________________________________________________ OH
-10 C, 75min
CHO Br CHO
To a solution of 3-cyclopropy1-2-hydroxy-benzaldehyde (5.1 g, 31.4 mmol, 1 eq)
in CH3CN (100
mL) was added 1-bromopyrrolidine-2, 5-dione (6.72 g, 37.7 mmol, 1.2 eq) at -10
C. The mixture
was stirred at -10 C for 75 min. TLC showed the reaction was completed. The
reaction mixture
was poured into H20 (50 mL) and extracted with Et0Ac (50 mL x 3). The combined
organic
layers were washed with brine (30 mL x 3), dried over Na2SO4, filtered and
concentrated under
reduced pressure to give a residue. The residue was purified by flash silica
gel chromatography
(ISCO ; 80 g SepaFlash Silica Flash Column, Eluent of 0-10% Ethyl
acetate/Petroleum ether
gradient @ 50 mL/min) to give 5-bromo-3-cyclopropy1-2-hydroxy-benzaldehyde
(5.6 g) as a
yellow solid. 1-11 NMIt (CDC13, 400 MHz) 6 11.31 (s, 1H), 9.83 (s, 1H), 7.48
(d, J= 2.4 Hz, 1H),
7.17 (d, J= 2.4 Hz, 1H), 2.22-2.17 (m, 1H), 1.07-1.00 (m, 2H), 0.74-0.66 (m,
2H).
[0416]
55.3 Preparation of 4-hromo-2-cyclopropy1-6-1(E) -2-(4, 4, 5, 5-tetramethyl-1,
3, 2-
dioxaborolan-2-y1) vinyl] phenol
262
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
V PinB BPin
LDA, PMDTA, THF
OH _______________________________________________ = OH
0 C, 3.5 hrs, N2
Br CHO Br BPin
To a solution of LDA (19 mL, 2N, 2 eq) in THF (50 mL) was added N'[2-
(dimethylamino)ethyl]
-N, N, N'-trimethyl-ethane-1, 2-diamine (6.61 g, 38.1 mmol, 7.97 mL, 2 eq) and
4, 4, 5, 5-
tetramethy1-2-[(4,4,5,5-tetramethy1-1, 3, 2-dioxaborolan-2-y1) methyl] -1, 3,
2-dioxaborolane
(10.2 g, 38.1 mmol, 2 eq) in portions at 0 C over 10 mins under N2. The
mixture was continue
stirred at 0 C for 20 mins. Then a solution of 5-bromo-3-cyclopropy1-2-hydroxy-
benzaldehyde
(4.6 g, 19.0 mmol, 1 eq) in THE (5 mL) was added at 0 C. The resulting mixture
was stirred at
0 C for another 3 hrs. TLC showed the reaction was completed. The reaction
mixture was
quenched by addition of sat. aq. NH4C1 (50 mL) at 0 C, and then extracted with
Et0Ac (50 mL x
3). The combined organic layers were washed with brine (30 mL x 3), dried over
Na2SO4, filtered
and concentrated under reduced pressure to give a residue. The residue was
purified by flash silica
gel chromatography (ISCOR; 40 g SepaFlashe Silica Flash Column, Eluent of 0-
10% Ethyl
acetate/Petroleum ether gradient @ 60 mL/min) to give 4-bromo-2-cyclopropy1-6-
[(E)-2-(4, 4, 5,
5-tetramethy1-1, 3, 2-dioxaborolan-2-y1) vinyl]phenol (6 g, 86.1% yield) as a
yellow solid. 1H
NMR (CDC13, 400 MHz) 6 = 7.64 (d, J = 18.4 Hz, 1H), 7.49 (d, J= 2.4 Hz, 1H),
7.15 (d, J= 2.4
Hz, 1H), 6.15 (d, J= 18.4 Hz, 1H), 5.80 (s, 1H), 1.80-1.71 (m, 11-1), 1.31 (s,
12H), 1.04-0.98 (m,
2H), 0.67-0.60 (m, 2H).
[0417]
55.4 Preparation of 6-bromo-8-eyelopropy1-2-hydroxy-1,2-benzoxaborinine
OH Ir(PPY)3 r'i0,B-
OH
MeCN, 25 C, 16h
Br BPin Br
To a mixture of 4-bromo-2-cyclopropy1-6-[(E) -2-(4, 4, 5, 5-tetramethy1-1,3,2-
dioxaborolan-2-y1)
vinyl]phenol (3 g, 8.22 mmol, 1 eq) in MeCN (20 mL) was added tris[2-(2-
pyridyl) phenyl] iridium
(Ir(PPY)3, 53 mg, 82.1 umol, 0.01 eq). The reaction mixture was stirred at 25
C and irradiated
using 34W blue LED lamps for 16 hrs. TLC showed the reaction was completed.
The reaction
mixture was quenched with water (30 mL) and extracted with Et0Ac (30 mL x 3).
Then the
organic phases were washed with brine (20 mL x 2), dried over Na2SO4, filtered
and concentrated
263
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
under reduced pressure to give a residue. The residue was purified by column
chromatography
(SiO2, Petroleum ether/Ethyl acetate= 1/0 to 20/1) to give 6-bromo-8-
cyclopropy1-2-hydroxy-1, 2-
benzoxaborinine (2.4 g, 55.1% yield) as a yellow solid. 1-11NMR (CDC13, 400
MHz) 6 7.68 (d, J=
12.0 Hz, 1H), 7.35 (d, .1= 2.4 Hz, 1H), 7.00 (d, J= 2.4 Hz, 1H), 6.27 (d, .1=
12.0 Hz, 1H), 4.51 (s,
1H), 2.45-2.39 (m, 1H), 1.08-1.02 (m, 2H), 0.76-0.70 (m, 2H).
[0418]
55.5 Preparation of 1-(trans-4-eyanotetrahydro-2H-pyran-3-y1)-3-[(8-
cyclopropyl-2-hydroxy-1,
2-benzoxaborinin-6-y1) amino] pyrazole-4-carboxamitle
j\ta ;IF, 2
0 NH2
Int A 0 0 õ
Pd2dba3, tBuXPhos, KOAc, iPrOH
0õOH
B4OH ________________________________________________________ N-N
90 C,16 h, N2
Br
0 NH2
A mixture of 3-amino-1 -(trans-4-cy anotetrahy dro-2H-py ran-3 -yl)pyrazol e-4-
carb oxami de (500
mg, 2.13 mmol, 1 eq), 6-bromo-8-cyclopropy1-2-hydroxy-1,2-benzoxaborinine (844
mg, 3.19
mmol, 1.5 eq), KOAc (417 mg, 4.25 mmol, 2 eq), Pd2(dba)3 (389 mg, 425 umol,
0.2 eq) and t-Bu
Xphos (361 mg, 850 umol, 0.4 eq) in i-PrOH (15 mL) was degassed and purged
with N2 for 3
times, and then the mixture was stirred at 90 'V for 16 h under N2 atmosphere.
LCMS indicated
the reaction was completed and desired MS observed. The reaction was cooled to
room
temperature and filtered. The filtrate was concentrated under reduced pressure
to give a residue.
The residue was purified by flash silica gel chromatography (ISC08; 80 g
SepaFlashe Silica
Flash Column, Eluent of 0-15% Ethyl acetate/Petroleum ether gradient @ 60
mL/min) to give
crude product (2.8 g) as yellow solid, which was further purified by prep-
IIPLC (column:
Phenomenex luna Cis 250*50mm*10 um; mobile phase: [water(HC1)-ACN]; B%: 30%-
60%, 10
min) to give 1-(4-cy anotetrahy dropyran-3 -y1) -3 -[(8-cy cl opropy1-2-hy
droxy-1, 2-b enzoxab orinin-
6-y1) amino] pyrazole-4-carboxamide (1.1 g, 2.62 mmol, 61.7% yield, 100%
purity) as a yellow
solid. 111 NNIR (CDC13, 400 MHz) 6 = 8.94 (s, 1H), 8.27 (s, 1H), 7.79 (d, J=
12.0 Hz, 1H), 7.68
(br s, 1H), 7.52 (d, J= 2.4 Hz, 1H), 7.14 (br s, 1H), 7.04 (d, .1= 2.4 Hz,
1H), 6.11 (d, J= 12.0 Hz,
1H), 4.55 (dt, J= 4.4, 10.0 Hz, 1H),4.06 (dd, J= 4.4, 11.2 Hz, 1H), 3.94 (br
d, J= 10.0 Hz, 1H),
264
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
3.73-3.60 (m, 2H), 3.52-3.42 (m, 1H), 2.44-2.38 (m, 1H), 2.18 (br d, J= 10.0
Hz, 1H), 2.06-1.97
(m, 1H), 1.04-0.94 (m, 2H), 0.79-0.70 (m, 2H). MS (ESI): mass calculated for
C211-122BN504
419.25; m/z found 420.3 [M-FFI]t HPLC: 100% (220 nm), 100% (254 nm). 1-(trans-
4-
cyanotetrahydro-2H-pyran-3-y1) -3-[(8-cyclopropy1-2-hydroxy-1, 2-
benzoxaborinin-6-y1) amino]
pyrazole-4-carboxamide (800 mg) was separated by SFC (condition: column:
REGIS(S,S)WHELK-01(250mm x 25mm,10um); mobile phase: [0.1%NH3H20 ETOH];B%:
45%-45%, 6 min) to give 1-[trans-4-cyanotetrahydro-2H-pyran-3-yl] -3-[(8-
cyclopropy1-2-
hydroxy-1, 2-benzoxaborinin-6-y1) amino] pyrazole-4-carboxamide (stereoisomer
one) 265.5 mg,
32.8% yield, 99.0% purity, 99.3% cc, first peak, Rt = 1.522 min) as a white
solid. 1H N1VIR
(DMSO-d6, 400 MHz) 6 = 8.94 (s, 1H), 8.76 (s, 1H), 8.27 (s, 1H), 7.79 (d, J=
12.0 Hz, 1H), 7.68
(brs, 1H), 7.52 (d, J= 2.4 Hz, 1H), 7.09 (m, 1H), 7.04 (d, J= 2.4 Hz, 1H),
6.11 (d, J= 11.6 Hz,
1H), 4.56 (dt, J= 4.4, 10.2 Hz, 1H), 4.06 (dd, J= 4.4, 11.2 Hz, 1H), 3.94 (br
d, J= 10.0 Hz, 1H),
3.73-3.60 (m, 2H), 3.52-3.42 (m, 1H), 2.44-2.38 (m, 1H), 2.18 (d, J= 10.0 Hz,
1H), 2.06-1.97 (m,
1H), 1.04-0.94 (m, 2H), 0.79-0.70 (m, 2H). MS (ESI): mass calculated for
C21H22BN504 419.25;
m/z found 420.2 [M+H]. HPLC: 98.68% (220 nm), 99.53% (254 nm) and 1-[trans-4-
cyanotetrahydro-2H-pyran-3-yl] -3-[(8-cyclopropy1-2-hydroxy-1, 2-
benzoxaborinin-6-y1) amino]
pyrazole-4-carboxamide (stereoisomer two) 194.6 mg, 24.0% yield, 98.6% purity,
98.2% ee,
second peak, Rt = 1.670 min) as a white solid. 1H NMR (DMSO-do, 400 MHz) 5 =
8.94 (s, 1H),
8.77 (s, 1H), 8.27 (s, 1H), 7.79 (d, J= 12.0 Hz, 1H), 7.74-7.61 (m, 1H), 7.52
(d, J= 2.4 Hz, 1H),
7.22-7.08 (m, 1H), 7.04 (d, .1= 2.4 Hz, 1H), 6.11 (d, .1= 12.0 Hz, 1H), 4.55
(dt, .1=4.4, 10.0 Hz,
1H), 4.06 (dd, J= 4.4, 11.2 Hz, 1H), 3.98-3.90 (m, 1H), 3.73-3.60 (m, 2H),
3.50-3.45 (m, 1H),
2.43-2.36 (m, 1H), 2.18 (d, J= 9.6 Hz, 1H), 2.06-1.92 (m, 1H), 1.06-0.95 (m,
2H), 0.82-0.69 (m,
2H) MS (ESI): mass calculated for C211-122BN504 419.25, m/z found 420.2 [M+H]
. HPLC: 100.00%
(220 nm), 100.00% (254 nm).
[0419]
56. Preparation of 1-(trans-4-eyanotetrahydro-211-pyran-3-y1)-3-[(3-ethyl-2-
hydroxy-1,2-
benzoxaborinin-6-yl)aininokyrazole-4-carboxamide
265
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
ain OH
B2Pin2 111--LIP 3
0, OH
0- Br ,
13'
1
Cul, t-BuONa, PhMe, LDA,
PMDTA, THF, Br --- --
100 C, 15h 0 C, 35h
0
OQ'"CN
I-12N N Nd' A
Pd2dba3, tBuXPhos, KOAc,
iPrOH, 85 C, 24 h
0 NH2
[0420]
56.1 Preparation of 4,4,5,5-tetramethy1-2-11-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-y1)
propy11-1,3,2-dioxaborolane
B2Pin2
o_
Cul, t-BuONa, PhMe, 0 0
100 C, 15 h
A mixture of propanal (0.5 g, 8.61 mmol, 626 uL, 1 eq), 4,4,5,5-tetramethy1-2-
(4,4,5,5-
tetramethy1-1,3,2-dioxaborolan-2-y1)-1,3,2-dioxaborolane (B2Pin2, 4.81 g, 18.9
mmol, 2.2 eq),
CuI (164 mg, 860 umol, 0.1 eq) and t-BuONa (1.08 g, 11.2 mmol, 1.3 eq) in
toluene (14 mL) was
degassed and purged with N2 for 3 times, and then the mixture was heated and
stirred at 100 C for
15 h under N2 atmosphere. The reaction was cooled to room temperature and
filtered. The filtrate
from 8 parallel reactions was concentrated under reduced pressure to give a
residue. The residue
was purified by flash silica gel chromatography (ISCOg; 220 g SepaFlash
Silica Flash Column,
Eluent of 0-20% Ethyl acetate/Petroleum ether gradient @ 100 mL/min) to give
4,4,5,5-
tetram ethy1-2-[1 -(4, 4,5,5-tetram ethyl-1,3 ,2-di oxab orol an-2-yl)propyl] -
1,3 ,2 -di oxab orol ane (9 g,
44.1% yield) as colorless oil. NMR (CDC13, 400 MHz) 6 1.60 (q, .1 = 7.6 Hz,
1H), 1.24-1.23
(m, 24H) 0.93 (q, J= 7.6 Hz, 1H), 0.67 (q, J= 7.6 Hz, 1H).
[0421]
56.2 Preparation of 6-bromo-3-ethyl-2-hydroxy-1,2-benzoxaborinine
266
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
OH
,0 3 0õOH
Br B
(14<- LDA, PMDTA, THF, Br
0 C, 3.5 h
To a solution of LDA (2 M, 5.7 mL, 2.3 eq) in THF (10 mL) was added N'42-
(dimethylamino)ethy1]-N,N,N'-trimethyl-ethane-1,2-diamine (1.98 g, 11.4 mmol,
2.4 mL, 2.3 eq)
and 4,4, 5,5 -tetram ethy1-2- [1 -(4,4,5,5 -tetram ethyl -1,3 ,2-di
oxab orol an-2-yl)propyl] -1,3,2 -
dioxaborolane (3.38 g, 11.4 mmol, 2.3 eq) in portions at 0 C over a period of
10 min under N2.
The mixture was stirred at 0 C for additional 20 min. Then a solution of 5-
bromo-2-hydroxy-
benzaldehyde (1 g, 4.97 mmol, 1 eq) in THF (5 mL) was added to the above
mixture at 0 C, the
resulting mixture was stirred at 0 C for 3 h. TLC showed the reaction was
completed. The reaction
mixture was quenched by addition of sat. aq. NH4C1 (40 mL) at 0 C, and then
extracted with
Et0Ac (30 mL x 3). The combined organic layers were washed with brine (20 mL x
3), dried over
Na2SO4, filtered and concentrated under reduced pressure to give a residue.
The residue was
purified by flash silica gel chromatography (ISCO(11); 40 g SepaFlash Silica
Flash Column, Eluent
of 0-70% Ethylacetate/Petroleum ether gradient @, 75 mL/min) to give 6-bromo-3-
ethy1-2-
hydroxy-1,2-benzoxaborinine (500 mg, 39.7% yield) as yellow oil. IFINMR (DMSO-
d6, 400 MHz)
6 9.06 (s, 1H), 7.68 (d, J = 2.8 Hz, 1H), 7.50-7.43 (m, 2H), 7.15 (d, J= 8.8
Hz, 1H), 2.40 (q, 1=
7.6 Hz, 2H), 1.10 (q, J= 7.6 Hz, 3H).
[0422]
56.3 Preparation of 1-(trans-4-eyanotetrahydr-2H-opyran-3-y1)-34(3-ethy1-2-
hydroxy-1,2-
benzoxaborinin-6-yl)aminolpyrazole-4-carboxamide
0
H2N -jC-N ¨0
OgCN
0,BõOH H2N - N A
C N N
H
Pd2dba3, tBuXPhos, KOAc,
Br
iPrOH, 85 C, 24 h
0 NH2
A mixture of 3-amino-1-(trans-4-cyanotetrahydro-2H-pyran-3-yl)pyrazole-4-
carboxamide (279
mg, 1.19 mmol, 1.2 eq), 6-bromo-3-ethyl-2-hydroxy-1,2-benzoxaborinine (250 mg,
988 umol, 1
eq), KOAc (145 mg, 1.48 mmol, 1.5 eq), Pd2(dba)3 (45.2 mg, 49 umol, 0.05 eq)
and t-BuXphos
(42 mg, 99 umol, 0.1 eq) in i-PrOH (15 mL) was degassed and purged with N2 for
3 times, and
267
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
then the mixture was stirred at 85 C for 24 h under N2 atmosphere. LCMS showed
the reaction
was completed and desired MS observed. The reaction mixture was cooled to room
temperature
and quenched with sat. aq. NH4C1 (0.3 mL). The resulting solution was filtered
and washed with
Et0H (10 mL x 3). The filtrate was concentrated under reduced pressure to give
a residue. The
residue was purified by prep-HPLC (column: Waters Xbridge BEH C18
100*30mm*10um;
mobile phase: [water (10mM NH4HCO3)-ACN];13%: 25%-55%,10min) to give 1-(trans-
4-
cyanotetrahydro-2H-pyran-3 -y1)-3 -[(3 -ethyl-2-hydroxy-1,2-b enzoxab ori nin-
6-yl)amino]
pyrazole-4-carboxamide (107.4 mg, 12.5% yield, 94.0% purity) as a yellow
solid. 1H NMR
(DMSO-d6, 400 MHz) 6 9.06 (s, 1H), 8.73 (s, 1H), 8.28 (s, 1H), 7.69 (br s,
1H), 7.59 (d, J = 2.8
Hz, 1H), 7.53-7.44(m, 2H), 7.15 (br s, 1H), 7.09 (d, J = 9.2 Hz, 1H), 4.55
(dt, .,1 = 3.6, 10.0 Hz,
1H), 4.04 (dd, J= 4.2, 10.8 Hz, 1H), 3.91 (d, 1= 10.4 Hz, 1H), 3.70 (t, J =
10.4 Hz, 2H), 3.51 (t,
J= 11.2 Hz, 1H), 2.38 (q, J= 7.2 Hz, 2H), 2.20-2.10 (m, 1H), 2.05-1.92 (m,
1H), 1.11 (t, J= 7.2
Hz, 3H). MS (ESI): mass calculated for C2oH22BN504 407.18; m/z found 406.2 [M-
H]. HPLC:
94.08% (220 nm), 97.39% (254 nm).
[0423]
57. Preparation of 1-(trans-4-cyanotetrahydro-2H-pyran-3-y0-3-1(2-hydroxy-
la,7b-dihydro-
11-1- eyelopropakill ,21benzoxahorinin-6-y0aminolpyrazole-4-earboxamide
0
1-1,1\rit'r-=
_ NiC) OQ'"CN
...4 0,e,.OH diethylzinc, CH212,TFA_ 0 0.13,..OH H2N
0 NC N-N B N ,
- A ¨0H
0
y DCM, 0-25 C, 17 h Br 411
Pd2dba3, tBuXPhos, KOAc,
Br N
1
iPrOH, 90 C, 1.5 h H
0 NH2
[0424]
7. 1 Preparation of 6-bromo-2-hydroxy-la,7b-dihydro-1H-cyclopropa[c][1,21
benzoxaborinine
0,B,-OH
0, B4OH d iethylzinc, CH2I2,TFA
0
Br ...-- DCM, 0-25 C, 17 h 1- Br
To a mixture of ZnEt2 (1 M, 16.0 mL, 9 eq) in DCM (8 mL) was added a solution
of TFA (1.62 g,
14.2 mmol, 1.1 mL, 8 eq) in DCM (2 mL) dropwise at 0 C under N2. The mixture
was stirred at
0 C for 0.5 h. And then added CH2I2 (4.29 g, 16.0 mmol, 1.3 mL, 9 eq) drop-
wise at 0 C, the
mixture was stirred at 0 C for 0.5 h. Then added a solution of 6-bromo-2-
hydroxy-1,2-
benzoxaborinine (0.4 g, 1.78 mmol, 1 eq) in DCM (4 mL) dropwise at 0 C. The
resulting mixture
was allowed to warm to 25 C and stirred at 25 C for 16 h. LCMS showed the
reaction was
268
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
completed and desired MS observed. The reaction was poured into ice-water (20
mL) and adjusted
pH to 4 with aq.HC1 (2 N). The resulting mixture was extracted with DCM (15 mL
x 3). The
combined organic layers were washed with brine (15 mL x 2), dried over Na2SO4,
filtered and
concentrated under reduced pressure to give a residue. The residue was
purified by prep-HPLC
(column: Waters Xbridge BEH C18 100*30mm*10um; mobile phase: [water (10mM
NEI4HCO3)-
ACN];B%. 15%-45%,10min) to give 6-brom o-2-hydroxy-la,7b -di hydro-1H-cycl
opropa[c] [1,2]
benzoxaborinine (180 mg, 41.0% yield, 96.9% purity) as a white solid. 1I-1 NMR
(DMSO-do, 400
MHz) 6 8.94 (br s, 1H), 7.51 (s, 1H), 7.20 (dd, J= 2.0, 8.4 Hz, 1H), 7.46 (d,
J = 8.4 Hz, 1H), 2.29-
2.23 (m, 1H), 1.35-1.25 (m, 1H), 0.57-0.46 (m, 1H), 0.35-0.25 (m, 1H). MS
(ESI): mass calculated
for C9H8BBrO2 237.98; m/z found 237.1 [M-H]". HPLC: 96.93% (220 nm), 95.61%
(254 nm).
[0425]
57.2 Preparation of 1-(trans-4-cyanotetrahydro-2H-pyran-3-y1)-3-[(2-hydroxy-
la,7b-dihydro-
111- cyclopropa[c][1,21benzoxaborinin-6-Aaminokyrazole-4-carboxamide
OBOH 3 Q"CN
H2N N A OBOh
NC N¨N 110
Br 1 Pd2dba3, tBuXPhos, KOAc,
1111
iPrOH, 90 C, 1.5 h
0
NH2
A mixture of 3-amino-1 -(trans-4-cy anotetrahy dro-2H-py ran-3 -yl)pyrazol e-4-
c arb oxami de (118
mg, 502 umol, 1.5 eq), 6-bromo-2-hydroxy-1a,7b-dihydro-1H-
cyclopropa[c][1,2]benzoxaborinine
(80 mg, 335 umol, 1 eq), KOAc (99 mg, 1.00 mmol, 3 eq), Pd2(dba)3 (92 mg, 100
umol, 0.3 eq)
and t-Bu Xphos (85 mg, 201 umol, 0.6 eq) in i-PrOH (2 mL) was degassed and
purged with N2 for
3 times, and then the mixture was stirred at 90 C for 1.5 h under N2
atmosphere. LCMS showed
the reaction was completed and desired MS observed. The reaction mixture was
quenched by
addition of sat. aq. NEI4C1 (10 mL) at 0 C, and then extracted with Et0Ac (10
mL x 3). The
combined organic layers were washed with brine (10 mL x 2), dried over Na2SO4,
filtered and
concentrated under reduced pressure to give a residue. The residue was
purified by prep-HPLC
(column: Waters Xbridge BEH C18 100*30mm*10um; mobile phase: [water (10mM NI-
14HCO3)-
ACN];B%. 5%-35%,10min) to give 1-(trans-4-cyanotetrahydro-2H-pyran-3-y1)-3-[(2-
hydroxy-
1a,7b-dihydro-1H-cyclopropa[c][1,2] benzoxaborinin-6-yl)amino]pyrazole-4-
carboxamide (27.2
mg, 18.7% yield, 90.7% purity) as a yellow solid. 1H N1V1R (DMSO-d6, 400 MHz)
6 8.96 (s, 1H),
8.92 (s, 1H), 8.26 (s, 1H), 7.68 (br s, 1H), 7.39 (t, J = 3.2 Hz, 1H), 7.29
(dd, J= 2.4, 8.4 Hz, 1H),
269
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
7.14 (br s, 1H), 6.72 (d, J = 8.8 Hz, 1H), 4.53 (dt, J= 4.4, 9.6 Hz, 1H), 4.06-
3.98 (m, 1H), 3.92-
3.85 (m, 1H), 3.72-3.61 (m, 2H), 3.48 (t, J= 11.2 Hz, 1H), 2.35-2.25 (m, 1H),
2.20-2.10(m, 1H),
2.04-1.90 (m, 1H), 1.30 (t, J= 7.6 Hz, 1H), 0.56-0.43 (m, 1H), 0.30-0.20 (m,
1H). MS (ESI): mass
calculated for C19H20BN504 393.16; m/z found 392.2 [M-Hr. HPLC: 90.78% (220
nm), 85.19%
(254 nm).
[0426]
BIOLOGICAL EXAMPLES
[0427] The compounds of the present disclosure were tested in multiple assays
as described
below. Representative results are compiled in Table 1.
[0428] Biochemical Kinase Assay Protocol (JAK)
Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA,
0.02%
Brifilvi 35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO, where required
cofactors
were added individually to each kinase reaction.
[0429] Reaction Procedure:
1. Prepared indicated substrate in freshly prepared Base Reaction Buffer
2. Delivered any required cofactors to the substrate solution above
3. Delivered indicated kinase into the substrate solution and gently mix
4. Delivered compounds in DMSO into the kinase reaction mixture by Acoustic
technology (Echo550; nanoliter range), incubated for 20 minutes at room
temperature
5. Delivered 33P-ATP into the reaction mixture to initiate the reaction.
6. Incubated kinase reaction for 2 hours at room temperature
7. Reactions were spotted onto P81 ion exchange paper
8. Detected kinase activity by filter-binding method.
[0430] Prophetic Cytokine inhibition Assay Protocol for IL-4 and IL-31
the test compounds are solubilized in DMSO, then diluted to make appropriate
stocks for
use in the assay, and diluted in culture medium to 20X assay concentrations.
PBMC's are
plated and allowed to settle for 1 hour at 37 C, 5% CO2. Test compounds and
controls are
added to the settled PBMC's and incubated for 1 hour at 37 C, 5% CO2. The
PBMC's are
then be treated with PHA (10 lAg/mL) and incubated for 24 hours at 37 C, 5%
CO2. DMSO
is used as a positive control and dexamethasone (100 nM) was used as a
reference inhibitor
270
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
control. After the main incubation, cell culture supernatants are harvested
and assayed for the
cytokines listed above, using standard Luminex protocols. Levels of cytokine
induction are
interpolated from standard curves using 5-parameter non-linear regression
analyses, where y
= (A+((B--E)/(E-A))*((x/C)AD))))). The interpolated data is normalized to DMSO
controls and analyzed to determine IC50 values using 4-parameter non-linear
regression
analyses, where y = (A+((B-A)/(1+((C/x)AD))))
[0431] Cytokine Function assay protocols for IL-4/pSTAT6 and GM-CSF/pSTAT5:
GM-CSF/pSTAT5:
Whole blood from a healthy donor was lysed to remove red blood cells. Cells
were plated
onto a 96 well plate. Compound was added and incubated for 1 hour (at 37 C).
After 1 hour,
cells were stimulated with GM-CSF for 15 minutes. Cells were fixed and stained
with anti-
pSTAT5 antibody. After staining, cells were read on a Beckman-Coulter
CytoFLEX.
[0432] IL-4/pSTAT6:
PBMC from a healthy donor was plated onto a 96w plate. Compound was added and
incubated for 1 hour (at 37 C). After 1 hour, cells were stimulated with IL-4
for 15 minutes.
Cells were fixed and stained with anti-pSTAT6 antibody. After staining, cells
were read on a
Beckman-Coulter CytoFLEX.
[0433] Cytokine Function assay protocols for IL-31:
1. Plate DH82 cells at a density of 125,000 cells per well in a 96-well plate
and incubate
overnight in EMEM medium (ATCC 30-2003) containing 15% FBS and 10 ng/mL
canine IFNr (R&D, Cat# 781-CG-050, Lot#DIA1320011) at 37 C.
2. After 24 hr, wash with 37 "V pre-warmed PBS (100 uL/well).
3. Add serum-free MEM, 90 uL per well, 2 hr, 37 'C.
4. Add 10 uL 10x 1L-31 (40, 10, 2.5 ug/mL) in duplicate, 5 min, 37 C.
5. Remove medium, add 60 uL lysis buffer per well. Agitate on a plate shaker (-
350 rpm)
for 10 min at RT.
6. Add 12 uL lysate/50%lysate to 384-well Opaque assay plate, 25% control
lysate and lysis
buffer were added to the assay plate in duplicate as positive and negative
controls.
271
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
7. Add 6 uL Acceptor Mix, cover with aluminum foil, quickly spin at 1000 rpm,
shake at
120 rpm for 2 min, then incubate at RT for lhr.
8. Add 6 uL Donor Mix, cover with aluminum foil, quickly spin at 1000 rpm,
shake at 120
rpm for 2 min, then incubate at RT for lhr.
9. Measure the fluorescence using EnVisionTm plate reader.
[0434] Activity of Compounds
Compounds according to the present invention were tested in the Biochemical
Kinase Assay
Protocol. The results are provided below in Table 1, wherein the potency
levels A, B, and C in
the columns labeled JAK1 (range) correspond to IC50 as follows: A < 10 nM; B =
10-50 nM and
C> 50 nM. The Example Number entries formatted ##a represent stereoisomer one
and entries
formatted ##b represent stereoisomer two.
Table 1: Biochemical Kinase Inhibition Assay Results
Example JAK1 Example JAK1 Example JAK1 Example JAK1
Number (range) Number (range) Number (range) Number (range)
1 B 16b A 33 A 45b A
2 C 17a C 34 B 46o C
3 A 17b C 35 B 46b C
3a A 18 A 36 A 47a A
3h B 19 A 36a A 47h A
4 A 20 B 36b A 48 A
A 21 A 37 A 48a A
6 A 22 A 38 A 48h A
6a A 23 A 38a B 49 A
6b B 23a A 38b A 50 A
7 A 23b C 39 A 51 A
8 A 24 B 40 B Ma A
9 A 25 B 41 A 51b A
B 26 A 41a A 52 A
11 A 27 A 41b A 52ct A
12 A 27a B 42 A 52h A
13 A 27b A 42a A 53a C
13a A 28a C 42b A 53b A
13b A 28b A 43 A 54 B
14 A 29 B 43a A 55o A
14a A 30 A 43b A 55b C
14h B 30a C 44 A 56 A
A 30b A 44a A 57 A
16 A 31 A 44b A -
16a C 32 A 45a A - -
272
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
[0435] In some embodiments, the compounds of the present disclosure are potent
JAK
inhibitors. As such, the compounds may be used for the treatment or control of
inflammation, auto-immune diseases, cancer, and other disorders and
indications where
modulation of JAK would be desirable.
[0436] All publications, patents, and patent applications cited in this
specification are
incorporated herein by reference for the teaching to which such citation is
used.
[0437] Test compounds for the experiments described herein were employed in
free or salt form.
[0438] The specific responses observed may vary according to and depending on
the particular
active compound selected or whether there are present carriers, as well as the
type of
formulation and mode of administration employed, and such expected variations
or
differences in the results are contemplated in accordance with practice of the
present
invention.
[0439] Although specific embodiments of the present invention are herein
illustrated and
described in detail, the invention is not limited thereto. The above detailed
descriptions are
provided as exemplary of the present invention and should not be construed as
constituting
any limitation of the invention. Modifications will be obvious to those
skilled in the art, and
all modifications that do not depart from the spirit of the invention are
intended to be
included with the scope of the appended claims.
The invention is further described by the following numbered paragraphs:
[0440]
#1. A compound of formula (IV):
273
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
R3 X2
Xi X3
R1
R3 2
N
R4
A
\ 4/
R4/
0 R
(IV),
or a pharmaceutically acceptable salt or a stereoisomer or a tautomer thereof,
wherein
Xi is selected from the group consisting of-O-, -N(R6)-, and -
C(R7)(R8)-,
X2 is selected from the group consisting of -0-, -N(R6)-, and -
C(R7)(1e)-, or
X2 comprises a bond between Xi and X3,
X3 is selected from the group consisting of -0-, -N(R6)-, and -
C(R7)(R8)-, except Xi and X2
cannot both be -0-, and X2 and X3 cannot both be -0-;
RI- is selected from the group consisting of hydrogen, halogen
(when X3 is -C(R7)(R8)),
hydroxy, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7
cycloalkyl(oxy), wherein
the last four members of the of the above-mentioned R1 group may optionally be
substituted independently of one another with one or more halogen;
R2 is selected from the group consisting of hydrogen, C1-6 alkyl,
C3-7 cycloalkyl, C1-6
alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the
above-
mentioned R2 group may optionally be substituted independently of one another
with
one or more halogen;
each R3 is independently selected from the group consisting of hydrogen,
halogen (when Xi is -
C(R7)(R8)), C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7
cycloalkyl(oxy),
wherein the last four members of the above-mentioned R3 group may optionally
be
substituted independently of one another with one or more halogen;
each R4 is independently selected from the group consisting of hydrogen, C1-6
alkyl, C3-7
cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the above-
mentioned
274
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
members of each R4 group, except hydrogen, may optionally be substituted
independently of one another with one or more halogen;
A is selected from the group consisting of benzo[c][1,2]oxaborol-
1(3H)-ol, 3,4-dihydro-
lHbenzo[c][1,2]oxaborinin-1-ol, and 2H-benzo[e][1,2]oxaborinin-2-ol, or a
derivative
thereof, such as a moiety selected from any one of A1-A6:
Rli
R14
HO
HO
µ \1.
/ - . ...:2--= -, . ...---
0
I Ai, O1(
A2,
= ...-"L.,...õ.
õ,,,...r4
iz,7 k =
= \)\--- = r ...
.
R htz .
R.*/ =
*
,4
OH re
1 1,, OH
1 R14
0-- :1--' ,...,-- '-..,
....-_, = ......\
,...-
1,12õ,
r'. N.,..,. A3, *I. ''",.., 1 . 1
A4,
R11..õ,e,' = . . 'N.I.,,),""' ---.'¨NZ'''. -
,s'. N's,. ..
1
ii.2 11. 12 .13
R.
R
-----N
---,E1 .---- . --7"--,,,y_..------
õ...
I As, or
1
A6;
R/2 ---- ...---- ---- R --T-- R
1"
Al 3
R6 is selected from the group consisting of hydrogen, C1-6 alkyl,
C3-7 cycloalkyl, C1-6
alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7-cycloalkyl, -(C1-
3-
alkyl)-(C3-6-cycloalkyl), -(C2-3-alky(oxy)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-
6-
275
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered
heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroaryl), wherein the
above-
mentioned members of the R6 group, except hydrogen, may optionally be
substituted
independently of one another by one or more substituents selected from the
group
consisting of C1-6 alkyl and halogen, except halogen may not be adjacent to a
heteroatom;
R7 and R8 are independently selected from the group consisting of hydrogen,
halogen, hydroxy, -
N(R9)(Rio), r, r,
) C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-
7 cycloalkyl(oxy), -
COO-C1-6 alkyl, -COO-C3-7-cycloalkyl, -(C1-3-alkyl)-(C3-6-cycloalkyl),
alkyl(oxy)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6-cycloalkyl), 4-7-membered
heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -heteroaryl,
and -(C1-
3-alkyl)-(heteroaryl), wherein the last fifteen members of the above-mentioned
R7 and
R8 groups may optionally be substituted independently of one another by one or
more
substituents selected from the group consisting of halogen and hydroxy, and
wherein
R7 and R8 may be linked together to form a ring;
R9 and R1 are independently selected from the group consisting of hydrogen,
C1-6 alkyl, C3-7
cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7-
cycloalkyl, -(C1-3-alkyl)-(C3-6-cycloalkyl), -(C2-3-alkyoxyl)-(C2-6-alkyl),
alkyl(oxy)-(C3-6-cycloalkyl), 4-7-membered heterocycloalkyl,
membered heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroary1);
wherein the
last fourteen members of the above-mentioned R9 and Rl groups may optionally
be
substituted independently of one another by one or more halogen, or R9 and
Rill may
be linked together to form a ring;
is selected from the group consisting of hydrogen, C1-6 alkyl, C3-7
cycloalkyl, C1-6
alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7-cycloalkyl,
alkyl)-(C3-6-cycloalkyl), -(C2-3-alkyoxyl)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-
6-
cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered
heterocycloalkyl), -heteroaryl, and -(CI-3-alkyl)-(heteroaryl), wherein the
last thirteen
members of the above-mentioned R" group may optionally be substituted
independently of one another by one or more substituents selected from the
group
consisting of halogen and hydroxy, except that said optional substitution may
not be
276
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
geminal;
each 1212 is independently selected from the group consisting of hydrogen,
halogen, C1-6 alkyl,
C3-7 cycloalkyl, 4-7-membered heterocycloalkyl, C1-6 alkyl(oxy), and C3-7
cycloalkyl(oxy), wherein the last four members of the above-mentioned W2 group
may optionally be substituted independently of one another by one or more
sub stituents selected from the group consisting of halogen and hydroxy,
except when
R-12 is adjacent to oxygen, R12 is not halogen, and two adjacent Ri2 may be
connected
to provide a fused cycloalkyl, such as cyclopropyl; and
R13 and R" are independently selected from the group consisting of hydrogen,
halogen, cyano,
C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-
alkyl)-(C3-6-
cycloalkyl), -(C2-3-alkyl(oxy)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6-
cycloalkyl), 4-7-
membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -N-
(R6)(R6), -S02-(R6), -S02-(R6)(R6), -S(0)-(R6), and -S-(R6), wherein the last
fourteen
members of the above-mentioned R1-3 and 1414 groups may optionally be
substituted
independently of one another by one or more sub stituents selected from the
group
consisting of halogen and hydroxy.
[0441]
#2. The compound according to paragraph 1, wherein
Xi is selected from the group consisting of -0-, -N(R6)-, and -
C(R7)(1e)-;
X2 is selected from the group consisting of -0-, -N(R6)-, and -
C(R7)(R8)-, or
X2 comprises a bond between Xi and X3;
X3 is -C(R7)(R8)-, except Xi and X2 cannot both be -0-;
is selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7
cycloalkyl, wherein
the last two members of the above-mentioned group may optionally be
substituted independently
of one another with one or more halogen;
R2 is selected from the group consisting of hydrogen, C1-6 alkyl,
and C3-7 cycloalkyl, wherein
the last two members of the above-mentioned R2 group may optionally be
substituted
independently of one another with one or more halogen;
each R3 is independently selected from the group consisting of hydrogen, CI-6
alkyl, and C3-7
cycloalkyl, wherein the last two members of the above-mentioned R3 group may
optionally be substituted independently of one another with one or more
halogen;
277
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
each R4 is independently selected from the group consisting of hydrogen, C1-6
alkyl, and C3-7
cycloalkyl, wherein the last two members of the above-mentioned R4 group may
optionally be substituted independently of one another with one or more
halogen;
R7 and le are independently selected from the group consisting of hydrogen, -
C1-6 alkyl, C1-7
cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four
members of
the above-mentioned R7 and R8 groups may optionally be substituted
independently of
one another by one or more substituents selected from the group consisting of
halogen
and hydroxy, and R7 and R8 may be linked together to form a ring; and
each R" is independently selected from the group consisting of hydrogen,
halogen, and C1-6
alkyl.
10442]
#3. The compound according to one or more of paragraphs 1 to 2, wherein
Xi is selected from the group consisting of -0-, -N(R6)-, and -
C(R7)(1e)-;
X2 is selected from the group consisting of -0- and -C(R7)(R8)-,
except Xi and X2 may not
both be -0-, or X2 comprises a bond between Xi and X3;
X3 is -C(R7)(R8)-;
is selected from the group consisting of hydrogen and C1-6 alkyl;
R2 is selected from the group consisting of hydrogen and C1-6
alkyl;
each R3 is independently selected from the group consisting of hydrogen and C1-
6 alkyl;
each R4 is independently selected from the group consisting of hydrogen and C1-
6 alkyl;
R7 and R8 are independently selected from the group consisting of hydrogen and
C1-6 alkyl,
wherein the C1-6 alkyl may optionally be substituted with one or more of
halogen,
R13 is hydrogen, and
each R14 is independently selected from the group consisting of hydrogen,
halogen, cyano, C1-6
alkyl, C3-7 cycloalkyl , C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-alkyl)-
(C3-6-
cycloalkyl), -(C2-3-alkyl(oxy)-(C2-6-alkyl), and 4-7-membered
heterocycloalkyl,
wherein the last seven members of the above-mentioned R'4 group may optionally
be
substituted independently of one another by one or more sub stituents selected
from the
group consisting of halogen and hydroxy.
278
CA 03201608 2023- 6-7
WO 2022/133420 PCT/US2021/072885
[0443]
#4. The compound according to any one or more of paragraphs 1-3, wherein
Xi is selected from the group consisting of -0-, -N(R6)-, and -
C(R7)(R8)-;
X2 is -C(R7)(R8)-;
X3 is -C(R7)(R8)-,
R1, R2, R3, and R4 are hydrogen;
R7 and R8 are independently selected from the group consisting of hydrogen and
C1-6 alkyl,
wherein C1-6 alkyl may optionally be substituted with one or more of halogen;
each 1112 is independently selected from the group consisting of hydrogen,
halogen, C1-6 alkyl,
and C3-7 cycloalkyl, wherein the last two substituents may optionally be
substituted
independently of one another by one or more halogen;
R13 is hydrogen; and
each R14 is independently selected from the group consisting of hydrogen,
halogen, cyano, C1-6
alkyl, C3-7 cycloalkyl, and C1-6 alkyl(oxy), wherein the last three members of
the
above-mentioned R14 group may optionally be substituted independently of one
another by one or more halogen.
[0444]
#5. A compound of formula (IVa) or (IVb):
X2 ,X2
X3 '\X3 Xi Xi
R R R3
R3
n3
rS. 2 rs. 2
N N
R4
R4
A A
\ a
R4/
0 R4 Ra/
0 R/
(IVa), (IVb),
or a pharmaceutically acceptable salt or a stereoisomer or a tautomer thereof
wherein
Xi is selected from the group consisting of -0-, -N(R6)-, and -
C(R7)(R8)-;
279
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
X2 is selected from the group consisting of-U-, -N(R6)-, and -
C(R7)(1e)-, or
X2 comprises a bond between Xi and X3;
X3 is selected from the group consisting of -0-, -N(R6)-, and -
C(R7)(R8)-, except Xi and X2
cannot both be ¨0-, and X2 and X3 cannot both be -0-;
RI- is selected from the group consisting of hydrogen, halogen
(when X3 is -C(R7)(R8)-),
hydroxy, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7
cycloalkyl(oxy), wherein
the last four members of the of the above-mentioned W group may optionally be
substituted independently of one another with one or more halogen;
R2 is selected from the group consisting of hydrogen, C1-6 alkyl,
C3-7 cycloalkyl, C1-6
alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four members of the
above-
mentioned R2 group may optionally be substituted independently of one another
with
one or more halogen;
each R3 is independently selected from the group consisting of hydrogen,
halogen (when Xi is -
C(R7)(R8)), C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), and C3-7
cycloalkyl(oxy),
wherein the last four members of the above-mentioned R3 group may optionally
be
substituted independently of one another with one or more halogen;
each -124 is independently selected from the group consisting of hydrogen, C1-
6 alkyl, C3-7
cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the above-
mentioned
members of each le group, except hydrogen, may optionally be substituted
independently of one another with one or more halogen;
A is selected from the group consisting of benzo[c]11,21oxaborol-
1(3H)-ol, 3,4-dihydro-
lHbenzo[c]11,21oxaborinin-1-ol, and 2H-benzo[e][1,2]oxaborinin-2-ol, or a
derivative
thereof, such as a moiety selected from any one of Al-A6 :
HO
13 HO
\B.
0
0
Az,
s
14t4
R 1 =
1 2 R
280
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
OH n14
1 i, OH
,.4
0----
,1--..
i . =-= ....,.."-- N"--,... :."3
õ.1
..i.i A R j:\'':,,,i,
)%S'
t t
12 ,...-- ---=="'
''',,,,,,,,..--= Rtz
R =
12 1
414
A4,
1
R R 4
H 0,,
N,
,.....,,õ.,õ ,..2.-. ....
Ii
I As, or
A6;
R --- R - ,----=- -"R.
i
k
R6 is selected from the group consisting of hydrogen, C1-6 alkyl,
C3-7 cycloalkyl, C1-6
alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7-cycloalkyl, -(C1-
3-
alkyl)-(C3-6-cycloalkyl), -(C2-3-alky(oxy)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-
6-
cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered
heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroary1), wherein the
above-
mentioned members of the R6 group, except hydrogen, may optionally be
substituted
independently of one another by one or more substituents selected from the
group
consisting of C1-6 alkyl and halogen, except halogen may not be adjacent to a
heteroatom;
R7 and R8 are independently selected from the group consisting of hydrogen,
halogen, hydroxy, -
N(R9)(Rio), _0(R11%
) C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -
COO-C1-6 alkyl, -COO-C3-7-cycloalkyl, -(C1-3-alkyl)-(C3-6-cycloalkyl), -(C2-3-
alkyl(oxy)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6-cycloalkyl), 4-7-membered
heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -heteroaryl,
and -
(C1-3-alkyl)-(heteroary1), wherein the last fifteen members of the above-
mentioned R7
281
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
and R8 groups may optionally be substituted independently of one another by
one or
more substituents selected from the group consisting of halogen and hydroxy,
and
wherein R7 and R8 may be linked together to form a ring;
R9 and R" are independently selected from the group consisting of hydrogen, C1-
6 alkyl, C3-7
cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-CI-7-
cycloalkyl, -(C1-3-alkyl)-(C3-6-cycloalkyl), -(C2-3-alkyoxyl)-(C2-6-alkyl), -
(C2-3-
alkyl(oxy)-(C3-6-cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-
7-
membered heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroary1),
wherein the
last fourteen members of the above-mentioned R9 and Rl groups may optionally
be
substituted independently of one another by one or more halogen, or R9 and R"
may
be linked together to form a ring;
Rtt is selected from the group consisting of hydrogen, C1-6 alkyl, C3-7
cycloalkyl, C1-6
alkyl(oxy), C3-7 cycloalkyl(oxy), -COO-C1-6 alkyl, -COO-C3-7-cycloalkyl, -(C1-
3-
alkyl)-(C3 -6-cycloalkyl), -(C2-3-alkyoxyl)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-
(C3
cycloalkyl), 4-7-membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered
heterocycloalkyl), -heteroaryl, and -(C1-3-alkyl)-(heteroaryl), wherein the
last thirteen
members of the above-mentioned R" group may optionally be substituted
independently of one another by one or more substituents selected from the
group
consisting of halogen and hydroxy, except that said optional substitution may
not be
geminal,
each R12 is independently selected from the group consisting of hydrogen,
halogen, C1-6 alkyl,
C3-7 cycloalkyl, 4-7-membered heterocycloalkyl, C1-6 alkyl(oxy), and C3-7
cycloalkyl(oxy), wherein the last four members of the above-mentioned R'2
group
may optionally be substituted independently of one another by one or more
substituents selected from the group consisting of halogen and hydroxy, except
when
102 is adjacent to oxygen, 1112 is not halogen, and two adjacent 1112 may be
connected
to provide a fused cycloalkyl, such as cyclopropyl; and
R" and R" are independently selected from the group consisting of hydrogen,
halogen, cyano,
C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-
alkyl)-(C3-6-
cycloalkyl), -(C2-3-alkyl(oxy)-(C2-6-alkyl), -(C2-3-alkyl(oxy)-(C3-6-
cycloalkyl), 4-7-
membered heterocycloalkyl, -(C1-3-alkyl)-(4-7-membered heterocycloalkyl), -N-
282
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
(R6)(R6), -S02-(R), -S02-(R6)(R6), -S(0)-(R6), and -S-(R6), wherein the last
fourteen
members of the above-mentioned R13 and R'4 groups may optionally be
substituted
independently of one another by one or more sub stituents selected from the
group
consisting of halogen and hydroxy.
[0445]
#6. The compound according to paragraph 5, wherein
Xi is selected from the group consisting of -0-, -N(R6)-, and -
C(R7)(R8)-;
X2 is selected from the group consisting of -0-, -N(R6)-, and -
C(R7)(R8)-, or
X2 comprises a bond between X1 and X3;
X3 is -C(R7)(R8)-, except Xi and X2 cannot both be -0-;
is selected from the group consisting of hydrogen, C1-6 alkyl, and C3-7
cycloalkyl, wherein
the last two members of the above-mentioned group may optionally be
substituted independently
of one another with one or more halogen;
R2 is selected from the group consisting of hydrogen, C1-6 alkyl,
and C3-7 cycloalkyl, wherein
the last two members of the above-mentioned group may optionally be
substituted
independently of one another with one or more halogen;
each R3 is independently selected from the group consisting of hydrogen, C1-6
alkyl, and C3-7
cycloalkyl, wherein the last two members of the above-mentioned group may
optionally
be substituted independently of one another with one or more halogen;
each le is independently selected from the group consisting of hydrogen, C1-6
alkyl, and C3-7
cycloalkyl, wherein the last two members of the above-mentioned group may
optionally
be substituted independently of one another with one or more halogen;
R7 and R8 are independently selected from the group consisting of hydrogen, -
C1-6 alkyl, C3-7
cycloalkyl, C1-6 alkyl(oxy), and C3-7 cycloalkyl(oxy), wherein the last four
members of
the above-mentioned group may optionally be substituted independently of one
another
by one or more substituents selected from the group consisting of halogen and
hydroxy,
and R7 and R8 may be linked together to form a ring; and
each R13 is independently selected from the group consisting of hydrogen,
halogen, and C1-6
alkyl.
283
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
[0446]
#7. The compound according to one or more of paragraphs 5 to 6, wherein
Xi is selected from the group consisting of -0-, -N(R6)-, and -
C(R7)(1e)-;
X2 is selected from the group consisting of -0- and -C(R7)(R8)-,
except Xi and X2 may not
both be -0-, or X2 comprises a bond between Xi and X3,
X3 is -C(R7)(R8)-;
RI- is selected from the group consisting of hydrogen and C1-6
alkyl;
R2 is selected from the group consisting of hydrogen and C1-6
alkyl;
each R3 is independently selected from the group consisting of hydrogen and C1-
6 alkyl;
each R4 is independently selected from the group consisting of hydrogen and C1-
6 alkyl;
R7 and R8 are independently selected from the group consisting of hydrogen and
C1-6 alkyl,
wherein C1-6 alkyl is optionally substituted with one or more of halogen;
R13 is hydrogen; and
each W4 is independently selected from the group consisting of hydrogen,
halogen, cyano, C1-6
alkyl, C3-7 cycloalkyl, C1-6 alkyl(oxy), C3-7 cycloalkyl(oxy), -(C1-3-alkyl)-
(C3-6-
cycloalkyl), -(C2-3-alkyl(oxy)-(C2-6-alkyl), and 4-7-membered
heterocycloalkyl,
wherein the last seven members said I214 group may optionally be substituted
independently of one another by one or more sub stituents selected from the
group
consisting of halogen and hydroxy.
[0447]
#8. The compound according to any one or more of paragraphs 1 to 7, wherein
X2 is -C(R7)(R8)-,
X3 is -C(R7)(R8)-;
R1, R2, R3, and RI are hydrogen;
R7 and R8 are independently selected from the group consisting of hydrogen and
C1-6 alkyl,
wherein C1-6 alkyl is optionally substituted with one or more of halogen;
each R12 is independently selected from the group consisting of hydrogen,
halogen, C1-6 alkyl,
and C3-7 cycloalkyl, wherein the last two members of the above-mentioned R'2
group
may optionally be substituted independently of one another with one or more
halogen;
284
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
each 1213 is hydrogen; and
each RH is independently selected from the group consisting hydrogen, halogen,
cyano, C1-6
alkyl, C3-7 cycloalkyl, and C1-6 alkyl(oxy), wherein the last three members of
the
above-mentioned W4 group may optionally be substituted independently of one
another by one or more halogen.
[0448]
#9. A compound selected from the group shown in the following table:
Example Example
Structure Structure
Number Number
0 Nt-i,
= .....
HN2 n-N HN
NC
1
NC 2
( 1
1,----
rs .2\11-01=1
\-...._<
---"µ
4
I N
N 0,-
H.,.
k9 ¨CN .(k* 1--ON
OH
6 1 b
Li
H
0-..'. 111-
N H a
0 9H 1........./¨CN
1,
'1='"t4 rr '''s--
431.--6'. 11
7
cll, ...),,,LUI, ) 8
-1--1 "
N --
0-...--
(.- -- NH
.:
285
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
4,e.--.....,,
te- \--eN
CN
011 Lte- OH
...,....., ii
." "N f
b
11 N- N I --T:so
12 ik, ,
y 4
0 ,.....õ ,
.,
., %
()N ,:>--GN et ON. I--CN F
0- n/1
'.--- ts
N ,,,,,,,..-0 ----c
, ,0ON
14 13 -,1 ".-':" L. IC õsi
,,,;\ 1),.. ,,,,....,.......õ, ,..µ,...,s.
r 11 )----
''c'"N -'''''''-'=
-Nti,
:
/--0
NN
16
'-'
.,,(1_,., ,N -õ ----= ,
H
O'r:k,f$4142 µ'`, i 13-=011
---(3
_.)----CN ...,,,,..)---- CN
----C,
17 p -Ntt r-1----,r ift- 18 N -N
NT;,,,, 'a.., -==-=\-- ---x.-1 p,i ,-
....--
X VI r H
,".....,,
\-.....
N -N rx.,,,,, , -
19 20
:... IL, . -\\ ' ''''' '''''' iµNI4 1NX. kf
tli
r ri
0,----3N
286
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
sk.41, e.r
21
ti..--k,..,..)..,õ..11,,,,e,.. 22
1.4 I--
uti
, .H., ...:......... .41,,,õ--......,,..
Nit,,
(---.''' ----- CS
)I. >
,), ., ,....10,õ8,..OH .N -N
v,,,, , sO 011
23 = .
yt is
i 24
,... ,
µC
N-N r ,,,,
25 4 -- ---A 0.11,:011
\ ,K, .-1" 1 LN 26
0 0
lYs'A'NFI
i,
\)¨CN 0
\,,õ<
N -N etr 11
27 <\ ik i 1 ,,, j 28
),----' N -
r,,,I. ti H
o
-
,
, ....õ
(k_,',>--cN
,N ,N F,,,,,..,;..õ0011
29 i1 30
H
0.¨'-'Nt1., 0.-^1.i a ,
...,
, '
1.,=
N_N (,), 0OH ,õ....,õ,.
31
32
0
) 32
0
287
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
\ ) CH
33 i 11 i i 34
P--\
N -N 1.,,,..-..""-',(-6.--- " 0 . et P4
"1, ..,--1 ...-:-...d 36 y4 OH
,--i\ 4 1 ii-,N HN
i
....-- 6
--
'',=,,,.
i -
.=
, \
''--.µ;). OH C=1\,,,2----== CH F= 01,4
...t
NC' Ns, N õ,. -.----, .4 1,:i
),,- ti, K .s.õ = N ...-
*:-,...õ,õ--,*---.1
H
'NH H
.-s-(') ' '''' = -CH
,.....,....".., . ,0,8,õ01-1 = -N
µ,,,aidii,,.. ,,O,s,Ofi
39 S ri 1 i 1..,,,.., 40
N ---k--N---k-
0, H
..---, = ....- = = ,..--' ....-
õ
=-,,
u
ii ,----0
1214'
41 42
cs, y--- -N-----µ.8-.
0,,d,,,.N142H 6H
288
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
Ot
N--.< F
H
--CN ?
L 0 = ---Cli.
\.....4
,13,,,OH "),4_,N --,,,,,,,
,, õ0,8,,OH
45 y-L ...,L,,...,-, ic-...,'L, 46
))L ,-L, 1 )
N
H
\
tkni,-
,,..,......,
.,:,.
N NN .- I,-4,---'-
N
47 IN, lk , i ,-. 48 '
.. c).--'' ti
tsõ."
)4_,.N f.õ-, 0,8,0H
49
\\)-1,..u1.,,,e...-- 50 i
H i S,,,IN1 N µ.õ,)--,,r
11
0 0 --:A
NH z NH
N H
51 ,,-:--rkp 52
iN - ,
( 1 H
$
OH
289
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
eN
OrThi¨
- -
_
Nr,,,õ--k,,,k -ir 13.-
54 IN
-, ...--k\\,z0-4
L-*
,--,. \_CN . :'µ S
56
.='-''\ik41,1- s.- ''''' 1 N
1 ti
0 ..>õõGN
\--1:4_1;si
57 e\ it 1
H
(r- Nti
#10. The compound according to any example in paragraph 9 which is a
stereoisomer having
trans relative stereochemistry as represented in formula (IVa) and (IVb):
x2 x2
....,
xi x. xi x,
R3
R3
"....,
R3 2 E
Fl N
N
i( i(
R4
\N ___________________________________________ R4
\N N A N A
\ / \ /
R4/
0 R4 R4/
0 R4
(IVa) and
(IVb).
[0449]
#11 The compound according to one or more of paragraphs 9 and 10,
wherein the compound
is a single stereoisomer having trans relative stereochemistry.
290
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
[0450]
#12. The compound according to paragraph 11, wherein the compound has trans
stereochemistry
as represented by formula (IVb).
[0451]
#13 A process for preparing a compound according to any one of
paragraphs 1-12.
[0452]
#14. A method for treating a patient having a disease or disorder susceptible
to modulation of
JAK comprising administering a therapeutically effective amount of a compound
according to
any one of paragraphs 1-12.
[0453]
#15. The method of paragraph 14, wherein the disease or disorder is a
condition that can be
ameliorated by the selective inhibition of a Janus kinase JAK 1 relative to
JAK 2.
[0454]
#16. The method of paragraph 14, wherein the disease or disorder is one or
more of atopic
dermatitis, flea allergy dermatitis, eczema, pruritus, psoriasis, psoriatic
arthritis,
inflammatory/autoimmune polyarthritis, Bechet's disease, pityriasis rubra
pilaris, alopecia areata,
discoid lupus erythematosus, vitiligo, palmoplantar pustulosis, mucocutaneous
disease erythema
multiforme, mycosis fungoides, graft-versus-host disease, cutaneous lupus,
rheumatoid arthritis
(RA), arthritis, ulcerative colitis, Crohn's disease, inflammatory bowel
disease (IBD), transplant
rejection, systemic lupus erythematosus (SLE), dermatomyositis, Sjogren's
syndrome, dry eye
disease, secondary hypereosinophilic syndrome (LIES), allergy, allergic
dermatitis, allergic
rhinitis, asthma, vasculitis, multiple sclerosis, diabetic nephropathy,
cardiovascular disease,
artherosclerosis, and cancer.
[0455]
#17. The method of paragraph 16, wherein the disease or disorder is one or
more of atopic
dermatitis, flea allergy dermatitis, psoriasis, and rheumatoid arthritis.
291
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
[0456]
#18. The method according to any one of paragraphs 14-17, wherein the compound
is
administered in an amount to perturb an immune regulatory pathway in a cell.
[0457]
#19. The method of paragraph 18, wherein the perturbation results in an effect
on the JAK-
STAT pathway.
[0458]
#20. A method of inhibiting JAK in a mammalian cell comprising contacting the
mammalian
cell with a compound any one of paragraphs 1-12.
[0459]
#21. The method according to paragraph 20, wherein the mammalian cell is a
cell from a
subject having an inflammatory condition.
[0460]
#22. A composition comprising a compound of any one of paragraphs 1-12 and a
pharmaceutically or veterinary acceptable carrier.
[0461]
#23. A combination comprising a compound of any one of paragraphs 1-12, and
one or more
other pharmaceutical or veterinary active substances.
[0462]
#24. A method for treating one or more diseases or disorders of inflammation,
auto-immune
dysfunction, and cancer comprising administering to a subject in need thereof
an effective
amount of a compound of any one of paragraphs 1-12.
[0463]
292
CA 03201608 2023- 6- 7
WO 2022/133420
PCT/US2021/072885
#25. The method of paragraph 24, wherein the disease or disorder is atopic
dermatitis, flea
allergy dermatitis, psoriasis, or rheumatoid arthritis.
[0464]
#26. The method of paragraph 24 or 25, wherein the compound is administered
orally,
parenterally, or topically.
[0465]
#27. The method of any one of paragraphs 24-26, wherein the subject is a
mammal.
[0466]
#28. The method of paragraph 27, wherein the mammal is selected from one or
more of
livestock mammals, domestic mammals, and companion animals.
[0467]
#29. The method of paragraph 27, wherein the mammal is selected from one or
more of
humans, cattle, sheep, goats, llamas, alpacas, pigs, horses, donkeys, dogs,
and cats.
[0468]
#30. The method of paragraph 27, wherein the mammal is a human, dog, or cat.
[0469]
#31. A compound of any one of paragraphs 1-12 for use in medicine.
[0470]
#32. Use of a compound of any one of paragraphs 1-12 for the manufacture of a
medicament
for the treatment of one or more diseases or disorder of inflammation, auto-
immune dysfunction,
and cancer.
[0471]
293
CA 03201608 2023- 6-7
WO 2022/133420
PCT/US2021/072885
#33. The use according to paragraph 32, wherein the disease or disorder is
atopic dermatitis,
flea allergy dermatitis, psoriasis, or rheumatoid arthritis.
[0472]
#34. The use according to paragraph 32, wherein the disease or a disorder is
ameliorated by
the selective inhibition of a Janus kinase JAK 1 relative to JAK 2.
[0473]
#35. Use of a compound of any one of paragraphs 1-12 and a second active
agent in the
manufacture of a medicament for the treatment of a disease or a disorder that
can be ameliorated
by the selective inhibition of a Janus kinase JAK 1 relative to JAK 2.
[0474]
#36. Use of a compound of any one of paragraphs 1-12 for the treatment of one
or more
diseases or disorders of inflammation, auto-immune dysfunction, and cancer.
[0475]
#37. The use according to paragraph 36, wherein the disease or disorder is
atopic dermatitis,
flea allergy dermatitis, psoriasis, or rheumatoid arthritis.
* * *
[0476] Having thus described in detail various embodiments of the present
invention, it is to be
understood that the invention defined by the above paragraphs is not to be
limited to particular
details set forth in the above description as many apparent variations thereof
are possible without
departing from the spirit or scope of the present invention.
294
CA 03201608 2023- 6-7
